ACUTE COMMUNICABLE DISEASE CONTROL PROGRAM

ANNUAL MORBIDITY REPORT AND SPECIAL STUDIES REPORT

2012

Public Health
Laurene Mascola, MD, MPH, FAAP
Chief, Acute Communicable Disease Control Program

Acute Communicable Disease Control Program

Annual Morbidity Report

2012

Los Angeles County
Department of Public Health

THIS PAGE IS INTENTIONALLY LEFT BLANK.

ACUTE COMMUNICABLE DISEASE CONTROL PROGRAM
ANNUAL MORBIDITY REPORT
2012

TABLE OF CONTENTS

Acute Communicable Disease Control Program
2012 Annual Morbidity Report

Table of Contents (cont.)

Disease Summaries

Disease Outbreak Summaries

ACUTE COMMUNICABLE DISEASE CONTROL PROGRAM
ANNUAL MORBIDITY REPORT
2012

MAP LIST

Los Angeles County Department of Public Health
Acute Communicable Disease Control Program
Annual Morbidity Report
2012

● EXECUTIVE SUMMARY ●

In Los Angeles County (LAC), more than 85 diseases and conditions, as well as unusual disease occurrences and outbreaks, are reportable by law. Acute Communicable Disease Control Program (ACDC) is the lead program for the surveillance and investigation of most communicable diseases—responsibilities exclude tuberculosis, sexually transmitted diseases, and HIV/AIDS; selected vaccine-preventable diseases are monitored by the Immunization Program. Surveillance is primarily passive, with reports submitted via facsimile, mail, or telephone by providers and hospitals. Electronic reporting from hospitals via a secure web-based application has steadily increased since its inception in 2002; nearly every hospital infection preventionist in addition to correctional health providers and several large clinics are now capable of electronic reporting. Electronic laboratory reporting has been in place since 2002 and has expanded to more than twenty-five clinical and reference laboratories that report an estimated 60% of all mandated laboratory reports.

ACDC Mission

To prevent and control communicable disease in Los Angeles County utilizing the tools of surveillance, outbreak response, education and preparedness activities.

ACDC also sets policy and develops procedures for LAC Department of Public Health (DPH) activities related to infectious and communicable disease prevention and control. Our program interprets and enforces state and federal laws and regulations, and interfaces with other jurisdictions, programs and agencies responsible for public health. ACDC frequently provides consultation to the medical community on issues of communicable and infectious diseases and education to medical professionals.

ACDC has several sections, units and special projects, each with unique goals and objectives for the surveillance and control of communicable disease. ACDC team members work to decrease morbidity from acute communicable diseases through surveillance to monitor trends and detect outbreaks. ACDC activities include working with:

Los Angeles County: A Description of Our Community

LAC is one of the nation's largest counties, covering over 4,000 square miles. While LAC enjoys fairly temperate, year-round weather, it encompasses a wide variety of geographic areas including mountain ranges, arid deserts, and over 80 miles of ocean coastline. Accordingly, one challenge of disease surveillance, response and control is responding to its enormous size. LAC presently has the largest population (nearly 10 million) of any county in the US and is exceeded by only eight states. LAC is densely populated, with over one-fourth of the state's population. LAC is home to approximately 100 hospitals with 74 emergency departments, more than 30,000 licensed physicians, over 450 sub-acute healthcare facilities, and about 25 thousand retail food purveyors.

Another challenge is the extensive diversity of our population coupled with a high level of immigration and foreign travel. Nearly half of our residents are Hispanic (49%), around one-third white (29%), and around one in ten are Asian (14%) or black (8%). Residents report over 90 languages as their primary spoken language. There is also substantial economic diversity within our county; the 2010 US census recorded over 1.5 million residents (nearly 16% of LAC's population) living in poverty.

LAC is a major port of entry for immigrants to the US. According to the 2011 Los Angeles County Health Survey, 46% of adult respondents stated they were born outside of the US. According the US Department of Homeland Security Yearbook of Immigration Statistics 2012, California remains to be the leading state of the residence of legal permanent residents/immigrants to the US. The population is also highly mobile. In terms of air travel alone, each year roughly 55 million travelers come through the Los Angeles International airport (over 40 million domestic and 14 million international travelers yearly)—making it the nation's 3rd busiest airport.

- foodborne illnesses, with special interest in *Listeria*, norovirus, *Salmonella* and shiga-toxin producing *E. coli* (STEC)
- the two most common vector-borne diseases in LAC continue to be West Nile virus infections and murine typhus
- pulse field electrophoresis (PFGE) that continues to be used to identify meningococcal case clusters
- acute care hospitals, sub-acute healthcare facilities (e.g., skilled nursing facilities), and ambulatory care settings for disease prevention, infection control, and outbreak investigations

- antimicrobial-resistant bacterial agents such as *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Clostridium difficile*, *Enterococcus*, *Acinetobacter*, and *Klebsiella*
- influenza (including pandemic influenza) and other respiratory pathogens through a variety of case-based, aggregate, and virologic surveillance parameters
- LAC DPH Community Health Services (CHS) for outbreak investigations in community settings, providing guidance, support and consultation on infection prevention and control
- other LAC programs such as Environmental Health, Veterinary Public Health, Public Health Investigation, Public Health Laboratory, Immunization Program, and Health Facilities for communicable disease outbreaks, investigations, and consultation
- selected vaccine-preventable diseases for surveillance, outbreak investigation and control
- healthcare providers to enhance preparedness and response through strengthened communications, collaboration, and consolidation of resources, engaging infection preventionists, emergency departments, and laboratories in these efforts
- automated disease surveillance systems to enhance surveillance and epidemiology capacity, to identify and respond to unusual occurrences and possible terrorist incidents; activities include syndromic surveillance and electronic laboratory reporting
- many programs of the California Department of Public Health (CDPH), including the Center for Infectious Diseases, as well as the Centers for Disease Control and Prevention (CDC) on communicable disease matters of regional and national scope
- the Varicella Surveillance Project, a research project examining the incidence of varicella and herpes zoster, as well as immunization coverage levels and the impact of immunization on this herpes zoster. The Project ceased data collection at the end of 2011 and came to an end in 2012.
- LAC Department of Coroner to identify infectious disease related deaths.
- CDC's projects such as the Influenza Incidence Surveillance Project and the childhood pneumococcal disease case-control study.

Other ACDC team members support and work with the disease surveillance units to:

- provide epidemiologic consultation and support, as well as assist with special projects, data maintenance, epidemiologic analysis, data presentation, and geographic information system (GIS)
- plan and evaluate cross-cutting ACDC activities with strategic planning and consequential epidemiology (application of public health research); establish and maintain performance measures for evidence-based public health practice and quality improvement activities
- train and educate internal and external partners to respond to potential or actual disease which may be the result of bioterrorism.

Additional information about ACDC and DPH is available at:
http://publichealth.lacounty.gov/acd/index.htm
http://publichealth.lacounty.gov/

Foodborne Diseases

Figure 1
Foodborne Disease Incidence Rates (cases per 100,000) by Year
LAC and US, 2001–2012



Diseases spread by food and food sources make up many of the investigations and activities conducted by ACDC and CHS. Overall, foodborne diseases have declined since the mid-1990's and have stabilized at lower rates as in Figure 1 (see individual chapters on campylobacteriosis, *E. coli* O157:H7, listeriosis, salmonellosis, shigellosis, typhoid fever, and vibriosis for more details). The declining trend in reported cases is most evident with the bacterial disease shigellosis. The rate of salmonellosis has risen slightly but is still within the normal range for the past ten years, though the campylobacteriosis rate continued to increase over the past six years. The majority of campylobacteriosis cases are now being diagnosed by antigen based tests, which may be overly sensitive

compared to traditional culture technology. Incidence of Shiga-toxin producing *E. coli* (STEC) serotypes has changed in the past three years. Serotype O157:H7 decreased while other serotypes are reported more often. The USDA and FDA both have zero tolerance for *E. coli* O157:H7 found in raw meat testing at meat processing plants, thus fewer outbreaks are occurring caused by *E. coli* O157:H7. Additionally, there is widespread use of rapid stool tests for Shiga toxins by commercial laboratories; both positive toxin tests and cultures are reportable to Public Health. The Public Health Laboratory is able to isolate these non-O157 strains that formerly would not have been reported. LAC enteric disease findings are similar to national trends depicting sustained decreases with occasional upsurges among many foodborne illnesses, particularly those of bacterial origin.[1] While the underlying causes for these local and national trends are not known, the implementation of control measures at several levels are believed to be important factors in the reduction of food and water-related illnesses. On a national level, these measures include the expansion of federal food safety and inspection services as well as increased attention to fresh produce safety. Locally, the restaurant grading system in operation in LAC since 1998 enforces food safety practices in the restaurants.

In 2012, the LAC salmonellosis crude rate was 11.2 per 100,000, a slight increase after a decreasing trend for the past three years. Nationally, the incidence of salmonellosis cases also has slightly increased, thus it appears that LAC is mirroring the national trend. Although many food items and both potable and recreational water sources have been implicated in the transmission of *Salmonella*, salmonellosis is most commonly associated with eggs, poultry, and fresh produce. Occasionally, an infected food service worker is the source of a salmonellosis outbreak. Another prominent exposure source is reptiles, either by direct contact or through contaminated surfaces or other people exposed to reptiles. In 2012, 9.2% of reported LAC salmonellosis cases had contact with turtles, lizards or snakes—a slight increase from 2011. Seventy-four percent of these cases had contact with small turtles demonstrating the ongoing need for continued efforts of the ACDC-led coalition of internal DPH partners and external community stakeholders engage in community-based reptile associated salmonellosis prevention interventions.

ACDC investigated 21 disease outbreaks in 2012 that were determined to be foodborne, in which at least 247 persons were ill and 12 were hospitalized. During 2012 one outbreak was caused by *Salmonella*, one by *Shigella*, 13 by norovirus, three were due to bacterial toxin, two were caused by scombroid fish toxin and one was foodborne botulism. In addition, LAC assisted state and federal investigators with 15 *Salmonella*, five *E. coli*, and two *Listeria* outbreak investigations and 18 additional salmonellosis clusters that were not designated as outbreaks by CDC. While the overall incidence of most foodborne diseases has been decreasing, they continue to account for considerable morbidity and mortality—most likely thousands of preventable infections occur yearly that go unreported. The majority of people affected by these illnesses improve without treatment and suffer no complications; however, some infections may become invasive, especially among children, the elderly and those with certain chronic medical conditions (e.g., immunocompromise), leading to hospitalization and death. In LAC, foodborne diseases were a contributing factor for at least 12 deaths in 2012. Accordingly, further efforts are needed to improve food quality and to educate the food industry and the public about proper food storage, handling, and preparation.

Efforts are needed to improve food quality and to educate the food industry and the public about proper food storage, handling, and preparation.

Waterborne Diseases

Diseases such as amebiasis, cryptosporidiosis, and giardiasis have the potential to be waterborne and could infect large numbers of persons; more commonly they are spread person to person by fecal contamination of hands, food, and drink. From 2006 to 2012, surveillance data reflect a growing proportion of reported amebiasis and giardiasis cases among immigrants and/or refugees. No outbreaks involving treated recreational water occurred in 2012; the last known such outbreak was in 2008, which was a *L.Pneumophila* associated outbreak involving a spa in an assisted living facility.[2]

[1] CDC, Preliminary FoodNet Data on the Incidence of Infection with Pathogens Transmitted Commonly Through Food---10 States, 2009. MMWR 2010; 59(14); 418-422. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5914a2.htm.

[2] CDC, Surveillance for Waterborne Disease Outbreaks and Other Health Events Associated with Recreational Water --- United States, 2007—2008. 2011; 60(ss12);1-32. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6012a1.htm?s_cid=ss6012a1_w

Vectorborne Diseases

In 2012, LAC documented the second highest count of human WNV infections since 2003, when it first emerged in the region.

Vectorborne disease surveillance has documented the re-emergence of endemic (murine) typhus and other rickettsial diseases in LAC. Murine typhus cases increased from nine reports in 2005 to 50 cases in 2012, the highest number reported in decades. Murine typhus cases have been documented from known endemic LAC areas of Los Feliz, South Pasadena, and Pasadena as well as newer foci including Santa Monica, downtown Los Angeles, and cities bordering Long Beach. In 2012, LAC documented the second highest count of human West Nile virus (WNV) infections since 2003, when it first emerged. Compared to the prior surveillance year, WNV infections increased from 63 in 2011 to 174 in 2012, including 118 cases of neuroinvasive disease (NID), 39 WNV fever cases, and 17 asymptomatic infections in blood donors. ACDC staff work closely with LAC DPH Veterinary Public Health, Environmental Health Vector Management, and the five local vector control agencies to routinely communicate data, control, and health education issues concerning these vector-borne diseases.

Since June 2012, Aedes aegypti, the primary mosquito vector for dengue fever, yellow fever, and chikungunya virus, has been detected in multiple central and northern CA counties. There have been no reports of local transmission of these arboviral diseases in CA.

Invasive Bacterial Diseases

Severe community acquired *Staphylococcus aureus* infection has been reportable disease in California since 2008. Twenty-four cases of severe community acquired Staphylococcus infection resulted in intensive care unit admission or death in 2012, considerably fewer cases than the 44 cases reported in 2011. Substantial under-reporting of this condition is suspected, since 42% of all cases were reported by only two reporting sources in 2012. Case investigation interviews with patients or surrogates revealed that current smoking, diabetes and intravenous drug use were the most frequently reported risk factors. Contrary to the publicity around the virulence of methicillin-resistant *S. aureus* (MRSA), only 29% of the 2012 cases were MRSA and those at highest risk for MRSA were $\geq$65 years old.

Risk factors for invasive group A streptococcal disease (IGAS) were similar to those for community acquired severe *S. aureus* infections; diabetes was the most frequently reported risk factor, followed by alcohol abuse. The total number of IGAS cases (N=168) was lower than the previous two years, but was within a 5-year range of cases (129-191). One outbreak of IGAS infections (N=3 [2 confirmed and 1 probable]) was identified in a skilled nursing facility. An investigation could not identify a source. However, several breakdowns in infection control were identified and the facility was provided with infection control training.

Viral Hepatitis

The rate of hepatitis A remained stable in LAC (0.51 per 100, 000) in 2012, however, was slightly higher than the national rate (0.45 per 100,000). The rate of acute hepatitis B in LAC (0.41 per 100,000) dropped to the lowest recorded level in the last five years. Surveillance for acute hepatitis C identified seven cases. Individual cases continue to be identified with possible health care associated transmission of acute hepatitis B and C viruses; detailed case investigations are carried out to identify suspected sources of nosocomial transmission. There were no outbreaks of hepatitis A, B, or C identified in 2012.

Influenza

The 2012-13 influenza season in LAC was moderately severe with the highest percent positive of influenza like illness (ILI) visits seen in emergency departments in the past six seasons. Peak activity occurred during the last week of January/beginning of February where almost 30% of emergency department visits were ILI related and the highest number of deaths occurred.

The 2012-13 influenza season also had a substantial increase in fatalities attributed to influenza compared with the previous two seasons, and relative to last season, there were more influenza attributed deaths across all age groups especially in the elderly. Sixty-nine deaths due to laboratory-confirmed influenza were reported; the median age at death (68 years) was higher than the previous three years (45-64 year range). Multiple source surveillance estimates support that laboratory-confirmed deaths represent a small proportion of all influenza related deaths. Since the 2009-2010 pandemic, influenza A pH1N1 prevalence has been decreasing at a greater magnitude each year (most likely due to immunizations and herd immunity). See Influenza Watch for a summary of the 2012-2013 influenza season in LAC.

The past three influenza seasons have been predominated by type A influenza (H3N2). However for the 2012-13 season a different strain emerged antigenically characterized as A/Victoria/361/2011 (H3N2), whereas the previous two seasons were primarily of the Perth lineage, A/Perth/16/2009. Despite the Victoria strain being included in the 2012-13 season vaccine, LAC identified the highest number of influenza deaths since the H1N1 pandemic season reflecting a moderately severe season. Comorbid factors remain similar to previous years, with high blood pressure and overweight/obesity continuing to be top risk factors. Unfortunately data collection on influenza vaccination rates in fatal cases is incomplete, preventing us from examining its relationship to mortality.

Vaccine Preventable Diseases

A marked resurgence of vaccine-preventable disease (VPD) cases and outbreaks continues to occur worldwide and notably in developed countries as more individuals opt out of vaccinations. The United Kingdom has once again declared measles endemic after years of eliminating disease transmission within its borders. Although 2012 showed a decrease in LAC pertussis cases to 2009 levels, VPD outbreaks and cases due to risk factors such as travel exposure and/or unvaccinated status continue to increase in LAC.

Despite the enactment and success (98% LAC school coverage) of a California school immunization law in 2011 requiring all 7th-12th grade students younger than 18 years of age to receive a Tdap vaccination, adolescents and adults continue to account for a higher proportion of 2012 cases similar to previous years. In addition, multiple pertussis elementary and middle school outbreaks occurred in the Fall of 2012 due to the waning immunity of students and/or the lack of Tdap immunizations.

Vaccine Preventable Diseases

- *LAC continues to experience an increase in VPD outbreaks/clusters annually.*
- *Starting October 2012, one dose of Tdap was recommended for women during every pregnancy.*

Another 2012 VPD outbreak occurred in LAC when a mother with mumps infected her entire family, and her child subsequently transmitted the infection to another student at a pre-school. The child infected at the school was unvaccinated due to parental personal beliefs. A cluster of 2012 LAC measles cases were unvaccinated due to similar personal beliefs and had acquired infection while traveling abroad to the United Kingdom or while exposed to individuals who had traveled there.

Although vaccine coverage levels in LAC remain high (over 80% in children) for disease-specific vaccine antigens, this alarming trend among parents to reject vaccines for their children for personal belief reasons is on the rise and has contributed to the increased VPD morbidity. Personal belief exemption rates in LAC kindergarten schools have increased steadily over the last 12 years and now comprise over 2% of the population. The percentage of pertussis cases less than 18 years of age with personal belief vaccine exemptions continues to rise annually. In 2012, 9% of the cases had a personal beliefs pertussis vaccine exemption. This rising personal beliefs exemption rate threatens herd immunity levels that are required to keep outbreaks and resurgences in cases at bay, thereby leading to an annual increase in observed VPD outbreaks/clusters in LAC.

Due to the international resurgence and high risk of exposure to VPDs during global travel, immunizations against measles, mumps, rubella, pertussis, diphtheria, and hepatitis A are strongly recommended at least two

weeks prior to travel. In addition, unvaccinated infants six months of age and older should be vaccinated with MMR if they are traveling out of the country. In October 2011, in another effort to reduce the burden of pertussis in infants, the Advisory Committee on Immunization Practices (ACIP) recommended that unvaccinated pregnant women receive a dose of Tdap. On October 24, 2012, ACIP voted to recommend use of Tdap during every pregnancy. This recommendation in conjunction with vaccinating household contacts before or immediately after delivery helps reduce the pertussis incidence and severe morbidity still observed among infants who are at most risk to acquire.

In conjunction with high vaccine coverage levels in children, the challenge is to also achieve and maintain high vaccine coverage levels in adults and adolescents, to curb VPD morbidity in the general community. Although Tdap coverage among LAC students in grades 7th-12th grades continues to remain high at 98% in 2012, attributable in large part to the 2011 California school immunization law, the HPV vaccination coverage level for ≥3 doses in LAC among girls 13-17 years was well below the national level at 19.8% in 2011. Nationally, HPV vaccination rates in girls aged 13-17 years failed to increase between 2011 and 2012 (34.8% and 33.4% respectively for ≥3 doses of HPV vaccine). Among girls unvaccinated for HPV nationally, 84% had a healthcare visit in 2012 where they received another vaccine (such as one aimed at meningitis or pertussis) but not HPV vaccine. If HPV vaccine had been administered, vaccination coverage nationally for ≥1 dose could be nearly 93% rather than 54%.

Although LAC VPD morbidity levels continue to be relatively low compared to other regions of the country, a multi-pronged effort is ongoing to incorporate innovative and tailored community-based strategies such as educating parents/guardians about the importance of vaccines to dispel vaccine myths, educating providers about consistently recommending all vaccinations to patients including HPV, reducing missed vaccination opportunities especially among international travelers, and increasing case reporting to the public health department as was observed in 2012 when perinatal hepatitis B case reports increased by 22%.

Meningococcal conjugate vaccine (MCV) coverage in California teens continues to increase, estimated at 76%. Although recent MCV coverage level data is not available for LAC, it is estimated to be in the same range as that for California as a whole. Consistent with national trends, the incidence of invasive meningococcal disease (IMD) in LAC has declined across all age and race-ethnic groups since 1995. In 2012, LAC experienced the lowest case count ever documented with 12 cases. Beginning mid-December 2012, two separate clusters of serogroup C cases occurred among adult males that were men who have sex with men (MSM) and adult males associated with recent travel history to Tijuana, Mexico. These clusters extended into 2013. ACDC staff worked closely with external organizations including CDPH, CDC, and other jurisdictions across the state and country to monitor this increase in serogroup C disease in males. ACDC also worked with LAC Public Health Laboratory, Health Education, and Public Information Office to summarize data and produce health education materials to quickly relay accurate information.

Healthcare Associated Infections and Outbreaks

Healthcare associated infections (HAIs) have generated a great deal of attention in the US in recent years, especially the issue of transparency and public reporting of individual hospital infection rates. California legislation mandates healthcare facility reporting of selected conditions and healthcare practices, and established a statewide HAI advisory committee to monitor implementation of these laws to reduce and prevent HAIs. ACDC Hospital Outreach Unit (HOU) participates in the state advisory committee and works with the CDPH and other public health organizations to make recommendations related to the prevention and control of HAIs, including compliance with HAI regulations and public reporting of HAI associated process and outcome measures. The CDPH public reports of healthcare associated bloodstream infections and surgical site infections in California hospitals can be found at http://www.cdph.ca.gov/programs/hai/Pages/default.aspx. The data in the report were collected using the CDC National Healthcare Safety Network (NHSN) as a method of standardizing the data.

In 2012, the HOU collaborated with CDPH to conduct joint information sessions with hospital infection preventionists (IP), hosting monthly conference calls and participating in statewide HAI collaboratives such as the Dialysis Project and Long Term Acute Care Collaborative.

Multidrug-resistant organisms are emerging diseases that have become of increasing public health concern and are frequently HAIs.

Multidrug-resistant organisms are an emerging and increasing public health concern that frequently cause HAIs. In 2012, LAC ended its laboratory surveillance of carbapenem-resistant *Klebsiella pneumoniae* (CRKP). Results of the first year of data were published in Infection Control and Hospital Epidemiology journal and showed that CRKP is more present in LAC than suspected, and rates were consistently higher in long-term acute care facilities than acute care hospitals. Heightened awareness of this problem is needed in all LAC healthcare facilities, as patients access services along the continuum of care.

The HOU investigated several interesting outbreaks in 2012, which included a Staphylococcal outbreak associated with neurosurgery, aspergillosis in a bone marrow transplant unit, and a Staphylococcal outbreak associated with cardiothoracic surgery (see special studies report).

The HOU continues to liaison with hospitals. To improve our communication with emergency departments (ED), the HOU created and distributed a public health directory with frequent contacts to all EDs (see 2012 Special Studies Report). The liaison public health nurses also collaborated with Emergency Preparedness and Response Program in community resilience efforts.

Ambulatory Care Settings

HAIs in ambulatory care settings (ACSs) continues to be a growing concern especially since more healthcare delivery is occurring in ACSs rather than acute care hospitals. ACSs are distinct entities, hospital-based or non-hospital-based, that operate exclusively on an outpatient basis for patients who do not require hospitalization with an expected stay of less than 24 hours.

In 2012, there was a multistate outbreak of post-procedural fungal endophthalmitis associated with two compounded medications labeled as sterile contaminated with two different environmental molds from a single out-of-state compounding pharmacy which affected at two LAC ACSs. This outbreak involved extensive multiagency collaboration to investigate, involving CDC, state and local health departments in 21 states and territories, the FDA, and Boards of Pharmacy in several states. There was an epidemiological investigation conducted of a situation of confirmed cases of a fungal agent following surgery at two separate surgical centers. In 2012, there was also an extensive follow-up with two separate ACSs that received recalled lots of a sterile product from an out-of-state compounding center implicated in a multistate outbreak of fungal meningitis and septic arthritis. Within both facilities, over 200 patients were potentially exposed to the contaminated product. After patient interviews, medical record reviews and investigation, no cases were identified in LAC.

In the investigations of the multistate outbreaks related to contaminated sterile products, it was discovered that clinics lack good record-keeping of inventory and need to maintain better tracking of lot numbers of medications administered to patients in order to quickly identify exposed patients in the event of an outbreak. Both of the multistate outbreaks confirm the need for more regulatory oversight of compounding pharmacies to help prevent future outbreaks.

Sub-acute Healthcare Facilities

The number of reported outbreaks in sub-acute healthcare facilities increased by 11% from 2011 (N=110) to 2012 (N=124). Gastroenteritis (GI) outbreaks were the most frequently reported outbreaks (67, 54%), 40 outbreaks were due to laboratory-confirmed norovirus infection. This increase in GI outbreaks was most likely due to the emergence of a new norovirus strain GII.4 Sydney, first identified in Australia in March 2012. Six GII.4 Sidney strain outbreaks were documented in skilled nursing facilities (SNFs) in LAC from October to December 2012. During the spring of 2012, a NOPP (Norovirus Outbreak Prevention Project) working group was convened to develop a “Norovirus Outbreak Prevention Toolkit” and to provide targeted norovirus outbreak prevention training to LAC Service Planning Area (SPA) 3 SNF administrators, nursing directors and line staff with the objective of decreasing the number and size of SNF-associated norovirus and other gastroenteritis outbreaks. In total, 165 SNF Directors of Nursing (DONs) and administrators and 2,264 line

staff, consisting of certified nursing assistants, licensed vocation nurses, and housekeeping staff completed the training. SNF-associated gastroenteritis outbreaks in the upcoming fall and winter of 2013-2014 will be followed closely. It is possible that decreases in outbreak reports and size of outbreaks will be apparent in the upcoming season.

Scabies was the second most frequently reported outbreak (24, 19%). Twelve respiratory outbreaks were reported in 2012, compared with six in 2011, and nineteen in 2009 when pandemic H1N1 influenza was first observed. Three of twelve respiratory outbreaks were due to the influenza virus with two outbreaks specifically to laboratory-confirmed influenza A subtype H3N2 and with the eight other respiratory outbreaks, the etiology of the outbreak was not determined. These influenza outbreaks involved at least 65 SNFs residents and 22 staff members. Several studies have documented diminished influenza vaccine efficacy in SNF residents and the elderly. Routine vaccination of all SNF residents and timely administration of post-exposure influenza antiviral prophylaxis to residents and staff in these and other residential settings involving the elderly is critical to preventing large influenza outbreaks, as is annual influenza vaccination of both direct and non-direct healthcare workers.

Automated Disease Surveillance

ACDC's automated disease surveillance in 2012 continued integration of early detection system activities into routine public health operations. Emergency department syndromic surveillance may provide early detection of bioterrorist-related activity or natural disease outbreaks. Syndromic surveillance can also track trends of known outbreaks as well as diseases and exposures of public health importance such as seasonal influenza, high temperatures, and air pollution.

Automated electronic reporting of communicable diseases from laboratories to DPH has been shown to yield more complete and rapid reporting of disease. Results are sent as soon as they are available rather than days later.

Syndromic surveillance proved capable of detecting patterns of illness and community outbreaks, complementing traditional disease surveillance activities; it is one of the tools used for influenza surveillance. In 2012, the near real-time syndromic surveillance system aided surveillance by monitoring heat related illness during the summer months, and acute respiratory illnesses during influenza season. Current hospital participation represents approximately 70% of all emergency department visits in the county. Nurse call line, coroner data, veterinary reports of zoonotic diseases, 911 calls, over-the-counter medication sales data, and emergency department ReddiNet, an emergency medical communications network, complement the early event detection system.

vCMR (Visual Confidential Morbidity Report) is a web-based electronic reporting system that manages the "life-cycle" of a disease incident investigation from the date of report to the final resolution. The system has been fully operational since May 2000. It features modules for disease incidents, outbreaks, foodborne illness reports, manual reporting via the Internet by hospital infection preventionists, and automated electronic laboratory reporting.

vCMR is aligned with CDC-sponsored initiatives such as the Public Health Information Network (PHIN) and National Electronic Disease Surveillance System (NEDSS). In January 2013, vCMR was successfully upgraded to a Reference Information Model (RIM) database structure. RIM is an Health Level 7 inspired database design that creates a single unified standard for storing patient data, exchanging medical information (laboratory results, etc.), and delivering a single unified view of a patient's entire medical profile. It continues being used by the following DPH programs: ACDC, Environmental Health Food and Milk, Immunization Program, Community Health Services' eight Service Planning Areas, Health Assessment and Epidemiology, Injury and Violence Prevention, STD and HIIV (electronic laboratory reports only for both).

ELR (Electronic Laboratory Reporting): Automated electronic reporting of communicable diseases from laboratories to DPH has been shown to yield more complete and rapid reporting of disease. Results are sent as soon as they are available rather than days later. LAC implemented ELR in 2002,

and has pursued efforts to recruit and implement additional laboratories, with data feeds from 25 laboratories in 2012.

Bioterrorism, Emergency Preparedness and Response Activities

The ACDC Bioterrorism Preparedness and Response Team continues active participation and association with the Consortium of Technical Responders (CTR), a multi-agency collaborative of agencies comprised of members from the Los Angeles Police Department, LAC Sheriff, DPH, Fire, Hazmat, United States Customs and Border Patrol, California Highway Patrol, Federal Bureau of Investigation (FBI), and United States Postal Inspectors. The goal of CTR is to unify the technical response community in incidents involving the use of chemical, biological and radiological agents.

Collaboration and partnership continues at the Joint Regional Intelligence Center (JRIC) with a public health nurse detailed to this fusion center, composed of public health, fire services, police, sheriff, and FBI departments working in partnership with other local, state, and federal programs to share and analyze information, disseminate intelligence, and assist with the coordination of resources for a unified response to a terrorism event. The PHN manages and directs the fusion center medical program. The public health section of the JRIC has been recognized as the national model for fusion centers throughout the United States. The Department of Homeland Security has sought LAC DPH to provide guidance to other fusion centers to replicate what has been established in Los Angeles by the PHN.

Continued emergency preparedness response activities ongoing, including DPH participation in a full-scale multi-agency bioterrorism response exercise on board on a military cargo vessel docked at a LAC Port, sponsored by the 9th Civil Support Team, California National Guard. For this exercise, the ACDC Training and Response Unit coordinated and guided a core team for response to a suspected bioterrorism threat in LAC and test capabilities to respond to ill victims in the field, use of PPE, epidemiological investigation, and coordinate response with other agencies/partners. The Unit also participated in the development of a disease (botulism) outbreak investigation exercise resulting in the activation of the DPH Department Operation Center (DOC) to test the integration of the epidemiological branch into the Planning Section of the Incident Command Structure within the DOC. This activity allowed for data sets to be gathered and findings to be developed into operational objectives in an efficient manner for appropriate intervention/response to the outbreak, as well as provide vital pieces of information from operational field elements to assist in determining the nature of the incident. Participation in these types of exercises provide opportunities to continue testing skills capabilities, improve workforce competence, and increase confidence in response to potential public health emergency events and incidents.

The Unit completed the 2012 Terrorism Agent Information and Treatment Guidelines for Clinicians and Hospitals (a.k.a. "Zebra Book"), which includes updates to the Anthrax, Botulism, Plague, Smallpox, Ricin, Glanders and Melioidosis, and Chemical Terrorism chapters. The Public Health Lab protocol for specimen collection for a chemical exposure is also included. The book contains two fold-out posters (11"x17") on Bioterrorism Syndromes and Evaluating Patients for Smallpox. For an online version of the Zebra Book see: http://www.publichealth.lacounty.gov/acd/Bioterrorism/TerrorismAgentInformation.pdf.



The Unit provides ongoing subject matter expertise consultation related to biological incidents to other public health programs, first responder agencies, hospitals and the community as needed. The team will respond in the field to quickly assess and evaluate situations reported as unusual or suspected or cases of Category A agents. In 2012, the unit responded to a suspicious rash (smallpox rule-out) notification by a local ED requiring collection of lesion samples for testing by the Public Health Laboratory as well as a

response to a report by an infectious disease specialist of a patient with recent travel history with a lesion suspicious for cutaneous anthrax.

Planning and Evaluation

The ACDC Planning and Evaluation Unit's activities and efforts are fundamentally based on the concept of syndemics—*two or more afflictions, interacting synergistically, contributing to excess burden of disease in a population*[3]—which is crucial to enhancing capacity to respond to communicable disease outbreaks and emerging infectious diseases, and to preparing for natural and man-made disasters. Building capacity and community resiliency with the networks of schools, healthcare professionals, and various public and private stakeholders will increase effectiveness and efficiency of public health prevention, preparedness, response, intervention, and mitigation efforts. The Unit continued to work with early childhood education providers for outreach and education on various communicable diseases and emerging infectious diseases. Further, the Unit strives to identify improvement needs and implement improvement activities of ACDC's work by using formal quality improvement processes and tools.

In 2012, the Unit evaluated the *fotonovela* intervention that began in 2009 with an interdisciplinary team—Reptile-Associated Salmonellosis (RAS) Working Group. The Working Group consisted of diverse public health professionals as well as community and academic agencies. A major partner was the early childhood education (ECE) providers because reptiles are common ECE classroom pets and also a common source of salmonellosis infection among children ages 0-5 years in low-income Latino families in SPAs 2 and 4 of LAC. The *fotonovela* intervention's goal was to raise awareness of risks of contracting salmonellosis from reptiles among ECE providers, parents, and children; and to influence a policy change in the ECE classrooms. A culturally-sensitive, bilingual (English/Spanish) *fotonovela* booklet was collaboratively developed to specifically target the population mostly affected in LAC. ECE providers were trained by the ACDC staff to maximize utilization of the *fotonovela* as an education tool for parents and children. There were nine major ECE provider sites (which each site consisted of smaller sub-sites) that have been reached with the project. Results showed that 5,590 copies of fotonovela disseminated, 143 ECE providers trained, and 4,721 families of children ages 0-5 years reached. Before this *fotonovela* education, only 67% of the ECE providers and merely 25% of the parents knew that reptiles could transmit salmonellosis; almost all (99%) of both ECE providers and parents think that the fotonovela was a good way to learn about the issue. Further, most of ECE providers (97%) and parents (96%) stated that they will not purchase pet turtles/reptiles. Many ECE providers also initiated policy changes and/or other activities that would reduce harm from reptiles. Of the eight ECE providers who were interviewed, four (50%) indicated that they had reptiles at their ECE site(s) prior to the intervention, however, they found more suitable homes after receiving the *fotonovela* education intervention. Other changes include adding *fotonovela* to their library, enacting policy not allowing reptiles or other pets in the classroom, giving parents homework to learn about the issue. (See 2012 Special Studies Report).

The Unit conducted a quality improvement (QI) project collaboratively with the ACDC's HOU to evaluate the ED Outreach. The HOU implemented an ED Outreach in order to enhance ED's awareness of local public health contacts by creating and distributing the *Frequently Called Directory for Communicable Diseases*—a single-page list of local public health references and telephone numbers. The goal of the QI project was to evaluate the effectiveness of the outreach by assessing whether the local EDs know to call their local public health agency (i.e., ACDC) in case public health emergencies or for urgent communicable disease situations. Methods included test calls to EDs and site visits and/or interviews with ED director (or supervisory staff). Results showed that 75 (57%) of the test call respondents answered "yes" to knowing who to call to report a

[3] CDC. Syndemics Prevention Network. Available at: http://www.cdc.gov/syndemics/definition.htm.

disease or to seek consultation. Based on the site visits and interviews, in-person in-service was the method of information dissemination most commonly used at participating EDs. For each encounter (via phone or in-person), ACDC staff answered questions raised by the ED staff, clarified roles of the local, state, and federal public health agencies, and provided additional information as requested. Improvement needs were identified for future outreach efforts to EDs and reaffirmed the importance for ACDC to establish and foster relationships with hospital infection preventionists who work closely with EDs and other hospital departments. (See 2012 Special Studies Report).

Acute Communicable Disease Control
STAFF AND CONTRIBUTORS

THIS PAGE IS INTENTIONALLY LEFT BLANK.

LOS ANGELES COUNTY
DEPARTMENT OF PUBLIC HEALTH
ACUTE COMMUNICABLE DISEASE CONTROL PROGRAM
2012*

Communicable Disease Control Programs, Director ..... Robert Kim-Farley, MD, MPH

Acute Communicable Disease Control Program, Chief ..... Laurene Mascola, MD, MPH

- Federal EIS Officer ..... Christina Mikosz, MD, MPH
- Epidemiology and Data Support Section, Chief Epidemiologist ..... Michael Tormey, MPH
- Disease Surveillance & Outbreak Investigation Section, Senior Physician .. David Dassey, MD, MPH
  - Hepatitis, Antibiotic Resistance, and Influenza (HARI) Unit, Physician Specialist ..... Elizabeth Bancroft, MD, SM
  - Hospital Outreach Unit, Physician Specialist ..... Dawn Terashita, MD, MPH
    - Hospital Outreach, Program Specialist ..... Sharon Sakamoto, RN, PHN, MSN/MPH
    - Hospital Outbreaks, Program Specialist ..... L'Tanya English, RN, PHN, MPH
  - Food and Water Safety Unit, Physician Specialist ..... Roshan Reporter, MD, MPH
  - Vectorborne Disease Unit, Physician Specialist……..Rachel Civen, MD, MPH
  - Water and Subacute Care Unit, Physician Specialist ..... Rachel Civen, MD, MPH
- Automated Disease Surveillance Section, Senior Physician, Acting ..... Bessie Hwang, MD, MPH
  - Real-Time Population Health/Syndromic Surveillance Unit, Physician Specialist ..... Bessie Hwang, MD, MPH
  - Electronic Disease Surveillance Unit, Senior Information Systems Analyst ..... Irene Culver
- Planning, Evaluation and Response Section ..... Moon Kim, MD, MPH
  - Planning and Evaluation Unit, Program Specialist ..... Y. Silvia Shin, RN, PHN, MSN/MPH
  - Training and Response Unit, Program Specialist ..... Clara Tyson, RN, PHN, MSN
- Policy and Prevention Section ..... Brit Oiulfstad, DVM, MPH

Immunization Program, Program Director ..... Michelle T. Parra, PhD

Immunization Program, Senior Physician ..... Alvin Nelson El Amin, MD, MPH

* Staff listed are their positions for the reporting year.

ACUTE COMMUNICABLE DISEASE CONTROL
2012 ANNUAL MORBIDITY REPORT

Disease Summaries Contributors

- Amebiasis……..Karen Kuguru, MPA
- Campylobacteriosis……Leticia Martinez, RN, PHN, MPA
- Coccidioidomycosis..... Merle Baron, BSN, RN, PHN
- Cryptosporidiosis..…… …… Karen Kuguru, MPA
- Encephalitis……..…….....Rachel Civen, MD, MPH
- *Escherichia coli* O157:H7…….... Leticia Martinez, RN, PHN, MPA
- Giardiasis……..Karen Kuguru, MPA
- *Haemophilus Influenzae*……Emmanuel Mendoza, MPH
- Hepatitis A…….....……...Susan Hathaway, RN, PHN, MPH
- Hepatitis B, Acute (Non-perinatal)…… …Susan Hathaway, RN, PHN, MPH
- Hepatits B, Perinatal……Kim Moore, RN, PHN, MSN, FNP
- Hepatitis C, Acute…… Susan Hathaway, RN, PHN, MPH
- Legionellosis ..... Juliet Bugante, RN, PHN
- Listeriosis, Nonperinatal……..Soodtida Tangpraphaphorn, MPH
- Listeriosis, Perinatal……..Soodtida Tangpraphaphorn, MPH
- Lyme Disease..…… .....Van Ngo, MPH
- Malaria…… .....Van Ngo, MPH
- Measles…….....Emmanuel Mendoza, MPH
- Meningitis, Viral……..Van Ngo, MPH
- Meningococcal Disease…….. .....Van Ngo, MPH
- Mumps……Emmanuel Mendoza, MPH
- Pertussis (Whooping Cough)…… Emmanuel Mendoza, MPH
- Pneumococcal Disease, Invasive……...Ramon Guevara, PhD, MPH
- Salmonellosis…….…… Rita Bagby, RN, PHN, MSN
- Shigellosis……Leticia Martinez, RN, PHN, MPA
- Staphylococcus aureus Infection, Severe…… ..……Susan Hathaway, RN, PHN, MPH
- Streptococcus, Group A Invasive Disease (IGAS)…… .....Christine Selzer, MPH
- Typhoid Fever, Acute and Carrier…….... Leticia Martinez, RN, PHN, MPA
- Typhus…… ..... ……Van Ngo, MPH
- Vibriosis…….... Soodtida Tangpraphaphorn, MPH
- West Nile Virus…….....……..Van Ngo, MPH

Disease Outbreak Summaries Contributors

- Community-Acquired Disease Outbreaks…… ..... Michael Tormey, MPH
- Foodborne Outbreaks…… ..... .Marifi Pulido, PhD
- Healthcare Associated Outbreaks, Acute Care ……L'Tanya English, RN, PHN, MPH
- Healthcare Associated Outbreaks, Subacute Care.....…… Karen Kuguru, MPA

Statistical Summaries Contributor.....Grace Run, MPH

Editing

- Y. Silvia Shin, RN, PHN, MSN/MPH, CNS

Formatting and Technical Assistance

- Johnathan Ngo

ACUTE COMMUNICABLE DISEASE CONTROL PROGRAM
PUBLICATIONS AND PRESENTATIONS
2012

Publications

Dassey DE, Terashita D, Sakamoto S. Infection Control: Public Health outreach to hospitals. Public Health: What Works. Edited by Fielding JE, Teutsch SM, 2012. Chapter 17, pp. 155-161.

Kwan JL, Park BK, Carpenter TE, Ngo V, Civen R, Reisen W. Comparison of enzoonotic risk measures predicting West Nile disease, Los Angeles, California, USA, 2004-2010. *Emerging Infectious Diseases*; 2012 August; 18 (8): 1298-1308.

Presentations and Abstracts

Civen R, Adeyemo M, Ngo V, Kim M, Tyson C, Chu S, Sturgeon J, Dassey D, Mascola L. Investigation of a meningococcal disease outbreak among homeless community in Los Angeles County. International Conference on Emerging Infectious Diseases, March 11-14, 2012, Atlanta, GA.

Civen R, Ngo v, Sturgeon J, Dassey D, Mascola L. Surveillance trends in invasive meningococcal disease (IMD), Los Angeles County, 1995-2009. ID Week 2012, Infectious Disease Society of America, San Diego, CA, October 2012.

Javan AC, Grein J, Marquez P, Censullo A, Morgan M, Terashita D, Murthy R. Carbapenem-resistant *Klebsiella pneumonia* in Los Angeles: A descriptive analysis of cases at one hospital. ID Week, Infectious Disease Society of America, San Diego, CA, October 2012. (poster)

Kajita E, Araki P, Luarca M, Hwang B. Monitoring the impact of heat waves with emergency service utilization data in Los Angeles County. 2012 International Society for Disease Surveillance Conference, San Diego, CA, December 2012. (poster)

Oyong K, Hindler J, Rosenberg J, Trivedi KK. Antibiotic susceptibility trends in California hospitals: Results from the California Antibiogram Project, 2008-2010. ID Week, Infectious Disease Society of America, San Diego, CA, October 2012. (poster)

Oyong K, Marquez P, Guevara R, Terashita D, Mascola L. Hospital-associated *Clostridium difficile* infections: First year results with National Healthcare Safety Network data, Los Angeles County, April 2010-March 2011. American Public Health Association Annual Meeting, San Francisco, CA, October 2012. (oral)

Terashita D. Healthcare-associated infections. California Association of Communicable Disease Controllers, Oakland, CA, November, 2012. (oral)

OVERVIEW

THIS PAGE IS INTENTIONALLY LEFT BLANK.

ACUTE COMMUNICABLE DISEASE CONTROL PROGRAM
ANNUAL MORBIDITY REPORT
OVERVIEW
2012

PURPOSE

The Acute Communicable Disease Control Program (ACDC) Annual Morbidity Report of the Los Angeles County (LAC) Department of Public Health (DPH) is compiled to:

1. summarize annual morbidity from several acute communicable diseases occurring in LAC;
2. identify patterns of disease as a means of directing future disease prevention efforts;
3. identify limitations of the data used for the above purposes and to identify means of improving that data; and
4. serve as a resource for medical, public health, and other healthcare authorities at county, state and national levels.

Note: The ACDC Annual Morbidity Report does not include information on tuberculosis, sexually transmitted diseases, or HIV and AIDS. Information regarding these diseases is available from their respective department programs (see LAC DPH website for more information at http://www.publichealth.lacounty.gov/index.htm).

LOS ANGELES COUNTY DEMOGRAPHIC DATA

LAC population estimates used for this report are created by the Population Estimates and Projections System (PEPS) provided to the LAC Public Health by Urban Research.[1] The LAC population is based on both estimates and projections that are adjusted when real relevant numbers become available (e.g., DMV records, voters' registry, school enrollment and immigration records, etc.).

National and California state counts of reportable diseases can be obtained from the Centers for Disease Control and Prevention (CDC) Final Summary of Nationally Notifiable Infectious Diseases on the CDC Morbidity and Mortality Weekly Report (MMWR) web page: http://www.cdc.gov/mmwr/mmwr_nd/index.html.

Cities of Long Beach and Pasadena are separate reporting jurisdictions, as recognized by the California Department of Public Health, and as such these two cities maintain their own disease reporting systems. Therefore, disease episodes occurring among residents of Long Beach and Pasadena have been excluded from LAC morbidity data, and their populations subtracted from LAC population data. Exceptions to this rule are noted in the text when they occur.

DATA SOURCES

Data on occurrence of communicable diseases in LAC were obtained through passive and sometimes active surveillance. Every healthcare provider or administrator of a health facility or clinic, and anyone in charge of a public or private school, kindergarten, boarding school, or preschool knowing of a **case or suspected case** of a communicable disease is required to report it to the local health department as specified by the California Code of Regulations (Section 2500). Immediate reporting by telephone is also required for any **outbreak** or **unusual incidence** of infectious disease and any **unusual disease** not listed in Section 2500. Laboratories have separate requirements for reporting certain communicable diseases (Section 2505). Healthcare providers must also give detailed instructions to household members in regard to precautionary measures to be taken for preventing the spread of disease (Section 2514).

[1] July 1, 2012 Population Estimates, prepared for County of Los Angeles, Internal Services Department, Social Services Systems Division, released 3/15/2013.

1. Passive surveillance relies on physicians, laboratories, and other healthcare providers to report diseases of their own accord to the DPH using the Confidential Morbidity Report (CMR) form, electronically, by telephone, or by facsimile.

2. Active surveillance entails ACDC staff regularly contacting hospitals, laboratories and other healthcare providers in an effort to identify all cases of a given disease.

DATA DESCRIPTION AND LIMITATIONS

Data in this report utilizes the following data descriptions, however, the report should be interpreted with caution of the notable limitations.

1. Underreporting
   The proportion of cases that are not reported varies for each disease. Evidence indicates that for some diseases as many as 98% of cases are not reported.

2. Reliability of Rates
   All vital statistics rates, including morbidity rates, are subject to random variation. This variation is inversely related to the number of events (observations, cases) used to calculate the rate. The smaller the frequency of occurrence of an event, the less stable its occurrence from observation to observation. As a consequence, diseases with only a few cases reported per year can have highly unstable rates. The observation and enumeration of these "rare events" is beset with uncertainty. The observation of zero events is especially hazardous.

   To account for these instabilities, all rates in the ACDC Annual Morbidity Report based on less than 19 events are considered "unreliable". This translates into a relative standard error of the rate of 23% or more, which is the cut-off for rate reliability used by the National Center for Health Statistics.

   In the Annual Morbidity Report, rates of disease for groups (e.g., Hispanic versus non-Hispanic) are said to differ significantly only when two criteria are met: 1) group rates are reliable and 2) the 95% confidence limits for these rates do not overlap. Confidence limits are calculated only those rates which are reliable.

3. Case Definitions
   To standardize surveillance, CDC/CSTE (Council of State and Territorial Epidemiologists) case definition for infectious diseases under public surveillance[2] is used with some exceptions as noted in the text of the individual diseases. Since verification by a laboratory test is required for the diagnosis of some diseases, cases reported without such verification may not be true cases. Therefore, an association between a communicable disease and a death or an outbreak possibly may not be identified.

4. Onset Date versus Report Date
   Slight differences in the number of cases and rates of disease for the year may be observed in subsequent annual reports. Any such disparities are likely to be small.

5. Population Estimates

   Estimates of the LAC population are subject to many errors. Furthermore, the population of LAC is in constant flux. Though not accounted for in census data, visitors and other non-residents may have an effect on disease occurrences.

[2] CDC. Case definitions for infectious conditions under public health surveillance. MMWR 1997; 46(RR10):1-55. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/00047449.htm

6. Place of Acquisition of Infections
   Some cases of diseases reported in LAC may have been acquired outside of the county. Therefore, some
   disease rates more accurately reflect the place of diagnosis than the location where an infection was acquired.

7. Health Districts and Service Planning Areas

   Since 1999, LAC is divided into eight "Service Planning Areas" (SPAs) for purposes of healthcare planning and provision of health services: SPA 1 Antelope Valley, SPA 2 San Fernando, SPA 3 San Gabriel, SPA 4 Metro, SPA 5 West, SPA 6 South, SPA 7 East, and SPA 8 South Bay. Each SPA is organized further into health districts (HDs) (see SPA map in this report). Due to variations in Community Health Services staffing, investigating District personnel can be different than the standard District of residence. Approximately 5% of County census tracts have been shifted in such a manner. For the purpose of this publication, case or outbreak location is consistently matched to the official District/SPA of record.

8. Race/Ethnicity Categories
   - **Asian** – person having origins in any of the original peoples of the Far East, Southeast Asia, the Indian subcontinent, or the Pacific Islands.
   - **Black** – person having origins in any of the black racial groups of Africa.
   - **Hispanic/Latino** – person of Mexican, Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin, regardless of race.
   - **White** – person having origins in any of the original peoples of Europe, North Africa, or the Middle East.

STANDARD REPORT FORMAT

1. Crude data
   - **Number of Cases**: For most diseases, this number reflects new cases of the disease with an onset in the year of the report. If the onset was unknown, the date of diagnosis was used.
   - **Annual Incidence Rates in LAC**: Number of new cases in the year of report divided by LAC census population (minus Long Beach and Pasadena) multiplied by 100,000.
   - **Annual Incidence Rates in the United States (US) and California**: Incidence rates for the US and California can be found in the CDC's Morbidity and Mortality Weekly Report (MMWR): Final Summary of Nationally Notifiable Infectious Diseases for the corresponding year. The MMWR records diseases by date of report rather than date of onset.
   - **Mean Age at Onset**: Average age of all cases.
   - **Median Age at Onset**: The age that represents the midpoint of the sequence of all case ages.
   - **Range of Ages at Onset**: Ages of the youngest and oldest cases in the year of the report. For cases under one year of age, less than one (<1) was used.

2. Description
   This includes the causative agent, mode of transmission, common symptoms, potential severe outcomes, susceptible groups, and/or vaccine-preventability; and other significant information (e.g., prevention and control methods) related to the disease.

3. Trends and Highlights
   This provides a synopsis or the highlights of disease activity in the year of the report. This section may highlight trends, seasonality, significance related age, sex, race/ethnicity, and/or location of the disease.

4. Table
   This is a main table for each disease chapter that includes numbers of reported cases, percentage, and rates per 100,000 by age group, race/ethnicity, and SPA of the reporting year and four years prior to the reporting year. Disease rates for <19 cases are omitted as the rates are unreliable

5. Figures

Figures include disease incidence rates of the Los Angeles County and/or California (CA) and/or US. Some diseases may not included CA or US rates as the jurisdiction does not maintain surveillance of that particular disease. For CA and US rates, refer to the Final Summary of Nationally Notifiable Infectious Diseases, United States on MMWR website http://www.cdc.gov/mmwr/mmwr_nd/index.html. In separate figures, incidence rates or percent cases are expressed by age group, race/ethnicity, SPA, and/or month of onset. Some disease chapters have other type of figures or tables depending on the significance of that particular disease (e.g., percent cases by serotype, vaccination rates). When stratified data are presented in figures and/or tables these following facts are to be considered.

- **Seasonality**: Number of cases that occurred during each month of the reporting year.
- **Age**: Annual rate of disease for individual age groups. Race-adjusted rates are presented for some diseases.
- **Sex**: Male-to-female rate ratio of cases.
- **Race/Ethnicity**: Annual rate of disease for the five major racial groups. Cases of unknown race are excluded; thus, race-specific rates may be underestimates. Age-adjusted rates are presented for some diseases.
- **Location**: Location presented most often is the health district or SPA of residence of cases. Note that "location" rarely refers to the site of disease acquisition. Age-adjusted rates by location are presented for some diseases.

Los Angeles County Demographic Data
2012

Table A. Los Angeles County* population by year, 2007–2012

Year	Population	% change
2007	9,689,462	
2008	9,728,653	0.4%
2009	9,767,825	0.4%
2010	9,811,210	0.4%
2011	9,259,218	-5.6%
2012	9,296,158	0.4%

* Does not include cities of Pasadena and Long Beach.

Table B. Los Angeles County* population by age group, 2012

Age (in years)	Population	%
<1	118,960	1.3%
1–4	475,134	5.1%
5–14	1,195,708	12.8%
15–34	2,766,893	29.8%
35–44	1,324,461	14.3%
45–54	1,286,529	13.8%
55-64	1,019,219	11.0%
65+	1,109,254	11.9%
Total	**9,296,158**	**100.0%**

* Does not include cities of Pasadena and Long Beach.

Table C. Los Angeles County* population by sex, 2012

Sex	Population	%
Male	4,586,835	49.3%
Female	4,709,323	50.7%
Total	**9,296,158**	**100.0%**

* Does not include cities of Pasadena and Long Beach.

Table D. Los Angeles County* population by race, 2012

Race	Population	%
Asian	1,321,113	14.2%
Black	774,147	8.3%
Latino	4,528,203	48.7%
White	2,654,839	28.6%
Other**	17,856	0.2%
Total	**9,296,158**	**100.0%**

* Does not include cities of Pasadena and Long Beach.
** Includes American Indian, Alaskan Native, Eskimo and Aleut.

Table E. Los Angeles County* population by health district and SPA, 2012**	
Health District	**Population**
SPA1	**387,512**
Antelope valley	387,512
SPA 2	**2,147,332**
East Valley	444,634
Glendale	337,231
San Fernando	499,947
West Valley	865,520
SPA 3	**1,617,105**
Alhambra	343,804
El Monte	434,581
Foothill	302,400
Pomona	536,320
SPA 4	**1,123,335**
Central	336,973
Hollywood Wilshire	481,917
Northeast	304,445
SPA 5	**638,878**
West	638,878
SPA 6	**1,017,508**
Compton	280,777
South	189,788
Southeast	171,012
Southwest	375,931
SPA 7	**1,298,211**
Bellflower	354,706
East Los Angeles	204,171
San Antonio	420,621
Whittier	318,713
SPA 8	**1,066,277**
Inglewood	410,329
Harbor	201,915
Torrance	454,033
Total	**9,296,158**

* Pasadena and Long Beach are separate health jurisdictions and as such are excluded from this table.


Los Angeles County
New Health District and Service Planning Area Boundaries
LEGEND
2002 Health Districts
2002 Service Planning Areas
SPA 1 - Antelope Valley
SPA 2 - San Fernando
SPA 3 - San Gabriel
SPA 4 - Metro
SPA 5 - West
SPA 6 - South
SPA 7 - East
SPA 8 - South Bay
Antelope Valley
SPA 1
San Fernando
SPA 2
East Valley
Foothill
SPA 3
West Valley
Glendale
Pasadena
NE
Hollywood/ Wilshire
SPA 4
Alhambra
West
SPA 5
Central
Pomona
El Monte
East LA
SW
SE
SPA 6
South
San Antonio
SPA 7
Whittier
Inglewood
Compton
Bellflower
Torrance
SPA 8
Long Beach
Harbor
N
5 0 5 10 Miles
Source: US Census Bureau, Redistricting Census 2000 TIGER/Line files
Prepared by Los Angeles County DHS, Public Health,
Office of Health Assessment and Epidemiology, September 2002

The following abbreviations and acronyms may be found throughout this report.

Table F. List of Acronyms

95%CI	95 percent confidence interval	**HCV**	Hepatitis C virus
ACDC	Acute Communicable Disease Control	**HD**	Health District
AIDS	Acquired Immunodeficiency Syndrome	**Hib**	*Haemophilus influenzae*, type b
ALT	Alanine aminotransferase	**HIV**	Human Immunodeficiency Virus
AR	Attack rate	**IFA**	Immunofluorescent Antibody
CA	California	**IgG**	Immunoglobulin G
CDC	Centers for Disease Control and Prevention	**IgM**	Immunoglobulin M
CDPH	California Department of Public Health	**LAC**	Los Angeles County
CHS	Community Health Services	**MMR**	Mumps-Measles-Rubella vaccine
CMR	Confidential morbidity report	**MMWR**	Morbidity and Mortality Weekly Report
CSF	Cerebral spinal fluid	**MSM**	Men who have sex with men
CSTE	Council of State and Territorial Epidemiologists	**N/A**	Not available
DPH	Department of Public Health	**OR**	Odds ratio
DTaP	Diphtheria-tetanus-acellular pertussis	**PCP**	*Pneumocystis carinii pneumonia*
DTP	Diphtheria-tetanus-pertussis vaccine	**PCR**	Polymerase Chain Reaction
EHS	Environmental Health Services	**PFGE**	Pulsed Field Gel Electrophoresis
EIA	Enzyme Immunoassay	**PHBPP**	Perinatal Hepatitis B Prevention Program
GI	Gastrointestinal	**RNA**	Ribonucleic Acid
GE	Gastroenteritis	**RR**	Rate ratio or relative risk
HAART	Highly Active Antiretroviral Therapy	**SNF**	Skilled nursing facility
HAV	Hepatitis A virus	**sp. or spp.**	Species
HBIG	Hepatitis B Immunoglobulin	**SPA**	Service Planning Area
HBsAg	Hepatitis B surface antigen	**US**	United States
HBV	Hepatitis B virus	**vCMR**	Visual confidential morbidity report (software)

LOS ANGELES COUNTY HEALTH DISTRICTS

AH	Alhambra	**FH**	Foothill	**SE**	Southeast
AV	Antelope Valley	**GL**	Glendale	**SF**	San Fernando
BF	Bellflower	**HB**	Harbor	**SO**	South
CE	Central	**HW**	Hollywood/Wilshire	**SW**	Southwest
CN	Compton	**IW**	Inglewood	**TO**	Torrance
EL	East Los Angeles	**NE**	Northeast	**WE**	West
EV	East Valley	**PO**	Pomona	**WV**	West Valley
EM	El Monte	**SA**	San Antonio	**WH**	Whittier

TABLES OF NOTIFIABLE DISEASES

THIS PAGE IS INTENTIONALLY LEFT BLANK.

Table G. Reported Cases of Selected Notifiable Diseases by Year of Onset
Los Angeles County, 2007-2012

Disease	Year of Onset						Previous 5-year Average	5-Yr 95% upper Limit[a]
	2007	2008	2009	2010	2011	2012		
Amebiasis	122	115	107	119	86	99	110	135
Botulism	1	5	1	1	3	4	2	5
Brucellosis	3	3	4	7	6	4	5	8
Campylobacteriosis[b]	825	1072	1135	1239	1259	1546	1106	1412
Cholera	0	0	0	0	0	0	0	0
Coccidioidomycosis[b]	145	228	171	235	304	327	217	325
Cryptosporidiosis	50	41	51	61	51	44	51	63
Cysticercosis	7	6	9	3	4	1	6	10
Dengue	3	0	2	1	0	2	1	3
E. *coli* O157:H7	12	16	17	12	21	19	16	22
E. *coli* Other Stec[b]	15	15	23	55	65	78	35	76
Encephalitis	65	89	51	51	59	75	63	90
Foodborne Outbreaks	21	18	16	17	22	21	19	23
Giardiasis	441	355	354	308	292	294	350	452
Haemophilus Influenzae Type B	1	0	2	0	0	0	1	2
Hansen's Disease (Leprosy)	5	1	3	2	2	3	3	5
Hepatitis A	78	80	66	51	45	47	64	92
Hepatitis B	55	66	41	54	60	38	55	71
Hepatitis C	3	5	8	4	10	7	6	11
Hepatitis Unspecified	10	4	19	5	4	0	8	20
Legionellosis	40	59	66	108	116	111	78	135
Listeriosis, Nonperinatal[b]	21	20	15	14	19	26	18	23
Listeriosis, Perinatal	6	2	5	4	6	7	5	8
Lyme Disease	8	9	4	5	6	1	6	10
Malaria	26	30	24	25	22	19	25	31
Measles	0	1	1	8	8	6	4	11
Meningitis, Viral	395	597	399	570	317	303	456	669
Meningococcal Infections	24	30	21	26	37	12	28	38
Mumps	5	7	7	20	3	13	8	20
Pertussis	69	80	156	972	453	154	346	1018
Pneumococcal Disease, Invasive	624	662	786	576	657	400	661	797
Psittacosis	0	0	1	0	0	0	0	1
Q-fever	2	2	0	1	0	3	1	3
Relapsing Fever	0	0	0	0	0	0	0	0
Rheumatic Fever, Acute	0	1	1	1	0	0	1	2
Rubella	0	1	0	0	1	0	0	1
Salmonellosis	1081	1638	1194	1142	900	1041	1191	1670
Shigellosis	463	498	259	355	264	306	368	561
Staphylococcus Aureus Infection	-	25	27	28	44	24	-	-
Streptococcus, Group A Invasive	173	156	129	191	175	168	165	206
Strongyloidiasis	0	0	0	0	0	0	0	0
Tetanus	0	2	0	0	0	0	0	2
Trichinosis	0	0	0	0	0	0	0	0
Tularemia	0	0	0	0	0	0	0	0
Typhoid Fever, Case	17	14	17	15	15	6	16	18
Typhoid Fever, Carrier	1	4	1	4	3	0	3	5
Typhus Fever[b]	17	18	9	31	38	50	23	43
Vibrio[b]	13	18	26	13	19	29	18	27
West Nile Virus	43	170	25	4	63	174	61	174

[a]The normal distribution assumption may not apply to some rare diseases.

[b]2012 data over 95% upper limit.

Table H. Annual Incidence Rates of Selected Notifiable Diseases by Year of Onset
Los Angeles County, 2007-2012

Disease	Annual Incidence Rate (Cases per 100,000)[b]					
	2007	2008	2009	2010	2011	2012
Amebiasis	1.26	1.18	1.10	1.21	0.93	1.06
Botulism	0.01	0.05	0.01	0.01	0.03	0.04
Brucellosis	0.03	0.03	0.04	0.07	0.06	0.04
Campylobacteriosis	8.51	11.02	11.62	12.63	13.60	16.63
Cholera	-	-	-	-	-	-
Coccidioidomycosis	1.50	2.34	1.75	2.40	3.28	3.52
Cryptosporidiosis	0.52	0.42	0.52	0.62	0.55	0.47
Cysticercosis	0.07	0.06	0.09	0.03	0.04	0.01
Dengue	0.03	-	0.02	0.01	-	0.02
E. *coli* O157:H7	0.12	0.16	0.17	0.12	0.23	0.20
E. *coli* Other Stec	0.15	0.15	0.24	0.56	0.70	0.84
Encephalitis	0.67	0.91	0.52	0.52	0.64	0.81
Giardiasis	4.55	3.65	3.62	3.14	3.15	3.16
Haemophilus Influenzae Type B	0.01	-	0.02	-	-	-
Hansen's Disease (Leprosy)	0.05	0.01	0.03	0.02	0.02	0.03
Hepatitis A	0.80	0.82	0.68	0.52	0.49	0.51
Hepatitis B	0.57	0.68	0.42	0.55	0.65	0.41
Hepatitis C	0.03	0.05	0.08	0.04	0.11	0.08
Hepatitis Unspecified	0.10	0.04	0.19	0.05	0.04	-
Legionellosis	0.41	0.61	0.68	1.10	1.25	1.19
Listeriosis, Nonperinatal	0.22	0.21	0.15	0.14	0.21	0.28
Listeriosis, Perinatal[a]	4.23	1.45	4.60	3.23	4.95	5.71
Lyme Disease	0.08	0.09	0.04	0.05	0.06	0.01
Malaria	0.27	0.31	0.25	0.25	0.24	0.20
Measles	-	0.01	0.01	0.08	0.09	0.06
Meningitis, Viral	4.08	6.14	4.08	5.81	3.42	3.26
Meningococcal Infections	0.25	0.31	0.21	0.27	0.40	0.13
Mumps	0.05	0.07	0.07	0.20	0.03	0.14
Pertussis	0.71	0.82	1.60	9.91	4.89	1.66
Pneumococcal Disease, Invasive	6.44	6.80	8.05	5.87	7.10	4.30
Psittacosis	-	-	0.01	-	-	-
Q-fever	0.02	0.02	-	0.01	-	0.03
Relapsing Fever	-	-	-	-	-	-
Rheumatic Fever, Acute	-	0.01	0.01	0.01	-	-
Rubella	-	0.01	-	-	0.01	-
Salmonellosis	11.16	16.84	12.22	11.64	9.72	11.2
Shigellosis	4.78	5.12	2.65	3.62	2.85	3.29
Staphylococcus Aureus Infection	-	0.26	0.28	0.29	0.48	0.26
Streptococcus, Group A Invasive	1.79	1.60	1.32	1.95	1.89	1.81
Strongyloidiasis	-	-	-	-	-	-
Tetanus	-	0.02	-	-	-	-
Trichinosis	-	-	-	-	-	-
Tularemia	-	-	-	-	-	-
Typhoid Fever, Case	0.18	0.14	0.17	0.15	0.16	0.06
Typhoid Fever, Carrier	0.01	0.04	0.01	0.04	0.03	-
Typhus Fever	0.18	0.19	0.09	0.32	0.41	0.54
Vibrio	0.13	0.19	0.27	0.13	0.21	0.31
West Nile Virus	0.44	1.75	0.26	0.04	0.68	1.87

[a] Rates for perinatal listeriosis were calculated as cases per 100,000 live births.

[b] Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table I. Five –Year Average of Notifiable Diseases by Month of Onset Los Angeles County, 2008-2012

Disease	Jan	Feb	Mar	Apr	May	June	July	Aug	Sept	Oct	Nov	Dec	Total
Amebiasis	8.6	7.8	11.4	6.4	7.8	9.0	8.6	8.2	7.2	9.0	7.8	9.2	105.2
Botulism	0.4	0.0	0.0	0.0	0.2	0.0	0.4	0.2	0.0	0.0	1.0	0.0	2.2
Brucellosis	0.6	0.2	0.2	1.2	0.4	0.0	0.0	0.4	0.0	0.0	0.0	0.2	4.8
Campylobacteriosis	56.0	36.0	46.8	54.0	62.6	75.6	83.6	81.8	72.0	66.8	64.4	47.0	1250.8
Cholera	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Coccidioidomycosis	22.2	20.4	17.6	15.6	19.8	24.0	21.4	21.0	20.2	22.4	23.6	23.6	253.0
Cryptosporidiosis	3.0	3.2	2.6	5.8	3.0	3.4	4.8	7.6	3.6	2.8	2.2	3.0	49.6
Cysticercosis	0.2	0.4	0.6	0.6	0.4	0.8	0.8	0.0	0.0	0.2	0.0	0.0	4.6
Dengue	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.4	0.0	0.2	1.0
E. *coli* O157:H7	1.0	0.4	0.8	0.8	1.2	2.4	3.4	2.4	1.6	2.0	0.2	0.6	17.2
E. *coli* Other Stec[a]	1.6	2.4	3.4	3.2	4.8	4.8	5.6	6.2	3.6	3.4	2.0	1.4	42.4
Encephalitis	3.0	2.8	4.6	1.2	2.2	3.0	4.4	8.8	14.0	6.6	4.0	2.2	65.0
Giardiasis	23.2	22.0	23.0	25.4	25.6	23.6	28.8	31.8	31.8	25.4	23.0	23.6	320.6
Haemophilus Influenzae Type B	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4
Hansen's Disease (Leprosy)[a]	-	-	-	-	-	-	-	-	-	-	-	-	-
Hepatitis A	4.8	5.2	3.6	4.6	4.8	5.0	4.4	6.2	7.0	4.4	4.8	3.0	57.8
Hepatitis B	5.0	4.4	5.2	3.8	5.4	5.0	4.0	4.4	4.2	4.2	4.0	2.2	51.8
Hepatitis C	0.4	0.2	0.6	0.4	0.2	1.2	0.2	0.8	0.6	1.6	0.4	0.2	6.8
Hepatitis Unspecified	0.4	0.2	0.2	0.0	0.2	0.4	0.2	0.0	0.0	0.0	0.0	0.2	6.4
Legionellosis	8.6	7.4	7.6	7.0	5.4	6.6	7.4	6.0	6.4	6.0	8.2	15.4	92.0
Listeriosis, Nonperinatal	0.8	1.0	1.0	0.6	2.2	1.8	1.4	3.2	2.6	1.8	1.2	1.0	18.8
Listeriosis, Perinatal	0.6	0.8	0.0	0.4	0.2	0.2	0.2	0.8	1.0	0.2	0.2	0.2	4.8
Lyme Disease	0.2	0.2	0.0	0.2	0.4	1.4	1.8	0.6	0.2	0.2	0.0	0.0	5.2
Malaria[a]	-	-	-	-	-	-	-	-	-	-	-	-	-
Measles	0.2	0.0	0.8	1.0	0.6	0.4	0.2	0.8	0.6	0.0	0.2	0.0	4.8
Meningitis, Viral	24.6	14.6	20.6	23.2	25.8	29.8	48.6	58.6	59.6	48.4	30.6	20.4	437.2
Meningococcal Infections	2.4	4.8	2.6	2.6	2.0	2.0	1.2	1.4	1.2	0.8	1.4	2.8	25.2
Mumps	0.4	1.0	1.0	1.4	1.2	1.0	1.0	0.8	0.2	0.4	0.4	1.2	10.0
Pertussis	23.8	18.4	21.0	19.4	22.6	31.8	51.2	49.0	39.4	33.0	30.0	23.4	363.0
Pneumococcal Disease, Invasive													
Psittacosis	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2
Q-fever	0.2	0.0	0.0	0.6	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.2
Relapsing Fever	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Rheumatic Fever, Acute	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6
Rubella	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4
Salmonellosis	59.4	55.6	58.2	67.8	103.8	97.0	122.6	126.6	109.2	204.8	82.0	69.0	1183.0
Shigellosis	16.8	15.2	14.2	16.8	34.0	23.4	35.8	48.6	45.2	32.4	26.0	18.8	336.4
Staphylococcus Aureus Infection	2.0	1.6	2.2	1.6	0.6	1.2	1.0	1.6	2.0	1.8	2.2	1.2	19.2
Streptococcus, Group A Invasive	18.0	15.4	19.6	15.0	12.8	14.0	9.0	10.2	9.2	9.8	11.8	14.4	159.2
Strongyloidiasis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tetanus	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.4
Trichinosis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tularemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Typhoid Fever, Case	1.0	1.6	0.4	2.6	1.4	1.2	0.6	1.4	0.8	0.6	1.2	0.6	13.4
Typhoid Fever, Carrier	0.2	0.2	0.2	0.2	0.8	0.0	0.2	0.0	0.0	0.2	0.0	0.2	2.4
Typhus Fever	2.2	0.6	0.6	0.4	2.0	1.4	3.0	3.8	4.6	3.8	4.4	2.4	29.2
Vibrio	0.6	0.2	0.6	1.2	0.8	1.4	3.0	4.6	3.8	2.0	1.2	0.6	21.0
West Nile Virus	0.0	0.0	0.0	0.0	0.2	1.2	8.4	25.8	36.6	13.4	1.6	0.0	87.2

[a] Not applicable.

Table J. Number of Cases of Selected Notifiable Diseases by Age Group
Los Angeles County, 2012

Disease	<1	1-4	5-14	15-34	35-44	45-54	55-64	65+	Total[a]
Amebiasis	0	1	5	33	24	18	9	9	99
Botulism	0	0	0	2	1	1	0	0	4
Brucellosis	0	0	0	1	0	1	0	2	4
Campylobacteriosis	46	136	181	418	169	186	163	238	1546
Cholera	0	0	0	0	0	0	0	0	0
Coccidioidomycosis	0	3	3	68	53	84	46	70	327
Cryptosporidiosis	0	2	4	13	8	8	4	4	44
Cysticercosis	0	0	0	1	0	0	0	0	1
Dengue	0	0	0	1	0	1	0	0	2
E. *coli* O157:H7	0	3	5	5	1	1	1	3	19
E. *coli* Other Stec	6	39	10	11	3	4	5	0	78
Encephalitis	1	3	8	6	0	9	12	36	75
Giardiasis	0	30	29	86	52	39	35	22	294
Haemophilus Influenzae Type B	0	0	0	0	0	0	0	0	0
Hansen's Disease (Leprosy)	0	0	0	1	2	0	0	0	3
Hepatitis A	0	0	3	24	9	3	5	3	47
Hepatitis B	0	0	0	10	13	10	3	2	38
Hepatitis C	0	0	0	4	1	2	0	0	7
Hepatitis Unspecified	0	0	0	0	0	0	0	0	0
Legionellosis	0	0	1	4	6	21	18	61	111
Listeriosis, Nonperinatal	0	0	1	1	0	8	1	15	26
Listeriosis, Perinatal[b]	0	0	0	4	3	0	0	0	7
Lyme Disease	0	0	0	0	0	0	0	1	1
Malaria	0	1	2	7	2	3	3	1	19
Measles	0	0	3	1	1	0	1	0	6
Meningitis, Viral	28	4	24	93	45	40	32	37	303
Meningococcal Infections	0	0	0	4	0	2	2	4	12
Mumps	0	3	1	2	2	1	2	2	13
Pertussis	30	22	53	23	8	6	6	6	154
Pneumococcal Disease, Invasive	9	20	11	27	29	62	74	168	400
Psittacosis	0	0	0	0	0	0	0	0	0
Q-fever	0	0	0	0	2	0	1	0	3
Relapsing Fever	0	0	0	0	0	0	0	0	0
Rheumatic Fever, Acute	0	0	0	0	0	0	0	0	0
Rubella	0	0	0	0	0	0	0	0	0
Salmonellosis	73	153	158	224	95	108	88	142	1041
Shigellosis	4	32	54	68	39	31	25	52	306
Staphylococcus Aureus Infection	1	0	1	3	2	3	5	9	24
Streptococcus, Group A Invasive	3	5	7	27	20	31	35	39	168
Strongyloidiasis	0	0	0	0	0	0	0	0	0
Tetanus	0	0	0	0	0	0	0	0	0
Trichinosis	0	0	0	0	0	0	0	0	0
Tularemia	0	0	0	0	0	0	0	0	0
Typhoid Fever, Case	0	0	1	3	1	1	0	0	6
Typhoid Fever, Carrier	0	0	0	0	0	0	0	0	0
Typhus Fever	0	0	6	11	13	10	4	6	50
Vibrio	0	0	3	7	4	7	4	4	29
West Nile Virus	0	0	2	24	17	33	34	64	174

[a] Totals include cases with unknown age.

[b] Mother's age.

Table K. Incidence Rates of Selected Notifiable Diseases by Age Group
Los Angeles County, 2012

Disease	Age-group Rates (Cases per 100,000)[b]							
	<1	1-4	5-14	15-34	35-44	45-54	55-64	65+
Amebiasis	0.0	0.2	0.4	1.2	1.8	1.4	0.9	0.8
Botulism	-	-	-	0.1	0.1	0.1	-	-
Brucellosis	-	-	-	-	-	0.1	-	0.2
Campylobacteriosis	38.7	28.6	15.1	15.1	12.8	14.5	16.0	21.5
Cholera	-	-	-	-	-	-	-	-
Coccidioidomycosis	-	0.6	0.3	2.5	4.0	6.5	4.5	6.3
Cryptosporidiosis	-	0.4	0.3	0.5	0.6	0.6	0.4	0.4
Cysticercosis	-	-	-	-	-	-	-	-
Dengue	-	-	-	-	-	0.1	-	-
E. *coli* O157:H7	-	0.6	0.4	0.2	0.1	0.1	0.1	0.3
E. *coli* Other Stec	5.0	8.2	0.8	0.4	0.2	0.3	0.5	-
Encephalitis	0.8	0.6	0.7	0.2	-	0.7	1.2	3.2
Giardiasis	-	6.3	2.4	3.1	3.9	3.0	3.4	2.0
Haemophilus Influenzae Type B	-	-	-	-	-	-	-	-
Hansen's Disease (Leprosy)	-	-	-	-	0.2	-	-	-
Hepatitis A	-	-	0.3	0.9	0.7	0.2	0.5	0.3
Hepatitis B	-	-	-	0.4	1.0	0.8	0.3	0.2
Hepatitis C	-	-	-	0.1	0.1	0.2	-	-
Hepatitis Unspecified	-	-	-	-	-	-	-	-
Legionellosis	-	-	0.1	0.1	0.5	1.6	1.8	5.5
Listeriosis, Nonperinatal	-	-	0.1	-	-	0.6	0.1	1.4
Listeriosis, Perinatal[a]	-	-	-	4.15	11.7	-	-	-
Lyme Disease	-	-	-	-	-	-	-	0.1
Malaria	-	0.2	0.2	0.3	0.2	0.2	0.3	0.1
Measles	-	-	0.3	-	0.1	-	0.1	-
Meningitis, Viral	23.5	0.8	2.0	3.4	3.4	3.1	3.1	3.3
Meningococcal Infections	-	-	-	0.1	-	0.2	0.2	0.4
Mumps	-	0.6	0.1	0.1	0.2	0.1	0.2	0.2
Pertussis	25.2	4.6	4.4	0.8	0.6	0.5	0.6	0.5
Pneumococcal Disease, Invasive	7.6	4.2	0.9	1.0	2.2	4.8	7.3	15.1
Psittacosis	-	-	-	-	-	-	-	-
Q-fever	-	-	-	-	0.2	-	0.1	-
Relapsing Fever	-	-	-	-	-	-	-	-
Rheumatic Fever, Acute	-	-	-	-	-	-	-	-
Rubella	-	-	-	-	-	-	-	-
Salmonellosis	61.4	32.2	13.2	8.1	7.2	8.4	8.6	12.8
Shigellosis	3.4	6.7	4.5	2.5	2.9	2.4	2.5	4.7
Staphylococcus Aureus Infection	0.8	-	0.1	0.1	0.2	0.2	0.5	0.8
Streptococcus, Group A Invasive	2.5	1.1	0.6	1.0	1.5	2.4	3.4	3.5
Strongyloidiasis	-	-	-	-	-	-	-	-
Tetanus	-	-	-	-	-	-	-	-
Trichinosis	-	-	-	-	-	-	-	-
Tularemia	-	-	-	-	-	-	-	-
Typhoid Fever, Case	-	-	0.1	0.1	0.1	0.1	-	-
Typhoid Fever, Carrier	-	-	-	-	-	-	-	-
Typhus Fever	-	-	0.5	0.4	1.0	0.8	0.4	0.5
Vibrio	-	-	0.3	0.3	0.3	0.5	0.4	0.4
West Nile Virus	-	-	0.2	0.9	1.3	2.6	3.3	5.8

[a]Rates for perinatal listeriosis were calculated as cases per 100,000 live births.

[b]Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table L. Number of Cases of Selected Notifiable Diseases by Race/Ethnicity
Los Angeles County, 2012

Disease	Asian	Black	Hispanic	White	Other[a]	Unknown
Amebiasis	6	4	39	33	0	16
Botulism	0	0	1	3	0	0
Brucellosis	0	0	4	0	0	0
Campylobacteriosis	37	34	161	228	11	1075
Cholera	0	0	0	0	0	0
Coccidioidomycosis	26	46	133	121	0	1
Cryptosporidiosis	1	1	9	19	0	14
Cysticercosis	0	0	1	0	0	0
Dengue	0	1	1	0	0	0
E. *coli* O157:H7	5	1	1	12	0	0
E. *coli* Other Stec	1	3	49	22	0	3
Encephalitis	8	3	23	31	5	5
Giardiasis	18	17	84	125	1	48
Haemophilus Influenzae Type B	0	0	0	0	0	0
Hansen's Disease (Leprosy)	1	0	2	0	0	0
Hepatitis A	8	0	20	14	0	4
Hepatitis B	1	5	13	14	0	5
Hepatitis C	0	1	3	2	1	0
Hepatitis Unspecified	0	0	0	0	0	0
Legionellosis	7	16	32	49	5	2
Listeriosis, Nonperinatal	5	1	8	11	0	1
Listeriosis, Perinatal[b]	1	0	2	4	0	0
Lyme Disease	0	0	0	1	0	0
Malaria	5	10	2	1	0	1
Measles	0	0	0	6	0	0
Meningitis, Viral	23	36	131	86	10	17
Meningococcal Infections	2	2	5	3	0	0
Mumps	2	0	1	10	0	0
Pertussis	8	10	71	54	1	10
Pneumococcal Disease, Invasive	33	69	153	141	2	2
Psittacosis	0	0	0	0	0	0
Q-fever	0	0	1	0	0	2
Relapsing Fever	0	0	0	0	0	0
Rheumatic Fever, Acute	0	0	0	0	0	0
Rubella	0	0	0	0	0	0
Salmonellosis	92	56	503	247	11	129
Shigellosis	2	29	153	104	0	18
Staphylococcus Aureus Infection	4	4	4	10	1	1
Streptococcus, Group A Invasive	8	24	58	44	2	32
Strongyloidiasis	0	0	0	0	0	0
Tetanus	0	0	0	0	0	0
Trichinosis	0	0	0	0	0	0
Tularemia	0	0	0	0	0	0
Typhoid Fever, Case	2	0	4	0	0	0
Typhoid Fever, Carrier	0	0	0	0	0	0
Typhus Fever	0	2	15	25	3	5
Vibrio	2	1	11	15	0	0
West Nile Virus	9	3	59	91	2	10

[a]Other includes Native American and any additional racial group that cannot be categorized as Asian, Black, Hispanic, and White.
[b]Mother's race.

Table M. Incidence Rates of Selected Notifiable Diseases by Race/Ethnicity
Los Angeles County, 2012

Disease	Race/Ethnicity Rates (Cases per 100,000)[b]			
	Asian	Black	Hispanic	White
Amebiasis	0.5	0.5	0.9	1.2
Botulism	-	-	-	0.1
Brucellosis	-	-	0.1	-
Campylobacteriosis	2.8	4.4	3.6	8.6
Cholera	-	-	-	-
Coccidioidomycosis	2.0	5.9	2.9	4.6
Cryptosporidiosis	0.1	0.1	0.2	0.7
Cysticercosis	-	-	-	-
Dengue	-	0.1	-	-
E. *coli* O157:H7	0.4	0.1	-	0.5
E. *coli* Other Stec	0.1	0.4	1.1	0.8
Encephalitis	0.6	0.4	0.5	1.2
Giardiasis	1.4	2.2	1.9	4.7
Haemophilus Influenzae Type B	-	-	-	-
Hansen's Disease (Leprosy)	0.1	-	-	-
Hepatitis A	0.6	-	0.4	0.5
Hepatitis B	0.1	0.6	0.3	0.5
Hepatitis C	-	0.1	0.1	0.1
Hepatitis Unspecified	-	-	-	-
Legionellosis	0.5	2.1	0.7	1.8
Listeriosis, Nonperinatal	0.4	0.1	0.2	0.4
Listeriosis, Perinatal[a]	5.4	-	2.8	18.6
Lyme Disease	-	-	-	-
Malaria	0.4	1.3	-	-
Measles	-	-	-	0.2
Meningitis, Viral	1.7	4.7	2.9	3.2
Meningococcal Infections	0.2	0.3	0.1	0.1
Mumps	0.2	-	-	0.4
Pertussis	0.6	1.3	1.6	2.0
Pneumococcal Disease, Invasive	2.5	8.9	3.4	5.3
Psittacosis	-	-	-	-
Q-fever	-	-	-	-
Relapsing Fever	-	-	-	-
Rheumatic Fever, Acute	-	-	-	-
Rubella	-	-	-	-
Salmonellosis	7.0	7.2	11.1	9.3
Shigellosis	0.2	3.7	3.4	3.9
Staphylococcus Aureus Infection	0.3	0.5	0.1	0.4
Streptococcus, Group A Invasive	0.6	3.1	1.3	1.7
Strongyloidiasis	-	-	-	-
Tetanus	-	-	-	-
Trichinosis	-	-	-	-
Tularemia	-	-	-	-
Typhoid Fever, Case	0.2	-	0.1	-
Typhoid Fever, Carrier	-	-	-	-
Typhus Fever	-	0.3	0.3	0.9
Vibrio	0.2	0.1	0.2	0.6
West Nile Virus	0.7	0.4	1.3	3.4

[a]Rates for perinatal listeriosis were calculated as cases per 100,000 live births.

[b]Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table N. Number of Cases and Annual Incidence Rate of Selected Notifiable Diseases by Sex Los Angeles County, 2012

Disease	Male		Female	
	Cases	Rate (Cases per 100,000)[b]	Cases	Rate (Cases per 100,000)[b]
Amebiasis	69	1.5	30	0.6
Botulism	3	0.1	1	0.0
Brucellosis	3	0.1	1	0.0
Campylobacteriosis	802	17.5	738	15.7
Cholera	0	-	0	-
Coccidioidomycosis	202	4.4	125	2.7
Cryptosporidiosis	24	0.5	20	0.4
Cysticercosis	0	-	1	0.0
Dengue	1	0.0	1	0.0
E. *coli* O157:H7	8	0.2	11	0.2
E. *coli* Other Stec	44	1.0	34	0.7
Encephalitis	49	1.1	26	0.6
Giardiasis	185	4.0	109	2.3
Haemophilus Influenzae Type B	0	-	0	-
Hansen's Disease (Leprosy)	2	0.0	1	0.0
Hepatitis A	27	0.6	20	0.4
Hepatitis B	27	0.6	11	0.2
Hepatitis C	5	0.1	2	0.0
Hepatitis Unspecified	0	-	0	-
Legionellosis	74	1.6	37	0.8
Listeriosis, Nonperinatal	15	0.3	11	0.2
Listeriosis, Perinatal[a]	0	-	7	11.7
Lyme Disease	1	0.0	0	-
Malaria	14	0.3	5	0.1
Measles	3	0.1	3	0.1
Meningitis, Viral	146	3.2	157	3.3
Meningococcal Infections	6	0.1	6	0.1
Mumps	6	0.1	7	0.1
Pertussis	62	1.4	92	2.0
Pneumococcal Disease, Invasive	240	5.2	160	3.4
Psittacosis	0	-	0	-
Q-fever	3	0.1	0	-
Relapsing Fever	0	-	0	-
Rheumatic Fever, Acute	0	-	0	-
Rubella	0	-	0	-
Salmonellosis	485	10.6	556	11.8
Shigellosis	178	3.9	128	2.7
Staphylococcus Aureus Infection	12	0.3	12	0.3
Streptococcus, Group A Invasive	96	2.1	71	1.5
Strongyloidiasis	0	-	0	-
Tetanus	0	-	0	-
Trichinosis	0	-	0	-
Tularemia	0	-	0	-
Typhoid Fever, Case	3	0.1	3	0.1
Typhoid Fever, Carrier	0	-	0	-
Typhus Fever	25	0.5	25	0.5
Vibrio	22	0.5	7	0.1
West Nile Virus	109	2.4	65	1.4

[a]Rates for perinatal listeriosis were calculated as cases per 100,000 live births.

[b]Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table O-1. Selected Notifiable Diseases
SPA 1. Antelope Valley Area
Los Angeles County, 2012

Disease	Frequency	Rate (Cases per 100,000)[b]
	Antelope	Antelope
Amebiasis	1	0.3
Botulism	0	-
Brucellosis	1	0.3
Campylobacteriosis	36	9.3
Cholera	0	-
Coccidioidomycosis	74	19.1
Cryptosporidiosis	5	1.3
Cysticercosis	0	-
Dengue	0	-
E. *coli* O157:H7	0	-
E. *coli* Other Stec	1	0.3
Encephalitis	6	1.5
Giardiasis	5	1.3
Haemophilus Influenzae Type B	0	-
Hansen's Disease (Leprosy)	0	-
Hepatitis A	2	0.5
Hepatitis B	2	0.5
Hepatitis C	2	0.5
Hepatitis Unspecified	0	-
Legionellosis	3	0.8
Listeriosis, Nonperinatal	1	0.3
Listeriosis, Perinatal[a]	0	-
Lyme Disease	0	-
Malaria	1	0.3
Measles	0	-
Meningitis, Viral	18	4.6
Meningococcal Infections	0	-
Mumps	0	-
Pertussis	7	1.8
Pneumococcal Disease, Invasive	10	2.6
Psittacosis	0	-
Q-fever	0	-
Relapsing Fever	0	-
Rheumatic Fever, Acute	0	-
Rubella	0	-
Salmonellosis	38	9.8
Shigellosis	3	0.8
Staphylococcus Aureus Infection	2	0.5
Streptococcus, Group A Invasive	0	-
Strongyloidiasis	0	-
Tetanus	0	-
Trichinosis	0	-
Tularemia	0	-
Typhoid Fever, Case	0	-
Typhoid Fever, Carrier	0	-
Typhus Fever	0	-
Vibrio	0	-
West Nile Virus	10	2.6

[a] Rates for perinatal listeriosis were calculated as cases per 100,000 women aged 15 to 44 years.

[b] Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table O-2. Selected Notifiable Diseases
SPA 2. San Fernando Area
Los Angeles County, 2012

	Frequency					Rate (Cases per 100,000)[b]				
Disease	**EV**	**GL**	**SF**	**WV**	**TOTAL**	**EV**	**GL**	**SF**	**WV**	**TOTAL**
Amebiasis	4	13	0	12	29	0.9	3.9	-	1.4	1.4
Botulism	0	0	0	0	0	-	-	-	-	-
Brucellosis	0	0	0	0	0	-	-	-	-	-
Campylobacteriosis	68	66	81	147	362	15.3	19.6	16.2	17.0	16.9
Cholera	0	0	0	0	0	-	-	-	-	-
Coccidioidomycosis	14	10	29	19	72	3.1	3.0	5.8	2.2	3.4
Cryptosporidiosis	1	2	6	3	12	0.2	0.6	1.2	0.3	0.6
Cysticercosis	0	0	0	0	0	-	-	-	-	-
Dengue	0	0	0	1	1	-	-	-	0.1	0.0
E. *coli* O157:H7	0	3	0	1	4	-	0.9	-	0.1	0.2
E. *coli* Other Stec	5	4	4	10	23	1.1	1.2	0.8	1.2	1.1
Encephalitis	7	8	1	6	22	1.6	2.4	0.2	0.7	1.0
Giardiasis	18	28	16	34	96	4.0	8.3	3.2	3.9	4.5
Haemophilus Influenzae Type B	0	0	0	0	0	-	-	-	-	-
Hansen's Disease (Leprosy)	0	0	0	0	0	-	-	-	-	-
Hepatitis A	2	2	7	6	17	0.4	0.6	1.4	0.7	0.8
Hepatitis B	0	2	0	3	5	-	0.6	-	0.3	0.2
Hepatitis C	1	0	0	0	1	0.2	-	-	-	0.0
Hepatitis Unspecified	0	0	0	0	0	-	-	-	-	-
Legionellosis	6	0	6	9	21	1.3	-	1.2	1.0	1.0
Listeriosis, Nonperinatal	2	2	1	4	9	0.4	0.6	0.2	0.5	0.4
Listeriosis, Perinatal[a]	2	0	0	0	2	1.0	-	-	-	0.2
Lyme Disease	1	0	0	0	1	0.2	-	-	-	0.0
Malaria	0	3	1	1	5	-	0.9	0.2	0.1	0.2
Measles	0	1	0	4	5	-	0.3	-	0.5	0.2
Meningitis, Viral	20	10	9	24	63	4.5	3.0	1.8	2.8	2.9
Meningococcal Infections	1	0	0	1	2	0.2	-	-	0.1	0.1
Mumps	1	1	2	0	4	0.2	0.3	0.4	-	0.2
Pertussis	7	13	8	15	43	1.6	3.9	1.6	1.7	2.0
Pneumococcal Disease, Invasive	18	25	16	35	94	4.0	7.4	3.2	4.0	4.4
Psittacosis	0	0	0	0	0	-	-	-	-	-
Q-fever	0	0	0	0	0	-	-	-	-	-
Relapsing Fever	0	0	0	0	0	-	-	-	-	-
Rheumatic Fever, Acute	0	0	0	0	0	-	-	-	-	-
Rubella	0	0	0	0	0	-	-	-	-	-
Salmonellosis	37	35	53	103	228	8.3	10.4	10.6	11.9	10.6
Shigellosis	8	3	15	26	52	1.8	0.9	3.0	3.0	2.4
Staphylococcus Aureus Infection	0	0	0	1	1	-	-	-	0.1	0.0
Streptococcus, Group A Invasive	5	5	8	14	32	1.1	1.5	1.6	1.6	1.5
Strongyloidiasis	0	0	0	0	0	-	-	-	-	-
Tetanus	0	0	0	0	0	-	-	-	-	-
Trichinosis	0	0	0	0	0	-	-	-	-	-
Tularemia	0	0	0	0	0	-	-	-	-	-
Typhoid Fever, Case	0	0	1	0	1	-	-	0.2	-	0.0
Typhoid Fever, Carrier	0	0	0	0	0	-	-	-	-	-
Typhus Fever	0	4	0	1	5	-	1.2	-	0.1	0.2
Vibrio	1	1	1	3	6	0.2	0.3	0.2	0.3	0.3
West Nile Virus	29	16	4	24	73	6.5	4.7	0.8	2.8	3.4

[a]Rates for perinatal listeriosis were calculated as cases per 100,000 women aged 15 to 44 years.

[b]Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table O-3. Selected Notifiable Diseases
SPA 3. San Gabriel Area
Los Angeles County, 2012

	Frequency					Rate (Cases per 100,000)[b]				
Disease	**AH**	**EM**	**FH**	**PO**	**TOTAL**	**AH**	**EM**	**FH**	**PO**	**TOTAL**
Amebiasis	0	2	0	2	4	-	0.5	-	0.4	0.2
Botulism	0	0	0	0	0	-	-	-	-	-
Brucellosis	0	0	0	0	0	-	-	-	-	-
Campylobacteriosis	33	36	49	82	200	9.6	8.3	16.2	15.3	12.4
Cholera	0	0	0	0	0	-	-	-	-	-
Coccidioidomycosis	4	9	3	9	25	1.2	2.1	1.0	1.7	1.5
Cryptosporidiosis	0	0	5	2	7	-	-	1.7	0.4	0.4
Cysticercosis	0	0	0	0	0	-	-	-	-	-
Dengue	0	0	0	0	0	-	-	-	-	-
E. *coli* O157:H7	0	0	0	1	1	-	-	-	0.2	0.1
E. *coli* Other Stec	0	1	2	8	11	-	0.2	0.7	1.5	0.7
Encephalitis	7	2	9	6	24	2.0	0.5	3.0	1.1	1.5
Giardiasis	8	5	5	9	27	2.3	1.2	1.7	1.7	1.7
Haemophilus Influenzae Type B	0	0	0	0	0	-	-	-	-	-
Hansen's Disease (Leprosy)	0	1	1	0	2	-	0.2	0.3	-	0.1
Hepatitis A	1	1	1	1	4	0.3	0.2	0.3	0.2	0.2
Hepatitis B	1	3	2	2	8	0.3	0.7	0.7	0.4	0.5
Hepatitis C	0	0	0	0	0	-	-	-	-	-
Hepatitis Unspecified	0	0	0	0	0	-	-	-	-	-
Legionellosis	2	7	4	4	17	0.6	1.6	1.3	0.7	1.1
Listeriosis, Nonperinatal	1	0	0	1	2	0.3	-	-	0.2	0.1
Listeriosis, Perinatal[a]	0	0	1	1	2	-	-	0.8	0.4	0.3
Lyme Disease	0	0	0	0	0	-	-	-	-	-
Malaria	0	0	0	0	0	-	-	-	-	-
Measles	0	0	0	0	0	-	-	-	-	-
Meningitis, Viral	14	12	21	21	68	4.1	2.8	6.9	3.9	4.2
Meningococcal Infections	0	0	0	0	0	-	-	-	-	-
Mumps	0	1	0	0	1	-	0.2	-	-	0.1
Pertussis	1	5	2	17	25	0.3	1.2	0.7	3.2	1.5
Pneumococcal Disease, Invasive	8	17	16	20	61	2.3	3.9	5.3	3.7	3.8
Psittacosis	0	0	0	0	0	-	-	-	-	-
Q-fever	0	1	0	1	2	-	0.2	-	0.2	0.1
Relapsing Fever	0	0	0	0	0	-	-	-	-	-
Rheumatic Fever, Acute	0	0	0	0	0	-	-	-	-	-
Rubella	0	0	0	0	0	-	-	-	-	-
Salmonellosis	26	52	31	55	164	7.6	12.0	10.3	10.3	10.1
Shigellosis	2	10	2	12	26	0.6	2.3	0.7	2.2	1.6
Staphylococcus Aureus Infection	4	1	1	2	8	1.2	0.2	0.3	0.4	0.5
Streptococcus, Group A Invasive	2	2	6	7	17	0.6	0.5	2.0	1.3	1.1
Strongyloidiasis	0	0	0	0	0	-	-	-	-	-
Tetanus	0	0	0	0	0	-	-	-	-	-
Trichinosis	0	0	0	0	0	-	-	-	-	-
Tularemia	0	0	0	0	0	-	-	-	-	-
Typhoid Fever, Case	0	1	0	0	1	-	0.2	-	-	0.1
Typhoid Fever, Carrier	0	0	0	0	0	-	-	-	-	-
Typhus Fever	4	3	8	3	18	1.2	0.7	2.6	0.6	1.1
Vibrio	0	2	0	1	3	-	0.5	-	0.2	0.2
West Nile Virus	14	7	17	9	47	4.1	1.6	5.6	1.7	2.9

[a]Rates for perinatal listeriosis were calculated as cases per 100,000 women aged 15 to 44 years.

[b]Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table O-4. Selected Notifiable Diseases
SPA 4. Metro Area
Los Angeles County, 2012

Disease	Frequency				Rate (Cases per 100,000)[b]			
	CE	HW	NE	TOTAL	CE	HW	NE	TOTAL
Amebiasis	6	18	1	25	1.8	3.7	0.3	2.2
Botulism	2	0	0	2	0.6	-	-	0.2
Brucellosis	1	1	0	2	0.3	0.2	-	0.2
Campylobacteriosis	70	121	43	234	20.8	25.1	14.1	20.8
Cholera	0	0	0	0	-	-	-	-
Coccidioidomycosis	16	25	12	53	4.7	5.2	3.9	4.7
Cryptosporidiosis	1	5	0	6	0.3	1.0	-	0.5
Cysticercosis	1	0	0	1	0.3	-	-	0.1
Dengue	0	0	0	0	-	-	-	-
E. *coli* O157:H7	2	1	0	3	0.6	0.2	-	0.3
E. *coli* Other Stec	3	4	3	10	0.9	0.8	1.0	0.9
Encephalitis	5	5	0	10	1.5	1.0	-	0.9
Giardiasis	16	34	7	57	4.7	7.1	2.3	5.1
Haemophilus Influenzae Type B	0	0	0	0	-	-	-	-
Hansen's Disease (Leprosy)	0	0	0	0	-	-	-	-
Hepatitis A	4	3	1	8	1.2	0.6	0.3	0.7
Hepatitis B	6	3	0	9	1.8	0.6	-	0.8
Hepatitis C	1	0	0	1	0.3	-	-	0.1
Hepatitis Unspecified	0	0	0	0	-	-	-	-
Legionellosis	5	7	1	13	1.5	1.5	0.3	1.2
Listeriosis, Nonperinatal	0	1	2	3	-	0.2	0.7	0.3
Listeriosis, Perinatal[a]	0	1	0	1	-	0.4	-	0.2
Lyme Disease	0	0	0	0	-	-	-	-
Malaria	1	0	0	1	0.3	-	-	0.1
Measles	0	1	0	1	-	0.2	-	0.1
Meningitis, Viral	4	8	4	16	1.2	1.7	1.3	1.4
Meningococcal Infections	4	1	0	5	1.2	0.2	-	0.4
Mumps	0	0	0	0	-	-	-	-
Pertussis	4	11	3	18	1.2	2.3	1.0	1.6
Pneumococcal Disease, Invasive	21	21	14	56	6.2	4.4	4.6	5.0
Psittacosis	0	0	0	0	-	-	-	-
Q-fever	0	0	0	0	-	-	-	-
Relapsing Fever	0	0	0	0	-	-	-	-
Rheumatic Fever, Acute	0	0	0	0	-	-	-	-
Rubella	0	0	0	0	-	-	-	-
Salmonellosis	50	54	58	162	14.8	11.2	19.1	14.4
Shigellosis	18	46	21	85	5.3	9.5	6.9	7.6
Staphylococcus Aureus Infection	0	2	0	2	-	0.4	-	0.2
Streptococcus, Group A Invasive	18	10	10	38	5.3	2.1	3.3	3.4
Strongyloidiasis	0	0	0	0	-	-	-	-
Tetanus	0	0	0	0	-	-	-	-
Trichinosis	0	0	0	0	-	-	-	-
Tularemia	0	0	0	0	-	-	-	-
Typhoid Fever, Case	0	1	1	2	-	0.2	0.3	0.2
Typhoid Fever, Carrier	0	0	0	0	-	-	-	-
Typhus Fever	7	2	4	13	2.1	0.4	1.3	1.2
Vibrio	0	4	0	4	-	0.8	-	0.4
West Nile Virus	5	11	2	18	1.5	2.3	0.7	1.6

[a]Rates for perinatal listeriosis were calculated as cases per 100,000 women aged 15 to 44 years.

[b]Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table O-5. Selected Notifiable Diseases
SPA 5. West Area
Los Angeles County, 2012

Disease	Frequency	Rate (Cases per 100,000)[b]
	West	West
Amebiasis	8	1.3
Botulism	0	-
Brucellosis	0	-
Campylobacteriosis	228	35.7
Cholera	0	-
Coccidioidomycosis	18	2.8
Cryptosporidiosis	6	0.9
Cysticercosis	0	-
Dengue	0	-
E. *coli* O157:H7	3	0.5
E. *coli* Other Stec	5	0.8
Encephalitis	2	0.3
Giardiasis	39	6.1
Haemophilus Influenzae Type B	0	-
Hansen's Disease (Leprosy)	0	-
Hepatitis A	4	0.6
Hepatitis B	3	0.5
Hepatitis C	1	0.2
Hepatitis Unspecified	0	-
Legionellosis	10	1.6
Listeriosis, Nonperinatal	5	0.8
Listeriosis, Perinatal[a]	0	-
Lyme Disease	0	-
Malaria	2	0.3
Measles	0	-
Meningitis, Viral	10	1.6
Meningococcal Infections	2	0.3
Mumps	5	0.8
Pertussis	22	3.4
Pneumococcal Disease, Invasive	23	3.6
Psittacosis	0	-
Q-fever	0	-
Relapsing Fever	0	-
Rheumatic Fever, Acute	0	-
Rubella	0	-
Salmonellosis	71	11.1
Shigellosis	48	7.5
Staphylococcus Aureus Infection	1	0.2
Streptococcus, Group A Invasive	10	1.6
Strongyloidiasis	0	-
Tetanus	0	-
Trichinosis	0	-
Tularemia	0	-
Typhoid Fever, Case	0	-
Typhoid Fever, Carrier	0	-
Typhus Fever	6	0.9
Vibrio	6	0.9
West Nile Virus	8	1.3

[a]Rates for perinatal listeriosis were calculated as cases per 100,000 women aged 15 to 44 years.

[b]Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table O-6. Selected Notifiable Diseases
SPA 6. South Area
Los Angeles County, 2012

	Frequency					Rate (Cases per 100,000)[b]				
Disease	**CN**	**SO**	**SE**	**SW**	**TOTAL**	**CN**	**SO**	**SE**	**SW**	**TOTAL**
Amebiasis	4	1	1	7	13	1.4	0.5	0.6	1.9	1.3
Botulism	0	0	0	0	0	-	-	-	-	-
Brucellosis	0	0	0	0	0	-	-	-	-	-
Campylobacteriosis	38	28	26	48	140	13.5	14.8	15.2	12.8	13.8
Cholera	0	0	0	0	0	-	-	-	-	-
Coccidioidomycosis	18	6	4	9	37	6.4	3.2	2.3	2.4	3.6
Cryptosporidiosis	0	0	0	1	1	-	-	-	0.3	0.1
Cysticercosis	0	0	0	0	0	-	-	-	-	-
Dengue	0	0	0	0	0	-	-	-	-	-
E. *coli* O157:H7	0	1	0	0	1	-	0.5	-	-	0.1
E. *coli* Other Stec	2	2	0	4	8	0.7	1.1	-	1.1	0.8
Encephalitis	0	0	1	3	4	-	-	0.6	0.8	0.4
Giardiasis	3	1	2	11	17	1.1	0.5	1.2	2.9	1.7
Haemophilus Influenzae Type B	0	0	0	0	0	-	-	-	-	-
Hansen's Disease (Leprosy)	0	0	0	0	0	-	-	-	-	-
Hepatitis A	0	0	0	0	0	-	-	-	-	-
Hepatitis B	0	1	0	1	2	-	0.5	-	0.3	0.2
Hepatitis C	0	1	0	0	1	-	0.5	-	-	0.1
Hepatitis Unspecified	0	0	0	0	0	-	-	-	-	-
Legionellosis	2	4	2	9	17	0.7	2.1	1.2	2.4	1.7
Listeriosis, Nonperinatal	0	0	2	1	3	-	-	1.2	0.3	0.3
Listeriosis, Perinatal[a]	0	0	0	0	0	-	-	-	-	-
Lyme Disease	0	0	0	0	0	-	-	-	-	-
Malaria	0	0	0	1	1	-	-	-	0.3	0.1
Measles	0	0	0	0	0	-	-	-	-	-
Meningitis, Viral	12	5	5	7	29	4.3	2.6	2.9	1.9	2.9
Meningococcal Infections	1	0	1	1	3	0.4	-	0.6	0.3	0.3
Mumps	0	0	0	0	0	-	-	-	-	-
Pertussis	3	2	3	2	10	1.1	1.1	1.8	0.5	1.0
Pneumococcal Disease, Invasive	12	13	6	30	61	4.3	6.8	3.5	8.0	6.0
Psittacosis	0	0	0	0	0	-	-	-	-	-
Q-fever	0	0	0	0	0	-	-	-	-	-
Relapsing Fever	0	0	0	0	0	-	-	-	-	-
Rheumatic Fever, Acute	0	0	0	0	0	-	-	-	-	-
Rubella	0	0	0	0	0	-	-	-	-	-
Salmonellosis	30	15	17	47	109	10.7	7.9	9.9	12.5	10.7
Shigellosis	2	14	8	13	37	0.7	7.4	4.7	3.5	3.6
Staphylococcus Aureus Infection	0	0	2	3	5	-	-	1.2	0.8	0.5
Streptococcus, Group A Invasive	3	7	8	6	24	1.1	3.7	4.7	1.6	2.4
Strongyloidiasis	0	0	0	0	0	-	-	-	-	-
Tetanus	0	0	0	0	0	-	-	-	-	-
Trichinosis	0	0	0	0	0	-	-	-	-	-
Tularemia	0	0	0	0	0	-	-	-	-	-
Typhoid Fever, Case	0	0	0	0	0	-	-	-	-	-
Typhoid Fever, Carrier	0	0	0	0	0	-	-	-	-	-
Typhus Fever	2	1	0	1	4	0.7	0.5	-	0.3	0.4
Vibrio	1	0	1	1	3	0.4	-	0.6	0.3	0.3
West Nile Virus	1	1	0	0	2	0.4	0.5	-	-	0.2

[a] Rates for perinatal listeriosis were calculated as cases per 100,000 women aged 15 to 44 years.

[b] Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table O-7. Selected Notifiable Diseases
SPA 7. East Area
Los Angeles County, 2012

Disease	Frequency					Rate (Cases per 100,000)[b]				
	BF	EL	SA	WH	TOTAL	BF	EL	SA	WH	TOTAL
Amebiasis	2	1	9	3	15	0.6	0.5	2.1	0.9	1.2
Botulism	0	0	1	0	1	-	-	0.2	-	0.1
Brucellosis	0	0	0	1	1	-	-	-	0.3	0.1
Campylobacteriosis	51	25	61	42	179	14.4	12.2	14.5	13.2	13.8
Cholera	0	0	0	0	0	-	-	-	-	-
Coccidioidomycosis	8	3	12	11	34	2.3	1.5	2.9	3.5	2.6
Cryptosporidiosis	1	0	0	0	1	0.3	-	-	-	0.1
Cysticercosis	0	0	0	0	0	-	-	-	-	-
Dengue	0	0	0	0	0	-	-	-	-	-
E. *coli* O157:H7	2	0	1	1	4	0.6	-	0.2	0.3	0.3
E. *coli* Other Stec	4	2	5	0	11	1.1	1.0	1.2	-	0.8
Encephalitis	0	0	2	3	5	-	-	0.5	0.9	0.4
Giardiasis	7	6	9	3	25	2.0	2.9	2.1	0.9	1.9
Haemophilus Influenzae Type B	0	0	0	0	0	-	-	-	-	-
Hansen's Disease (Leprosy)	0	0	0	0	0	-	-	-	-	-
Hepatitis A	1	1	4	1	7	0.3	0.5	1.0	0.3	0.5
Hepatitis B	1	0	2	3	6	0.3	-	0.5	0.9	0.5
Hepatitis C	0	0	0	0	0	-	-	-	-	-
Hepatitis Unspecified	0	0	0	0	0	-	-	-	-	-
Legionellosis	4	3	2	5	14	1.1	1.5	0.5	1.6	1.1
Listeriosis, Nonperinatal	0	0	0	0	0	-	-	-	-	-
Listeriosis, Perinatal[a]	0	0	0	1	1	-	-	-	0.7	0.2
Lyme Disease	0	0	0	0	0	-	-	-	-	-
Malaria	0	0	1	0	1	-	-	0.2	-	0.1
Measles	0	0	0	0	0	-	-	-	-	-
Meningitis, Viral	22	4	17	14	57	6.2	2.0	4.0	4.4	4.4
Meningococcal Infections	0	0	0	0	0	-	-	-	-	-
Mumps	1	0	0	0	1	0.3	-	-	-	0.1
Pertussis	0	7	3	6	16	-	3.4	0.7	1.9	1.2
Pneumococcal Disease, Invasive	9	5	13	9	36	2.5	2.4	3.1	2.8	2.8
Psittacosis	0	0	0	0	0	-	-	-	-	-
Q-fever	0	0	1	0	1	-	-	0.2	-	0.1
Relapsing Fever	0	0	0	0	0	-	-	-	-	-
Rheumatic Fever, Acute	0	0	0	0	0	-	-	-	-	-
Rubella	0	0	0	0	0	-	-	-	-	-
Salmonellosis	30	38	48	29	145	8.5	18.6	11.4	9.1	11.2
Shigellosis	7	10	10	6	33	2.0	4.9	2.4	1.9	2.5
Staphylococcus Aureus Infection	0	1	2	1	4	-	0.5	0.5	0.3	0.3
Streptococcus, Group A Invasive	2	2	9	4	17	0.6	1.0	2.1	1.3	1.3
Strongyloidiasis	0	0	0	0	0	-	-	-	-	-
Tetanus	0	0	0	0	0	-	-	-	-	-
Trichinosis	0	0	0	0	0	-	-	-	-	-
Tularemia	0	0	0	0	0	-	-	-	-	-
Typhoid Fever, Case	0	1	0	0	1	-	0.5	-	-	0.1
Typhoid Fever, Carrier	0	0	0	0	0	-	-	-	-	-
Typhus Fever	2	0	1	0	3	0.6	-	0.2	-	0.2
Vibrio	0	1	2	0	3	-	0.5	0.5	-	0.2
West Nile Virus	5	1	2	5	13	1.4	0.5	0.5	1.6	1.0

[a] Rates for perinatal listeriosis were calculated as cases per 100,000 women aged 15 to 44 years.

[b] Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especially hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

Table O-8. Selected Notifiable Diseases
SPA 8. South Bay Area
Los Angeles County, 2012

	Frequency				Rate (Cases per 100,000)[b]			
Disease	**HB**	**IW**	**TO**	**TOTAL**	**HB**	**IW**	**TO**	**TOTAL**
Amebiasis	0	3	1	4	-	0.7	0.2	0.4
Botulism	0	0	1	1	-	-	0.2	0.1
Brucellosis	0	0	0	0	-	-	-	-
Campylobacteriosis	29	51	77	157	14.4	12.4	17.0	14.7
Cholera	0	0	0	0	-	-	-	-
Coccidioidomycosis	4	3	7	14	2.0	0.7	1.5	1.3
Cryptosporidiosis	0	1	2	3	-	0.2	0.4	0.3
Cysticercosis	0	0	0	0	-	-	-	-
Dengue	0	1	0	1	-	0.2	-	0.1
E. *coli* O157:H7	2	0	1	3	1.0	-	0.2	0.3
E. *coli* Other Stec	3	3	3	9	1.5	0.7	0.7	0.8
Encephalitis	0	0	2	2	-	-	0.4	0.2
Giardiasis	5	11	12	28	2.5	2.7	2.6	2.6
Haemophilus Influenzae Type B	0	0	0	0	-	-	-	-
Hansen's Disease (Leprosy)	0	1	0	1	-	0.2	-	0.1
Hepatitis A	0	0	5	5	-	-	1.1	0.5
Hepatitis B	0	2	1	3	-	0.5	0.2	0.3
Hepatitis C	0	1	0	1	-	0.2	-	0.1
Hepatitis Unspecified	0	0	0	0	-	-	-	-
Legionellosis	3	3	8	14	1.5	0.7	1.8	1.3
Listeriosis, Nonperinatal	1	0	2	3	0.5	-	0.4	0.3
Listeriosis, Perinatal[a]	0	0	1	1	-	-	0.6	0.2
Lyme Disease	0	0	0	0	-	-	-	-
Malaria	3	3	2	8	1.5	0.7	0.4	0.8
Measles	0	0	0	0	-	-	-	-
Meningitis, Viral	6	15	15	36	3.0	3.7	3.3	3.4
Meningococcal Infections	0	0	0	0	-	-	-	-
Mumps	0	0	2	2	-	-	0.4	0.2
Pertussis	0	10	3	13	-	2.4	0.7	1.2
Pneumococcal Disease, Invasive	7	24	17	48	3.5	5.8	3.7	4.5
Psittacosis	0	0	0	0	-	-	-	-
Q-fever	0	0	0	0	-	-	-	-
Relapsing Fever	0	0	0	0	-	-	-	-
Rheumatic Fever, Acute	0	0	0	0	-	-	-	-
Rubella	0	0	0	0	-	-	-	-
Salmonellosis	38	35	50	123	18.8	8.5	11.0	11.5
Shigellosis	4	12	6	22	2.0	2.9	1.3	2.1
Staphylococcus Aureus Infection	0	0	0	0	-	-	-	-
Streptococcus, Group A Invasive	6	9	6	21	3.0	2.2	1.3	2.0
Strongyloidiasis	0	0	0	0	-	-	-	-
Tetanus	0	0	0	0	-	-	-	-
Trichinosis	0	0	0	0	-	-	-	-
Tularemia	0	0	0	0	-	-	-	-
Typhoid Fever, Case	0	1	0	1	-	0.2	-	0.1
Typhoid Fever, Carrier	0	0	0	0	-	-	-	-
Typhus Fever	1	0	0	1	0.5	-	-	0.1
Vibrio	1	0	3	4	0.5	-	0.7	0.4
West Nile Virus	1	1	1	3	0.5	0.2	0.2	0.3

[a]Rates for perinatal listeriosis were calculated as cases per 100,000 women aged 15 to 44 years.

[b]Rates of disease based on less than 19 cases or events are considered "unreliable." A zero rate made from no events is especiallly hazardous and are not reported here, except with a dash ("-"). Conclusions drawn from unreliable rates should be made with caution, if they are to be made at all.

DISEASE SUMMARIES

THIS PAGE IS INTENTIONALLY LEFT BLANK.

AMEBIASIS

CRUDE DATA	
Number of Cases	99
Annual Incidence[a]	
LA County	1.06
California[b]	--
United States	N/A
Age at Diagnosis	
Mean	40
Median	39
Range	4 - 96

[a]Cases per 100,000 population.

DESCRIPTION

Amebiasis is caused by the protozoan parasite *Entamoeba histolytica*. Cysts shed in human feces may contaminate food or drinking water or be transferred sexually, on hands, or fomites. Incubation period is 1 to 4 weeks. Recreational waters, such as pools, may also serve as transmission vehicles, since cysts are relatively chlorine-resistant. While intestinal disease is often asymptomatic, symptoms may range from acute abdominal pain, fever, chills, and bloody diarrhea to mild abdominal discomfort with diarrhea alternating with constipation. Extraintestinal infection occurs when organisms become bloodborne, leading to amebic abscesses in the liver, lungs or brain. Complications include colonic perforation. There is no vaccine.

Visual inspection of stool for ova and parasites in the microbiology laboratory cannot differentiate between pathogenic *E. histolytica* and non-pathogenic *E. dispar*. Many clinicians only obtain ova and parasite testing without pursuing more specific EIA stool antigen testing which can differentiate between *E. histolytic* and *E. dispar*. Many case reports lack complete testing with stool antigens, thus many infections may represent infection with the non-pathogenic *E. dispar*, thus leading to an overestimation of E. histolytic infection.

Proper hand hygiene before meals and after using the restroom is a major way to prevent infection and transmission of amebiasis. Persons who care for diapered/incontinent children and adults should ensure that they properly wash their hands.

Individuals with diarrheal illness should avoid swimming in recreational waters for at least two weeks after symptoms have ceased.

2012 TRENDS AND HIGHLIGHTS

- From 2011 to 2012, the overall incidence rate of amebiasis increased slightly from 0.93 to 1.06 cases per 100,000 population.
- The largest proportion of cases was in the 15 to 34 year age group (33, 33%), consistent with previous years (Figure 2).
- Consistent with prior years, a greater proportion of cases were reported in Hispanics (39, 39%) compared to whites (33, 33%).
- Service Planning Area (SPA) 2 had the largest proportion of reported amebiasis cases (29, 29%) compared to other SPAs in 2012. SPA 4 had the second largest proportion of cases (25, 25%) and highest incidence rate of amebiasis (2.2 cases per 100,000) (Figure 4).
- The number of cases reported in 2012 peaked in March and July with fourteen and thirteen cases, respectively, in comparison to the previous five-year average cases peaked in March and October (Figure 5).
- Males comprised the majority of reported cases which is consistent with previous years. In 2012, the incidence rates were 1.5 per 100,000 for males and 0.6 per 100,000 for females compared to 1.1 per 100,000 for males and 0.7 per 100,000 for females in 2011.
- Risk factor information was available for 98% of the cases reported in 2012. The most frequently reported risk factor was immigration to the US (31, 31%). Of those, immigrants from Iraq (13, 42%) and Mexico (10, 32%) were the most frequently reported countries of origin. Twenty-two cases were reported to have travelled to another country. Mexico was the most frequently travelled destination (7, 32%).

Reported Amebiasis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2007-2012

	2008 (N=115)			2009 (N=107)			2010 (N=119)			2011 (N=86)			2012 (N=99)		
	No.	(%)	Rate/	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	0.0	0	0	0.0	0	0	0.0	1	1.1	0.7	0	0	0.0
1-4	1	0.9	0.2	1	0.9	0.2	5	4.2	0.9	1	1.1	0.2	1	1.0	0.2
5-14	8	7.0	0.6	6	5.6	0.4	8	6.7	0.6	4	4.7	0.3	5	5.1	0.4
15-34	37	32.2	1.3	33	30.	1.2	38	31.	1.3	26	30.	0.9	33	33.3	1.2
35-44	26	22.6	1.7	23	21.	1.5	25	21	1.7	17	19.	1.2	24	24.2	1.8
45-54	22	19.1	1.6	22	20.	1.6	25	21	1.8	15	17.	1.1	18	18.2	1.4
55-64	12	10.4	1.3	14	13.	1.5	11	9.2	1.1	9	10.	0.9	9	9.1	0.9
65+	9	7.8	0.9	8	7.5	0.8	7	5.9	0.7	13	15.	1.2	9	9.1	0.8
Race/ Ethnicity															
Asian	8	6.6	0.6	7	6.1	0.5	2	1.9	0.2	1	1.1	0.1	6	6.1	0.5
Black	10	8.2	1.2	3	2.6	0.4	0	0.0	0.0	7	8.1	0.8	4	4.0	0.5
Hispanic	44	36.1	1.0	36	31.	0.8	37	34.	0.8	40	46.	0.8	39	39.4	0.9
White	50	41.0	1.7	56	48.	1.9	43	40.	1.5	27	31.	0.9	33	33.3	1.2
Other	8	6.6	38.4	4	3.5	16.	1	0.9		2	2.3		0	0.0	
Unknown	2	1.6		9	7.8		24	22.		9	10.		17	17.2	
SPA															
1	6	4.9	1.7	1	0.9	0.3	2	1.9	0.5	0	0.0		1	1.0	0.3
2	51	41.8	2.4	52	45.	2.4	49	45.	2.2	25	29.	1.1	29	29.3	1.4
3	14	11.5	0.8	14	12.	0.8	9	8.4	0.5	7	8.1	0.4	4	4.0	0.2
4	16	13.1	1.3	17	14.	1.3	18	16.	1.4	20	23.	1.6	25	25.3	2.2
5	9	7.4	1.4	6	5.2	0.9	8	7.5	1.2	6	7.0	0.9	8	8.1	1.3
6	8	6.6	0.8	11	9.6	1.0	4	3.7	0.4	13	15.	1.2	13	13.1	1.3
7	11	9.0	0.8	7	6.1	0.5	12	11.	0.9		11.	0.7	15	15.2	1.2
8	6	4.9	0.5	7	6.1	0.6	3	2.8	0.3	4	4.7	0.4	4	4.0	0.4
Unknown	1	0.8		0	0.0		0	0.0		1	1.2	-	0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Incidence Rates of Amebiasis
CA and LAC, 2002 - 2012



Figure 2. Proportion of Amebiasis Cases by Age Group
LAC, 2012, N=99



Figure 3. Percent Cases of Amebiasis by Race/Ethnicity
LAC, 2012, N=99



Figure 4. Incidence Rates of Amebiasis by SPA
LAC, 2012



* Other includes Native American and any additional racial/ethnic group that cannot be categorized as Asian, black, Hispanic, and white.

Figure 5. Reported Amebiasis Cases by Month of Onset
LAC, 2012, N=99



Figure 6. Amebiasis Incidence by Race/Ethnicity
LAC, 2006 - 2012, N=99



Map 1. Amebiasis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

CAMPYLOBACTERIOSIS

CRUDE DATA	
Number of Cases	1546
Annual Incidence[a]	
LA County	16.6
California[b]	N/A
United States[b]	N/A
Age at Diagnosis	
Mean	36.44
Median	34
Range	0-98

[a]Cases per 100,000 population.
[b]Not nationally notifiable.

DESCRIPTION

Campylobacteriosis is a bacterial disease caused by several species of Gram-negative bacilli including *Campylobacter jejuni, C. upsaliensis, C. coli* and *C. fetus*. It is transmitted through ingestion of organisms in undercooked poultry or other meat, contaminated food, water or raw milk, or contact with infected animals. The incubation period is two to five days. Common symptoms include watery or bloody diarrhea, fever, abdominal cramps, myalgia, and nausea. Sequelae include Guillain-Barré syndrome and Reiter syndrome, both of which are rare.

To reduce the likelihood of contracting campylobacteriosis, all food derived from animal sources should be thoroughly cooked, particularly poultry. Cross contamination may be avoided by making sure utensils, counter tops, cutting boards and sponges are cleaned or do not come in contact with raw poultry or meat or their juices. Hands should be thoroughly washed before, during and after food preparation. The fluids from raw poultry or meat should not be allowed to drip on other foods in the refrigerator or in the shopping cart. It is especially important to wash hands and avoid cross contamination of infant foods, bottles and eating utensils. It is recommended to consume only pasteurized milk, milk products or juices. In addition, it is important to wash hands after coming in contact with any animal or its environment.

2012 TRENDS AND HIGHLIGHTS

- There was a 22.7% increase in the incidence of campylobacteriosis from the previous year and a 44.2% increase in cases since 2008 (Figure 1).
- The highest rates were among children aged <1 (38.7 per 100,000) followed by persons aged 1 to 4 years (28.6 per 100,000) (Figure 2). The largest increase in incidence rates was among persons aged ›65 years since 2008 (Table).
- Service Planning Area (SPA) 5 had the highest rate (35.7 per 100,000) which is consistent with previous years (Figure 3).
- No outbreaks of campylobacteriosis were detected in 2012.
- Routine interviewing of campylobacteriosis cases was discontinued in 2010; however, surveillance continues to assess for clusters and foodborne illness reports.
- Most diagnosis is now made by antigen-based tests that may not be reliable compared with culture.

Reported Campylobacteriosis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=1072)			2009 (N=1135)			2010 (N=1139)			2011 (N=1259)			2012 (N=1546)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	42	3.9	30.1	30	2.6	21.9	24	1.9	17.2	16	1.2	11.5	46	2.9	38.7
1-4	137	12.8	24.2	138	12.1	24.6	150	12.1	25.8	158	12.5	27.2	136	8.7	28.6
5-14	152	14.2	10.8	146	12.8	10.7	175	14.1	13.2	146	11.5	11.0	181	11.7	15.1
15-34	285	26.6	9.9	316	27.8	11.2	318	25.6	10.8	366	29.0	12.4	418	27.0	15.1
35-44	129	12.0	8.5	119	10.4	8.0	157	12.6	10.9	133	10.5	9.2	169	10.9	12.8
45-54	127	11.8	9.4	137	12.0	10.0	136	10.9	10.1	142	11.2	10.5	186	12.3	14.5
55-64	90	8.4	9.9	100	8.8	10.5	96	7.7	10.0	114	9.0	11.9	163	10.5	16.0
65+	110	10.3	10.8	143	12.6	13.5	165	13.3	15.6	172	13.6	16.2	238	19.1	21.5
Unknown	0	0.0		6	0.5	0	0	0	0	12	0.9	0	9	0.6	0
Race/Ethnicity															
Asian	100	9.3	7.7	42	3.7	3.2	35	2.8	2.6	28	2.2	2.1	37	2.3	2.8
Black	31	2.9	3.6	15	1.32	1.8	13	1.0	1.5	21	1.6	2.5	34	2.1	4.4
Hispanic	542	50.6	11.6	156	13.7	3.3	182	14.6	3.8	157	12.4	3.3	161	10.4	3.6
White	373	34.8	12.8	81	7.1	2.8	118	9.5	4.1	119	9.4	4.2	228	14.7	8.6
Other	0	0.0	0	9	0.7	0	13	1.0	0	14	1.1	0	11	0.7	0
Unknown	26	2.4	0	832	73.0	0	878	70.8	0	920	73.0	0	1075	69.5	0
SPA															
1	27	2.5	7.4	32	2.8	8.7	39	3.1	10.5	46	3.6	12.3	36	2.3	9.3
2	271	25.3	12.4	292	25.7	13.2	346	2.7	15.6	347	27.5	15.7	362	23.4	16.9
3	154	14.4	8.9	157	13.8	9.1	166	13.3	9.6	164	13.0	9.5	200	12.9	12.4
4	99	9.2	7.8	158	13.9	12.7	158	1.2	12.6	156	12.3	12.4	234	15.1	20.8
5	155	14.5	24.0	151	13.3	23.2	130	10.4	19.7	142	11.2	21.5	228	14.7	35.7
6	122	11.4	11.6	114	10.0	10.8	122	9.8	11.4	123	9.7	11.5	140	9.0	13.8
7	127	11.8	9.2	104	8.8	9.1	145	11.7	10.5	136	10.8	9.9	179	11.5	13.8
8	117	10.9	10.4	114	10.0	10.8	127	10.2	11.3	145	11.5	12.9	157	10	14.7
Unknown	0	0.0		13	1.1	0	0	0	0	0	0	0	10		0

*Rates calculated based on less than 19 cases or events are considered unreliable. Data provided in section race/ethnicity is incomplete.

**Figure 1. Reported Campylobacteriosis Rates by Year
LAC, 2001-2012**



**Figure 2. Reported Campylobacteriosis Rates by Age Group
LAC, 2012 (N=1546)**



**Figure 3. Reported Campylobacteriosis Rates by SPA
LAC, 2012 (N=1546)**



Map 2. Campylobacteriosis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

COCCIDIOIDOMYCOSIS

CRUDE DATA	
Number of Cases	327
Annual Incidence[a]	
LA County	3.5
California[b]	11.8
United States[b]	5.7
Age at Diagnosis	
Mean	49
Median	50
Range	1-93

[a]Cases per 100,000 population.
[b]Calculated from Final 2012 Reports

DESCRIPTION

Coccidioidomycosis, or valley fever, is a fungal disease transmitted through the inhalation of *Coccidioides immitis* spores that are carried in dust. Environmental conditions conducive to an increased occurrence of coccidioidomycosis include arid to semi-arid regions, dust storms, hot summers, warm winters, and sandy, alkaline soils. The fungus is endemic in the southwestern US and parts of Mexico and South America; Southern California is a known endemic area. Most infected individuals exhibit no symptoms or have mild respiratory illness, but a few individuals develop severe illness such as pneumonia, meningitis, or dissemination to other parts of the body. Among the wide range of clinical presentations, only the most severe cases are usually diagnosed and reported to the health department. Blacks, Filipinos, pregnant women, the very young (age <5 years), the elderly, and immunocompromised individuals are at high risk for severe disease. Currently no safe and effective vaccine or drug to prevent coccidioidomycosis exists. Prevention lies mainly in dust control (e.g., planting grass in dusty areas, putting oil on roadways, wetting down soil, air conditioning homes, wearing masks or respirators). Other options may be to warn people at high risk for severe disease not to travel to endemic areas when conditions are most dangerous for exposure. Recovery from the disease confers lifelong immunity to reinfection, providing the rationale for development of a vaccine for prevention of symptomatic or serious forms of the disease. Increasing construction, a growing naïve population in the endemic area, antifungal treatments that are toxic and not uniformly effective validate the need for prevention efforts.

2012 TRENDS AND HIGHLIGHTS

- Overall, the Los Angeles County incidence rate for coccidioidomycosis has been gradually increasing in the last ten years, but relatively stable since 2005. (Figure 1)
- Cases occurred primarily in older adults; the greatest number of reported cases was in the 45-54 year age group, which also had the highest incidence rate, 6.5 cases per 100,000 (Figure 2).
- Males represented 62% of cases; females 38%. Of note, the percentage of males in SPA 1 continues to be lower than the other SPAs. The significance is unknown. (Figure 3).
- Hispanics had the highest percentage of cases with 41% (n=133) as compared to other racial groups. However, the incidence rate for blacks at 5.9 cases per 100,000 (n=46) was highest among racial groups, consistent with previous years (Figure 4).
- SPA 1 reported the highest incidence rate of coccidioidomycosis in LAC, 19.1 per 100,000 (n=74); though, this represents a decrease from the previous year (Figure 5).
- Coccidioidomycosis cases began to increase in the late spring of 2012, compared to the five-year average (Figure 6).
- The case fatality rate was 2%, a decrease from 2011. There were 21 cases of disseminated coccidioidomycosis reported in LAC.

Reported Coccidioidomycosis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=228)			2009 (N=171)			2010 (N=235)			2011 (N=304)			2012 (N=327)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	0.0	0	0.0	0.0	1	0.4	0.7	0	0.0	0	0	-	-
1-4	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	1	0.3	0.2	3	9.2	0.6
5-14	6	2.6	0.4	3	1.8	0.2	5	2.1	0.4	3	1.0	0.2	3	9.2	0.3
15-34	41	18.0	1.5	30	17.5	1.1	43	18.3	1.5	62	20.4	2.1	68	20.8	2.5
35-44	33	14.5	2.2	38	22.2	2.6	38	16.2	2.6	35	11.5	2.4	53	16.2	4.0
45-54	58	25.4	4.3	30	17.5	2.2	55	23.4	4.1	67	22.0	5.0	84	25.7	6.5
55-64	38	16.7	4.1	33	19.3	3.5	42	17.9	4.4	54	17.8	5.6	46	14.1	4.5
65+	52	22.8	5.0	37	21.6	3.5	51	21.7	4.8	82	27.0	7.7	70	21.4	6.3
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0		
Race/Ethnicity															
Asian	27	11.8	2.1	11	6.4	0.8	26	11.1	1.9	23	7.6	1.7	26	8.0	2.0
Black	37	16.2	4.3	27	15.8	3.2	43	18.3	5.0	48	15.8	5.6	46	14.1	5.9
Hispanic	86	37.7	1.8	67	39.2	1.4	71	30.2	1.5	94	30.9	2.0	133	40.7	2.9
White	62	27.2	2.1	56	32.7	1.9	76	32.3	2.7	134	44.1	4.7	121	37.0	4.6
Other	1	0.4	4.1	2	1.2		3	1.3		1	0.3		0	-	-
Unknown	15	6.6		8	4.7		16	6.8		4	1.3		1	0.3	-
SPA															
1	52	22.8	14.2	45	26.3	12.2	87	37.0	23.3	93	30.6	24.9	74	22.6	19.1
2	62	27.2	2.8	52	30.4	2.3	54	23.0	2.4	86	28.3	3.9	72	22.0	3.4
3	21	9.2	1.2	16	9.4	0.9	17	7.2	1.0	13	4.3	0.7	25	7.6	1.5
4	20	8.8	1.6	13	7.6	1.0	20	8.5	1.6	26	8.6	2.1	53	16.2	4.7
5	9	3.9	1.4	11	6.4	1.7	7	3.0	1.1	17	5.6	2.6	18	5.5	2.8
6	24	10.5	2.3	15	8.8	1.4	19	8.1	1.8	29	9.5	2.7	37	11.3	3.6
7	21	9.2	1.5	9	5.3	0.7	14	6.0	1.0	20	6.6	1.5	34	10.3	2.6
8	13	5.7	1.2	9	5.3	0.8	16	6.8	1.4	18	5.9	1.6	14	4.2	1.3
Unknown	6	2.6								2	0.7		0	-	-

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Incidence Rates of Coccidioidomycosis US, CA and LAC, 2000-2012



Figure 2. Incidence Rates of Coccidioidomycosis by Age Group LAC, 2012



Figure 3. Percent of Reported Coccidioidomycosis Male Cases by SPA LAC, 2012



Figure 4. Coccidioidomycosis Incidence Rates by Race/Ethnicity LAC 2008-2012



Figure 5. Incidence Rates of Coccidioidomycosis by SPA LAC, 2008-2012



Figure 6. Reported Coccidioidomycosis Cases by Month of Onset, LAC, 2012 (N=327)



Map 3. Coccidioidomycosis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

CRYPTOSPORIDIOSIS

CRUDE DATA	
Number of Cases	44
Annual Incidence[a]	
LA County	0.47
California[b]	0.59
United States[b]	2.57
Age at Diagnosis	
Mean	37
Median	36
Range	2-100 years

[a]Cases per 100,000 population.
[c]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Cryptosporidiosis is fecal-orally transmitted when cysts of the parasite *Cryptosporidium spp.* are ingested. Common causes include unprotected sexual contact, particularly among men who have sex with men (MSM), and ingestion of contaminated recreational or untreated water. The usual incubation period is 2 to 10 days with typical symptoms of watery diarrhea, abdominal cramps, and low-grade fever; however, asymptomatic infection is also common. Symptoms last up to 2 weeks in healthy individuals. Those who have a weakened immune system may experience prolonged illness. Immunocompromised individuals (e.g., HIV/AIDS patients, cancer patients, transplant patients), young children and pregnant women are at risk for more severe illness.

Proper hand hygiene before meals and after using the restroom is a major way to prevent infection and transmission of cryptosporidiosis. Hand washing is also important for individuals who come in contact with diapered/incontinent children and adults. Persons with diarrhea should not go swimming in order to prevent transmission to others. Persons should avoid drinking untreated water that may be contaminated. Lastly, it is important to avoid fecal exposure during sexual activity.

2012 TRENDS AND HIGHLIGHTS

- The incidence of cryptosporidiosis cases in Los Angeles County (LAC) decreased slightly from 0.55 to 0.47 cases per 1000,000 in 2011 and 2012, respectively (Figure 1). This decline is consistent with the previous two years, 2010 and 2011.
- The 35-44 and 45-54 year old age groups had the highest incidence rates for cryptosporidiosis, each with 0.6 cases per 100,000 (Figure 2). The 35-44 age-group has consistently had the highest incidence rate in previous reporting periods.
- Whites (19, 43%) accounted for the largest proportion of cases in 2012, though a large percentage (32%) of cases had unknown race/ethnicity data (Figure 3). Whites had the highest incidence rate of all the race/ethnicity groups, 0.7 cases per 100,000.
- Service Planning Area (SPA) 2 (12, 27%) reported the largest proportion of cases and SPA 1 had the highest incidence rate, 1.3 cases per 100,000. (Figure 4).
- The number of cases reported peaked in April, compared with the previous 5 years when the number of reported cases peaked in August (Figure 5).
- The male to female ratio for 2012 was approximately 6:5 which differs from 2011 when the ratio was approximately 2:1. Males have consistently comprised the larger proportion of cases.
- Complete risk factor data were available for 91% of cases. The most frequently reported risk factor was contact with animals (21, 48%), of those, the majority had contact with dogs at home (15, 34%). Other reported risk factors were HIV positive status (11, 25%) of which (7, 16%) were MSM (men who have sex with men). In total, 9 (20%) cryptosporidiosis cases reported MSM.

Reported Cryptosporidiosis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008 - 2012

	2008 (N=41)			2009 (N=51)			2010 (N=61)			2011 (N=51)			2012(N=44)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0.0	0.0
1-4	2	4.9	0.4	4	7.8	0.7	2	3.3	0.3	3	5.8	0.5	2	4.6	0.4
5-14	7	17.1	0.5	4	7.8	0.3	5	8.2	0.4	6	11.7	0.5	4	9.1	0.3
15-34	10	24.4	0.3	16	31.4	0.6	15	24.6	0.5	16	31.3	0.5	13	29.5	0.5
35-44	15	36.6	1.0	13	25.5	0.9	14	23	1.0	10	19.6	0.7	8	18.2	0.6
45-54	4	9.8	0.3	4	7.8	0.3	13	21.3	1.0	6	11.7	0.4	8	18.2	0.6
55-64	1	2.4	0.1	6	11.8	0.6	5	8.2	0.5	3	5.8	0.3	4	9.1	0.4
65+	2	4.9	0.2	4	7.8	0.4	7	11.5	0.7	7	13.7	0.7	4	9.1	0.4
Unknown	0	0.0		0	0.0		0			0			1	2.2	
Race/Ethnicity															
Asian	1	2.4	0.1	1	2.0	0.1	2	3.3	0.1	3	5.8	0.2	1	2.3	0.1
Black	5	12.2	0.6	8	15.7	0.9	11	18.0	1.3	6	11.7	0.7	1	2.3	0.1
Hispanic	10	24.4	0.2	10	9.6	0.2	13	21.3	0.3	11	21.5	0.2	9	20.4	0.2
White	12	29.3	0.4	16	31.4	0.5	22	36.1	0.8	20	39.2	0.7	19	43.2	0.7
Other	2	4.9	8.1	1	2.0		0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
Unknown	11	26.8		15	29.4		13	21.3		11	21.5		14	31.8	
SPA															
1	2	4.9	0.5	5	9.8	1.4	3	4.9	0.8	6	11.7	1.6	5	11.4	1.3
2	14	34.1	0.6	12	23.5	0.5	16	26.2	0.7	15	29.4	0.7	12	27.3	0.6
3	0	0.0	0.0	5	9.8	0.3	9	14.8	0.5	4	7.8	0.2	7	15.9	0.4
4	12	29.3	0.9	11	21.6	0.9	10	16.4	0.8	8	15.7	0.7	6	13.6	0.5
5	5	12.2	0.8	4	7.8	0.6	5	8.2	0.8	5	9.8	0.8	6	13.6	0.9
6	1	2.4	0.1	5	9.8	0.5	10	16.4	0.9	4	7.8	0.4	1	2.3	0.1
7	3	7.3	0.2	3	5.9	0.2	1	1.6	0.1	1	2.0	0.5	1	2.3	0.1
8	4	9.8	0.4	4	7.8	0.4	4	6.6	0.4	1	2.0	0.1	3	6.8	0.3
Unknown	0	0.0					0	0.0		7	13.7		3	6.8	

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Incidence Rates of Cryptosporidiosis US, CA and LAC, 2002 - 2012



Figure 2. Incidence Rates of Cryptosporidiosis by Age Group, LAC, 2012, N=44



Figure 3. Proportion of Cryptosporidiosis by Race/Ethnicity LAC, 2012, N=44



Figure 4. Incidence Rates of Cryptosporidiosis by SPA LAC, 2012, N=44



* Other includes Native American and any additional racial/ethnic group that cannot be categorized as Asian, black, Hispanic, and white.

Figure 5. Reported Cryptosporidiosis Cases by Month of Onset LAC, 2012, N=44



Figure 6. Cryptosporidiosis Incidence by Race/Ethnicity LAC, 2006 - 2012, N=44



ENCEPHALITIS

CRUDE DATA	
Number of Cases	75
Annual Incidence[a]	
LA County	0.81
California	N/A
United States	N/A
Age at Diagnosis	
Mean	55 years
Median	64 years
Range	0 -91 years

[a]Cases per 100,000 population.

DESCRIPTION

Encephalitis, an inflammation of parts of the brain, spinal cord and meninges, causes headache, stiff neck, fever and altered mental status. It can result from infection with a number of different agents including viral, parasitic, fungal, rickettsial, and bacterial pathogens as well as chemical agents. Public health conducts passive surveillance and is limited to cases with suspected or confirmed viral and bacterial etiologies, which includes primary and post-infectious encephalitis but excludes individuals with underlying human immunodeficiency virus (HIV) infection. Of special concern are arthropod-borne viruses (i.e., arboviruses), which are maintained in nature through biological transmission between susceptible vertebrate hosts by blood feeding arthropods (mosquitoes, ticks, and certain mites and gnats). All arboviral encephalitides are zoonotic, being maintained in complex life cycles involving a nonhuman vertebrate primary host and a primary arthropod vector. Arboviruses have a global distribution. The five main viral agents of encephalitis in the United States are West Nile virus (WNV), eastern equine encephalitis (EEE) virus, western equine encephalitis (WEE) virus, St. Louis encephalitis (SLE) virus and La Crosse (LAC) virus, all of which are transmitted by mosquitoes and thus can be prevented by personal protection and mosquito control (see West Nile virus chapter).

2012 TRENDS AND HIGHLIGHTS

- Seventy-five cases of encephalitis were confirmed in 2012 compared to 59 cases reported in 2011. The increase in case reports is largely due to the increased WNV – encephalitis case reported in 2012. The 2012 surveillance year was the second highest number of total WNV infections since 2004 (see special report).
- Forty-six (61%) cases of WNV-encephalitis were laboratory confirmed, the most frequently reported etiology. Cases of WNV encephalitis were reported from early July through late November. The peak month of encephalitis reports, September, coincided with the WNV-infection peak in 2012 (Figure 4).
- Herpes zoster complicated by encephalitis was the 2nd most common etiology for reported encephalitis cases; four (5%) cases were documented.
- Twenty-five (33%) encephalitis cases were assessed to be due to an unknown viral etiology based on review of medical records.
- The greatest incidence of encephalitis was in persons 65 years and older (3.3 cases per 100,000) followed by those 55-64 years of age (1.2 cases per 100,000 population) (See Table). The peak incidence in persons 55 years and older corresponds to age as a risk factor for WNV- associated neuroinvasive disease.
- The highest encephalitis case incidence rates were documented within SPAs 1 and 3 and can be attributed to the increased number of WNV- associated encephalitis cases in this region of Los Angeles County (Figure 3).
- Fifteen (20%) encephalitis cases were reported to public health that had laboratory testing conducted by the Neurologic Testing and Surveillance Branch of the California Department of Public Health. All cases were classified as viral encephalitis of unknown etiology; extensive testing revealed no clear viral etiology. More information on the California Department of Public Health Neurological Surveillance and Testing Program can be found at http://www.cdph.ca.gov/programs/vrdl/Pages/NeurologicSurveillanceTesting.aspx.

Reported Encephalitis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=89)			2009 (N=51)			2010 (N=51)			2011 (N=59)			2012 (N=75)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	4	4.5	2.9	0	0	-	1	2.0	0.7	3	5.1	2.5	1	1.3	0.8
1-4	8	9.0	1.4	4	7.8	0.7	4	7.8	0.7	4	6.8	0.8	3	4.0	0.6
5-14	14	15.7	1.0	17	33.4	1.2	21	41.2	1.6	10	16.5	0.8	8	10.7	0.7
15-34	4	4.5	0.1	10	19.6	0.4	11	21.6	0.4	8	13.6	0.3	6	8.0	0.2
35-44	1	1.1	0.1	2	3.9	0.1	1	2.0	0.1	2	3.4	0.2	0	0.0	-
45-54	11	12.4	0.8	7	13.7	0.5	4	7.8	0.3	9	15.7	0.7	9	12.0	0.7
55-64	14	15.7	1.5	2	3.9	0.2	6	11.8	0.6	8	13.5	0.8	12	16.0	1.2
65+	33	37.1	3.2	8	15.7	0.8	3	5.9	0.3	15	25.4	1.4	36	48.0	3.3
Unknown	0	0.0		1	2.0	0	0	0.0							
Race/Ethnicity															
Asian	3	3.4	0.2	5	9.8	0.4	6	11.8	0.4	0	-	-	8	10.7	0.6
Black	5	5.6	0.6	2	3.9	0.2	3	5.9	0.4	4	6.8	0.5	3	4.0	0.4
Hispanic	40	44.9	0.9	22	43.2	0.5	27	52.9	0.6	33	55.9	0.7	23	30.7	0.5
White	38	42.7	1.3	9	17.6	0.3	7	13.7	0.2	14	23.7	0.5	31	41.3	1.2
Other	1	1.1	4.1	1	2.0	-	1	2.0	-	1	1.7	-	5	6.7	1.2
Unknown	2	2.2		12	23.5	-	7	13.7	-	7	11.9	-	5	6.7	-
SPA															
1	3	3.4	0.8	3	5.9	0.8	2	3.9	0.5	2	3.4	0.5	6	8.0	1.5
2	9	10.1	0.4	11	21.7	0.5	10	19.6	0.5	20	33.9	0.9	22	29.3	1.1
3	25	28.1	1.4	10	19.6	0.6	7	13.7	0.4	9	15.2	0.6	24	32.0	1.5
4	10	11.2	0.8	7	13.7	0.6	4	7.8	0.3	4	6.8	0.4	10	13.3	0.9
5	0	0.0	0.0	0	0.0	-	2	3.9	0.3	1	1.7	0.2	2	2.7	0.3
6	3	3.4	0.3	7	13.7	0.7	13	25.5	1.2	4	6.8	0.4	4	5.3	0.4
7	16	18.0	1.2	9	17.6	0.7	5	9.8	0.4	8	13.5	0.6	5	6.7	0.4
8	9	10.1	0.8	2	3.9	0.2	4	7.8	0.4	5	8.2	0.5	2	2.7	0.2
Unknown	14	15.7		2	3.9		4	7.8		6	10.2		0	0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Incidence Rates* of Encephalitis
LAC, 2000-2012**



*See text for limitations.

**Figure 2. Percent Cases of Encephalitis by Race/Ethnicity
LAC, 2012 (N=76)**



* Other includes Native American and any additional racial group that cannot be categorized as Asian, black, Hispanic, or white.

**Figure 3. Incidence Rates of Encephalitis by SPA
LAC, 2012 (N=76)**



**Figure 4. Reported Encephalitis Cases by Month of Onset
LAC, 2012 (N=76)**



**Figure 5. Reported Encephalitis Cases by Race/Ethnicity
LAC, 2006-2012**



Map 4. Encephalitis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

ESCHERICHIA COLI O157:H7, Other STEC

CRUDE DATA	O157:H7	Other Serotypes	All Serotypes
Number of Cases	19	78	97
Annual Incidence[a]			
LA County	0.20	0.84	1.04[c]
California[b]	--	--	1.32[c]
United States[b]	--	--	1.79[c]
Age at Diagnosis			
Mean	29	13	
Median	28	3	
Range	1-69	0-60	

[a] Cases per 100,000 population.
[b] See Final Summary of Nationally Notifiable Infectious Diseases, United States on MMWR website http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6233a6.htm.
[c] Incudes E.coli O157:H7; shiga toxin-positive, serogroup non-O157: and Shiga toxin-positive, not serogrouped. All cases are now reported as STEC (Shiga toxin producing E.coli) in order to simplify the reporting process.

DESCRIPTION

Escherichia coli is a Gram-negative bacillus with numerous serotypes, several of which produce shiga toxin, called STEC. Gastrointestinal infection with a shiga toxin-producing serotype causes abdominal cramps and watery diarrhea, often developing into bloody diarrhea; fever is uncommon. Incubation period is two to eight days. These organisms naturally occur in the gut of many animals; likely modes of transmission to humans from animals include foodborne (e.g., undercooked ground beef; raw milk; fresh produce and unpasteurized juice contaminated with feces), direct exposure to animals and their environments, and exposure to recreational water contaminated with animal or human feces. Person-to-person transmission such as between siblings or within a daycare center is also well described.

The most common STEC serotype in the US is *E. coli* O157:H7, but several other serotypes occur and cause illness. A positive test for shiga toxin in stool as well as cultures of STEC are reportable to Public Health. All reported positive STEC broths or isolates are confirmed and serotyped by the Public Health Laboratory.

Hemolytic uremic syndrome (HUS) is a disorder consisting of hemolytic anemia, kidney failure, and thrombocytopenia. It is diagnosed clinically and is most frequently associated with recent infection due to *E. coli* O157:H7, but may also be caused by other serotypes. Children younger than five years of age are at highest risk for HUS. Adults may develop a related condition called thrombotic thrombocytopenic purpura (TTP) after STEC infection.

Increased public education to prevent STEC infection is important. Information should focus on safe food handling practices, proper hygiene, and identifying high-risk foods and activities both in the home and while eating out. To avoid infection, beef products should be cooked thoroughly. Produce, including pre-washed products, should be thoroughly rinsed prior to eating. In addition, one should drink only treated water and avoid swallowing water during swimming or wading. Careful handwashing is essential, especially before eating and after handling raw beef products or coming in contact with or being around animals. Strengthening of national food processing regulations to decrease contamination is also important to reduce contamination.

2012 TRENDS AND HIGHLIGHTS

- There was a 9% (n=19) decrease in the frequency of confirmed *E. coli* O157:H7 cases in 2012 (Figure1).
- Cases of *E. coli* "other serotypes" had a younger mean age than O157:H7 cases (3 vs. 13 years). One possible rationale is that cases with other serotypes are largely Hispanic (62.8%), a group that has historically had less access to health care to be diagnosed, with the exception of Hispanic children who have health care coverage through government programs. This would, in effect, drive the mean age down for the "other serotypes" group.
- The number of confirmed cases of other STEC (non-O157:H7) infections increased by 20% (n=78) compared to 2011. They included ten different serotypes with serotypes O103, O111, O26 being predominant.
- For serotype O157:H7, the highest number of cases reported was among persons ages

5-34 years (n=10) (Figure 2); it continues to be mainly observed among whites (n=12) (Figures 3, 6). Cases were reported from all SPAs except SPA 1. (Table 2, Figure 4).

- For all other serotypes of STEC, the highest number of cases reported was among children aged 1-4 years (n=30) (Figure 2) and in the Hispanic population (n=42) (Figures 3, 7). The reasons for these differences are unknown.
- Two HUS cases were reported and were laboratory confirmed with STEC serotype other STEC (non-O157:H7). No deaths occurred.
- There were no Los Angeles County outbreaks of STEC in 2012. Acute Communicable Disease Control Program participated in four multistate cluster investigations.

Table 1. Reported *Escherichia coli* O157:H7 Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA Los Angeles County, 2008-2012

	2008 (N=16)			2009 (N=18)			2010 (N=12)			2011 (N=21)			2012 (N=19)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	1	6.3	0.7	0	0	0	0	0	0	0	0	0	0	0	0
1-4	4	25.0	0.7	5	27.7	0.9	3	25.0	0.5	6	28.5	1.0	3	15.7	0.6
5-14	3	18.8	0.2	3	16.6	0.2	2	16.6	0.2	6	28.5	0.5	5	26.3	0.4
15-34	4	25.0	0.1	5	27.7	0.2	5	41.6	0.2	3	14.2	0.1	5	26.3	0.2
35-44	1	6.3	0.1	2	11.1	0.1	0	0	0	2	9.5	0.1	1	5.2	0.1
45-54	1	6.3	0.1	0	0	0	1	8.3	0.1	0	0	0	1	5.2	0.1
55-64	0	0.0	0.0	1	5.5	0.1	0	0	0	2	9.5	0.2	1	5.2	0.1
65+	2	12.5	0.2	2	11.1	0.2	1	8.3	0.1	2	9.5	0.2	3	15.7	0.3
Unknown	0	0.0		0	0	0	0	0	0	0	0	0			
Race/Ethnicity															
Asian	0	0.0	0.0	1	5.5	0.1	3	25.0	0.2	1	4.7	0.1	5	26.3	0.4
Black	5	31.3	0.6	0	0	0	1	8.3	0.1	1	4.7	0.1	1	5.2	0.1
Hispanic	5	31.3	0.1	4	22.2	0.1	2	16.6	--	8	38.0	0.2	1	5.2	0.0
White	6	37.5	0.2	13	72.2	0.4	6	50.0	0.2	11	52.3	0.4	12	63.1	0.5
Other	0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	0	0.0		0	0	0	0	0	0	0	0	0	0	0	0
SPA															
1	0	0.0	0.0	1	5.5	0.3	0	0	0	1	4.7	0.3	0	0	0
2	5	31.3	0.2	5	27.7	0.2	5	41.6	0.2	4	19.0	0.2	4	21.0	0.2
3	1	6.3	0.1	1	5.5	0.1	0	0	0	3	14.2	0.2	1	5.2	0.1
4	3	18.8	0.2	0	0	0	0	0	0	5	23.8	0.4	3	15.7	0.3
5	6	37.5	0.9	3	16.6	0.5	3	25.0	0.5	1	4.7	0.2	3	15.7	0.5
6	0	0.0	0.0	0	0	0	0	0	0	3	14.2	0.3	1	5.2	0.1
7	0	0.0	0.0	4	22.2	03	2	16.1	0.1	1	4.7	0.1	4	21.0	0.3
8	1	6.3	0.1	4	22.2	0.4	2	16.1	0.1	3	14.2	0.2	3	15.7	0.3
Unknown	0	0.0					0	0	0				0	0	0

*Rates calculated based on less than 19 cases or events are considered unreliable

Table 2. Reported *Escherichia coli* Non O157:H7 Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA Los Angeles County, 2008-2012

	2008 (N=11)			2009 (N=20)			2010 (N=45)			2011 (N=67)			2012 (N=78)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0	0	0	0	0	4	8.8	2.9	8	11.9	5.7	6	7.6	5.0
1-4	1	14.2	0.2	9	42.8	1.6	23	51.1	4.0	30	44.7	5.2	39	50.0	8.2
5-14	1	7.1	0.1	2	9.5	0.1	2	4.4	0.2	8	11.9	0.6	10	12.8	0.8
15-34	7	50.0	0.2	4	23.8	0.1	8	17.8	0.3	12	17.9	0.4	11	14.1	0.4
35-44	0	7.1	0	1	4.7	0.1	1	2.2	0.1	2	2.9	0.1	3	3.8	0.2
45-54	1	7.1	0.1	1	4.7	0.1	6	13.3	0.4	0	0	0	4	5.1	0.3
55-64	0	0	0	1	4.7	0.1	1	2.2	0.1	3	4.4	0.3	5	6.4	0.5
65+	2	14.2	0.2	2	9.5	0.2	0	0	0	4	5.9	0.4	0	0	0
Unknown	0	0	0	0	0	0	0	0	0				0	0	0
Race/Ethnicity															
Asian	2	21.4	0.2	2	9.5	0.2	1	2.2	0.1	5	7.4	0.4	1	1.2	0.1
Black	1	7.1	0.1	0	0	0	2	4.4	0.2	2	2.9	0.2	3	3.8	0.4
Hispanic	5	42.8	0.1	6	28.5	0.1	31	68.8	0.7	42	62.6	0.9	49	62.8	1.1
White	4	28.5	0.1	12	61.9	0.4	10	22.2	0.3	17	25.3	0.6	22	28.2	0.8
Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	0	0	0	0	0	0	1	2.2	0	1	1.4	0	0	0	0
SPA															
1	1	14.2	0.3	0	0	0	1	2.2	0.3	2	2.9	0.5	1	1.2	0.3
2	3	14.2	0.1	4	19.0	0.2	14	31.1	0.6	14	20.8	0.6	23	29.4	1.1
3	1	14.2	0.1	3	14.2	0.2	7	15.5	0.4	8	11.9	0.5	11	14.1	0.7
4	2	21.4	0.2	3	19.0	0.2	6	40.0	0.5	4	5.9	0.3	10	12.8	0.9
5	4	28.5	0.6	6	28.5	0.9	3	6.6	0.5	7	10.4	1.1	5	6.4	0.8
6	0	0	0	0	0	0	4	8.8	0.4	8	11.9	0.7	8	10.2	0.8
7	1	7.1	0.1	2	9.5	0.1	6	13.1	0.4	20	29.8	1.5	11	14.1	0.8
8	0	0	0	2	9.5	0.2	4	8.8	0.4	4	5.9	0.4	3	3.8	0.3
Unknown	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

*Data not available for 2005. Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Number Cases of Shiga Toxin-producining *E. coli*
LAC, 2002-2012



*Other STEC data not available before 2005

Figure 2. Reported Cases of Shiga Toxin-producing *E. coli*
by Serotype and Age Group
LAC, 2012



Figure 3. Percent Cases of Shiga Toxin-producing *E. coli*,
by Race/Ethnicity, LAC, 2012



Figure 4. Reported Cases of Shiga Toxin-producing
***E. coli* by Serotype and SPA**
LAC, 2012



Figure 5. Reported Shiga Toxin-producing *E. coli* Cases by Serotype Month of Onset, LAC, 2012



Figure 6. Reported *E. coli* O157:H7 Cases by Race/Ethnicity LAC, 2007-2012



Figure 7. Reported Cases of *E. coli* Non-O157:H7 Serotype by Race/Ethnicity LAC, 2007-2012



Map 5. E. Coli Other Stec
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

GIARDIASIS

CRUDE DATA	
Number of Cases	294
Annual Incidence[a]	
LA County	3.2
California[b]	4.6
United States[b]	4.9
Age at Diagnosis	
Mean	35
Median	35
Range	1 - 88

[a]Cases per 100,000 population.
[b]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Giardiasis is an intestinal infection caused by the zoonotic protozoan parasite *Giardia intestinalis* (previously *G. lamblia*). *Giardia* cysts shed in animal or human feces may contaminate food or drinking water or be transferred on hands or fomites; recreational waters such as lakes and pools may also serve as vehicles of transmission. Incubation can range from 3 to 25 days or longer, but the median incubation time is 7 to 10 days. While often asymptomatic, symptoms can include sulfurous burps, chronic diarrhea, frequent loose and pale greasy stools, bloating, cramps, fatigue, and weight loss. Complications are rare, but may include malabsorption of fats and fat-soluble vitamins. Children in day care represent a reservoir of disease in developed countries. There is no vaccine.

To prevent transmission of giardiasis, individuals should wash their hands before eating, after using the toilet, and after changing diapers. Persons ill with diarrhea should avoid swimming. Fecal exposure during sexual activity should also be avoided.

2012 TRENDS AND HIGHLIGHTS

- Giardiasis disease incidence has remained stable over the years with 3.2 cases per 100,000 in 2011 and 2012 and 3.1 cases per 100,000 in 2010. (Figure 1).
- The highest age-specific incidence rate occurred among children aged 1-4 years with 6.3 cases per 100,000; the highest total number of cases was reported in the 15-34 year age group (86, 29%) which is consistent with 2011 which had 84 (29%) (Figure 2).
- Whites continue to have highest race/ethnicity-specific incidence rates and proportion of cases compared to other races. Whites accounted for 43% (125) of the reported cases in 2012 and 50% (146) in 2011 (Figure 3).
- Within Los Angeles County (LAC), Service Planning Area (SPA) 5 reported the highest incidence rate of giardiasis with 6.1 cases per 100,000 in 2012 compared with 5.6 cases per 100,000 in 2011. The second highest incidence rate was reported from SPA 2 (4.5 per 100,000) in 2012 and 4.6 cases per 100,000 in 2011 (Figure 4).
- The number of cases reported in 2012 peaked from September to December compared with the previous 5 year average which peaked in July, August and September. (Figure 5).
- Males have consistently accounted for a larger proportion of cases in previous reporting periods. Similarly males accounted for 63% (185) and females 37% (109) of the cases in 2012.
- The most frequently reported risk factor was contact with animals (137, 47%), predominantly dogs. Travel to another country was also frequently reported (78, 27%). Travel to Mexico was the most frequently reported country (18, 23%) by cases followed by India (9, 12%). Immigration to the US (50, 17%) was also cited as a risk factor: approximately one fifth of immigrant cases were from Mexico (11, 22%). These risk factors are consistent with risk factor information for other waterborne parasitic diseases reported in LAC.

Reported Giardiasis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2007-2012

	2008 (N=355)			2009 (N=354)			2010 (N=308)			2011 (N=292)			2012 (N=294)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	4	1.1	2.9	1	0.3	0.7	5	0.2	3.6	1	0.3	0.7	0	0.0	0
1-4	45	12.7	7.9	46	13.0	8.2	41	13.3	7.1	22	7.5	3.8	30	10.2	6.3
5-14	41	11.5	2.9	40	11.3	2.9	37	12.0	2.8	39	13.7	2.9	29	9.9	2.4
15-34	96	27.0	3.3	85	24.0	3.0	81	26.3	2.7	84	28.7	2.8	86	29.3	3.1
35-44	63	17.7	4.2	67	19.0	4.5	46	14.9	3.2	49	16.8	3.4	52	17.7	3.9
45-54	62	17.5	4.6	43	12.1	3.1	36	11.7	2.7	44	15.0	3.3	39	13.3	3.0
55-64	27	7.6	3.0	41	11.6	4.3	37	12.0	3.8	29	9.8	3.0	35	11.9	3.4
65+	17	4.8	1.7	30	8.5	2.8	24	7.8	2.3	23	7.9	2.2	22	7.5	2.0
Unknown		0.0		1	0.3		0	0		1	0.3	-	1	0.3	
Race/Ethnicity															
Asian	21	5.9	1.6	13	3.7	1.0	23	7.5	1.7	20	6.8	1.5	18	6.1	1.4
Black	16	4.5	1.9	25	7.1	2.9	28	9.1	3.3	18	6.2	2.1	17	5.8	2.2
Hispanic	106	29.9	2.3	102	28.8	2.2	90	29.2	1.9	89	30.5	1.9	84	28.6	1.9
White	167	47.0	5.7	129	36.4	4.4	137	44.5	4.8	146	50.0	5.1	125	42.5	4.7
Other	5	1.4	20.3	4	1.1		8	27.3		2	0.7		1	0.3	
Unknown	40	11.3		81	22.9		22	7.1		17	5.8		49	16.3	
SPA															
1	8	2.3	2.2	5	1.4	1.4	11	3.6	2.9	8	2.7	2.1	5	1.7	1.3
2	161	45.4	7.4	138	39.0	6.2	10	3.2	0.5	102	35	4.6	96	32.7	4.5
3	34	9.6	2.0	27	7.6	1.6	27	8.8	1.6	22	7.5	1.3	27	9.2	1.7
4	36	10.1	2.8	46	13.0	3.7	49	15.9	3.9	47	16.1	3.7	57	19.4	5.1
5	37	10.4	5.7	43	12.1	6.6	31	10.0	4.7	37	12.7	5.6	39	13.3	6.1
6	27	7.6	2.6	29	8.2	2.8	21	6.8	2.0	20	6.8	1.9	17	5.8	1.7
7	25	7.0	1.8	26	7.3	1.9	31	10.1	2.3	26	8.9	1.9	25	8.5	1.9
8	26	7.3	2.3	36	10.2	3.2	26	8.4	2.3	28	9.6	2.5	28	9.4	2.6
Unknown	1	0.3		0	0.0		0	0.0		2	0.7		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Incidence Rates of Giardiasis
LAC, CA and US, 2002 - 2012**



**Figure 2. Cases of Giardiasis by Age Group
LAC, 2012, N=293**



**Figure 3. Proportion of Giardiasis Cases by Race/Ethnicity
LAC, 2012, N=294**



**Figure 4. Incidence Rates of Giardiasis by SPA
LAC, 2012, N=294**



* Other includes Native American and any additional racial/ethnic group that cannot be categorized as Asian, black, Hispanic, and white.

Figure 5. Reported Giardiasis Cases by Month of Onset
LAC, 2012,N=294



Figure 6. Giardiasis Incidence by Race/Ethnicity
LAC, 2006 - 2012



Map 6. Giardiasis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

HAEMOPHILUS INFLUENZAE INVASIVE DISEASE

CRUDE DATA	
Number of Cases	54
Annual Incidence[a]	
LA County	0.6
California[b]	0.08
United States[c]	1.10
Age at Diagnosis	
Mean	56.9 years
Median	64.5 years
Range	Birth – 99 years

[a] Cases per 100,000 population.
[b] The incidence rates for California only include cases age <15 years
[c] Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Haemophilus influenzae (H. influenzae) is a Gram-negative coccobacillus that can cause both invasive and non-invasive disease. Invasive disease includes meningitis, sepsis, pneumonia, cellulitis, and septic arthritis. Transmission is via respiratory secretions of infected individuals. There are six encapsulated, typeable strains (a–f), as well as unencapsulated, nontypeable strains. *H. influenzae* serotype B (Hib) is the only serotype that is vaccine-preventable and for which chemoprophylaxis is recommended. Thus, determining the serotype on laboratory specimens for all suspect cases is critical. Since June 2007, in accordance with the revised California Department of Public Health guidelines, the only cases of invasive *H. influenzae* investigated in Los Angeles County (LAC) are those in persons less than 15 years of age.

Immunization Recommendations:

- Prior to the introduction of the Hib conjugate vaccine in 1990, most cases of invasive disease in children were caused by serotype B.
- Currently, all infants, including those born prematurely, are recommended to receive a primary series of conjugate Hib vaccine beginning at 2 months of age. The number of primary doses (2 or 3) depends on the brand of vaccine used.
- A booster dose is recommended at 12-15 months regardless of which brand of vaccine is used for the primary series.
- California State law requires that all children, up to age 4 years and 6 months, receive 1 dose of Hib vaccine on or after their first birthday, if they attend child care.
- Individuals older than 59 months of age do not need Hib vaccination unless they have a health condition that puts them at increased risk for invasive Hib disease.

2012 TRENDS AND HIGHLIGHTS

- For the third year in a row, no serotype B cases were identified; thus, none of the H. influenza cases were vaccine-preventable (Figures 6, 7, 8).
- The highest incidence rates of H. influenzae continued to occur in the <1 and 65+ age groups (Figure 2). No cases between the ages of 5-14 years were reported (Figure 2).
- None of the cases were linked. SPA 6 and SPA 8 reported the highest incidence rates (Figure 4).
- The highest incidence rates for 2012 occurred in the first half of the year, with a peak in February. This is in contrast to the previous five years, when incidence rates would usually start to increase in February and peak in April (Figure 5).
- Reported cases were either non-B (n=18) or unknown serotypes (n=36) (Figures 6, 7, 8). All of the 36 cases with unknown serotype were ≥15 years of age so serotype testing was not requested. Among all 54 cases, 87% (n=47) were ≥15 years of age and were also not investigated further. Thus, data on race/ethnicity and locations are missing for many of the cases (Figure 3).

Reported H. Influenzae Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=64)			2009 (N=69)			2010 (N=70)			2011 (N=66)			2012 (N=54)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	6	9.4	4.3	7	10.1	5.1	9	12.8	6.4	3	4.5	2.5	4	7.4	3.4
1-4	2	3.1	0.4	4	5.8	0.7	3	4.3	0.5	4	6.1	0.8	3	5.6	0.6
5-14	3	4.7	0.2	0	0.0	-	4	5.7	0.3	7	10.6	0.6	0	0.0	0.0
15-34	4	6.3	0.1	7	10.1	0.2	3	4.3	0.1	6	9.1	0.2	4	7.4	0.1
35-44	5	7.8	0.3	2	2.9	0.1	6	8.6	0.4	6	9.1	0.5	7	13.0	0.5
45-54	11	17.2	0.8	8	11.6	0.6	9	12.9	0.7	4	6.1	0.3	4	7.4	0.3
55-64	2	3.1	0.2	11	15.9	1.2	8	11.4	0.8	7	10.6	0.7	5	9.3	0.5
65+	31	48.4	3.0	30	43.5	2.8	28	40.0	2.6	29	43.9	2.8	27	50.0	2.4
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	3	4.7	0.2	3	4.4	0.2	0	0.0	-	3	4.5	0.2	4	7.4	0.3
Black	2	3.1	0.2	6	8.7	0.7	2	2.9	0.2	3	4.5	0.4	3	5.6	0.4
Hispanic	13	20.3	0.3	8	11.6	0.2	15	21.4	0.3	12	18.2	0.3	8	14.8	0.2
White	9	14.1	0.3	10	14.5	0.3	20	28.6	0.7	9	13.6	0.3	10	18.5	0.4
Other	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	0.0
Unknown	37	57.8		42	60.8		33	47.1		39	59.1		29	53.7	
SPA															
1	0	0.0	-	2	2.9	0.5	4	5.7	1.1	0	0.0	-	2	3.7	0.5
2	7	10.9	0.3	16	23.2	0.7	26	37.1	1.2	20	30.3	0.9	10	18.5	0.5
3	10	15.6	0.6	7	10.1	0.4	4	5.7	0.2	6	9.1	0.4	6	11.1	0.4
4	8	12.5	0.6	5	7.3	0.4	7	10.0	0.6	4	6.1	0.4	8	14.8	0.7
5	4	6.3	0.6	2	2.9	0.3	2	2.9	0.3	5	7.6	0.8	4	7.4	0.6
6	10	15.6	0.9	8	11.6	0.8	4	5.7	0.4	3	4.5	0.3	9	16.7	0.9
7	10	15.6	0.7	11	15.9	0.8	6	8.6	0.4	7	10.6	0.5	3	5.6	0.2
8	9	14.1	0.8	7	10.2	0.6	7	10.0	0.6	7	10.6	0.7	8	14.8	0.8
Unknown	6	9.4		11	15.9		10	14.3		14	21.2		4	7.4	

*Rates calculated based on less than 19 cases or events are considered unreliable. A zero rate is reported with a dash ("-").

Figure 1. Incidence Rates of *H. influenzae* Invasive Disease US, CA and LAC, 2003-2012*



*The incidence rates for CA only includes cases aged <30 years (2001-2006) and cases aged <15 years (2007-2010).

Figure 2. Incidence Rates of *H. influenzae* Invasive Disease by Age Group LAC, 2012 (N=54)



Figure 3. Percent Cases of *H. influenzae* Invasive Disease by Race/Ethnicity, LAC, 2012 (N=54)



Figure 4. Incidence Rates of *H. influenzae* Invasive Disease by SPA, LAC, 2012 (N=54)



Figure 5. Reported *H. influenzae* Invasive Disease Cases by Month of Onset, LAC, 2012 (N=54)



Figure 6. Reported *H. influenzae* Invasive Disease Cases by Serotype, LAC, 2003-2012



Figure 7.Reported *H. influenzae* Invasive Disease Cases by Serotype, 2012 (N=54) vs. Previous 5-Year Average

	B		Non-B		Unknown[2]	
	2012	Previous 5-Year Average	2012	Previous 5-Year Average	2012	Previous 5-Year Average
Total Cases	0	0.6	18	39.6	36	26.2
Age at Onset (years)						
Mean	--	61.8	41.4	44.9	64.7	62.4
Median	--	61.8	49.0	51.3	67.5	65.4
Range	--	48 – 71	<1 – 90	<1 – 99	27 - 99	<1 –98
Case Fatality	--	0.0%	11.1%[1]	1.5%	5.6%	7.6%

[1]Two deaths were reported. The first case was born prematurely and was hospitalized for sepsis. The second case was >15 years of age and was hospitalized for pneumonia and sepsis.

[2]All of the unknown serotype cases are >15 years of age so no further serotype testing is requested.

Figure 8. Percent Cases of *H. influenzae* Invasive Disease by Serotype LAC, 2012 (N=54)



HEPATITIS A

CRUDE DATA	
Number of Cases	47
Annual Incidence[a]	
LA County	0.51
California[b]	0.56
United States[C]	0.5
Age at Diagnosis	
Mean	35
Median	31
Range	5-72 years

[a]Cases per 100,000 population
[b]http://www.cdph.ca.gov/programs/immunize/Documents/HAVByCounty2006-2012.pdf.
[c]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.
.

DESCRIPTION

Hepatitis A virus (HAV), a RNA virus, is a vaccine-preventable disease transmitted fecal-orally, person-to-person, or through vehicles such as food. In the United States (US), among adults with identified risk factors, the majority of cases are among men who have sex with other men, persons who use illegal drugs, and international travelers. Sexual and household contacts of HAV-infected persons are also at increased risk for getting the disease.

The average incubation period is 28 days (range 15–50 days). Signs and symptoms of acute hepatitis A include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain, and jaundice. Many cases, especially in children, are mild or asymptomatic. Recovery usually occurs within one month. Infection confers life-long immunity.

Hepatitis A vaccination is the most effective means of preventing HAV transmission among persons at risk for infection. Hepatitis A vaccination is recommended for all children at age 1 year, for persons who are at increased risk for infection, for persons who are at increased risk for complications from hepatitis A, and for any person wishing to obtain immunity.

Los Angeles County (LAC) Department of Public Health uses the Centers for Disease Control and Prevention/Council of State and Territorial Epidemiologists 2012 criteria for acute hepatitis A to standardize surveillance of this infection. A case of hepatitis A is defined as a person with 1) an acute illness with discrete onset of symptoms and 2) jaundice or elevated aminotransferase levels, and 3) either IgM anti-HAV positive, or an epidemiologic link to a person who has laboratory confirmed hepatitis A.

2012 TRENDS AND HIGHLIGHTS

- The 2012 incidence rate of acute hepatitis A in LAC was slightly higher than 2011, 0.51 per 100,000 versus 0.49 per 100,000, respectively (Figure 1).
- The rate was highest among those between the ages of 15-34 years (0.9 per 100,000), followed by the 35-44 year old age group (0.7 per 100,000) (Figure 2).
- In 2012, the highest incidence rate was seen in Asians (0.6 per 100,000) followed by whites (0.5 per 100,000), and Hispanics (0.4 per 100,000). There were no black cases for 2012 (Figure 3).
- The male:female ratio was 1:0.74.
- Forty percent (n=19) of acute hepatitis A cases were hospitalized, and the remainder were managed as outpatients.
- Three Service Planning Areas (SPA) had incidence rates greater than the overall county incidence rate of 0.51 per 100,000—to include: SPA 2 (0.8 per 100,000), SPA 4 (0.7 per 100,000), and SPA 5 (0.6 per 100,000) (Figure 4).
- Of the 46 cases with complete investigations, 63% reported at least one risk factor. Recent travel outside of the US (n=20, 43%) was the most frequently reported risk factor reported, followed by eating raw shellfish (n=10, 21%), having a household member who traveled outside of the US in 3 months prior to onset of illness (n=10, 21%), MSM (n=2, 7% of males), close contact of child/employee at daycare center (n=1, 2%), using street drugs but not injecting (n=1, 2%), having multiple sexual partners (n=1, 2%) and contact with a suspected or confirmed hepatitis A (n=1, 2%) (Figure 5).

Reported Hepatitis A Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=80)			2009 (N=66)			2010 (N=51)			2011 (N=45)			2012 (N=47)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0
1-4	0	0.0	0.0	0	0	0	2	3.9	0.3	1	2.2	0.2	0	0	0
5-14	7	8.8	0.5	1	1.5	0.1	3	5.9	0.2	3	6.7	0.2	3	6.4	0.3
15-34	34	42.5	1.2	34	51.5	1.2	27	52.9	0.9	18	40.0	0.6	24	51.0	0.9
35-44	14	17.5	0.9	10	15.1	0.7	6	11.8	0.4	11	24.4	0.8	9	19.1	0.7
45-54	9	11.3	0.7	6	9.1	0.4	3	5.9	0.2	5	11.1	0.4	3	6.4	0.2
55-64	7	8.8	0.8	5	7.6	0.5	3	5.9	0.3	3	6.7	0.3	5	10.6	0.5
65+	9	11.3	0.9	10	15.1	0.9	7	13.7	0.7	4	8.9	0.4	3	6.4	0.3
Unknown	0	0		0	0	0	0	0	0	0	0	0	0	0	0
Race/Ethnicity															
Asian	14	17.5	1.1	18	27.3	1.4	12	23.5	0.9	13	28.9	1.0	8	17.0	0.6
Black	6	7.5	0.7	2	3.0	0.2	3	5.9	0.4	2	4.4	0.3	0	0	0
Hispanic	36	45.0	0.8	21	31.8	0.4	22	43.1	0.5	8	17.8	0.2	20	42.6	0.4
White	23	28.8	0.8	24	36.4	0.8	14	27.4	0.5	22	48.9	0.8	14	29.8	0.5
Other	1	1.3	4.1	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	0	0.0		1	1.5		0	0		0			5	10.6	
SPA															
1	3	3.8	0.8	2	3.0	0.5	3	5.9	0.8	2	4.4	0.5	2	4.3	0.5
2	17	21.3	0.8	22	33.3	1.0	18	35.3	0.8	17	37.8	0.8	17	36.1	0.8
3	17	21.3	1.0	8	12.1	0.5	3	5.9	0.2	10	22.2	0.6	4	8.5	0.2
4	7	8.8	0.5	6	9.1	0.5	9	17.6	0.7	6	13.3	0.5	8	17.0	0.7
5	10	12.5	1.5	8	12.1	1.2	6	11.8	0.9	2	4.4	0.3	4	8.5	0.6
6	2	2.5	0.2	8	12.1	0.8	4	7.8	0.4	3	6.7	0.3	0	0	0
7	15	18.8	1.1	6	9.1	0.4	6	11.8	0.4	1	2.2	0.1	7	14.9	0.5
8	7	8.8	0.6	6	9.1	0.5	1	2.0	0.1	4	8.9	0.4	5	10.6	0.5
Unknown	2	2.5		0			1	2.0		0			0		

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Incidence Rates of Hepatitis A
LAC, CA and US, 2008-2012



Figure 2. Incidence Rates* of Hepatitis A by Age Group
LAC, 2011-2012



Figure 3. Hepatitis A Incidence Rates* by Race/Ethnicity
LAC, 2011-2012



Figure 4. Incidence Rates* of Hepatitis A by SPA
LAC, 2012 (N=47)



* Rates based on fewer than 19 cases are unreliable

Figure 5. Hepatitis A Reported Risk Factors*
LAC, 2012 (N=47)



*Includes cases with multiple risk factors

HEPATITIS B, ACUTE (NONPERINATAL)

CRUDE DATA	
Number of Cases	38
Annual Incidence[a]	
LA County	0.41
California[b]	0.4
United States[b]	0.9
Age at Diagnosis	
Mean	43
Median	39
Range	26-68 years

[a]Cases per 100,000 population
[b]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Hepatitis B is a DNA-virus transmitted through activities that involve percutaneous or mucosal contact with infectious blood or body fluids, most often through injection drug use, sexual contact with an infected person, or contact from an infected mother to her infant during birth. Transmission also occurs among household contacts of a person with hepatitis B. Healthcare-associated transmission of hepatitis B is documented in the United States (US) and should be considered in persons without traditional risk factors.

Symptoms, which occur in less than half of those acutely infected, begin an average of 90 days (range: 60–150 days) after exposure and can include: fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain, and jaundice. Approximately 2-10% of adults infected with hepatitis B virus (HBV) are unable to clear the virus within six months and become chronic carriers. Death from cirrhosis or liver cancer is estimated to occur in 15–25% of those with chronic infection. Overall, hepatitis B is more prevalent and infectious than HIV.

The absence of acute hepatitis B in persons under age 19 in the US is evidence of the successful immunization strategy to eliminate HBV transmission. This strategy includes: screening all pregnant women and providing immunoprophylaxis to infants of HBV-infected women, routine immunization of all infants, and catch-up vaccination of all previously unvaccinated children aged < 19 years.

Adult vaccination is recommended for those in high risk groups including; men who have sex with men (MSM), history of multiple sex partners, injection drug users, persons seeking treatment for sexually transmitted disease; household and sex contacts of persons with chronic HBV infections, healthcare workers, persons with chronic liver disease, persons with HIV, hemodialysis patients and unvaccinated adults with diabetes mellitus aged 19 through 59.

For the purpose of surveillance, Los Angeles County (LAC) Department of Public Health uses the 2012 Centers for Disease Control and Prevention (CDC)/Council of State and Territorial Epidemiologists (CSTE) criteria for acute hepatitis B. The criteria include: 1) discrete onset of symptoms and 2) jaundice *or* elevated aminotransferase (ALT) levels >100 IU/L, and 3) HBsAg positive and anti-HBc IgM positive, (if done). In 2012, the CDC/CSTE modified the acute hepatitis B case definition to include documented seroconversion cases (documented negative HBV test result within 6 months prior to HBV diagnosis) without the acute clinical presentation.

2012 TRENDS AND HIGHLIGHTS

- One acute hepatitis B case was a documented seroconversion and the remainder of the cases met the 2012 CDC/CSTE acute Hepatitis B case criteria.
- The 2012 incidence rate decreased from the previous year (0.41 per 100,000 versus 0.65 per 100,000) (Figure 1).
- The incidence rate was highest in persons between the ages of 35-44 years (1.0 per 100,000) (Figure 2).
- The male-to-female ratio was 1:0.4.
- As in 2011, blacks had the highest incidence rate in 2012 (0.6 per 100,000) compared to other race/ethnicities (Figure 3).
- Five Service Planning Areas (SPA) had rates greater than the overall county mean rate of 0.41 per 100,000)—SPA 4 (0.8 per 100,000), SPA 1 (0.5 per 100,000), SPA 3 (0.5 per 100,000), SPA 5 (0.5 per 100,000), and SPA 7 (0.5 per 100,000) (Figure 4).
- A risk factor interview was conducted for 89% (n=34) of the confirmed cases. Of the cases interviewed, 100% reported at least one risk factor. The most frequently reported risk factor was having multiple sexual partners (n=14, 37%) followed by MSM (n=8, 30% of males), incarceration (n=6, 16%), non-injection street drugs (n=6, 16%), dental work (n=6, 16%), IV/IM

injections (n=6, 16%), fingersticks (n=5, 13%), having a diagnostic medical procedure (n=5, 16%), tattoo (n=4, 11%), acupuncture (n=3, 8%), accidental exposure to blood (n=3, 8%), contact with a confirmed or suspected case of hepatitis B (n=1, 3%), hemodialysis (n=1, 3%), accidental needle stick (n=1, 3%), transfusion (n=1, 3%), and IVDU (n=1, 3%) (Figure5).

Reported Hepatitis B, Acute, (Nonperinatal) Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=66)			2009 (N=41)			2010 (N=54)			2011 (N=60)			2012 (N=38)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0	0
1-4	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0	0
5-14	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0	0
15-34	18	27.3	0.6	12	29.3	0.4	18	33.3	0.6	12	20.0	0.4	10	26.3	0.4
35-44	14	21.2	0.9	7	17.1	0.5	13	24.1	0.9	10	16.7	0.8	13	34.2	1.0
45-54	13	19.7	1.0	16	39.0	1.2	11	20.4	0.8	21	35.0	1.6	10	26.3	0.8
55-64	14	21.2	1.5	4	9.7	0.4	7	13.0	0.7	12	20.0	1.2	3	7.9	0.3
65+	7	10.6	0.7	2	4.9	0.2	5	9.2	0.5	5	8.3	0.5	2	5.3	0.2
Unknown	0	0		0	0		0	0		0	0		0		
Race/Ethnicity															
Asian	7	10.6	0.5	5	12.2	0.4	11	20.4	0.8	3	5.0	0.2	1	2.6	0.1
Black	15	22.7	1.8	11	26.8	1.3	14	25.9	1.6	13	21.7	1.7	5	13.2	0.6
Hispanic	16	24.2	0.3	12	29.3	0.3	14	25.9	0.3	19	31.7	0.4	13	34.2	0.3
White	22	33.3	0.8	11	26.8	0.4	14	25.9	0.5	23	38.3	0.9	14	36.8	0.5
Other	1	1.5	4.1	0	0		1	1.8		0	0		0	0	
Unknown	5	7.6		2	4.9		0	0		2	3.3		5	13.2	
SPA															
1	2	3.0	0.5	0	0	0	2	3.7	0.5	0	0	0.0	2	5.3	0.5
2	9	13.6	0.4	4	9.8	0.2	5	9.3	0.2	13	21.7	0.6	5	13.2	0.2
3	6	9.1	0.3	6	14.6	0.3	10	18.5	0.6	8	13.3	0.5	8	21.0	0.5
4	7	10.6	0.5	13	31.7	1.0	8	14.8	0.6	15	25.0	1.3	9	23.7	0.8
5	9	13.6	1.4	1	2.4	0.2	4	7.4	0.6	1	1.7	0.2	3	7.9	0.5
6	22	33.3	2.1	10	24.4	1.0	8	14.8	0.7	10	16.7	1.0	2	5.3	0.2
7	6	9.1	0.4	2	4.9	0.1	7	13.0	0.5	3	5.0	0.2	6	15.8	0.5
8	4	6.1	0.4	4	9.8	0.4	10	18.5	0.9	8	13.3	0.8	3	7.9	0.3
Unknown	1	1.5		1	2.4		0	0		2	3.3		0	0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Incidence Rates of Acute Hepatitis B
LAC, CA and US, 2008-2012**



**Figure 2. Incidence Rates* of Acute Hepatitis B by Age Group
LAC, 2010-2012**



* Rates bases on fewer than 19 cases are unreliable

**Figure 3. Acute Hepatitis B Incidence Rates* by Race/Ethnicity
LAC, 2010-2012**



* Rates based on fewer than 19 cases are unreliable

**Figure 4. Incidence Rates* of Hepatitis B by SPA
LAC, 2012 (N=38)**



* Rates based on fewer than 19 cases are unreliable

Fig. 5. Hepatitis B Reported Risk Factors*
LAC, 2012 (n=38)



*Includes cases with multiple risk factors

HEPATITIS B, PERINATAL

CRUDE DATA	
Infants Born to HBsAg+ Mothers	867
Incidence of Exposure[a] LA County	6.5
HBsAg+ Infants[b]	1
Maternal Age at Diagnosis	
Mean	31.9 years
Median	32 years
Range	17-45 years
Infant Age at Diagnosis	12 months

[a]Number of infants born to HBsAg-positive mothers per 1000 live births in 2012.
[b]Based on number of infants that had post vaccine serology testing.

DESCRIPTION

Hepatitis B is a vaccine-preventable disease transmitted through parenteral or mucous membrane exposure to blood and other body fluids of individuals infected with the hepatitis B virus (HBV). A woman can transmit the HBV to her infant during pregnancy and from exposure to cervical secretions and blood during the birthing process. In Los Angeles County (LAC), it is estimated that over 40% of infants born to hepatitis B surface antigen (HBsAg) positive women will become infected without prophylaxis. An estimated 90% of infants who become infected by perinatal transmission develop chronic HBV infection and up to 25% will die from chronic liver disease as adults. Post-exposure prophylaxis with hepatitis B vaccine and hepatitis B immune globulin (HBIG) administered 12 to 24 hours after birth, followed by completion of a three-dose vaccine series, has demonstrated 85 to 95% effectiveness in preventing acute and chronic HBV infection in infants born to mothers who are positive for both HBsAg and hepatitis B e-antigen. Post-vaccination serologic (PVS) testing is recommended at age 9–18 months after completing immunoprophylaxis to verify vaccine success or failure. The LAC Immunization Program's Perinatal Hepatitis B Prevention Unit (PHBPU) conducts enhanced case management of HBsAg-positive pregnant women, their newborns, and household and sexual contacts (SC). Household contacts (HHC) are defined as an individual(s) with anticipated continuous household exposure to the HBsAg-positive mother for greater than one year (often limited to nuclear family).

2012 TRENDS AND HIGHLIGHTS

- Eight hundred sixty-seven infants (includes thirteen sets of twins) were born to 854 HBsAg+ women.
- The incidence of exposure increased by 23% from 5.3 to 6.5 per 1000 infants born in 2012 compared to 2011 (Figure 1).
- Sixty-nine percent (n=589) of women screened for HBsAg were 15-34 years of age.
- Eighty-seven percent (n=741) of HBsAg+ women were born outside of the United States.
- Seventy-nine percent (n=678) of HBsAg+ women were Asian followed by 5% (n=46) Hispanic, 5% (n=41) white, 5% (n=39) unknown, 4% (n=30) black, 1% (n= 14) other and 1% (n=6) Pacific Islander. (Figures 2 and 3).
- Fifty-eight percent (n=491) of the HBsAg+ women reside in Service Planning Area (SPA) 3, which has a large Asian population (Figure 4).
- Ninety-eight percent (n=848) of infants received the first dose of Hepatitis B vaccine and HBIG within 12 hours of birth (Figure 5).
- Six percent (n=55) of infants born to HBsAg+ women received post-vaccination serology (PVS) testing to determine immunity to hepatitis B after receipt of one dose of HBIG and completion of the three dose hepatitis B vaccination series. Infants born in the later part of 2012 are too young for PVS testing. One infant was HBsAg+, indicating infection (Figure 6).
- Among the HHCs, 38% (n=460) were 0-10 years and 33% (n=394) were 31-40 years (Figure 7).
- Hepatitis B virus marker status of HHCs (n=1185) was: 65% (n=771) were previously immunized by report. For the others, 16% (n=184) had positive antibodies to HBsAg (anti-HBs), 12% (n=140) were HBsAg negative, 3% (n=34) were susceptible (anti-

HBs negative), 2% (n=31) were infected (HBsAg-positive), 1% (n=16) had positive hepatitis B core antibodies and 1% (n=9) were unknown. The PHBPU recommends the Hepatitis B vaccine series for those who are susceptible (Figure 8).

Reported Hepatitis B, Perinatal Cases and Rates* per 100,000 by Maternal Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=778)			2009 (N=760)			2010 (N=653)			2011 (N=700)			2012 (N=854)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.00
1-4	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.00
5-14	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.00
15-34	550	70.7	19.2	520	58.4	18.4	448	68.6	15.2	476	68	16.1	589	69.0	20
35-44	225	28.9	14.9	237	31.2	10.7	204	31.2	14.2	219	31.3	15.2	263	31.0	18.3
45-54	3	0.4	0.2	3	0.4	0.2	0	0	0	2	0.3	0.1	1	0.1	0.1
55-64	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
65+	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
Unknown	0	0.0		0	0.0		1	0.2		3	0.4		1	0.1	
Race/Ethnicity															
Asian	611	78.5	46.9	570	75.0	43.8	491	75.2	37.4	555	79.3	42.3	678	79.0	51.7
Black	32	4.1	3.7	33	4.0	3.9	22	3.4	2.6	25	3.6	2.9	30	4.0	3.5
Hispanic	71	9.1	1.5	76	10.0	1.6	50	7.7	1.1	55	7.9	1.2	46	5.0	1.0
White	30	3.9	1.0	40	5.0	1.4	38	5.8	1.3	33	4.7	1.2	41	5.0	1.4
Other	34	4.4	137	41	5.0	1.6	19	2.9	40.4	13	1.9	34.9	20	2.3	82.4
Unknown	0	0.0		0	0.0		33	5.1		19	2.7		39	5.0	
SPA															
1	4	0.5	1.1	6	0.8	1.6	9	1.4	2.4	10	1.4	2.7	15	1.8	4.0
2	96	12.3	4.4	117	15.4	5.3	85	13	3.8	78	11.1	3.5	93	10.9	4.2
3	394	50.6	22.7	355	46.7	20.5	329	50.4	19.0	369	52.7	21.3	491	57.5	28.3
4	96	12.3	7.5	83	10.9	6.7	83	12.7	6.6	74	10.6	5.9	82	9.6	6.5
5	37	4.8	5.7	32	4.2	4.9	19	2.9	2.9	30	4.3	4.5	34	4.0	5.2
6	43	5.5	4.1	38	5.0	3.6	19	2.9	1.8	29	4.1	2.7	24	2.8	2.2
7	55	7.1	4.0	50	6.6	3.6	42	6.4	3.0	46	6.6	3.3	34	4.0	2.5
8	50	6.4	4.4	75	9.9	6.7	58	8.9	5.2	47	6.7	4.2	69	8.1	6.1
Unknown	3	0.4		4	0.5		9	1.4		17	2.4		12	1.4	

*Rates calculated based on less than 19 cases or events are considered unreliable

Figure 1. Perinatal Hepatitis B Incidence of Exposure LAC, 2002-2012



Figure 2.
Perinatal Hepatitis B Maternal Race/Ethnicity
LAC, 2012 (N=854)



Other includes Native-American and any racial group that cannot be categorized as Asian, Black, Hispanic, White or unknown. Other Asian is Japanese, Asian-Indian, Cambodian non-Hmong, Thai, Lao or unknown Asian.

Figure 3. Perinatal Hepatitis B Maternal Race/Ethnicity LAC, 2004-2012 (N= 6817)



Figure 4. Perinatal Hepatitis B Maternal by SPA LAC, 2012 (N=854)



Figure 5. Perinatal Hepatitis B Summary of Infant Hepatitis B Immunoprophylaxis, LAC, 2012 (N=867)



Note: As of the date of this report, many infants born in the later part of 2012 are not due to receive the 3rd dose hepatitis B vaccine.

Figure 6. Perinatal Hepatitis B Infant Post Vaccination Serology (PVS) Results LAC, 2012 (N=55)



*Antibody to Hepatitis B Surface Antigen

Note: As of the date of this report, many infants born in the later part of 2012 are not eligible for PVS testing. PVS testing is recommended at 9-18 months of age after completion of at least 3 doses of hepatitis B vaccine.

Figure 7. Perinatal Hepatitis B Household & Sexual Contacts Age Range, LAC, 2012 (N=1217)



Figure 8. Hepatitis B Status of Household Contacts LAC, 2012 (N=1185)



*Antibody to Hepatitis B Surface Antigen

HEPATITIS C, ACUTE

CRUDE DATA	
Number of Cases	7
Annual Incidence	
LA County	0.08[a]
California[b]	0.16
United States[b]	0.57
Age at Diagnosis	
Mean	35
Median	30
Range	20-52 years

[a]Rates calculated based on less than 19 cases or events are considered unreliable.
[b]Calculated from Final 2012 Reports of Nationally NotifiableInfectious Disease. MMWR 62(33);669-682.

DESCRIPTION

The Hepatitis C virus (HCV) is a RNA-virus primarily transmitted though percutaneous exposure to infectious blood. Traditional risk factors include: injection drug use (IDU), receipt of a blood transfusion prior to 1992, needle-stick injuries in healthcare settings, birth to infected mothers, having multiple sexual partners, tattoos or body-piercing and hemodialysis. The presence of HIV infection is associated with increased risk of infection among men engaging in certain sexual practices with other men. Household or familial contact does not appear to increase the risk of transmission of hepatitis C. An estimated 30% of cases have no identifiable exposure risk. Healthcare related transmission has been documented and should be considered in persons without identified traditional risk factors for hepatitis C. HCV is the most common chronic bloodborne infection in the US.

The average incubation period is 4-12 weeks (range: 2-24 weeks). Up to 85% of persons with newly acquired HCV infection are asymptomatic but when symptoms occur they can include: fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain, and jaundice. After acute infection, 15%-25% of persons appear to resolve their infection, while chronic infection develops in 75%-85% of persons. Most studies have reported that medical complications occur decades after initial infection including cirrhosis, liver failure, and hepatic cancer.

Primary prevention activities are recommended for prevention and control of HCV infection including; screening and testing of blood donors and persons born during 1945 through 1965, viral inactivation of plasma-derived products, risk-reduction counseling and screening of persons at risk for HCV infection, and routine practice of injection safety in healthcare settings. There is no vaccine or post-exposure prophylaxis for HCV and vaccines for hepatitis A and B do not provide immunity against hepatitis C.

For the purpose of surveillance, Los Angeles County Department of Public Health uses the 2012 Centers for Disease Control (CDC)/Council of State and Territorial Epidemiologists (CSTE) criteria for acute hepatitis C: 1) discrete onset of symptoms and 2) jaundice or alanine aminotransferase (ALT) levels > 400IU/L, and 3) (a) anti-HCV screening test positive with signal to cut-off ratio predictive of true positive or (b) HCV RIBA positive or (c) Nucleic Acid Test (NAT) for HCV RNA positive 4) no evidence of either acute hepatitis A or B disease.

In 2012, the CDC/CSTE acute hepatitis C case definition also included documented seroconversion cases as acute hepatitis C cases (documented negative HCV test result within 6 months prior to HCV diagnosis).

2012 TRENDS AND HIGHLIGHTS

- Of the seven confirmed acute hepatitis C cases for 2012, two cases were documented seroconversions and the remainder of the cases met the 2012 CDC/CSTE acute hepatitis C case criteria.
- The majority of cases were in the 15-34 year age group (n=4, 57%) (Figure 2).
- The majority of cases were Hispanic (n=3, 43%), there were no Asian cases (Figure 3).
- The male to female ratio was 1:0.4.
- Risk factors were identified in 100% (n=7) of the confirmed cases interviewed. Receiving a tattoo (n=3 [2 in prison, 1 in home], 43%), IDU (n=3, 43%) and incarceration (n=3, 43%) were the most common risk factors reported, followed by using street drugs but not injecting (n=2, 29%), exposure to someone's blood (n=2, 29%), contact with a suspected case (n=2, 29%), receiving a diagnostic medical procedure (n=2, 29%), IV/IM injection (n=2,

29%), and transfusion (n=2, 29%); and one case each was identified with an accidental needle stick (n=1, 14%), body piercing (n=1, 14%), and having multiple sexual partners (n=1, 14%)
(Figure 4).

Reported Hepatitis C, Acute Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=5)			2009 (N=8)			2010 (N=4)			2011 (N=10)			2012 (N=7)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0		0	0.0		0	0.0		0	0.0		0	0	
1-4	0	0.0		0	0.0		0	0.0		0	0.0		0	0	
5-14	0	0.0		0	0.0		0	0.0		0	0.0		0	0	
15-34	1	20.0		1	12.5		1	25.0		4	40.0	0.1	4	57.1	0.1
35-44	1	20.0		2	25.0		2	50.0		2	20.0	0.1	1	14.3	0.1
45-54	2	40.0		3	37.5		1	25.0		1	10.0	0.1	2	28.6	0.2
55-64	0	0.0		1	12.5		0	0.0		1	10.0	0.1	0	0	
65+	1	20.0		1	12.5		0	0.0		2	20.0	0.2	0	0	
Unknown	0	0.0		0	0.0		0	0.0					0	0	
Race/Ethnicity															
Asian	1	20.0		1	12.5		0	0.0		1	10.0	0.1	0	0	0
Black	0	0.0		0	0		0	0.0		0	0.0	0.0	1	14.3	0.1
Hispanic	1	20.0		1	12.5		1	25.0		6	60.0	0.1	3	42.9	0.1
White	3	60.0		6	75.0		3	75.0		2	20.0	0.1	2	28.6	0.1
Other	0	0.0		0	0		0	0.0		0	0.0	0.0	1	14.3	
Unknown	0			0			0	0.0		1	10.0		0	0	0
SPA															
1		0.0		1	12.5		0	0.0		0	0.0	0.0	2	28.6	0.5
2	3	60.0		0	0.0		3	75.0		1	10.0	0.0	1	14.3	0.0
3	1	20.0		0	0.0		0	0.0		2	20.0	0.1	0	0	0
4	0	0.0		2	25.0		0	0.0		3	30.0	0.2	1	14.3	0.1
5	0	0.0		2	25.0		0	0.0		1	10.0	0.2	1	14.3	0.2
6	0	0.0		0	0.0		0	0.0		0	0.0	0.0	1	14.3	0.1
7	0	0.0		1	12.5		0	0.0		2	20.0	0.1	0	0	0
8	1	20.0		2	25.0		1	25.0		1	10.0	0.1	1	14.3	0.1
Unknown	0	0.0		0	0.0					0	0.0	0.0	0	0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Incidence Rates* of Acute Hepatitis C
LAC, CA and US, 2008-2012**



*Rates based on fewer than 19 cases are unreliable

**Figure 2. Cases of Acute Hepatitis C by Age Group
LAC, 2010-2012**



**Figure 3. Percent Cases of Acute Hepatitis C by Race/Ethnicity
LAC, 2012 (N=7)**



Figure 4. Hepatitis C Reported Risk Factors*
LAC, 2012 (n=7)



LEGIONELLOSIS

CRUDE DATA	
Number of Cases	111
Number of Deaths	14
Annual Incidence[a]	
LA County	1.19
California[b]	0.58
United States[b]	1.18
Age at Diagnosis	
Mean	65.8
Median	68
Range	6-94

[a]Cases per 100,000 population.
[b]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Legionellosis is a bacterial infection with two distinct clinical forms: 1) Legionnaires' disease (LD), the more severe form characterized by pneumonia, and 2) Pontiac fever, an acute, self-limited flu-like illness without pneumonia. *Legionella* bacteria are common inhabitants of aquatic systems that thrive in warm environments. Ninety percent of cases of LD are caused by *Legionella pneumophila serogroup 1,* although at least 46 *Legionella* species and 70 serogroups have been identified. Transmission occurs through inhalation of aerosolized water containing the bacteria or by aspiration of contaminated water. Person-to-person transmission does not occur. The case fatality rate for LD ranges from 10% to 15%, but can be higher in outbreaks occurring in a hospital setting. People of any age may get LD, but the disease most often affects older persons, particularly those who are heavy smokers, have chronic lung disease, or whose immune systems are suppressed by illness or medication.

The implementation of water safety plans to control the risk of transmission of *legionella* to susceptible hosts in hospitals, hotels and public places with water related amenities remains the primary means of reducing LD. Plans include periodic inspection of water sources, distribution systems, heat exchangers, and cooling towers. Prevention strategies include appropriate disinfection, monitoring, and maintenance of both cold and hot water systems, and setting the hot water temperature to 50 degrees Celsius or higher to limit bacterial growth. All healthcare-acquired LD case reports are investigated to identify potential outbreak situations. Early recognition and investigation is crucial for timely implementation of control measures.

2012 TRENDS AND HIGHLIGHTS

- In 2012, there were 111 cases reported (incidence 1.19/100,000) which is slightly less than 2011. (Figure 1)
- Three cases of Pontiac fever were reported.
- The case fatality rate decreased from 15.5% in 2011 to 12.6% in 2012.
- The most affected age group in Los Angeles county (LAC) was persons 65 years of age and older. (Figure 2).
- Service Planning Area (SPA) 6 had the highest incidence this year followed by SPA 5 (Figure 3).
- The number of cases reported in December was exceptionally high as compared to all other months. This seasonality has been seen in previous years, but not consistently (Figure 4).
- The highest incidence rate occurred among blacks (2.1 per 100,000) followed by whites (1.8 per 100,000). (Figure 5).
- People staying overnight in hotels during the incubation period accounted for 6.3% of confirmed cases, an increase from 3.4% in 2011. According to the CDC, more than 20% of all LD cases reported are associated with recent travel. No LAC resident was linked to any CDC reports of legionellosis found nationwide.
- Nosocomial legionellosis cases associated with skilled nursing facilities increased from 3.4% to 6.3% with three fatalities and from 4.3% to 4.5% in retirement assisted living facilities. Investigation and active case finding found no outbreak in either setting. However, another confirmed case was identified and linked to a retirement assisted living facility investigation in 2011-2012. The water system in this particular facility was remediated intensively during the time of the investigation. One acute care hospital had two fatal cases of possibly hospital acquired legionella. Two non-LAC residents were confirmed between August 2011 and February 2012 with hospital acquired legionellosis in an acute care hospital in LAC

that houses severely immunocompromised patients. Combined epidemiologic surveillance and environmental investigation to determine the source were conducted. Culture results of the two cases were the same serogroup, but environmental water culture results identified two different serogroups both of which differed from the cases.However, numerous environmental cultures were notable for non-pneumophila Legionella bacteria. A cluster of two confirmed cases from the same household, who regularly utilized a membership recreational gym with water amenities was investigated. ACDC and Recreational Waters investigated, which resulted in recommendations of minor violations. It was not determined if the gym was the source of the cluster of cases.

Reported Legionellosis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=59)			2009 (N=66)			2010 (N=108)			2011 (N=116)			2012 (N=111)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	0.0	1	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
1-4	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
5-14	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	1	0.9	0.1
15-34	1	1.7	0.0	2	3.0	0.1	3	3.0	0.1	5	4.0	0.2	4	3.6	0.1
35-44	5	8.5	0.3	3	4.5	0.2	9	8.0	0.6	7	6.0	0.5	6	5.4	0.5
45-54	7	11.9	0.5	11	16.6	0.8	25	23	1.8	21	18	1.6	21	18.9	1.6
55-64	12	20.3	1.3	14	21.2	1.5	27	25.0	2.8	22	19	2.3	18	16.2	1.8
65+	33	55.9	3.2	36	54.5	3.4	44	41	4.2	61	53	5.8	61	55.0	5.5
Unknown	0	0.0		0	0.0		0	0.0		0			0	0.0	0.0
Race/Ethnicity															
Asian	5	8.5	0.4	7	10.6	0.5	15	14.0	1.1	8	7.0	0.6	7	6.3	0.5
Black	11	18.6	1.3	14	21.2	1.6	25	23.1	2.9	20	17.2	2.3	16	14.4	2.1
Hispanic	13	22.0	0.3	13	19.6	0.3	25	23.1	0.5	37	32	0.8	32	28.8	0.7
White	30	50.8	1.0	32	48.4	1.1	41	38	1.4	47	40.5	1.6	49	44.1	1.8
Other	0	0.0	0.0	0	0.0	0.0	2	2.0	0.0	2	1.7	--	5	4.5	--
Unknown	0	0.0		0	0.0		0	0.0		2	1.7	--	2	1.8	--
SPA															
1	1	1.7	0.3	0	0	0	2	1.8	0.8	2	1.7	0.5	3	2.7	0.8
2	18	30.5	0.8	14	21.2	0.6	22	20.3	1.0	19	16.3	0.9	21	18.9	1.0
3	9	15.3	0.5	7	10.6	0.4	13	12.0	0.7	15	13	0.9	17	15.3	1.1
4	7	11.9	0.5	9	13.6	0.7	15	13.8	1.2	13	11.2	1.0	13	11.7	1.2
5	8	13.6	1.2	13	19.6	2.0	12	11.1	1.8	8	7.0	1.2	10	9.0	1.6
6	4	6.8	0.4	10	15.1	1.0	12	11.1	1.1	23	19.8	2.2	17	15.3	1.7
7	4	6.8	0.3	8	12.1	0.6	13	12.0	0.9	15	13	1.1	14	12.6	1.1
8	8	13.6	0.7	5	7.5	0.4	16	14.8	0.4	19	16.3	1.7	14	12.6	1.3
Unknown	0	0.0		0	0.0		3	2.7	0.1	2	1.7	0.5	2	1.8	---

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Incidence Rates of Legionellosis
LAC, CA and US, 2003-2012**



**Figure 2. Incidence Rates of Legionellosis by Age Group
LAC, 2008 - 2012**



**Figure 3. Incidence Rates of Legionellosis by SPA
LAC, 2009-2012**



**Figure 4. Reported Legionellosis Cases by Month of Onset
LAC, 2012 (N=111)**



**Figure 5. Legionellosis Rates by Race/Ethnicity
LAC, 2008 - 2012**



Map 7. Legionellosis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

LISTERIOSIS, NONPERINATAL

CRUDE DATA	
Number of Cases	26
Annual Incidence[a]	
LA County[b]	0.28
California[c]	0.30
United States[d]	0.17
Age at Diagnosis	
Mean	64
Median	70
Range	13 - 91

[a]Cases per 100,000 population.
[b]Rates calculated based on less than 19 cases or events are considered unreliable.
[c]California combines non-perinatal and perinatal cases, thus making non-comparable rates.
[d]Based on 2011 CDC Listeria Initiative data and 2011 US census data.

DESCRIPTION

Listeriosis is a disease caused by infection with *Listeria monocytogenes*, a Gram-positive rod found in soil throughout the environment. Listeriosis is often caused by ingestion of foods contaminated with *L. monocytogenes.* Foods often associated with *Listeria* contamination include raw fruits and vegetables, cold cuts, deli meats, and unpasteurized dairy products. The disease affects primarily persons of advanced age, pregnant women, newborns, and adults with weakened immune systems. On rare occasions, people without these risk factors have also contracted listeriosis. Symptoms of listeriosis include: fever, muscle aches, and sometimes nausea or diarrhea. If infection spreads to the nervous system, meningitis with symptoms such as headache, stiff neck, confusion, loss of balance, or convulsions can occur. Infected pregnant women may experience only a mild, flu-like illness; however, infection during pregnancy can lead to miscarriage or stillbirth, premature delivery, or infection of the newborn.

In general, listeriosis may be prevented by thoroughly cooking raw food from animal sources, such as beef, pork, or poultry; washing raw fruits and vegetables thoroughly before eating; and keeping uncooked meats separate from raw produce and cooked foods. Avoiding unpasteurized milk or foods made from unpasteurized milk and washing hands, knives, and cutting boards after handling uncooked foods also may prevent listeriosis.

Individuals at risk should follow additional recommendations: avoid soft cheeses such as feta, Brie, Camembert, blue-veined, and Mexican-style cheese. Hard cheeses, processed cheeses, cream cheese, cottage cheese, or yogurt need not be avoided altogether; however, individuals with severely compromised immune systems and/or several disease risk factors should avoid them.

Leftover foods or ready-to-eat foods, such as hot dogs and deli meats, should be cooked until steaming hot before eating. Finally, although the risk of listeriosis associated with foods from deli counters is relatively low, immunocompromised persons should avoid these foods or thoroughly heat cold cuts before eating.

2012 TRENDS AND HIGHLIGHTS

- No single race category comprised a majority of cases. Non-Hispanic whites comprised 42% of all non-perinatal listeriosis cases, whereas Hispanics comprised 31% cases. Asians made up19% of cases, the highest percentage since 2008 (Figure 3). Despite increased prevalence of conditions such as diabetes, that predispose to listeriosis, blacks consistently make up a smaller than expected proportion of cases.
- Regionally there is greater incidence of listeriosis in Service Planning Area (SPA) 2 compared to other SPAs in LAC (Figure 4). However SPA 5 has the highest incidence rate, 0.8 per 100,000.
- Historically the occurrence of listeriosis cases peaks in August and September (Figure 5). However in 2012, cases peaked in September and October. Most cases still occurred during warm-weather months.
- Nonperinatal listeriosis disproportionately affects the elderly and immunocompromised. The mean age of cases in 2012 was 64 years, with a median of 70 years, ranging from 13-91 years.
- There were three deaths due to nonperinatal listeriosis, at a case-fatality rate of 11.5%.

Reported Listeriosis, nonperinatal Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=20)			2009 (N=15)			2010 (N=14)			2011 (N=19)			2012 (N=26)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate*/ 100,000	No.	(%)	Rate*/ 100,000
Age Group															
<1	0	0.0	0.0	0	0.0		0	0.0		0	0.0	0.0	0	0.0	0.0
1-4	0	0.0	0.0	0	0.0		0	0.0		0	0.0	0.0	0	0.0	0.0
5-14	1	5.0	0.1	1	6.7		1	7.1		0	0.0	0.0	1	3.8	0.1
15-34	1	5.0	0.0	1	6.7		2	14.1		0	0.0	0.0	1	3.8	0.0
35-44	1	5.0	0.1	0	0.0		2	14.1		0	0.0	0.0	0	0.0	0.0
45-54	1	5.0	0.1	2	13.3		2	14.1		4	21.1	0.3	8	30.8	0.6
55-64	5	25.0	0.5	1	6.7		2	14.1		5	26.3	0.5	1	3.8	0.1
65+	11	55.0	1.1	10	66.7		5	35.7		10	52.6	0.9	15	57.7	1.4
Unknown	0	0.0	0.0	0	0.0		0	0.0		0	0.0	0.0	0	0.0	0.0
Race/Ethnicity															
Asian	6	30.0	0.5	0	0.0		1	7.1		2	10.5	0.1	5	19.2	0.4
Black	1	5.0	0.1	1	6.7		1	7.1		0	0.0	0.0	1	3.8	0.1
Hispanic	5	25.0	0.1	7	46.7		7	50.0		4	21.1	0.2	8	30.8	0.2
White	8	40.0	0.3	7	46.7		5	35.7		13	68.4	4.5	11	42.3	0.4
Other	0	0.0	0.0	0	0.0		0	0.0		0	0.0	0.0	0	0.0	0.0
Unknown	0	0.0	0.0	0	0.0		0	0.0		0	0.0	0.0	1	3.8	
SPA															
1	0	0.0	0.0	0	0.0		0	0.0		0	0.0	0.0	1	3.8	0.3
2	3	15.0	0.1	4	26.7		5	35.7		5	26.3	0.2	9	34.6	0.4
3	6	30.0	0.3	2	13.3		1	7.1		4	21.1	0.2	2	7.7	0.1
4	3	15.0	0.2	3	20.0		4	28.6		1	5.3	0.1	3	11.5	0.3
5	1	5.0	0.2	0	0.0		0	0.0		4	21.1	0.6	5	19.2	0.8
6	2	10.0	0.2	2	13.3		1	7.1		0	0.0	0.0	3	11.5	0.3
7	3	15.0	0.2	2	13.3		1	7.1		2	10.5	0.2	0	0.0	0.0
8	2	10.0	0.2	2	13.3		2	14.1		3	15.8	0.3	3	11.5	0.3
Unknown	0	0.0	0.0	0	0.0		0	0.0		0	0.0	0.0	0	0.0	0.0

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Reported Cases of Nonperinatal Listeriosis
LAC, 2003-2012**



**Figure 2. Reported Cases of Nonperinatal Listeriosis
by Age Group, LAC, 2012 (N=26)**



**Figure 3. Percent Cases of Nonperinatal Listeriosis
by Race/Ethnicity, LAC, 2012 (N=26)**



**Figure 4. Reported Cases of Nonperinatal Listeriosis by SPA
LAC, 2012 (N=26)**



Figure 5. Reported Nonperinatal Listeriosis Cases by Month of Onset LAC, 2012 (N=26)



LISTERIOSIS, PERINATAL

CRUDE DATA	
Number of Cases	7
Annual Incidence[a]	
LA County[b]	5.71
California[c]	N/A
United States[d]	0.013
Age at Diagnosis	
Mean	31
Median	32
Range	18-41

[a]Cases per 100,000 live births.
[b]Rates calculated based on less than 19 cases or events are considered unreliable.
[c] California combines non-perinatal and perinatal cases, thus making non-comparable rates.
[d]Based on 2011 CDC Listeria Initiative data and 2010 US census data.

DESCRIPTION

Listeriosis is a disease caused by infection with *Listeria monocytogenes*, a Gram-positive rod that is found in soil throughout the environment. Listeriosis is often caused by ingestion of foods contaminated with *L. monocytogenes.* Foods often associated with *Listeria* contamination include raw fruits and vegetables; undercooked meat, such as beef, pork, poultry, and pâté; cold cuts from deli counters; and unpasteurized dairy products—milk, milk products and soft cheeses (Mexican-style, Brie, feta, blue-veined, Camembert).

The disease affects primarily persons of advanced age, pregnant women, newborns, and adults with weakened immune systems. On rare occasions, people without these risk factors have also contracted listeriosis. Symptoms of listeriosis include: fever, muscle aches, and sometimes nausea or diarrhea. If infection spreads to the nervous system, symptoms such as headache, stiff neck, confusion, loss of balance, or convulsions can occur. Infected pregnant women may experience only a mild, flu-like illness; however, infections during pregnancy can lead to miscarriage, stillbirth, premature delivery, or infection of the newborn.

Pregnant women should avoid foods associated with *Listeria*, particularly cheeses sold by street vendors or obtained from relatives/friends in other countries, where food processing quality assurance is unknown.

Additionally fruits and vegetables should be thoroughly washed. Uncooked meats should be stored separately from vegetables, cooked foods, and ready-to-eat foods. Hands, utensils, and cutting boards should be washed after handling uncooked foods. Leftover foods or ready-to-eat foods, such as hot dogs, should be cooked until steaming hot before eating.

Finally, although the risk of listeriosis associated with foods from deli counters is relatively low, it is recommended that pregnant women avoid these foods or thoroughly heat cold cuts before eating.

Prevention strategies for healthcare providers include education during prenatal checkups, outreach to Latino communities, and food safety notices at food and deli markets.

2012 TRENDS AND HIGHLIGHTS

- In 2012, there were seven cases of perinatal listeriosis. Two cases were Hispanic expectant mothers; one case was Asian. There were four cases who were white non-Hispanic. All of the cases were single gestations. Six of the babies were born sick, with one neonatal fatality. One baby was treated at 35 weeks gestation and delivered at full term alive and well.
- Maternal ages ranged from 18 to 41 years.
- The number of perinatal listeriosis cases in 2012 is consistent within the range of incidence of listeriosis over the past ten years, excluding an aberrant increase in 2006 (Figure 1).
- Unlike previous years, non-Hispanic white mothers comprised the majority of cases of non-perinatal listeriosis in 2012, exceeding numbers seen in the past 5 years (Figure 2). Incidence of perinatal listeriosis remains consistent among Hispanic mothers. There have been no cases of perinatal listeriosis in black expectant mothers since 2006.
- None of the mothers reported eating fresh raw milk (unpasteurized, Mexican style) cheeses while pregnant. However one

mother ate pasteurized salted ricotta cheese that had been implicated in a listeriosis outbreak. She delivered a baby boy at 27 weeks, but the baby died four days after he was born. Her *Listeria* isolate was indistinguishable by PFGE from the *Listeria* isolated from the ricotta cheese.

Reported Perinatal Listeriosis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=2)			2009 (N=5)			2010 (N=4)			2011 (N=6)			2012 (N=7)		
	No.	(%)	Rate*/ 100,000	No.	(%)	Rate*/ 100,000	No.	(%)	Rate*/ 100,000	No.	(%)	Rate*/ 100,000	No.	(%)	Rate*/ 100,000
Age Group															
<1	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
1-4	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
5-14	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
15-34	2	100		4	80.0		3	75.0		3	50.0		4	57.1	
35-44	0	0.0		1	20.0		1	25.0		3	50.0		3	42.9	
45-54	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
55-64	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
65+	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	0	0.0		2	40.0		1	25.0		2	33.3		1	14.3	
Black	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Hispanic	2	100		3	60.0		2	50.0		3	50.0		2	28.6	
White	0	0.0		0	0.0		1	25.0		1	16.7		4	57.1	
Other	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
SPA															
1	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
2	0	0.0		0	0.0		2	0.0		0	0.0		2	28.6	
3	1	50.0		0	0.0		0	0.0		3	50.0		2	28.6	
4	0	0.0		2	40.0		0	0.0		0	0.0		1	14.3	
5	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
6	0	0.0		1	20.0		1	25.0		1	16.7		0	0.0	
7	1	50.0		0	0.0		1	25.0		0	0.0		1	14.3	
8	0	0.0		2	40.0		0	0.0		2	33.3		1	14.3	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Reported Cases of Perinatal Listeriosis LAC, 2003-2012



Figure 2. Perinatal Listeriosis Cases by Race/Ethnicity LAC, 2008-2012



Figure 3. Reported Perinatal Listeriosis Cases by Month of Onset, LAC, 2012 (N=7)



LYME DISEASE

CRUDE DATA	
Number of Cases	1
Annual Incidence [a]	
LA County [b]	0.01
California	0.16
United States	7.1
Age at Diagnosis	
Mean	72
Median	72
Range	--

[a]Cases per 100,000 population.
[b]Rates calculated based on less than 19 cases or events are considered unreliable.
[c]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Lyme disease (LD) is caused by the spirochete *Borrelia burgdorferi*, which is transmitted to humans by the bite of *Ixodes* ticks; the vector in the Pacific coast states is the western blacklegged tick (*Ixodes pacificus*). This disease is rarely acquired in Los Angeles County (LAC); most reported cases have been acquired in known endemic regions in the United States (US). The most common clinical presentation is a distinctive circular rash called erythema migrans (EM). When EM is not present, other early symptoms such as fever, body aches, headaches, and fatigue are often unrecognized as indicators of LD. If untreated, patients may develop late stage symptoms such as aseptic meningitis, cranial neuritis, cardiac conduction abnormalities and arthritis of the large joints. Early disease is treated with a short course of oral antibiotics, while late symptom manifestations may require longer treatment with oral or intravenous antibiotics. Currently, there is no vaccine.

For purposes of surveillance, the Centers for Disease Control and Prevention (CDC) require a confirmed case of LD to have:

- Physician-diagnosed EM that is at least 5 cm in diameter with known tick exposure (laboratory evidence is necessary without tick exposure), or
- At least one late manifestation of LD with supporting laboratory results.

Laboratory criteria for case confirmation include a positive culture for *B. burgdorferi* or demonstration of diagnostic IgM or IgG to *B.* burgdorferi in serum or cerebral spinal fluid. A coalition of several public health and medical organizations recommends a two-step serologic testing procedure for LD: an initial enzyme immunoassay or immunofluorescent antibody screening test, and if positive or equivocal, followed by IgM and IgG Western immunoblotting.[1]

Avoiding tick bite exposure is the primary means of preventing LD. The risk of acquiring infection with LD increases when the tick has attached to the body for at least 24 hours. Tips for preventing exposure to tick bites include checking the body regularly for prompt removal of attached ticks; wearing light-colored clothing so that ticks can be easily seen; wearing long pants and long-sleeved shirts and tucking pants into boots or socks; tucking shirts into pants; using tick repellant; treating clothing with products containing permethrin; staying in the middle of trails when hiking to avoid contact with bushes and grasses where ticks are most common; and checking for and controlling ticks on pets.

2012 TRENDS AND HIGHLIGHTS

- The national incidence rose as high as 13.4 cases per 100,000 in 2009 and dropped to 7.8 cases per 100,000 by 2011. The incidence in LAC in 2012 was 0.01 per 100,000 and has remained well below the national and state rates (Figure 1).
- The single confirmed case reported tick bite exposure in a highly endemic LD region outside of LAC (Massachussetts) (Figure 3).

[1]Recommendations for Test Performance and Interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR August 11, 1995/44(31);590-591, http://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm.

Reported Lyme Disease Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=9)			2009 (N=4)			2010 (N=5)			2011 (N=6)			2012 (N=1)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
1-4	2	22.2		0	0.0		0	0.0		0	0.0		0	0.0	
5-14	1	11.1		1	25.0		1	20.0		0	0.0		0	0.0	
15-34	1	11.1		0	0.0		2	40.0		1	16.7		0	0.0	
35-44	1	11.1		2	50.0		1	20.0		0	0.0		0	0.0	
45-54	3	33.3		0	0.0		0	0.0		3	50		0	0.0	
55-64	0	0.0		1	25.0		1	20.0		1	16.7		0	0.0	
65+	1	11.1		0	0.0		0	0.0		1	16.7		1	100	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Black	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Hispanic	0	0.0		0	0.0		1	20.0		0	0.0		0	0.0	
White	9	100		4	100		4	80.0		6	100		1	100	
Other	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0		
SPA															
1	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
2	2	22.2		1	25.0		0	0.0		2	33.3		1	100	
3	0	0.0		0	0.0		0	0.0		1	16.7		0	0.0	
4	1	11.1		0	0.0		2	40.0		0	0.0		0	0.0	
5	4	44.4		1	25.0		2	40.0		3	50.0		0	0.0	
6	0	0.0		1	25.0		1	20.0		0	0.0		0	0.0	
7	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
8	2	22.2		1	25.0		0	0.0		0	0.0		0	0.0	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0		

*Rates were not calculated because rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Incidence Rates of Lyme Disease LAC* and CA, 2000-2012



*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 2. Reported Lyme Disease Cases by Month of Onset LAC, 2012



Figure 3. Locations of Tick and Outdoor Exposure in Lyme Disease Cases LAC, 2000-2012



MALARIA

CRUDE DATA	
Number of Cases	19
Annual Incidence[a]	
LA County	0.20
California[b]	0.29
United States[b]	0.48
Age at Diagnosis	
Mean	35.1
Median	34
Range	2-81

[a]Cases per 100,000 population.
[b]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Human malaria is a febrile illness caused by infection with one or more species of the protozoan parasite, *Plasmodium* (usually *P. vivax*, *P. falciparum, P. malariae,* or *P. ovale*). Recently *P. knowlesi*, a parasite of Asian macaques, has been documented as a cause of human infections, including some deaths, in Southeast Asia. The first case in a US traveler was identified in 2008. An additional species similar to *P. ovale*, yet to be named, has also been recently discovered as a human pathogen. Transmission occurs by the bite of an infected *Anopheles* mosquito and mainly in tropical and subtropical areas of the world. The disease is characterized by episodes of chills and fever every 2 to 3 days. *P. falciparum* poses the greatest risk of death because it invades red blood cells of all stages and is often drug-resistant. The more severe symptoms of *P. falciparum* include jaundice, shock, renal failure, and coma.

For the purpose of surveillance, confirmation of malaria requires the demonstration of parasites in thick or thin blood smears or the detection of *Plasmodium* sp. by nucleic acid test, regardless of whether the person experienced previous episodes of malaria.

Before the 1950s malaria was endemic in the southeastern US. Now, it is usually acquired outside the continental US through travel and immigration. Although there is no recent documentation of malaria being transmitted locally, a particular mosquito, *A. hermsi*, exists in southern California in rare numbers, and is capable of transmitting the parasite.

Prevention methods for malaria include avoiding mosquito bites or, once exposed, preventing the development of disease by using antimalarial drugs as prophylaxis. Travelers to countries where malaria is endemic should take precautions by taking the appropriate antimalarial prophylaxis as prescribed, using mosquito repellants, utilizing bednets, and wearing protective clothing as well as avoiding outdoor activities between dusk and dawn when mosquito activity is at its peak.

2012 TRENDS AND HIGHLIGHTS

- The number of reported cases continues to decrease in Los Angeles County (LAC) from a peak of 60 cases in 2003 to only 19 cases in 2012 (Figure 1), of which all were confirmed by blood smear.
- Nearly one-third of all cases (n=6, 32%) were caused by *P. falciparum* and about a quarter (n=5, 26%) were caused by *P. vivax* (Figure 5). Twenty percent of cases could not be speciated (n=4, 21%).
- All cases reported a travel history to a country with endemic malaria (Table 1). This year, travelers to Africa represented 63% (n=12) of all cases and 100% (n=6) of *P. falciparum* cases.
- Twelve cases were residents of the US for at least 12 months, two of which (17%) used prophylaxis during their travels (Table 2). Both reported completing their regimen and traveled for pleasure.

Reported Malaria Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=30)			2009 (N=24)			2010 (N=25)			2011 (N=22)			2012 (N=19)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
1-4	0	0.0		3	12.5		1	4.0		0	0.0		1	5.3	
5-14	1	3.3		0	0.0		1	4.0		5	22.7		2	10.5	
15-34	12	40.0		6	25.0		12	48.0		3	13.6		7	36.8	
35-44	6	20.0		2	8.3		4	16.0		2	9.1		2	10.5	
45-54	7	23.3		5	20.8		4	16.0		8	36.4		3	15.8	
55-64	4	13.3		7	29.2		3	12.0		3	13.6		3	15.8	
65+	0	0.0		1	4.2		0	0.0		1	4.5		1	5.3	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	4	13.3		3	12.5		8	32.0		2	9.1		5	26.3	
Black	16	53.3		8	33.3		10	40.0		12	54.5		10	52.6	
Hispanic	1	3.3		9	37.5		1	4.0		1	4.5		2	10.5	
White	4	13.3		2	8.3		2	8.0		2	9.1		1	5.3	
Other	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Unknown	5	16.7		2	8.3		4	16.0		5	22.7		1	5.3	
SPA															
1	0	0.0		1	4.2		2	8.0		2	9.1		1	5.3	
2	8	26.7		6	25.0		3	12.0		6	27.3		5	26.3	
3	3	10.0		1	4.2		4	16.0		3	13.6		0	0.0	
4	2	6.7		0	0.0		2	8.0		2	9.1		1	5.3	
5	3	10.0		4	16.7		5	20.0		1	4.5		2	10.5	
6	5	16.7		4	16.7		5	20.0		2	9.1		1	5.3	
7	1	3.3		1	4.2		1	4.0		1	4.5		1	5.3	
8	6	20.0		7	29.2		3	12.0		5	22.7		8	42.1	
Unknown	2	6.7		0	0.0		0	0.0		0	0.0		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Number of Malaria Cases
LAC and US, 2000-2012**



**Figure 2. Malaria Cases by Age Group
LAC, 2012 (N=19)**



**Figure 3. Percent of Malaria Cases by Race/Ethnicity
LAC, 2012 (N=19)**



**Figure 4. Number of Reported Malaria Cases by Race/Ethnicity
LAC, 2008-2012**



Figure 5. Percent Cases of Malaria by Species LAC, 2012 (N=19)



Table 1. Malaria Cases by Country of Acquisition and *Plasmodium* Species, 2012, N=19						
Country of Acquisition	***P. falciparum***	***P. vivax***	***P. malariae***	**Unable to speciate**	**Unknown***	**Total**
Africa	**6**	**0**	**2**	**3**	**1**	**12**
Congo	1	0	0	0	0	1
Ghana	2	0	0	0	0	2
Liberia	1	0	0	0	0	1
Nigeria	2	0	1	1	0	4
Sierra Leone	0	0	0	0	1	1
Sudan	0	0	0	2	0	2
Uganda	0	0	1*	0	0	1
Asia/Oceania	**0**	**3**	**0**	**1**	**1**	**5**
India	0	2	0	0	1	3
Pakistan	0	0	0	1	0	1
Papua New Guinea	0	1	0	0	0	1
Latin America	**0**	**2**	**0**	**0**	**0**	**2**
Guatemala	0	1	0	0	0	1
Honduras	0	1	0	0	0	1
Total	**6**	**5**	**2**	**4**	**2**	**19**

* Reported as positive malaria smear but no species identification available.

Table 2. Prophylaxis Use Among US Residents* with Malaria, LAC 2012, N=12			
Reason for Travel	**Total Cases**	**Prophylaxis Use**	
	(n)	**(n)**	**(%)**
Pleasure	8	2	25
Work	1	0	0
Other	1	0	0
Unknown	2	0	0
Total	12	2	17

*Residing in US ≥12 months.

MEASLES

CRUDE DATA	
Number of Cases	6
Annual Incidence[a]	
LA County	0.06[b]
California[c]	0.02
United States[c]	0.02
Age at Diagnosis	
Mean	26.0 years
Median	21.5 years
Range	10 – 57 years

[a]Cases per 100,000 population.
[b]Rates calculated based on less than 19 cases or events are considered unreliable.
[c]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Measles is a vaccine-preventable disease caused by a paramyxovirus and is transmitted by contact with respiratory droplets or by airborne spread. The clinical case definition for measles is a fever of at least 101°F, a generalized rash lasting at least three days, and either cough, coryza, or conjunctivitis. Complications can include acute encephalitis and death from respiratory or neurologic complications. Immunocompromised individuals are more likely to develop complications. A case is confirmed by a positive IgM titer, a four-fold increase in acute and convalescent IgG titers, isolation of measles virus, or detection of viral RNA (RT-PCR).

Immunization Recommendations:

- Measles disease can be effectively prevented by Measles-Mumps-Rubella (MMR) or Measles-Mumps-Rubella-Varicella (MMRV) vaccine.
- Usually, two doses of measles-containing vaccine are given via MMR/MMRV vaccine. The first dose is recommended at 12 months of age. The second dose can be given as early as four weeks after the first dose, but is usually given at ages 4 to 6 years. When MMRV vaccine is used, the minimum interval between doses is 3 months.
- Vaccination is recommended for those born in 1957 or later who have no prior MMR vaccination, no serological evidence of measles immunity, or no documentation of physician-diagnosed measles. Proof of immunization with two MMR doses or serologic evidence of immunity is recommended for healthcare workers, persons attending post-high school educational institutions, as well as others who work or live in high-risk settings.
- Women should not become pregnant within 4 weeks of vaccination.
- Individuals who are severely immunocompromised for any reason should not be given MMR or MMRV.
- Measles is common in most regions of the world outside of North and South America. Large outbreaks have been reported in Europe, Africa, and Asia. All international travelers who are not immune to measles should be vaccinated, ideally 2 weeks prior to travel. Unvaccinated infants age ≥6 months should be vaccinated if they are traveling out of the country. Infants who are vaccinated before age 12 months should receive two more doses at the recommended schedule.

2012 TRENDS AND HIGHLIGHTS

- Six cases were reported in LAC in 2012, which, is the second highest incidence of cases reported since 2001 (Figure 1, Figure 2).
- Consistent with previous years, most (5) of the six cases in LAC were associated with travel. One case traveled to/from Asia. Two of the cases, a mother and her child, were visiting from the United Kingdom (U.K.) where measles is once again endemic, and subsequently infected two persons residing in LAC.
- Four of the cases were epidemiologically linked, with all of them related to the cluster of cases from the U.K. exposure. All four of the epidemiologically linked cases were unvaccinated due to personal beliefs (Figure 6).
- With the exception of one case, the distribution of cases was similar to previous years in which all cases were <45 years of age (Figure 3). All of the cases were eligible for vaccination but were not up-to-date. Unlike previous years, all of the cases in 2012 were white (n=6).
- The cases resided in SPA 2 and SPA 4 (Figure 4).
- Unlike previous years when cases occurred throughout the year, no cases were reported after April. The month of April had a significant increase in cases, due in large part to the linked cases from the U.K. (Figure 5).

Reported Measles Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=1)			2009 (N=1)			2010 (N=8)			2011 (N=8)			2012 (N=6)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	-	0	0.0	-	1	12.5	0.7	0	0.0	-	0	0.0	-
1-4	1	100.	0.2	0	0.0	-	1	12.5	0.2	3	37.5	0.6	0	0.0	-
5-14	0	0.0	-	0	0.0	-	2	25.0	0.2	0	0.0	-	3	50.0	0.3
15-34	0	0.0	-	0	0.0	-	2	25.0	0.1	5	62.5	0.2	1	16.7	-
35-44	0	0.0	-	1	100.	0.1	2	25.0	0.1	0	0.0	-	1	16.7	0.1
45-54	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-
55-64	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	1	16.7	0.1
65+	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	0	0.0	-	0	0.0	-	0	0.0	-	4	50.0	0.3	0	0.0	-
Black	0	0.0	-	0	0.0	-	2	25.0	0.2	0	0.0	-	0	0.0	-
Hispanic	1	100.	-	0	0.0	-	4	50.0	0.1	2	25.0	-	0	0.0	-
White	0	0.0	-	1	100.	-	2	25.0	0.1	1	12.5	-	6	100.	0.2
Other	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-
Unknown	0	0.0		0	0.0		0	0.0		1	12.5		0	0.0	
SPA															
1	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-
2	1	100.	-	1	100.	-	4	50.0	0.2	1	12.5	-	5	83.3	0.2
3	0	0.0	-	0	0.0	-	0	0.0	-	2	25.0	0.1	0	0.0	-
4	0	0.0	-	0	0.0	-	0	0.0	-	2	25.0	0.2	1	16.7	0.1
5	0	0.0	-	0	0.0	-	1	12.5	0.2	2	25.0	0.3	0	0.0	-
6	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-
7	0	0.0	-	0	0.0	-	3	37.5	0.2	0	0.0	-	0	0.0	-
8	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-
Unknown	0	0.0		0	0.0		0	0.0		1	12.5		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable. A zero rate is reported with a dash ("-").

**Figure 1. Incidence Rates of Measles
LAC, CA and US, 2003-2012**



**Figure 2. Reported Measles Cases
LAC, 2003-2012**



**Figure 3. Reported Confirmed Measles Cases by Age Group
LAC, 2012 (N=6)**



**Figure 4. Reported Confirmed Measles Cases by SPA
LAC, 2012 (N=6)**



Figure 5. Reported Confirmed Measles Cases by Month of Onset LAC, 2012 (N=6) vs. Previous Five-Year Average



Figure 6. Vaccination Status of Reported Measles Cases LAC, 2012

	Reported Cases	Cases Too Young to Be Vaccinated[1]	Cases Eligible for Vaccination and Up-to-Date[2]	Cases Eligible for Vaccination and Not Up-To-Date[3]	Personal Beliefs Exemption School Vaccine Waivers Among Cases Age <18 Years (n=3)
No.	6	0	0	6	3
%	100%	0.0%	0.0%	100%	100%

[1]Cases less than 12 months of age

[2]Cases 12 months of age and older and who are up-to-date with the measles immunization recommendations for their age

[3]Cases 12 months of age and older and who are not up-to-date with the measles immunization recommendations for their age. Includes cases that have unknown immunization status, have personal belief exemption school vaccine waivers, or have no valid documentation of receiving measles vaccines prior to disease onset.

MENINGITIS, VIRAL

CRUDE DATA	
Number of Cases	303
Annual Incidence[a]	
LA County	3.26
Age at Diagnosis	
Mean	35.8
Median	35
Range	0-88

[a]Cases per 100,000 population.

DESCRIPTION

Viruses are the major cause of aseptic meningitis syndrome, a term used to define any meningitis (infectious or noninfectious), particularly one with a cerebrospinal fluid lymphocytic pleocytosis, for which a cause is not apparent after initial evaluation and routine stains and cultures do not support a bacterial or fungal etiology. Viral meningitis can occur at any age but is most common among the very young. Symptoms are characterized by sudden onset of fever, severe headache, stiff neck, photophobia, drowsiness, confusion, nausea and vomiting and usually last from seven to ten days.

The most common cause of viral meningitis is the nonpolio enteroviruses which are not vaccine-preventable and account for 85% to 95% of all cases in which a pathogen is identified. Transmission of enteroviruses may be by the fecal-oral, respiratory or other route specific to the etiologic agent. Other viral agents that can cause viral meningitis include herpes simplex virus (HSV), varicella-zoster virus (VZV), mumps virus, lymphocytic choriomeningitis virus, human immunodeficiency virus, adenovirus, parainfluenza virus type 3, influenza virus, measles virus and arboviruses, such as West Nile virus (WNV). In most cases, only supportive measures are available; several are vaccine-preventable. Antiviral agents are available for HSV and VZV. Recovery is usually complete and associated with low mortality rates. Several are vaccine-preventable (VZV, mumps, influenza, measles).

Good personal hygiene, especially hand washing and avoiding contact with oral secretions of others, is the most practical and effective preventive measure.

2012 TRENDS AND HIGHLIGHTS

- In 2012, viral/aseptic meningitis incidence was 3.3 cases per 100,000, similar to the prior year. The incidence was as high as 9.6 per 100,000 in 2002 and has been declining since then (Figure 1).
- Though SPA 1 (Antelope Valley) continued to report the highest rate of viral meningitis in LAC (4.6 cases per 100,000), the rate was very similar to SPAs 3 and 7 (Figure 2). This is the lowest rate documented in SPA 1 since 2001. From 2002 through 2011, SPA 1 has recorded rates consistently over 10 cases per 100,000, much higher than the overall rate for LAC. The Varicella Active Surveillance Project, a study conducted since 1997 in the Antelope Valley and ended September 2012, likely contributed by enhancing reporting to LAC DPH.
- The incidence of viral/aseptic meningitis stratified by age groups remained similar to rates in 2011. The <1 year old age group remained the highest age-specific incidence rate at 23.5 per 100,000 (Figure 3).
- The etiologies of 88 cases were identified (29%). Of those, 67 (76%) were caused by WNV, 10 (12%) by an enterovirus, and 8 (9%) by HSV (Figure 6).
- Two deaths (<1%) were reported; their etiologies were not determined.

Reported Viral Meningitis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=597)			2009 (N=399)			2010 (N=570)			2011 (N=317)			2012 (N=303)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	80	13.4	57.3	53	13.3	38.6	89	15.6	63.8	33	10.4	23.6	28	9.2	23.5
1-4	24	4.0	4.2	14	3.5	2.5	33	5.8	5.7	6	1.9	1.0	4	1.3	0.8
5-14	148	24.8	10.5	71	17.8	5.2	138	24.2	10.4	53	16.7	4.0	24	7.9	2.0
15-34	164	27.5	5.7	148	37.1	5.2	164	28.8	5.6	102	32.2	3.5	93	30.7	3.4
35-44	52	8.7	3.4	42	10.5	2.8	56	9.8	3.9	39	12.3	2.7	45	14.9	3.4
45-54	44	7.4	3.3	34	8.5	2.5	39	6.8	2.9	41	12.9	3.0	40	13.2	3.1
55-64	29	4.9	3.2	18	4.5	1.9	17	3.0	1.8	24	7.6	2.5	32	10.6	3.1
65+	51	8.5	5.0	19	4.8	1.8	33	5.8	3.1	18	5.7	1.7	37	12.2	3.3
Unknown	5	0.8		0	0.0		1	0.2					0	0.0	
Race/Ethnicity															
Asian	37	6.2	2.8	21	5.3	1.6	36	6.3	2.7	21	6.6	1.6	23	7.6	1.7
Black	43	7.2	5.0	23	5.8	2.7	64	11.2	7.5	37	11.7	4.3	36	11.9	4.7
Hispanic	275	46.1	5.9	208	52.1	4.4	259	45.4	5.5	147	46.4	3.1	131	43.2	2.9
White	121	20.3	4.2	80	12.5	2.7	112	19.6	3.9	78	24.6	2.7	86	28.4	3.2
Other	20	3.4		4	1.0		13	2.3		7	2.2		10	3.3	
Unknown	101	16.9		63	15.8		86	15.1		27	8.5		17	5.6	
SPA															
1	69	11.6	18.8	46	11.5	12.5	45	7.9	12.1	33	10.4	8.8	18	5.9	4.6
2	80	13.4	3.7	88	22.1	4.0	86	15.1	3.9	67	21.1	3.0	63	20.8	2.9
3	86	14.4	5.0	63	15.8	3.6	98	17.2	5.6	75	23.7	4.3	68	22.4	4.2
4	24	4.0	1.9	18	4.5	1.4	29	5.1	2.3	14	4.4	1.1	16	5.3	1.4
5	29	4.9	4.5	22	5.5	3.4	13	2.3	2.0	15	4.7	2.3	10	3.3	1.6
6	79	13.2	7.5	45	11.3	4.3	76	13.3	7.1	26	8.2	2.4	29	9.6	2.9
7	131	21.9	9.5	62	15.5	4.5	92	16.1	6.7	48	15.1	3.5	57	18.8	4.4
8	90	15.1	8.0	53	13.3	4.7	121	21.2	10.8	35	11.0	3.1	36	11.9	3.4
Unknown	9	1.5		2	0.5		10	1.8		4	1.3		6	2.0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Incidence Rates of Viral Meningitis
LAC, 2000-2012**



**Figure 2. Incidence Rates of Viral Meningitis by SPA
LAC, 2012 (N=303)**



**Figure 3. Incidence Rates of Viral Meningitis by Age Group
LAC, 2012 (N=303)**



**Figure 4. Reported Viral Meningitis Cases by Month of Onset
LAC, 2012 (N=303)**



Figure 5. Incidence Rates of Viral Meningitis by Race/Ethnicity LAC, 2008-2012



Figure 6. Percent Cases of Viral Meningitis by Etiology, LAC, 2012 (N=303)



Map 8. Viral Meningitis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

MENINGOCOCCAL DISEASE

CRUDE DATA	
Number of Cases	12
Annual Incidence[a]	
LA County	0.13
California[b]	0.23
United States[b]	0.18
Age at Diagnosis	
Mean	52.8
Median	51
Range	21-94

[a]Cases per 100,000 population.
[b]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Meningococcal disease occurs most often as meningitis, an infection of the cerebrospinal fluid (CSF), or meningococcemia, an infection of the bloodstream. It is transmitted through direct or droplet contact with nose or throat secretions of persons colonized in the upper respiratory tract with the *Neisseria meningitidis* bacterium. Common symptoms include sudden onset of fever, headache, nausea, vomiting, stiff neck, petechial rash and lethargy which can progress to overwhelming sepsis, shock and death within hours. Despite effective antibiotic therapy, the mortality rate remains between 10% and 15%. Long-term sequelae include significant neurologic or orthopedic complications such as deafness or amputation. Meningococcal disease affects all age groups but occurs most often in infants. Of the 13 serogroups, A, B, C, Y, and W-135 are responsible for causing nearly all cases of meningococcal disease.

For the purpose of surveillance, the Los Angeles County (LAC) Department of Public Health (DPH) defines reports of invasive meningococcal disease as confirmed when *N. meningitidis* has been isolated from a normally sterile site (e.g., blood or CSF). In the absence of a positive culture, reports are defined as probable if there is evidence of the bacteria in a normally sterile site by polymerase chain reaction (PCR) analysis or CSF antigen test. Reports are classified as suspected cases when they present with clinical diagnosis of purpura fulminans or demonstrate gram-negative diplococci by gram staining.[1]

Three vaccines are available in the US that protect against serogroups A, C, Y, and W-135 but not B. A quadrivalent unconjugated polysaccharide meningococcal vaccine (Menomune®) is licensed for persons > 55 years and for those ≥2 years old when quadrivalent conjugated-polysacharide vaccine are not available. Two quadrivalent conjugate vaccines, MenACWY-D (Menactra®) and MenACWY-CRM (Menveo®), are licensed for use in persons aged 2 to 55 years; MenACWY-D is also licensed for used in children age 9 through 23 months. Both vaccines are recommended for all adolescents between ages 11-18 years, preferably at 11 or 12 years, and for those between 2-55 years who are at increased risk for meningococcal disease. An additional booster dose is needed if the primary dose was given before 16 years old. Routine vaccination is recommended for college freshman living in dormitories, persons at increased risk for meningococcal disease. An additional conjugate vaccine, Hib-MenCY-TT (MenHibrix®), has been licensed for infants 6 weeks to 18 months old, but only protects against serogroups C and Y disease.[2]

Antimicrobial chemoprophylaxis of close contacts of sporadic cases of meningococcal disease remains the primary means for prevention of meningococcal disease among close contacts, who include: a) household members, b) daycare center contacts, and c) anyone directly exposed to the patient's oral secretions (e.g., through kissing, mouth-to-mouth resuscitation, endotracheal intubation, or endotracheal tube management). Because the rate of secondary disease for close contacts is highest during the first few days after onset of disease in the primary patient, antimicrobial chemoprophylaxis should be administered as soon as possible (ideally within 24 hours after the case is identified). Conversely, chemoprophylaxis administered >10 days after onset of illness in the index case-patient is probably of limited or no value. Prophylactic treatment and follow-up of close contacts are routinely handled by the LAC DPH Community Health Services.

2012 TRENDS AND HIGHLIGHTS

- The incidence of meningococcal disease declined by 60% from 0.38 cases per 100,000 in 2011 to 0.13 cases per 100,000 in 2012. The incidence rate has declined consistently since 2001 when there was a peak of 0.64 cases per 100,000 (Figure 1).
- There were no cases reported among persons less than 21 years old (Figure 2). The highest number of cases occurred among those 15 to 34 years old and 65 years and older. However, in a typical distribution curve for meningococcal disease the peak incidence occurs among infants <1 year old.

1. Centers for Disease Control and Prevention. National Notifiable Disease Surveillance System. Meningococcal Disease (Neisseria meningitidis), 2010 Case Definition. http://wwwn.cdc.gov/NNDSS/script/casedef.aspx?CondYrID=774&DatePub=1/1/2010 12:00:00 AM. Accessed: May 29, 2013.
2. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. Prevention and Control of Meningococcal Disease, Recommendations of the Advisory Committee on Immunization Practices (ACIP). 22 Mar 2013, 62 (2): 1-28.

- The monthly onset of disease did not follow the typical seasonal trend of peaks in the winter season. The highest numbers of cases usually occur in January and February. In 2012, the highest numbers of cases were recorded in December and May (Figure 4).
- Nearly all of the cases were culture-confirmed (n=11, 92%): 10 (83%) were cultured from blood and one from (8%) from cerebrospinal fluid (CSF). One case was probable by PCR. Of the culture-confirmed cases all cases had serogroup identified; 5 (42%) were serogroup C, 3 (25%) were serogroup B, and 3 (25%) were serogroup W-135. The probable case was serogroup Y. Serogroup W-135 accounted for more cases than usual (Figure 6).
- The case fatality rate, 33% (n=4), is much higher than what has been usually recorded for LAC. Three of the fatalities were serogroup C disease and one was serogroup W-135.
- Beginning mid-December 2012, three cases of serogroup C meningococcal disease occurred among males aged 30 to 51 years. Two were men who have sex with men (MSM), of which one was fatal. The third case had recent travel history to Tijuana, Mexico. These three cases became associated with two separate clusters that extended into 2013, one among MSM and the other among cases who reported travel to Tijuana or high risk contact with travelers to Tijuana. Molecular analysis showed that the strains affecting the two MSM were related, and strain affecting the traveler to Tijuana matched other cases associated with Tijuana. However, within each of the two clusters, none of the MSM or Tijuana cases had direct social links to each other.[3]

3. Centers for Disease Control and Prevention. Notes from the field: serogroupo C invasive meningococcal disease among men who have sex with men – New York City, 2010-2012. Morbidity and Mortality Weekly Report. 4 Jan 2013; 61(51): 1048.

Reported Meningococcal Disease Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=30)			2009 (N=21)			2010 (N=26)			2011 (N=37)			2012 (N=12)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	3	10.0		1	4.8		2	7.7		0	0.0		0	0.0	
1-4	1	3.3		1	4.8		2	7.7		1	2.7		0	0.0	
5-14	6	20.0		1	4.8		1	3.8		1	2.7		0	0.0	
15-34	6	20.0		10	47.6		8	30.8		12	32.4		4	33.3	
35-44	5	16.7		0	0.0		4	15.3		10	27.0		0	0.0	
45-54	3	10.0		4	19.0		5	19.2		3	8.1		2	16.7	
55-64	4	13.3		4	19.0		1	3.8		5	13.5		2	16.7	
65+	2	6.7		0	0.0		3	11.5		5	13.5		4	33.3	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	1	3.3		0	0.0		1	3.8		4	10.8		2	16.7	
Black	4	13.3		4	19.0		7	26.9		12	32.4		2	16.7	
Hispanic	20	66.7		9	42.9		11	42.3		11	29.7		5	41.7	
White	4	13.3		7	33.3		7	26.9		10	27.0		3	25.0	
Other	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Unknown	1	3.3		1	4.8		0	0.0		0	0.0		0	0.0	
SPA															
1	2	6.6		1	4.8		1	3.8		1	2.7		0	0.0	
2	3	10.0		5	23.8		3	11.5		9	24.3		2	16.7	
3	4	13.3		1	4.8		3	11.5		2	5.4		0	0.0	
4	6	20.0		2	9.5		2	7.7		5	13.5		5	41.7	
5	5	16.7		2	9.5		2	7.7		1	2.7		2	16.7	
6	7	23.3		5	23.8		6	23.1		9	24.3		3	25.0	
7	2	6.7		2	9.5		3	11.5		4	10.8		0	0.0	
8	1	3.3		3	14.3		6	23.1		6	16.2		0	0.0	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Incidence Rates* of Meningococcal Disease LAC and US, 2000-2012



*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 2. Meningococcal Disease Cases by Age Group, LAC, 2012 (N=12)



Figure 3. Meningococcal Disease Cases by Race/Ethnicity, LAC, 2008-2012



3. Centers for Disease Control and Prevention. Notes from the field: serogroupo C invasive meningococcal disease among men who have sex with men – New York City, 2010-2012. Morbidity and Mortality Weekly Report. 4 Jan 2013; 61(51): 1048.

Figure 4. Reported Meningococcal Disease Cases by Month of Onset, LAC, 2012 (N=12)



Figure 5. Meningococcal Disease Cases by SPA LAC, 2012 (N=12)



Figure 6. Meningococcal Disease by Serogroup LAC, 2008–2012



MUMPS

CRUDE DATA	
Number of Cases	13
Annual Incidence[a]	
LA County	0.14[b]
California[c]	0.09
United States[c]	0.07
Age at Diagnosis	
Mean	35.5 years
Median	40.0 years
Range	3.0 – 73.0 years

[a]Cases per 100,000 population.
[b]Rates calculated based on less than 19 cases or events are considered unreliable.
[c]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Mumps is a vaccine-preventable disease caused by an RNA paramyxovirus that is transmitted by direct contact with respiratory droplets from infected persons. The clinical case definition for mumps is an acute onset of unilateral or bilateral swelling of the parotid or other salivary glands lasting ≥2 days without other apparent cause. Complications include encephalitis, meningitis, orchitis, arthritis, and deafness. A case is confirmed by isolation of mumps virus or detection of viral RNA (RT-PCR).

Immunization Recommendations:

- Mumps disease can be prevented by Measles-Mumps-Rubella (MMR) or Measles-Mumps-Rubella-Varicella (MMRV) vaccine.
- Usually, two doses of mumps-containing vaccine are given via MMR or MMRV vaccine. Vaccine effectiveness for the mumps component is about 88% after two doses. The first dose is recommended at 12 months of age. The second dose can be given as early as four weeks after the first dose, but is usually given at ages 4 to 6 years. When MMRV vaccine is used, the minimum interval between doses is 3 months.
- Vaccination is recommended for those born in 1957 or later who have no prior MMR vaccination, no serological evidence of mumps immunity, or no documentation of physician-diagnosed mumps. Proof of immunization with two MMR doses or serologic evidence of immunity is recommended for health care workers, persons attending post-high school educational institutions, international travelers as well as others who work or live in high-risk settings (e.g., healthcare facility, daycare, college/university, or correctional facility).
- Pregnant women and individuals who are severely immunocompromised for any reason are contraindicated to receive MMR or MMRV vaccine.

2012 TRENDS AND HIGHLIGHTS

- In 2012, the classification for a confirmed and probable case of mumps was revised. A case can now only be confirmed by isolation of mumps virus or detection of viral RNA (RT-PCR). Cases previously classified as confirmed by a positive IgM titer, a significant increase in acute and convalescent IgG titers, or epidemiologic linkage to a confirmed case are now classified as probable. Thus, probable cases in 2012 are included in the analysis to be comparable to previous years.
- Of the 13 reported mumps cases in 2012, 1 (7.7%) was confirmed and 12 (92.3%) were probable. Ten of the probable cases were confirmed by a positive IgM titer. This represents a significant increase in comparison to the three cases in 2011, all of which were confirmed by a positive IgM titer. The reason for this increase is unknown.
- Four cases in 2012 were epidemiologically linked, all of them from a cluster of 4 cases in SPA 5.
- The index case in this cluster was a female who infected her husband and child. The index case's child subsequently infected a 3 year old classmate in a pre-school setting. The 3 year old exposed in the pre-school setting was the lone confirmed case for 2012 and was unvaccinated. Based on this cluster of cases, Los Angeles County released a health alert in July 2012 to health care providers recommending heightened surveillance for mumps. A vaccination clinic was also organized with the school to increase mumps vaccine access for children residing in the area.
- Of those eligible for vaccination, 69.2% were not up-to-date according to the immunization recommendation for their age. (Figure 6).
- The mean age of cases in 2012 (mean=35.5 years) remained relatively the same compared to 2011 (mean=36.0). However, the mean age of cases in 2012 increased when compared to the

previous three year average (mean=27.3), (Figure 7). The lower mean age for the previous three years can be attributed to a cluster of cases in the 5-14 and 15-34 age groups during the 2010 outbreak.

- Although persons born prior to 1957 are generally considered to be immune to mumps, two of the cases were in the 65+ age group (Figure 3).
- Similar to the last two years, whites comprised of most the cases reported in 2012 (76.9%) (Figure 4).

Reported Mumps Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=7)			2009 (N=7)			2010 (N=20)			2011 (N=3)			2012 (N=13)**		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-
1-4	0	0.0	-	2	28.6	0.4	1	5.0	0.2	0	0.0	-	3	23.1	0.6
5-14	1	14.3	0.1	0	0.0	-	8	40.0	0.6	0	0.0	-	1	7.7	0.1
15-34	2	28.6	0.1	4	57.1	0.1	8	40.0	0.3	2	66.7	0.1	2	15.4	0.1
35-44	1	14.3	0.1	0	0.0	-	0	0.0	-	0	0.0	-	2	15.4	0.2
45-54	3	42.9	0.2	0	0.0	-	2	10.0	0.1	0	0.0	-	1	0.0	0.1
55-64	0	0.0	-	0	0.0	-	1	5.0	0.1	0	0.0	-	2	15.4	0.2
65+	0	0.0	-	1	14.3	0.1	0	0.0	-	1	33.3	0.1	2	15.4	0.2
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	1	14.3	0.1	3	42.8	0.2	0	0.0	-	0	0.0	-	2	15.4	0.2
Black	0	0.0	-	1	14.3	0.1	1	5.0	0.1	0	0.0	-	0	0.0	-
Hispanic	3	42.9	0.1	2	28.6	-	3	15.0	0.1	0	0.0	-	1	7.7	-
White	3	42.9	0.1	1	14.3	-	16	80.0	0.6	3	100	0.1	10	76.9	0.4
Other	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
SPA															
1	1	14.3	0.3	1	14.3	0.3	0	0.0	-	0	0.0	-	0	0.0	-
2	2	28.6	0.1	1	14.3	-	4	20.0	0.2	0	0.0	-	4	30.8	0.2
3	1	14.3	0.1	1	14.3	0.1	1	5.0	0.1	1	33.3	0.1	1	7.7	0.1
4	1	14.3	0.1	0	0.0	-	7	35.0	0.6	0	0.0	-	0	0.0	-
5	2	28.6	0.3	2	28.6	0.3	2	10.0	0.3	1	33.3	0.2	5	38.5	0.8
6	0	0.0	-	1	14.3	0.1	0	0.0	-	0	0.0	-	0	0.0	-
7	0	0.0	-	0	0.0	-	0	0.0	-	0	0.0	-	1	7.7	0.1
8	0	0.0	-	1	14.3	0.1	6	30.0	0.5	1	33.3	0.1	2	15.4	0.2
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable. A zero rate is reported with a dash ("-").
**Includes newly defined probable cases.

Figure 1. Incidence Rates of Confirmed Mumps LAC, CA and US, 2003-2012*



*Confirmed and probable case classifications were revised in 2012, so probable cases are included in the analysis to be comparable to previous years.

Figure 2. Reported Confirmed Mumps Cases LAC, 2003-2012*



*Confirmed and probable case classifications were revised in 2012, so probable cases are included in the analysis to be comparable to previous years.

Figure 3. Reported Confirmed* Mumps Cases by Age Group LAC, 2012 (N=13)



*Includes newly probable cases.

Figure 4. Percent Cases of Confirmed* Mumps by Race/Ethnicity LAC, 2013 (N=13)



*Includes newly defined probable cases.

Figure 4. Reported Confirmed Mumps Cases by SPA LAC, 2012 (N=13)



*Includes newly defined probable cases.

Figure 5. Reported Confirmed Mumps Cases by Month of Onset LAC, 2012 (N=13) vs. Previous Five-Year Average



*Includes newly defined probable cases.

Figure 6. Vaccination Status of Reported Confirmed* Mumps Cases, LAC, 2012

	Reported Cases	Cases Too Young to Be Vaccinated[1]	Cases Eligible for Vaccination and Up-to-Date[2]	Cases Eligible for Vaccination and Not Up-To-Date[3]	Personal Beliefs Exemption School Vaccine Waivers Among Cases Age <18 Years (n=4)
No.	13	**0**	**4**	**9**	**0**
%	100%	**0%**	**30.8%**	**69.2%**	**0%**

*Includes probable cases.
[1]Cases less than 12 months of age.
[2]Cases12 months of age and older and who are up-to-date with the mumps immunization recommendations for their age.
[3]Cases12 months of age and older and who are not up-to-date with the mumps immunization recommendations for their age. Includes cases that have unknown immunization status, have personal belief exemption school vaccine waivers, or have no valid documentation of receiving mumps vaccines prior to disease onset.

Figure 7. Reported Mumps Cases by Case Classification LAC, 2012 vs. Previous Three-Year Average

	Confirmed*	Confirmed
	2012	**2009-2011 Average**
Total Cases	**13**	**10.0**
Age at Onset (years)		
Mean	**35.5**	**27.3**
Median	**40.0**	**19.8**
Range	**3.0 – 73.0**	**2.0 – 70.0**

*Confirmed and probable case classifications were revised in 2012, so probable cases are included in the analysis to be comparable to previous years.

PERTUSSIS (WHOOPING COUGH)

CRUDE DATA	
Number of Cases	154
Annual Incidence[a]	
LA County	1.66
California[b]	2.11
United States[b]	15.49
Age at Diagnosis	
Mean	16.2 years
Median	10.0 years
Range	Birth – 79 years

[a]Cases per 100,000 population.
[b]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Pertussis, commonly known as whooping cough, is a vaccine-preventable disease spread by close contact with the respiratory secretions of infected individuals. The clinical case definition for pertussis is a cough lasting at least two weeks with paroxysms of coughing, a inspiratory "whoop," or post-tussive vomiting, without other apparent causes. Complications include pneumonia, seizures, and encephalopathy. Infants under one year of age are at highest risk for developing severe complications. Pertussis is confirmed by either positive *Bordetella pertussis* culture or PCR.

Immunization Recommendations:

- A pertussis-containing vaccine (DTP/DTaP) should be administered at 2, 4, 6, 15-18 months, and 4-6 years of age to provide protection against the disease.
- Immunity conferred by the pertussis component of the DTP/DTaP vaccine decreases over time, with some vaccinated individuals becoming susceptible to pertussis 5 to 10 years following their last dose. Two Tdap vaccines are licensed and are recommended for use in adolescents and adults.
- Since July 2011, the California school immunization law requires that all students entering the 7th grade be vaccinated with Tdap.

2012 TRENDS AND HIGHLIGHTS

- In 2012, a total of 154 pertussis cases (97 confirmed, 57 probable) (1.66 cases per 100,000) were reported to Los Angeles County (LAC), a decrease of more than 60% from 2011 (Figures 1 and 2). This continued decrease in cases brings LAC to a level comparable to 2009, the year prior to the 2010 resurgence. Unlike previous years, the incidence trend peaking in the summer was not observed (Figure 7). No deaths were reported.
- Similar to previous years, infants less than one year of age had the highest incidence rate (25.2 cases per 100,000) (Figure 3). However, infants continued to account for a smaller proportion of reported cases (19.5%) compared to a previous five year average of 41.4%. The highest proportion of cases was reported in the 5-14 and 15-34 year age groups, accounting in total for nearly half (49.3%) of all cases reported in 2012 and underscoring the importance of Tdap immunizations among adolescents and adults.
- Similar to previous years, Hispanics and whites accounted for the highest proportion of cases and age-adjusted incidence rates (Figure 4, Figure 5).
- In 2012 and for the third year in a row, SPA 2 had the highest proportion of cases observed (27.9%). However, the highest incidence rate was observed in SPA 5 (3.4 cases per 100,000) (Figure 6). This high incidence rate was attributable to school outbreaks that occurred towards the end of the year and accounted for 73% of all cases.
- Among the 27 cases that had epidemiological linkages to other cases, nearly half resided in SPA 2 (n=7, 25.9%) and SPA 5 (n=6, 22.2%). A similar proportion was observed for SPA 2 in 2011 (25.3%), but the proportion for SPA 5 is the highest percentage observed in the last 5 years, in part due to the school outbreaks. In SPA 2, the vast majority of epidemiologically linked cases were household contacts.
- Of the total 154 cases, 51.9% (n=79) were either too young to be vaccinated (5.8%) or were not up-to-date with the immunization recommendations for their age (46.1%) indicating that more work needs to be done to increase pertussis vaccination rates. Additionally, 8.8% (n=10) of the cases less than 18 years of age had personal belief

exemption school vaccine waivers which is similar to the percentage reported in 2011 (8.0%), but is more than twice the percentage reported in 2010 (4.2%) (Figure 8). The increasing proportion in the last two years is due in part to the rise of personal belief exemption (PBE) rates throughout LAC.

Reported Pertussis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=80)			2009 (N=156)			2010 (N=972)			2011 (N=453)			2012 (N=154)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	42	52.5	30.1	79	50.7	57.6	273	28.1	195.	139	30.7	117.	30	19.5	25.2
1-4	7	8.8	1.2	10	6.4	1.8	158	16.2	27.2	73	16.1	15.1	22	14.3	4.6
5-14	13	16.3	0.9	18	11.5	1.3	304	31.3	22.9	133	29.4	11.0	53	34.4	4.4
15-34	12	15.0	0.4	20	12.8	0.7	122	12.5	4.1	48	10.6	1.7	23	14.9	0.8
35-44	1	1.3	0.1	9	5.8	0.6	40	4.1	2.8	26	5.7	2.0	8	5.2	0.6
45-54	2	2.5	0.1	12	7.7	0.9	28	2.9	2.1	14	3.1	1.1	6	3.9	0.5
55-64	2	2.5	0.2	5	3.2	0.5	24	2.5	2.5	9	2.0	0.9	6	3.9	0.6
65+	1	1.3	0.1	3	1.9	0.3	23	2.4	2.2	11	2.4	1.0	6	3.9	0.5
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	4	5.0	0.3	10	6.4	0.8	32	3.3	2.4	17	3.8	1.3	8	5.2	0.6
Black	4	5.0	0.5	6	3.9	0.7	50	5.1	5.9	24	5.3	3.1	10	6.5	1.3
Hispanic	52	65.0	1.1	100	64.1	2.1	655	67.4	13.8	286	63.1	6.4	71	46.1	1.6
White	18	22.5	0.6	39	25.0	1.3	216	22.2	7.5	110	24.3	4.1	54	35.1	2.0
Other	0	0.0	-	1	0.6	3.9	2	0.2	7.7	0	0.0	-	1	0.6	5.6
Unknown	2	2.5		0	0.0		17	1.8		16	3.5		10	6.5	
SPA															
1	2	2.5	0.5	9	5.8	2.4	19	1.9	5.1	19	4.2	4.9	7	4.5	1.8
2	12	15.0	0.5	21	13.5	0.9	209	21.5	9.4	99	21.8	4.6	43	27.9	2.0
3	4	5.0	0.2	24	15.4	1.4	147	15.1	8.5	86	19.0	5.3	25	16.2	1.5
4	17	21.3	1.3	18	11.5	1.4	162	16.7	12.9	51	11.3	4.6	18	11.7	1.6
5	10	12.5	1.5	17	10.9	2.6	57	5.8	8.6	27	6.0	4.2	22	14.3	3.4
6	9	11.3	0.9	24	15.4	2.3	158	16.3	14.8	63	13.9	6.2	10	6.5	1.0
7	13	16.3	0.9	22	14.1	1.6	129	13.3	9.4	60	13.2	4.6	16	10.4	1.2
8	13	16.3	1.2	21	13.5	1.9	90	9.3	8.0	48	10.6	4.5	13	8.4	1.2
Unknown	0	0.0		0	0.0		1	0.1		0	0.0		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable. A zero rate is reported with a dash ("-").

**Figure 1. Incidence Rates of Pertussis
LAC, CA and US, 2003-2012**



**Figure 2. Reported Cases of Pertussis
LAC, 2003-2012**



**Figure 3. Incidence Rates of Pertussis by Age Group
LAC, 2012 (N=154)**



**Figure 4. Percent Cases of Pertussis by Race/Ethnicity
LAC, 2012 (N=154)**



*Other includes Native American and any additional racial/ethnic group that cannot be categorized as Asian, Black, Hispanic, or White.

Figure 5. Age-Adjusted Incidence Rates of Pertussis by Race/Ethnicity, LAC, 2012 (N=154) vs. Previous Five-Year Average



* Incidence rates based on <19 cases are considered unreliable.

Figure 6. Incidence Rates of Pertussis by SPA LAC, 2012 (N=154)



Figure 7. Reported Pertussis Cases by Month of Onset LAC, 2012 (N=154) vs. Previous Five-year Average



Figure 8. Vaccination Status of Reported Pertussis Cases, LAC, 2012

	Reported Cases	Cases Too Young to Be Vaccinated[1]	Cases Eligible for Vaccination and Up-to-Date[2]	Cases Eligible for Vaccination and Not Up-To-Date[3]	Personal Beliefs Exemption School Vaccine Waivers Among Cases Age <18 years (n=114)
No.	154	9	74	71	10
%	100%	5.8%	48.1%	46.1%	8.8%

[1]Cases less than 2 months of age.
[2]Cases 2 months of age and older and who are up-to-date with the pertussis immunization recommendations for their age.
[3]Cases 2 months of age and older and who are not up-to-date with the pertussis immunization recommendations for their age. Includes cases that have unknown immunization status, have personal belief exemption school vaccine waivers, or have no valid documentation of receiving pertussis vaccines prior to disease onset.

Map 9. Pertussis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

PNEUMOCOCCAL DISEASE, INVASIVE

CRUDE DATA	
Number of Cases	503
Annual Incidence[a]	
LA County	5.4
California[b]	N/A
United States[b]	11.8
Age at Diagnosis	
Mean	56
Median	59
Range	0 mos – 102 yrs

[a]Cases per 100,000 population.
[b]Not notifiable, 2011 rate based on CDC ABCS report.

DESCRIPTION

Invasive pneumococcal disease (IPD) is a leading cause of illness in young children and causes considerable illness and death in the elderly. The infectious agent, *Streptococcus pneumoniae*, is spread by direct and indirect contact with respiratory discharge and can cause pneumonia, bacteremia, meningitis, and death. *S. pneumoniae* is one of the most common bacterial causes of community acquired pneumonia and otitis media (ear infections). However, these non-invasive forms of infection are not counted in LA County (LAC) surveillance. Therefore, the data presented in this report underestimate all disease caused by *S. pneumoniae* in LAC.

ACDC has followed IPD as a special antibiotic resistance surveillance project since late 1995 and added IPD to its list of reportable diseases in October 2002. Cases are defined as LAC residents with a positive isolate for *S. pneumoniae* collected from a normally sterile site (e.g., blood, cerebral spinal fluid).

Led by successful ongoing surveillance of IPD, ACDC was awarded a grant from the Centers for Disease Control and Prevention (CDC) to evaluate the effectiveness of the 13-valent pneumococcal conjugate vaccine (Prevnar13®) amongst children aged 2-59 months. Starting in 2010, the ongoing grant significantly enhanced epidemiologic capacity across all age groups. This is evidenced by improvements in IPD surveillance data quality and completeness since 2010 (Table).

Antibiotic susceptibility is determined by disk or dilution diffusion. Minimum inhibitory concentration (MIC) breakpoints utilized by participating laboratories are based on standards developed by the Clinical and Laboratory Standards Institute. For this report, an isolate of *S. pneumoniae* is considered nonsusceptible to an antibiotic if the results indicate intermediate or high-level resistance.

Two effective vaccines are available for pneumococcal disease. In February 2010, Prevnar13® was licensed and it is recommended by the Advisory Committee on Immunization Practices (ACIP) for all children aged 2-59 months, and for children aged 60-71 months at high risk of invasive pneumococcal infections. The 23-valent pneumococcal polysaccharide vaccines (Pnu-Imune®23 and Pneumovax®23) are recommended for all adults ≥65 years and those >2 years at high risk of IPD. For children aged 2 to 5 years at high risk of invasive pneumococcal infections, ACIP recommends the use of pneumococcal conjugate vaccine followed at least 2 months later by the 23-valent pneumococcal polysaccharide vaccine. This regimen provides protection against a broader range of serotypes, although supporting data are limited. Between 2006 and 2009, IPD incidence rate increased from 5.5 to 8.0 cases per 100,000 people. Since the release of the new vaccine in 2010, there has been a general decrease in IPD incidence rate.

2012 TRENDS AND HIGHLIGHTS

- The incidence (N=503) rate this year of 5.4 cases per 100,000 people was lower than the average annual incidence of 6.9 cases per 100,000 people of the past five years (range 6.2-8.0 cases per 100,000) (Figure 1). This year's incidence rate was 24% lower than last year's rate (7.1 cases per 100,000, N=658). The large decreases in incidence rate and number of cases may be attributable to a herd immunity effect from the 13-valent pneumococcal conjugate vaccine which is also shown in Figure 2 and the Table.
- Mortality in 2012 (15.5%, n=78 deaths) was similar to 2010 (15.3%, n=88 deaths) and

slightly higher than in 2011 (12.8%, n=84 deaths). Annual mortality during 2007-2009 ranged from 14.8% to 17.4% (34–84 deaths) among cases with known disease outcome; however, validating and interpreting a mortality trend is difficult because disease outcome data were missing for 50% of the cases during 2007-2009 versus 4% of the cases in 2010-2012.

- In 2012, 93% (n=428) of cases were reported hospitalized, which is similar to 2010-2011 (92%, mean=566). In 2007-2009, the annual percentage of cases hospitalized ranged from 89% to 94% among cases with hospitalization data; however, trend analysis may be inaccurate because 20% of cases during 2007-2009 were missing hospitalization data, versus 0% of cases in 2010-2011 missing such data.
- Median length of hospital stay was 6 days (n=410 cases; mean=9.6 days and range=0-97 days) which was similar to 2010-2011 (median=6 days, mean=9.7 days, range=0-159 days). Length of hospital stay was not recorded for most of 2009 and all of 2007-2008.
- Incidence rates decreased amongst all age groups compared to the previous 5-year average (Figure 2). Amongst cases aged 1 to 4 years old, the incidence rate was 47% lower (from 9.1 to 4.8 cases per 100,000) and the number of cases was 53% lower (from 49 to 23 cases) than the previous 5-year average. This age group is part of the target population for the new 13-valent pneumococcal conjugate vaccine released in the spring of 2010. The decrease in incidence (Table) in this group is indicative of vaccine effectiveness.
- Amongst cases 35-44 years of age, the incidence rate decreased 36% (from 4.4 to 2.8 cases per 100,000) and the number of cases decreased 41% (from 62.6 to 37 cases).
- For all other age groups, incidence rates decreased by 12% (<1 year olds) up to 31% (15-34 year olds), compared to the previous 5-year average.
- Cases aged 65 years and older and <1 had the highest incidence rates (18.9 and 10.1 cases per 100,000, respectively) (Table, Figure 2).
- Incidence rates decreased by 15% (blacks) up to 24% (Hispanics) across all race/ethnic groups (Table, Figure 3), compared to 2010-2011.
- Similar to previous years, the 2012 incidence rate in blacks was the highest compared to rates of the other race/ethnic groups (Table, Figure 3).
- Valid comparisons cannot be made across 5-year averages as race information was missing for 32% to 45% of cases in previous years. Percent of cases missing race/ethnicity information was similar for 2010-2011 (2%) and 2012 (5%).
- As in previous years, Service Planning Area (SPA) 6 had the highest incidence rate of IPD (6.9 cases per 100,000; Table, Figure 4).
- Compared to the previous 5-year average, the incidence rate and number of cases in SPA 5 both decreased by 43% (from 7.2 to 4.1 cases per 100,000) and 44% (from 46.2 to 26 cases), respectively (Table).
- Incidence rate decreased across all SPAs except SPA 4 which stayed about the same compared to the previous 5-year average.
- IPD peaked in March (n=84 cases) instead of February as seen in the previous five years (Figure 5).
- The percentage of isolates susceptible to penicillin increased 7% compared to the previous five years (Figure 6).
- The percentage of isolates susceptible to TMP-SMZ decreased 9% compared to the previous five years (Figure 6).
- Susceptibility to erythromycin, cefotaxime, ceftriaxone, and levofloxacin was similar to the previous 5 years (Figure 6).

Reported Invasive Pneumococcal Disease Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=662)			2009 (N=785)			2010 (N=576)			2011 (N=658)			2012 (N=503)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	19	2.4	11.5	20	2.5	14.6	12	2.1	10.0	7	1.1	5.9	12	2.4	10.1
1-4	57	8.6	10.1	56	7.1	10.0	48	8.3	9.9	36	5.3	7.5	23	4.6	4.8
5-14	11	1.8	0.9	33	4.2	2.4	21	3.6	1.7	31	4.7	2.6	17	3.4	1.4
15-34	30	4.4	1.0	64	8.1	2.3	38	6.6	1.4	64	9.7	2.3	33	6.6	1.2
35-44	67	10.6	4.6	75	9.5	5.0	47	8.2	3.5	57	8.7	4.3	37	7.4	2.8
45-54	98	14.2	7.0	136	17.3	9.9	84	14.6	6.5	107	16.3	8.3	81	16.1	6.3
55-64	114	17.4	12.6	123	15.6	12.9	108	18.8	11.3	128	19.5	12.9	90	17.9	8.8
65+	264	40.2	26.1	278	34.4	26.2	218	37.8	21.7	227	34.6	21.5	210	41.7	18.9
Unknown	2	0.3		1	0.1		0	0.0		1	0.2		0	0.0	
Race/Ethnicity															
Asian	32	4.8	2.5	50	6.4	3.8	46	8.0	3.5	49	7.5	3.7	38	7.6	2.9
Black	76	11.5	8.9	86	10.9	10.1	83	14.2	10.7	130	19.8	16.8	90	17.9	11.6
Hispanic	124	18.7	2.6	197	25.1	4.2	213	37.0	4.8	244	37.1	5.4	176	35.0	3.9
White	135	20.4	4.6	192	24.4	6.6	209	36.3	7.8	234	35.5	8.8	172	34.2	6.5
Other	0	0.0	0.0	9	1.1	35.4	2	0.3	11.4	0	0	0.0	4	0.8	0
Unknown	295	44.6		252	32.1		23	4.0		1	0.2		23	4.6	
SPA															
1	18	2.7	4.9	25	3.2	6.8	13	2.3	3.4	17	2.6	4.4	18	3.6	4.6
2	137	20.7	6.3	156	19.8	7.0	130	22.6	6.1	127	19.3	5.9	110	21.9	5.1
3	99	15.0	5.7	116	14.8	6.7	80	13.9	5.0	85	12.9	5.3	77	15.3	4.8
4	62	9.4	4.9	103	13.1	8.3	70	12.2	6.3	93	14.2	8.3	69	13.7	6.1
5	48	7.3	7.4	54	6.9	8.3	44	7.6	6.9	49	7.5	7.7	26	5.2	4.1
6	107	16.2	10.1	111	14.1	10.6	79	13.7	7.9	90	13.7	8.9	70	13.9	6.9
7	73	11.0	5.3	102	13.0	7.4	69	12.0	5.3	81	12.3	6.3	53	10.5	4.1
8	78	11.8	6.9	89	11.3	7.9	77	13.4	7.3	90	13.7	8.5	57	11.3	5.3
Unknown	40	6.0		29	3.8		14			25	3.8		23	4.6	

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Annual Incidence Rates of Invasive Pneumococcal Disease, LAC and US, 2000-2012



Figure 2. Annual Incidence Rates of Invasive Pneumococcal Disease 2007-2012



Figure 3. Annual Incidence Rates of Invasive Pneumococcal Disease by Race/Ethnicity, LAC, 2007-2012



* For 2007, 2008, 2009, 2010, 2011, and 2012 total numbers of cases (and percent with race-ethnicity missing) were 624 (46%), 662 (45%), 785(32%), 576 (4%), 657 (0%), and 503 (5%), respectively.

Figure 4. Annual Incidence Rates of Invasive Pneumococcal Disease by SPA, LAC, 2007-2012



Figure 5. Invasive Pneumococcal Disease Cases by Month of Onset LAC, 2007-2012



Figure 6. Reported Antibiotic Susceptibility of Invasive Pneumococcal Disease Cases, LAC, 2007-2012



*Range of number of isolates tested 2007-2012: Cefotaxime (238-389), Ceftriaxone (330-485), Erythromycin (294-455), Levofloxacin (261-394), Penicillin (443-667), and TMP-SMZ (199-330).

Map 10. Pneumococcal Disease, Invasive
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

SALMONELLOSIS

CRUDE DATA	
Number of Cases	1041
Annual Incidence[a]	
LA County	11.2
California[b]	11.9
United States[b]	17.1
Age at Diagnosis	
Mean	30.8
Median	26
Range	<1 - 95

[a]Cases per 100,000 population.
[b]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Salmonellosis is caused by the Gram-negative bacillus *Salmonella enterica*, of which there are more than 2,500 serotypes. This disease is transmitted by the fecal-oral route, from animal or human, with or without intermediary contamination of foodstuffs. The most common symptoms include diarrhea, fever, headache, abdominal pain, nausea and sometimes vomiting. Occasionally, the clinical course is that of enteric fever or septicemia. Asymptomatic infections may occur. The incubation period is usually 12 to 36 hours for gastroenteritis, longer and variable for other manifestations. Communicability lasts as long as organisms are excreted, usually from 2 to 5 weeks, but may last for months to years. Healthy people are susceptible, but persons especially at risk are those who are on antacid therapy, have recently taken or are taking broad-spectrum antibiotic therapy or immunosuppressive therapy, or those who have had gastrointestinal surgery, neoplastic disease, or other debilitating conditions. Severity of the disease is related to the serotype, the number of organisms ingested, and host factors. Immunocompromised persons, such as those with cancer or HIV infection, are at risk for recurrent *Salmonella* septicemia. Occasionally the organism may localize anywhere in the body, causing abscesses, osteomyelitis, arthritis, meningitis, endocarditis, pericarditis, pneumonia, or pyelonephritis.

Los Angeles County (LAC)'s review of investigation reports shows that many persons engage in high-risk food handling behaviors such as: consumption of raw or undercooked meats, produce; use of raw eggs; not washing hands and/or cutting boards after handling raw poultry or meat; and having contact with reptiles. Travel is also a risk factor.

Reptile-associated salmonellosis (RAS) increased from 8.7 % (n=76) of non-outbreak related cases in 2011 to 9.2 % (n=99) in 2012. Among RAS cases, turtle related cases increased from 57% to 73%. LAC residents were part of a national outbreak related to small turtles. Interventions of an interdisciplinary RAS working group established in 2007 to address the issue continue. Interventions are described in the ACDC Special Reports 2009 and 2010. Continued interventions include:

- Development and launching of a *fotonovela* and readers theater to educate families of at-risk persons;
- Outreach activities to target groups and the general public to educate on the risk of RAS;
- Targeted education programs to reach practitioners, educators, and stakeholders in at-risk areas.

2012 TRENDS AND HIGHLIGHTS

- There were four salmonellosis outbreaks investigated in 2012; one was a probable foodborne outbreak. For more information see the Foodborne Outbreak summary in this ACDC Annual Morbidity Report 2012.
- SPA rates ranged from 9.8 (SPA 1) to 14.4(SPA 4) (Figure 4). SPA 4 had the highest rate in 2012 and historically SPA 5 had the highest rate in 2011. All SPAs showed an increase in rates in 2012. SPA 4 had seven family clusters of two or more cases. There were no outbreaks or large clusters identified in that SPA.
- Twenty-five percent of cases were hospitalized for two or more days.
- There were eight deaths in persons diagnosed with salmonellosis. Ages ranged from 53 to 88 years with a mean of 70 years. One elderly case had aortic graft rupture, another had organ failure and all other cases had chronic liver disease, kidney disease, or cancer.

Reported Salmonellosis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=1638)			2009 (N=1194)			2010 (N=1142)			2011 (N=900)			2012 (N= 1041)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	89	5.4	63.7	89	7.5	64.9	56	4.9	40.1	61	6.8	43.7	73	7.0	61.4
1-4	613	37.4	108	229	19.2	40.8	186	16.2	32.0	134	14.9	22.9	153	14.7	32.2
5-14	170	10.4	12.1	195	16.3	14.3	174	15.2	13.1	148	16.4	11.1	158	15.2	13.2
15-34	278	17.0	9.7	271	22.7	9.6	262	22.9	8.9	186	20.7	6.3	224	21.5	8.1
35-44	151	9.2	10.0	110	9.2	7.4	131	11.5	9.1	93	10.3	6.5	95	9.1	7.2
45-54	116	7.1	8.6	101	8.5	7.4	87	7.6	6.4	86	9.5	6.4	108	10.4	8.4
55-64	91	5.6	10.0	76	6.4	8.0	100	8.8	10.4	86	9.5	8.9	88	8.5	8.6
65+	127	7.8	12.4	123	10.3	11.6	146	12.8	13.8	106	11.8	10.0	142	13.6	12.8
Unknown	3	0.2					0								
Race/Ethnicity															
Asian	114	7.0	8.7	103	8.6	7.9	115	10.0	8.6	64	7.1	4.8	92	8.8	7.0
Black	77	4.7	9.0	75	6.3	8.8	50	4.4	5.9	53	5.9	6.2	56	5.4	7.2
Hispanic	1071	65.4	22.9	620	52.0	13.3	570	50.1	12.0	465	51.7	9.8	503	48.3	11.1
White	326	19.9	11.2	367	30.7	12.6	387	33.9	13.5	279	31.0	9.7	247	23.7	9.3
Other	3	0.2	12.2	10	0.8		3	0.3		8	0.9		11	1.1	
Unknown	47	2.9		19	1.6		17	1.5		31	3.4		132	12.6	
SPA															
1	35	2.1	9.5	40	3.4	10.9	36	3.2	9.6	24	2.7	6.4	38	3.7	9.8
2	657	40.1	30.0	316	26.5	14.3	303	26.5	13.7	215	23.9	9.7	228	21.9	10.6
3	204	12.5	11.8	179	15.0	10.3	221	19.4	12.7	162	18.0	9.3	164	15.8	10.1
4	135	8.2	10.6	138	11.6	11.1	156	13.7	12.4	80	8.9	6.4	162	15.6	14.4
5	46	2.8	7.1	107	9.0	16.4	86	7.5	13.0	70	7.8	10.6	71	6.8	11.1
6	123	7.5	11.7	134	11.2	12.7	86	7.5	8.0	107	11.9	10.0	109	10.5	10.7
7	309	18.9	22.3	152	12.7	11.0	140	12.3	10.2	122	13.5	8.9	145	13.9	11.2
8	129	7.9	11.5	128	10.7	11.4	114	10.0	10.2	117	13.0	10.4	123	11.8	11.5
Unknown	0			0			0			3	0.33		1	0.09	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Reported Salmonellosis Rates by Year
LAC, CA and US, 2003-2012**



**Figure 2. Reported Salmonellosis Rates by Age Group
LAC, 2012 (N=1041)**



**Figure 3. Reported Cases of Salmonellosis by Race/Ethnicity
LAC, 2012 (N=1041)**



* Other includes Native American and any additional racial/ethnic group that cannot be categorized as Asian, black, Hispanic, or white.

**Figure 4. Reported Salmonellosis Rates by SPA
LAC, 2012 (N=1041)**



Figure 5. Reported Salmonellosis Cases by Month of Onset
LAC, 2012 (N=1041)



Map 11. Salmonellosis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

SHIGELLOSIS

CRUDE DATA	
Number of Cases	306
Annual Incidence[a]	
LA County	3.29
California[b]	2.42
United States[b]	4.35
Age at Diagnosis	
Mean	35
Median	34
Range	0-98

[a]Cases per 100,000 population.
[b]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Shigellosis is caused by a Gram-negative bacillus with four main serogroups: *Shigella dysenteriae* (group A), *S. flexneri* (group B), *S. boydii* (group C) and *S. sonnei* (group D). Incubation period is 1 to 3 days. Humans are the definitive host; fecal-oral transmission occurs when individuals fail to thoroughly wash their hands after defecation and spread infective particles to others, either directly by physical contact, including sexual behaviors, or indirectly by contaminating food. Infection may occur with ingestion of as few as ten organisms. Common symptoms include diarrhea, fever, nausea, vomiting, and tenesmus. Stool may contain blood or mucous. In general, the elderly, the immunocompromised, and the malnourished are more susceptible to severe disease outcomes.

Hand washing is vital in preventing this disease. Children or anyone with uncertain hygiene practices should be monitored to promote compliance. Hand washing is especially important when out in crowded areas. Children with diarrhea, especially those in diapers, should not be allowed to swim or wade in public swimming areas. In Los Angeles County (LAC) cases and symptomatic contacts in sensitive occupations or situations (e.g., food handling, daycare and healthcare workers) are routinely removed from work or the situation until their stool specimen cultures are negative when tested in the LAC Public Health Laboratory.

2012 TRENDS AND HIGHLIGHTS

- *Shigella sonnei* was confirmed in one outbreak this year. This outbreak involved 43 cases who ate at a private bridge club. Fourteen club members and staff tested positive for *Shigella sonnei.* Ten of the 14 samples underwent PFGE and yielded the same outbreak pattern. One club employee who tested positive was a food handler who was involved in the preparation of the majority of foods identified as being associated with illness (see 2012 Special Studies Report for details).
- No other outbreaks were identified in 2012. For more information see 2012 ACDC Special Studies Reports and Foodborne Outbreak summary in this report.
- There was a 16% increase in reported cases in 2012 after a 26% decrease in cases during 2011 (Figure 1). There was an increase observed among all races except Asians. (Figure 6).
- The highest age group incidence rate was observed in the 1 to 4 years age group (6.7 per 100,000) as observed in previous years (Figure 2) (not adjusted for race/ethnicity). The shigellosis rate in the 1 to 4 years age group in LAC this year has decreased when compared to the last five years (range: 6.7 versus 20.8 per 100,000).
- In 2012, the incidence of shigellosis among the white population (34% of cases, 3.9 per 100,000) was the highest; however, in the previous years the highest frequency was seen among Hispanics (Figures 3, 6). The increase of cases among the white population is due to the May outbreak. Service Planning Area (SPA) 4 sustained the highest rate (7.6 per 100,000), followed by SPA 5 (7.5 per 100,000) (Figure 4). There was a 5.4% increase in reported cases in SPA 5 when compared to previous year. The increase in SPA 5 can be attributed to the May outbreak.
- The May outbreak greatly impacted the number of cases by month of onset when compared to other months and previous years. (Figure 5).
- In 2012, the percentage of shigellosis cases hospitalized for at least two days has

decreased to 8.1% (N=25) from 14.7% (N=39) in 2011. The numbers of cases of men who have sex with men (MSM) in 2012 have decreased to 8.8% (N=27) from 16.2% (N=43) in 2011. No deaths were reported among diagnosed shigellosis cases.

Reported Shigellosis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=498)			2009 (N=259)			2010 (N=355)			2011 (N=264)			2012 (306)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	8	1.6	5.7	4	1.5	2.9	1	1.1	0.7	4	1.5	2.9	4	1.3	3.4
1-4	118	23.7	20.8	34	13.1	6.1	79	22.2	13.6	30	11.3	5.2	32	10.5	6.7
5-14	137	27.5	9.8	47	18.1	3.4	68	19.1	5.1	37	14.0	2.8	54	17.6	4.5
15-34	122	24.5	4.3	67	25.9	2.4	75	21.1	2.5	80	30.3	2.7	68	22.2	2.5
35-44	42	8.4	2.8	51	19.7	3.4	63	17.7	4.4	41	15.5	2.8	39	12.7	2.9
45-54	26	5.2	1.9	33	12.7	2.4	36	10.1	2.7	44	16.6	3.3	31	10.1	2.0
55-64	23	4.6	2.5	12	4.6	1.3	17	4.7	1.8	15	5.6	1.6	25	8.2	2.5
65+	22	4.4	2.2	11	4.2	1.0	15	4.2	1.4	12	4.5	1.1	52	17.0	4.7
Unknown	0	0		0	0	0	0	0	0	0	0	0	1	0.3	0
Race/Ethnicity															
Asian	10	2.0	0.8	6	2.3	0.5	15	4.2	1.1	4	1.5	0.3	2	0.6	0.2
Black	25	5.0	2.9	17	6.6	2.0	31	8.7	3.6	24	9.0	2.8	29	9.4	3.7
Hispanic	376	75.5	8.0	154	59.5	3.3	203	57.1	4.3	149	56.4	3.1	153	50.0	3.4
White	71	14.3	2.4	69	26.6	2.4	94	26.4	3.3	78	29.5	2.7	104	33.9	3.9
Other	3	0.6	12.2	0	0	0	0	0	0	0	0	0	0	0	0
Unknown	13	2.6		13	5.0	0	12	3.3	--	0	0	0	18	5.9	
SPA															
1	11	2.2	3.0	5	1.9	1.9	3	0.8	0.8	7	2.6	1.9	3	0.9	0.8
2	89	17.9	4.1	46	17.7	2.1	61	17.2	2.8	40	15.1	1.8	52	1.6	2.4
3	66	13.3	3.8	23	8.9	1.3	33	9.2	1.9	32	12.1	1.8	26	8.4	1.6
4	71	14.3	5.6	74	28.6	5.9	91	25.6	7.2	82	31.0	6.51	85	27.7	7.6
5	23	4.6	3.6	22	8.5	3.4	30	8.4	4.5	14	5.3	2.1	48	15.6	7.5
6	109	21.9	10.3	41	15.8	3.9	58	16.3	5.4	38	14.3	3.6	37	12.0	3.6
7	93	18.7	6.7	33	12.7	2.4	54	15.2	3.9	24	9.1	1.7	33	10.7	2.5
8	34	6.8	3.0	14	5.4	1.2	25	7.0	2.2	26	9.8	2.3	22	7.1	2.1.
Unknown	2	0.4		0	0	0	0	0	0	0	0	0	0	0	0

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Reported Shigellosis Rates by Year
LAC, CA and US, 2002-2012**



**Figure 2. Reported Shigellosis Rates by Age Group
LAC, 2012 (N=306)**



**Figure 3. Percent Cases of Shigellosis by Race/Ethnicity
LAC, 2012 (N=306)**



**Figure 4. Reported Shigellosis Rates by SPA
LAC, 2012 (N=306)**



**Figure 5. Reported Shigellosis Cases by Month of Onset
LAC, 2012 (N=306)**



**Figure 6. Shigellosis Incidence by Race/Ethnicity
LAC, 2008-2012**



Map 12. Shigellosis
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

SEVERE *STAPHYLOCOCCUS AUREUS* INFECTION IN PREVIOUSLY HEALTHY PERSONS

CRUDE DATA	
Number of Cases	24
Annual Incidence	
LA County[a]	0.26
California[b]	--
United States[c]	N/A
Age at Diagnosis	
Mean	56
Median	58
Range	0-98 years

[a]Cases per 100,000 population
[b]See Yearly Summary Reports of Selected General Communicable Diseases in California at: http://www.cdph.ca.gov/data/statistics/Pages/CD-YearlyTables.aspx
[c]Not notifiable.

DESCRIPTION

Staphylococcus aureus (S. aureus) is bacteria that can cause a number of diseases as a result of infection of various tissues of the body. *S. aureus*-related illness can range from mild and requiring no treatment to severe and potentially fatal. It is a common cause of skin infections, causing boils, abscesses, and cellulitis. It can also cause invasive skin and soft-tissue infection, necrotizing fasciitis, musculoskeletal infection, and osteomyelitis. Infection can result in severe illness, including bacteremia, sepsis, pneumonia, empyema and necrotizing pneumonia.

Certain groups of people are at greater risk, including people with chronic conditions such as diabetes, cancer, vascular disease, and lung disease. Injecting drug users, those with skin injuries or disorders, intravenous catheters, surgical incisions, and those with a weakened immune system due either to disease or a result of immune suppressing medications all have an increased risk of developing *S. aureus* infections.

In February 2008 in response to the significant public health burden and potential severity of community-associated *S. aureus* infections, the California Department of Public Health added severe cases of *S. aureus* infections, including methicillin-resistant *S. aureus* (MRSA), to the state list of reportable diseases and conditions. This is not a nationally notifiable disease.

For surveillance purposes, a case of community-associated severe *S. aureus* infection is defined as a laboratory-confirmed *S. aureus* infection in a person resulting in admission to an intensive care unit (ICU) or death who had not been hospitalized or had surgery, dialysis, or residency in a long-term care facility in the year prior to illness, and did not have an indwelling catheter or percutaneous medical device at the onset of illness. If any of these conditions were present, the case would be considered healthcare-associated.

S. aureus is one of the most common bacterial causes of skin infections that result in a visit to a doctor or the hospital. However, most of these infections do not result in ICU admission or death. Therefore, the data presented in this report underestimate all disease caused by this organism in Los Angeles County (LAC).

2012 TRENDS AND HIGHLIGHTS

- Cases >65 years of age and cases aged <1 year had the highest rate (0.8 per 100,000) (Figure 1).
- The incidence rate of Hispanics in 2012 (0.1 per 100,000) decreased four-fold compared to 2011 (0.4 per 100,000) (Figure 2).
- The male:female ratio was 1:1.
- Incidence rates decreased in four SPAs in 2012 compared with 2011, and increased in two SPAs. In 2012, the incidence rate was highest in SPAs 1, 3, and 6 (0.5 per 100,000). (Figure 3).
- Seven (29%) of the reported cases were *S. aureus* infections resistant to methicillin (Figure 5).
- The most frequently reported risk factors were being a current smoker, diabetic, and intravenous drug user (Table 1).
- Severe *S. aureus* cases presented most often with bacteremia and pneumonia (Table 2).
- Forty-two percent of cases were reported from 2 reporting sources in LAC. Thus, underreporting of severe *S. aureus* infections in LAC is likely.

Reported Severe *Staphylococcus Aureus* Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=25)			2009 (N=27)			2010 (N=28)			2011 (N=44)			2012 (N=24)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	1	4.0	0.7	0	0.0	0.0	1	4.0	0.7	0	0.0	0.0	1	4.2	0.8
1-4	0	0.0	0.0	1	3.7	0.2	0	0.0	0	0	0.0	0.0	0	0	0
5-14	2	8.0	0.1	2	7.4	0.1	3	10.7	0.2	2	4.5	0.2	1	4.2	0.1
15-34	1	4.0	0.0	5	18.5	0.2	6	21.4	0.2	6	13.6	0.2	3	12.5	0.1
35-44	2	8.0	0.1	3	11.1	0.1	3	10.7	0.2	6	13.6	0.5	2	8.3	0.2
45-54	7	28.0	0.5	6	22.2	0.4	7	25.0	0.5	9	20.4	0.7	3	12.5	0.2
55-64	4	16.0	0.4	4	14.8	0.4	3	10.7	0.3	8	18.2	0.8	5	20.8	0.5
65+	8	32.0	0.8	6	22.2	0.6	5	17.9	0.5	13	29.5	1.2	9	37.5	0.8
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0		
Race/Ethnicity															
Asian	3	12.0	0.2	1	3.7	0.1	4	14.2	0.3	7	15.9	0.5	4	16.7	0.3
Black	4	16.0	0.5	3	11.1	0.4	4	14.2	0.5	3	6.8	0.4	4	16.7	0.5
Hispanic	5	20.0	0.1	12	44.4	0.3	7	25.0	0.1	17	38.6	0.4	4	16.7	0.1
White	13	52.0	0.4	11	40.7	0.4	13	46.4	0.5	15	34.1	0.6	10	41.7	0.4
Other	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	1	2.3		1	4.2	
Unknown	0	0.0		0	0.0		0	0.0		1	2.3		1	4.2	
SPA															
1	2	8.0	0.5	3	11.1	0.8	1	4.0	0.3	0	0.0	0.0	2	8.3	0.5
2	5	20.0	0.2	2	7.4	0.1	6	21.4	0.3	12	27.3	0.6	1	4.2	0.0
3	8	32.0	0.5	4	14.8	0.3	6	21.4	0.3	7	15.9	0.4	8	33.3	0.5
4	1	4.0	0.1	3	11.1	0.2	4	14.2	0.3	2	4.5	0.2	2	8.3	0.2
5	3	12.0	0.5	1	3.7	0.2	2	7.1	0.3	5	11.4	0.8	1	4.2	0.2
6	2	8.0	0.2	9	33.3	0.9	2	7.1	0.2	11	25.0	1.1	5	20.8	0.5
7	1	4.0	0.1	2	7.4	0.1	4	14.2	0.3	5	11.4	0.4	4	16.7	0.3
8	3	12.0	0.3	2	7.4	0.2	2	7.1	0.2	1	2.3	0.1	0	0	0
Unknown		0.0		1	3.7		1	4.0		1	2.3		1	4.2	

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Incidence Rates* of Severe S. *aureus* Infection by Age Group LAC, 2011-2012



Figure 2. Severe S. *aureus* Infection Incidence Rates* by Race/Ethnicity LAC, 2011-2012



Figure 3. Incidence Rates* of Severe S. *aureus* Infection by SPA LAC, 2011-2012



Figure 4. Reported Severe S. *aureus* Cases by Month of Onset LAC, 2012 (N=24)



*Rates calculated based on less than 19 cases or events are considered unreliable

Figure 5. Percent Cases of Severe *S. aureus* Infection by Methicillin-Resistance Type LAC, 2012 (N=24)



*MRSA=Methicillin Resistance *Staphylococcus aureus*
**MSSA=Methicillin Sensitive *Staphylococcus aureus*

Table 2. Frequency and Percentage of Severe *S. aureus* Clinical Syndromes, LAC, 2012

Syndrome	Number	Percent*
Bacteremia (without focus)	17	71
Pneumonia	9	38
Endocarditis	5	21
Skin Infection	4	17
Wound Infection	2	8
Septic emboli	1	4
Meningitis	1	4
Other	3	13

*Overlapping syndromes will total over 100%.

Table 1. Severe *S. aureus* Medical Conditions by Date of Onset, 2011-2012

	2011 N = 44	2012 N = 24
	N(%)*	N(%)*
Current Smoker	7(16)	5(21)
Diabetes	14(32)	4(17)
Intravenous Drug Use	5(11)	4(17)
Alcohol Abuse	4(9)	3(13)
Emphysema	3(7)	3(13)
Eczema	0(0)	3(13)
Liver Disease	4(9)	2(8)
Asthma	4(9)	2(8)
Malignancy-Solid	1(5)	2(8)
Chronic Dermatitis	0(0)	2(8)
Heart Failure/CHF	4(9)	2(8)
HIV/AIDS	1(2)	1(4)
Chronic Renal Insufficiency	1(2)	0(0)
Other	17(39)	10(41)
None	8(18)	4(17)

*Overlapping risk factors will total over 100%.

INVASIVE GROUP A STREPTOCOCCUS (IGAS)

CRUDE DATA	
Number of Cases	168
Annual Incidence[a]	
LA County	1.8
California[b]	N/A
United States[b]	N/A
Age at Diagnosis	
Mean	49
Median	52
Range	0–94 years

[a]Cases per 100,000 population.
[b]Not notifiable.

DESCRIPTION

Invasive group A streptococcal disease (IGAS) is caused by the group A beta-hemolytic *Streptococcus pyogenes* bacterium. Transmission is by direct or, rarely, indirect contact with infectious material. Illness manifests as various clinical syndromes including bacteremia without focus, sepsis, cutaneous wound or deep soft-tissue infection, septic arthritis, and pneumonia. It is the most frequent cause of necrotizing fasciitis, and is commonly known as "flesh eating bacteria." IGAS occurs in all age groups but more frequently occurs among the very old. Infection can result in severe illness, including death.

For surveillance purposes in Los Angeles County (LAC), a case of IGAS is defined as isolation of *S. pyogenes* from a normally sterile body site (e.g., blood, cerebrospinal fluid, synovial fluid, or from tissue collected during surgical procedures) or from a non-sterile site if associated with streptococcal toxic shock syndrome (STSS) or necrotizing fasciitis (NF). IGAS cases are characterized as STSS if the diagnosis fulfills the Centers for Disease Control and Prevention (CDC) or Council of State and Territorial Epidemiologists case definition for this syndrome, or as NF if the diagnosis was made by the treating physician.

S. pyogenes more commonly causes non-invasive disease that presents as strep throat and skin infections. However, these diseases are not counted in LAC surveillance of invasive disease; therefore, the data presented in this report underestimates all disease caused by *S. pyogenes* in LAC.

The spread of IGAS can be prevented by good hand washing. CDC guidelines for hand washing can be found at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5605a4.htm. All wounds should be kept clean and monitored for signs of infection such as redness, swelling, pus, and pain. A person should seek medical care if any signs of wound infection are present, especially if accompanied by fever. High risk groups such as diabetics are encouraged to seek medical care sooner if experiencing fever, chills, and any redness on the skin.

2012 TRENDS AND HIGHLIGHTS

- The incidence rate of reported IGAS was 1.8 cases per 100,000 during 2012, slightly lower than the previous year (2011) but higher than the previous five-year average (Figure 1).
- Cases aged 65 years and older had the highest rate of IGAS (3.5 per 100,000) followed by cases aged 55 to 64 years (3.4 per 100,000) (Figure 2). All age groups showed declines in incidence from 2011 to 2012 with exception of the <1 year age group with an incidence rate increasing from 0.6 to 2.5 cases per 100,000 in 2011 and 2012, respectively.
- Blacks continued to have the highest rate of IGAS. In 2012, blacks had the highest rate relative to the three most recent years (2009-2011). In 2012, rates of all race/ethnicities increased or remained the same except for Asians. Asians had a lower rate of disease compared to the previous four years (2008-2011) (Figure 3).
- SPA 4 and 6 had the highest incidence rate at 3.4 and 2.4 cases per 100,000, respectively (Figure 4). SPA 4 had the largest incidence rate increase, 2.8 to 3.4 per 100,000 from 2011 to 2012, respectively.
- In 2012, the number of reported cases peaked in January with 24 cases, followed by 20 cases in March. May, July and September had the lowest number of reported cases, with nine cases. The number of reported cases throughout the year was higher overall than the previous five-year average (Figure 5).
- IGAS cases presented most often with bacteremia (without focus) and other, non-traditional symptoms (Table 1).
- Although reported with much lower frequency than 2011, diabetes was reported more than any other risk factor (26%) followed by and alcohol abuse (13%). Twenty-six percent of cases

reported having none of the traditional risk factors (Table 2).

- One invasive group A Streptococcus (IGAS) outbreak was documented in a skilled nursing facility. Three IGAS cases were identified including two confirmed and one probable case. The investigation and site visit conducted by an Acute Communicable Disease Control Program investigation team revealed several breaches in infection control including improper hand washing practices, poor access to sanitizing hand gels and sinks in addition to infection control policies that were not consistent with CDC guidelines.

Reported Invasive Group A Streptococcus Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=156)			2009 (N=129)			2010 (N=191)			2011 (N=175)			2012 (N=168)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	2	1.3	1.4	1	0.8	0.7	4	2.1	2.9	1	0.6	0.7	3	1.8	2.5
1-4	6	3.8	1.1	3	2.3	0.5	6	3.1	1	6	3.4	1	5	3	1.1
5-14	14	9	1	9	7	0.7	6	3.1	0.5	10	5.7	0.8	7	4.2	0.6
15-34	24	15.4	0.8	15	11.6	0.5	33	17.3	1.1	16	9.1	0.5	27	16.1	1
35-44	22	14.1	1.5	14	10.9	0.9	21	11	1.5	28	16	1.9	20	11.9	1.5
45-54	13	8.3	1	29	22.5	2.1	34	17.8	2.5	32	18.3	2.4	31	18.5	2.4
55-64	27	17.3	3	23	17.8	2.4	29	15.2	3	36	20.6	3.7	35	20.8	3.4
65+	48	30.8	4.7	35	27.1	3.3	58	30.4	5.5	46	26.3	4.3	39	23.2	3.5
Unknown	0	0		0	0		0	0		0	0		1	0.6	
Race/Ethnicity															
Asian	14	8.3	1.1	10	7.8	0.8	16	8.4	1.2	13	7.4	1	8	4.8	0.6
Black	30	17.8	3.5	16	12.4	1.9	25	13.1	2.9	22	12.6	2.6	24	14.3	3.1
Hispanic	50	29.6	1.1	43	33.3	0.9	52	27.2	1.1	49	28	1	58	34.5	1.3
White	49	29	1.7	40	31	1.4	53	27.7	1.8	45	25.7	1.6	44	26.2	1.7
Other	0	0	0	1	0.8	3.9	3	1.6	11.6	0	0	0	2	1.2	
Unknown	26	15.4		19	14.7		42	22		46	26.3		32	19	
SPA															
1	4	2.6	1.1	3	2.3	0.8	2	1	0.5	3	1.7	0.8	0	0	0
2	35	22.4	1.6	22	17.1	1	34	17.8	1.5	34	19.4	1.5	32	19	1.5
3	19	12.2	1.1	17	13.2	1	30	15.7	1.7	22	12.6	1.3	17	10.1	1.1
4	24	15.4	1.9	9	7	0.7	38	19.9	3	31	17.7	2.5	38	22.6	3.4
5	17	10.9	2.6	6	4.7	0.9	12	6.3	1.8	14	8	2.1	10	6	1.6
6	14	9	1.3	14	10.9	1.3	29	15.2	2.7	22	12.6	2.1	24	14.3	2.4
7	15	9.6	1.1	16	12.4	1.2	12	6.3	0.9	20	11.4	1.5	17	10.1	1.3
8	22	14.1	2	12	9.3	1.1	13	6.8	1.2	28	16	2.5	21	12.5	2
Unknown	6	3.8		30	23.3					1	0.57		9	5.4	

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Incidence Rates of Invasive Group A Streptococcus LAC and US, 2000-2012



Figure 2. Incidence Rates* of Invasive Group A Streptococcus by Age Group LAC, 2012 (N=168)



*Rates based on fewer than 19 cases are unreliable

Figure 3. Invasive Group A Streptococcus Incidence Rates* by Race/Ethnicity LAC, 2008-2012



*Rates based on fewer than 19 cases are unreliable

Figure 4. Incidence Rates* of Invasive Group A Streptococcus by SPA LAC, 2012 (N=168)



*Rates based on fewer than 19 cases are unreliable

Figure 5. Reported Invasive Group A Streptococcus Cases by Month of Onset, LAC, 2012 (N=168)



Table 1. Frequency and Percentage of IGAS Clinical Syndromes LAC, 2012 (N=168)

Syndrome	Number	Percent*
Other	58	34
Bacteremia (without focus)	53	31
Cellulitis	33	20
Sepsis	32	19
Pneumonia	31	18
Non-Surgical Wound Infection	21	13
Necrotizing Fasciitis	11	7
STSS	9	5

*Overlapping syndromes will total over 100%.
**Cases with unknown symptoms excluded.

Table 2. Percentage of IGAS Risk Factors – Based on Date of Onset Between 1/1/10-12/31/2012

Risk Factors*	2010 (N = 191)	2011 (N =175)	2012 (N =168)
	%**	%**	%**
Alcohol Abuse	6	16	13
Chronic Heart Disease	12	23	11
Chronic Lung Disease	6	12	3
Cirrhosis	4	8	9
Diabetes	23	45	26
History of Blunt Trauma	10	33	10
HIV/AIDS	1	6	1
IV Drug Use	3	5	6
Malignancy	5	14	4
Other	26	41	1
None	30	55	26

*Persons with unknown risk factor information excluded.
**Overlapping risk factors will total over 100%.

Map 13. Streptococcus, Group A Invasive Disease Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

TYPHOID FEVER, ACUTE AND CARRIER

ACUTE TYPHOID CRUDE DATA	
Number of Cases	6
Annual Incidence[a]	
LA County[b]	0.06
California[c]	0.16
United States[c]	0.11
Age at Diagnosis	
Mean	29.5
Median	23
Range	14-45

[a]Cases per 100,000 population.
[b]Rates based on less than 19 observations are considered unreliable.
[c]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Typhoid fever, or enteric fever, is an acute systemic disease caused by the Gram-negative bacillus *Salmonella typhi*. Transmission may occur person to person or by ingestion of food or water contaminated by the urine or feces of acute cases or carriers. Common symptoms include insidious onset of persistent fever, headache, malaise, anorexia, constipation (more commonly than diarrhea), bradycardia, enlargement of the spleen, and rose spots on the trunk. Humans are the only known reservoir for *S. typhi*. Vaccines are available to those at high risk from close exposure to a typhoid carrier in the house or travel to developing foreign countries.

Among untreated acute cases, 10% will shed bacteria for three months after initial onset of symptoms and 2% to 5% will become chronic typhoid carriers. Some carriers are diagnosed by positive tissue specimen. Chronic carriers are by definition asymptomatic.

Hand washing after using the toilet, before preparing or serving food, and before and after direct or intimate contact with others is important in preventing the spread of typhoid. When traveling to locations where sanitary practices are uncertain, foods should be thoroughly cooked; bottled water should be used for drinking, brushing teeth, and making ice. Vaccination should be considered when traveling in endemic areas. Los Angeles County (LAC) Department of Public Health (DPH) screens household contacts of confirmed cases for *S. typhi* to identify any previously undiagnosed carriers or cases. A modified order of isolation restricts a carrier from engaging in a sensitive occupation or situation. LAC DPH monitors compliance with such isolation order and offers the case the chance to clear the infection with antibiotics.

2012 TRENDS AND HIGHLIGHTS

- The LAC rate for acute typhoid fever cases is slightly below the US rate (Figure 1).
- As in the previous year, Hispanics have had the highest percentage of acute cases; however, in the previous years this disease was prevalent among the Asian population (Figure 3).
- Service Planning Areas (SPAs) 4 had the highest number of acute cases (Figure 4). There was at least one case reported within each of the SPAs 2, 3, 7, and 8.
- Typically, most cases occur in the spring, which was consistent in 2012, however, cases were also observed in the winter. Cases peaked in January above the five year average (Figure 5).
- No new chronic carriers were reported.
- LAC continues to semi-annually monitor existing carriers that are on the state typhoid registry until they are cleared of infection (Figure 6). In 2012, there were none.

Reported Acute Typhoid Fever Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=14)			2009 (N=17)			2010 (N=15)			2011 (N=15)			2012 (N=6)		
	No.	(%)	Rate/ 100,000	No.	No.	(%)	Rate/ 100,000	No.	No.	(%)	Rate/ 100,000	No.	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0		0	0		0	0		1	6.6		0	0	
1-4	1	7.1		0	0		3	20.0		0	0		0	0	
5-14	5	35.7		3	17.6		4	26.6		1	6.6		1	16.7	
15-34	5	35.7		6	35.2		5	33.3		6	40.0		3	50.0	
35-44	1	7.1		3	17.6		1	6.6		2	13.3		1	16.7	
45-54	0	0.0		4	23.5		1	6.6		3	20.0		1	16.7	
55-64	1	7.1		1	5.8		1	6.6		1	6.6		0	0	
65+	1	7.1		0	0		0	0		1	6.6		0	0	
Unknown	0	0.0		0	0		0	0		0	0		0	0	
Race/Ethnicity															
Asian	8	57.1		9	52.9		11	73.3		7	46.6		2	33.3	
Black	0	0.0		0	0		0	0		0	0		0	0	
Hispanic	5	35.7		8	47.0		3	20		8	53.3		4	66.7	
White	1	7.1		0	0		1	0		0	0		0	0	
Other	0	0.0		0	0		0	0		0	0		0	0	
Unknown	0	0.0		0	0		0	0		0	0		0	0	
SPA															
1	0	0.0		0	0		1	6.6		1	6.6		0	0	
2	5	35.7		4	23.5		6	40.0		4	26.6		1	16.7	
3	3	21.4		3	17.6		2	13.3		0	0		1	16.7	
4	3	21.4		2	11.7		2	13.3		4	26.6		2	33.3	
5	0	0.0		3	17.6		1	6.6		3	20.0		0	0	
6	1	7.1		2	11.7		2	13.3		1	6.6		0	0	
7	2	14.3		0	0		1	6.6		1	13.3		1	16.7	
8	0	0.0		3	17.6		3	20.0		1	6.6		1	16.7	
Unknown	0	0.0		0	0		0	0		0	0		0	0	

*Rates calculated based on less than 19 cases or events are considered unreliable

Reported Typhoid Fever Carrier Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=4)			2009 (N=1)			2010 (N=4)			2011 (N=3)			2012 (N=0)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0		0	0.0		0	0		0	0		0	0	
1-4	0	0.0		0	0.0		0	0		0	0		0	0	
5-14	0	0.0		1	100		0	0		0	0		0	0	
15-34	1	25.0		0	0.0		0	0		0	0		0	0	
35-44	2	50.0		0	0.0		2	50.0		1	33.3		0	0	
45-54	0	0.0		0	0.0		0	0		1	33.3		0	0	
55-64	0	0.0		0	0.0		2	50.0		1	33.3		0	0	
65+	1	25.0		0	0.0		0	0		0	0		0	0	
Unknown	0	0.0		0	0.0		0	0		0	0		0	0	
Race/Ethnicity															
Asian	1	25.0		0	00.0		2	50.0		0	0		0	0	
Black	0	0.0		0	0.0		0	0		0	0		0	0	
Hispanic	3	75.0		1	100		2	50.0		3	100		0	0	
White	0	0.0		0	0.0		0	0		0	0		0	0	
Other	0	0.0		0	0.0		0	0		0	0		0	0	
Unknown	0	0.0		0	0.0		0	0		0	0		0	0	
SPA															
1	0	0.0		0	0.0		0	0		0	0		0	0	
2	1	25.0		0	0.0		0	0		0	0		0	0	
3	1	25.0		0	0.0		1	25.0		0	0		0	0	
4	2	50.0		0	0.0		0	0		1	33.3		0	0	
5	0	0.0		0	0.0		2	50.0		0	0		0	0	
6	0	0.0		0	0.0		0	0		1	33.3		0	0	
7	0	0.0		0	0.0		0	0		0	0		0	0	
8	0	0.0		1	100		1	25.0		1	33.3		0	0	
Unknown	0	0.0		0	0.0		0	0		0	0		0	0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Incidence Rates by Year of Onset of Acute Typhoid Fever
LAC and US, 2002-2012**



**Figure 2. Acute Typhoid Fever Cases by Age Group
LAC, 2012 (N=6)**



**Figure 3. Reported Acute Typhoid Fever Cases by Race/Ethnicity
LAC, 2012 (N=6)**



**Figure 4. Reported Acute Typhoid Fever Cases by SPA
LAC, 2012 (N=6)**



**Figure 5. Acute Typhoid Fever Cases by Month of Onset
LAC, 2012 (N=6)**



**Figure 6. Cases of Chronic Typhoid Carrier by Year of Detection
LAC, 2002-2012**



TYPHUS FEVER

CRUDE DATA	
Number of Cases	50
Annual Incidence[a]	
LA County	0.54
California[b]	N/A
United States[b]	N/A
Age at Diagnosis	
Mean	40
Median	41
Range	5-71

[a]Cases per 100,000 population.
[b]Not notifiable.

DESCRIPTION

Typhus fever (murine typhus, endemic typhus) is caused by the bacteria *Rickettsia typhi* and *Rickettsia felis* and is transmitted through contact with feces that is discharged when an infected flea bites. Reservoir animals are predominantly rats, opossums, and feral cats. In Los Angeles County (LAC), most reported cases of typhus occur in residents of the foothills of central LAC. However, since 2006 the distribution of typhus has expanded to other regions of LAC, particularly towards the western part of the county (SPA 5). Symptoms include fever, severe headache, chills, and myalgia. A fine, macular rash may appear three to five days after onset. Occasionally, complications such as pneumonia or hepatitis may occur. Fatalities are uncommon, occurring in less than 1% of cases, but increase with age. The disease is typically mild in young children. Typhus is not vaccine preventable, but can be treated with antibiotics.

Because typhus fever is not a nationally reportable disease, there is no national case definition. In California, a standard case definition was developed beginning 2012 because of expansion of the agent into new regions, including Long Beach and Orange County. Cases included in LAC surveillance have, at minimum, a single high IgM or IgG titer positive for any *Rickettsia* species, along with the appropriate symptoms

Typhus infection can be prevented through flea control measures implemented on pets. Foliage in the yard should be trimmed so that it does not provide harborage for small mammals. Screens can be placed on windows and crawl spaces to prevent entry of animals and their fleas into the house.

2012 TRENDS AND HIGHLIGHTS

- LAC documented a record number of typhus fever cases in 2012. There were 50 cases in 2012, up from the previous record of 38 cases in 2011 (Figure 1). Most reported cases were hospitalized (n=39, 78%), indicating that milder cases may not have been diagnosed and reported in which would make actual total number of cases occur even higher.
- The mean age of cases was 40 years, with the majority of cases being over 35 years old (n=33, 66%). Cases occurring in young children <5 years are rare.
- The large majority of cases were of Hispanic/Latino and white race/ethnicity (n=15, 30%, and n=25, 50%, respectively). Asians and blacks have been consistently underrepresented in comparison to the general LAC population (Figure 5).
- The number of typhus cases continued to be highest in SPA 3 (n=18) (Figure 3), which has had high numbers historically. Typhus cases resided in nearly all SPAs with the exception of SPA 1, indicating that typhus has established itself in new areas where it has not been usually seen for decades.
- The monthly number of typhus cases began rising in May, earlier than previous years (Figure 4). Cases were documented in nearly all months of the year. Physicians and residents should assume that there is risk of typhus infection throughout the entire year in LAC.
- Only seventeen cases recalled a flea exposure (34%). A large proportion of cases reported an exposure to cats or dogs at or around their home (n=34, 68%) (Table 1). This is much higher than the overall rate of pet ownership in LAC (40%).[1] Animal exposures at their place of employment was negligible.

[1] 2007 Los Angeles County Health Survey. Los Angeles County Department of Public Health. http://www.publichealth.lacounty.gov/ha/hasurveyintro.htm

- The increase in cases may be due to a number of factors including the natural relocation of host animals (possums and feral cats) to regions not previously enzootic for typhus; changes in weather that favor flea survival; increased testing and reporting due to better educated physicians; and increase reporting to public health department by electronic laboratory reporting.

Reported Typhus Fever Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=18)			2009 (N=9)			2010 (N=31)			2011 (N=38)			2012 (N=50)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
1-4	0	0.0		0	0.0		0	0.0		1	2.6		0	0.0	
5-14	3	16.7		2	22.2		3	9.7		3	7.9		6	12.0	
15-34	3	16.7		1	11.1		4	12.9		5	13.2		11	22.0	
35-44	4	22.2		0	0.0		7	22.6		5	13.2		13	26.0	
45-54	4	22.2		4	44.9		5	16.1		9	23.7		10	20.0	
55-64	3	16.7		2	22.2		10	32.3		9	23.7		4	6.7	
65+	1	5.6		0	0.0		2	6.5		6	15.8		6	12.0	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	1	5.6		1	11.1		2	6.5		1	2.6		0	0.0	
Black	0	0.0		0	0.0		2	6.5		2	5.3		2	4.0	
Hispanic	5	27.8		1	11.1		10	32.3		9	23.7		15	30.0	
White	12	66.7		7	77.8		14	45.2		23	60.5		25	50.0	
Other	0	0.0		0	0.0		0	0.0		0	0.0		3	6.0	
Unknown	0	0.0		0	0.0		3	9.7		3	7.9		5	10.0	
SPA															
1	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
2	2	11.1		1	11.1		5	16.1		9	23.7		5	10.0	
3	9	50.0		5	55.6		9	29.0		13	34.2		18	36.0	
4	1	5.6		3	33.3		5	16.1		5	13.2		13	26.0	
5	3	16.7		0	0.0		6	19.4		5	13.2		6	12.0	
6	1	5.6		0	0.0		4	12.9		0	0.0		4	6.7	
7	2	11.1		0	0.0		0	0.0		5	13.2		3	6.0	
8	0	0.0		0	0.0		2	6.5		1	2.6		1	2.0	
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

Figure 1. Typhus Fever Cases by Year
LAC, 2000-2012



Figure 2. Typhus Fever by Age Group
LAC, 2012 (N=50)



Figure 3. Typhus Fever Cases by SPA
LAC, 2012 (N=50)



Figure 4. Typhus Fever Cases by Month of Onset
LAC, 2012 (N=50)



Figure 5. Typhus Fever Cases by Race/Ethnicity LAC, 2008 -2012



Table 1. Animal Exposure* of Cases, LAC, 2012 (N=50)

	Home n (%)	Employment n (%)
Cat	25 (50)	3 (6)
Dog	24 (48)	2 (4)
Cat or Dog	34 (68)	--
Opossum	23 (46)	1 (2)
Rodent	6 (12)	2 (4)

*Exposures will total more than 100% as cases may report more than one exposure.

VIBRIOSIS

CRUDE DATA	
Number of Cases	27
Annual Incidence[a]	
LA County[b]	0.31
California[c]	0.45
United States[c]	0.50
Age at Diagnosis	
Mean	44
Median	46
Range	12-75

[a]Cases per 100,000 population.
[b]Rates calculated based on less than 19 cases or events are considered unreliable.
[c]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

Vibriosis is an infection caused by comma-shaped, Gram-negative bacteria of the genus *Vibrio*. Vibriosis most commonly presents as acute diarrhea, but may also occur as wound infection or septicemia. Vibriosis is transmitted by ingesting food or water contaminated with *Vibrio*, or by contact between open wounds and contaminated water. The most common species that cause vibriosis are *V. parahæmolyticus*, *V. alginolyticus*, *V. vulnificus* and *V. choleræ*. Two serotypes of *V. choleræ* – O1 and O139 -- may cause cholera, an acute, life-threatening diarrheal illness. The infection may be mild or without symptoms, but sometimes it can be severe. Approximately one in 20 infected persons has severe disease characterized by profuse watery diarrhea, vomiting, and leg cramps. In these persons, rapid loss of body fluids leads to dehydration and shock. Without treatment, death can occur within hours. The disease can spread rapidly in areas with inadequate treatment of sewage and drinking water. Vibriosis is commonly associated with consumption of raw or undercooked seafood, particularly shellfish. Many vibriosis patients often have recent history of travel to developing countries.

2012 TRENDS AND HIGHLIGHTS

- This year ACDC changed the way it calculates incidence rates of vibriosis. Prior to 2012, rates were calculated from unadjusted US population data taken from the Census. This year, rates were adjusted to reflect populations in states reporting vibriosis morbidity, excluding states where vibriosis is not a reportable condition.
- In 2012, non-Hispanic whites comprised the largest proportion of all vibriosis cases (48%) (Figure 3). There were nine cases among Hispanics. There was one confirmed case in a black person, and two confirmed cases among Asians.
- SPA 2 and 5 each had six confirmed cases of vibriosis in 2012 (Figure 4). In both these regions, raw oyster or other seafoods were significant sources of vibriosis. SPA 4 had five confirmed cases reporting raw oyster consumption or foreign travel prior to their onset.
- Typically vibriosis cases peak during July and August because *Vibrio* flourish in rising water temperatures. In 2012, the summer peak in vibriosis cases extended into September (Figure 5).
- *V. parahæmolyticus* was the most common etiologic agent isolated (n=19). Eleven cases reported having eaten raw oysters prior to onset, including one case that ate oysters that were harvested in Mexico by a neighbor. Two cases reported eating “shellfish” and “seafood,” but did not specify raw oysters. Two cases reported foreign travel; one case went to Mexico, the other

went to Northern Africa and the Middle East. Exposure history could not be determined in four cases.

- There were four confirmed cases of *V. alginolyticus*: in two boys under 14 years who had separate histories of recreational water exposure, and two men who are avid surfers who frequent Malibu. None of the cases are epidemiologically linked.
- *V. choleræ* non-O1, non-O139 was isolated from one case with a history of alcohol abuse that traveled to Mexico.
- There were two confirmed cases of *V. fluvialis*; one case had traveled to Mexico, the other case had no obvious exposures, but had received a kidney transplant and was on immunosuppressant therapy. *V. furnissii* was isolated from a diabetic man who was being treated for a wound infection.
- No cases of cholera were reported.
- Six cases of vibriosis occurred among women, while 21 cases occurred among men (77.8%). Historically, vibriosis cases have been predominantly male, but in recent years, women have made up a greater proportion of cases. The high proportion of male cases in 2012 appears to be reversing the recent trend.

Reported Vibriosis Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=18)			2009 (N=26)			2010 (N=13)			2011 (N=19)			2012 (N=27)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0		0	0.0	0.0	0	0.0		0	0.0	0.0	0	0.0	0.0
1-4	0	0.0		1	3.8	0.2	0	0.0		0	0.0	0.0	0	0.0	0.0
5-14	2	11.1		0	0.0	0.0	2	15.4		1	5.3	0.1	3	11.1	0.3
15-34	3	16.7		11	42.3	0.4	5	38.5		5	26.3	0.2	7	25.9	0.3
35-44	3	16.7		4	15.4	0.3	0	0.0		3	15.8	0.2	4	14.8	0.3
45-54	3	16.7		5	19.2	0.4	3	23.1		5	26.3	0.4	5	18.5	0.5
55-64	5	27.8		3	11.5	0.3	2	15.4		3	15.8	0.3	4	14.8	0.4
65+	2	11.1		2	7.7	0.2	1	7.7		2	10.5	0.2	4	14.8	0.4
Unknown	0	0.0		0	0.0		0	0.0		0	0.0	0.0	0	0.0	
Race/Ethnicity															
Asian	2	11.1		1	3.8	0.1	1	7.7		0	0.0	0.0	2	7.4	0.2
Black	0	0.0		0	0.0	0.0	0	0.0		1	5.3	0.1	1	3.7	0.1
Hispanic	4	22.2		8	30.8	0.1	4	30.8		9	47.4	0.2	9	33.3	0.2
White	12	66.7		15	57.7	0.5	4	30.8		9	47.4	0.3	13	48.1	0.6
Other	0	0.0		0	0.0	0.0	0	0.0		0	0.0	0.0	0	0.0	0.0
Unknown	0	0.0		2	7.7		4	30.8		0	0.0	0.0	2	7.4	--
SPA															
1	1	5.6		2	7.7	0.5	0	0.0		0	0.0	0.0	0	0.0	0.4
2	4	22.2		6	23.1	0.3	1	7.7		4	21.1	0.2	6	22.2	0.3
3	3	16.7		3	11.5	0.2	0	0.0		2	10.5	0.1	2	7.4	0.2
4	0	0.0		4	15.4	0.3	1	7.7		4	21.1	0.3	5	18.5	0.4
5	3	16.7		5	19.2	0.8	4	30.8		1	5.3	0.2	6	22.2	0.9
6	1	5.6		0	0.0	0.0	2	15.4		4	21.1	0.3	2	7.4	0.3
7	0	0.0		2	7.7	0.1	1	7.7		2	10.5	0.1	2	7.4	0.2
8	5	27.8		3	11.5	0.3	3	23.1		2	15.8	0.2	4	14.8	0.4
Unknown	1	5.6		1	3.8										

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Reported Cases of Vibriosis
LAC, 2003-2012**



**Figure 2. Reported Cases of Vibriosis by Age Group
LAC, 2012 (N=27)**



**Figure 3. Percent Cases of Vibriosis by Race/Ethnicity
LAC, 2012 (N=27)**



**Figure 4. Reported Cases of Vibriosis by SPA
LAC, 2012 (N=27)**



Figure 5. Reported Vibriosis Cases by Month of Onset LAC, 2012 (N=27)



Figure 6. Reported Cases of Vibriosis by Race/Ethnicity LAC, 2008-2012



WEST NILE VIRUS

CRUDE DATA	
Number of Cases[a]	174
Annual Incidence[b]	
LA County[a]	1.87
California[c]	1.27
United States[c]	1.82
Age at Diagnosis	
Mean	56.8
Median	59
Range	10-94

[b]Includes asymptomatic infections.
[b]Cases per 100,000 population. CA and US rates do not include asymptomatic infections.
[c]Calculated from Final 2012 Reports of Nationally Notifiable Infectious Disease. MMWR 62(33);669-682.

DESCRIPTION

West Nile virus (WNV) is a flavivirus related to the viruses that cause Japanese encephalitis (JE) and Saint Louis encephalitis (SLE). Indigenous to Africa, Asia, Europe, and Australia, WNV was first detected in North America in New York City in 1999. Since then, human and non-human WNV surveillance data have documented its establishment as an enzootic disease throughout the continental US, Canada and Mexico.

Normally transmitted by mosquitoes (usually *Culex* or *Anopheles* species) between bird reservoir hosts, humans are incidentally infected with the virus when bitten by an infected mosquito. About 20% of persons infected will develop WNV fever with symptoms that include fever, headache, rash, muscle weakness, fatigue, nausea and vomiting, and occasionally lymph node swelling. Fewer than 1% will develop more severe illness, manifesting as WNV neuro-invasive disease (NID), including meningitis, encephalitis, and acute flaccid paralysis. WNV-associated meningitis usually involves fever, headache, and stiff neck, and has a good prognosis. WNV-associated encephalitis is commonly associated with fever, altered mental status, headache, and seizures, and usually necessitates a high level of specialized medical care. Long-term neurological and cognitive sequelae are not uncommon.

After being infected with WNV, most people sustain a viremia and may remain asymptomatic or eventually develop symptoms. In 2002, asymptomatic blood donors were documented to transmit WNV to blood product recipients. Beginning 2003, blood products have been screened for WNV utilizing polymerase chain reaction (PCR) testing. To date, there have been no blood transfusion-associated secondary WNV infections from asymptomatic WNV-infected blood donors from Los Angeles (LAC) residents. However, four cases of WNV-associated infection including three cases of NID were documented from a LAC organ donor in 2011, not known to be infected with WNV infection at the time of organ donation. Additional routes of transmission that can occur include vertical transmission transplacentally, occupational exposure, and through breast milk.

Prevention and control of WNV and other arboviral diseases are most effective with vector management programs. These programs include surveillance for WNV activity in mosquito vectors, birds, horses, other animals, and humans; and implementation of appropriate mosquito control measures to reduce mosquito populations when necessary. When virus activity is detected in an area, residents are advised to increase measures to reduce contact with mosquitoes. Currently, there is no human vaccine available against WNV but several vaccines are under development. Important preventive measures against WNV include the following:

- Apply insect repellant to exposed skin. A higher percentage of DEET in a repellent will provide longer protection. DEET concentrations higher than 50% do not increase the length of protection.
- When possible, wear long-sleeved shirts and long pants when outdoors for long periods of time.
- Stay indoors at dawn, dusk, and in the early evening, which are peak mosquito biting times.
- Help reduce the number of mosquitoes in areas outdoors by draining sources of standing water. This will reduce the number of places mosquitoes can lay their eggs and breed.

A wide variety of insect repellent products are available. CDC recommends the use of products containing active ingredients which have been registered with the US Environmental Protection Agency (EPA) for use as repellents applied to skin and clothing. Products containing these active ingredients typically provide longer-lasting protection than others:

DEET (N,N-diethyl-m-toluamide)

Picaridin (KBR 3023)

Oil of lemon eucalyptus IR3535 (3-[N-Butyl-N-acetyl]-aminopropionic acid, ethyl ester).

2012 TRENDS AND HIGHLIGHTS

- The number of WNV infections reported in 2012 (N=174) is the second highest number documented in LAC since WNV appeared in 2003 (Figure 1). A peak number of cases has occurred every four years – 2004, 2008, and 2012. These peak years have been characterized by differences in demographic and environmental trends (see ACDC Special Studies Report).
- Of 157 reported symptomatic WNV infections, there were 39 cases of WNV fever and 118 NID cases (67 with meningitis, 47 encephalitis, and 4 acute flaccid paralysis) (Figure 2). Six WNV-associated deaths were reported among symptomatic cases (3.8%). Seventeen asymptomatic donors (9.7%) were reported from local blood banks, organ procurement agencies, and a cord blood bank.
- The mean age of cases was 56.8 years with the largest proportion of cases in the 65 years and older age group (n=64, 37%). Incidence increased as age increased (Figure 3).
- Most cases were of Hispanic/Latino or white race/ethnicity (n=59, 34%, and n=91, 52%, respectively).
- The male to female ratio was 1.7:1.
- WNV cases occurred in all SPAs. The highest number of cases resided in the San Fernando (n=73) and San Gabriel Valley (n=47) areas. Though relatively fewer cases occurred in the Antelope Valley area (n=10), the incidence rate (2.6 per 100,000) was almost just as high (Figure 5).
- Peak onset occurred in September (Figure 6). The last case had an onset on 11/25/2012, which is the latest onset ever documented in LAC. Statewide, 471 human cases were reported in 31 counties. Nationally, the number of WNV cases reported, 5387, is also the highest since 2003.

Reported West Nile Virus Cases and Rates* per 100,000 by Age Group, Race/Ethnicity, and SPA
Los Angeles County, 2008-2012

	2008 (N=170)			2009 (N=25)			2010 (N=4)			2011 (N=63)			2012 (N=174)		
	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000	No.	(%)	Rate/ 100,000
Age Group															
<1	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
1-4	1	0.6	0.2	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0
5-14	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	1	1.6	0.1	2	1.1	0.2
15-34	19	11.2	0.7	5	20.0	0.2	1	25.0	0.0	5	7.9	0.2	24	13.8	0.9
35-44	15	8.8	1.0	0	0.0	0.0	0	0.0	0.0	3	4.8	0.2	17	9.8	1.3
45-54	34	20.0	2.5	10	50.0	0.7	1	25.0	0.1	16	25.4	1.2	33	19.0	2.6
55-64	36	21.2	3.9	4	16.0	0.4	0	0.0	0.0	17	27.0	1.8	34	19.5	3.3
65+	65	38.2	6.4	6	24.0	0.6	2	50.0	0.2	21	33.3	2.0	64	36.8	5.8
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	
Race/Ethnicity															
Asian	6	3.5	0.5	1	4.0	0.1	0	0.0	0.0	1	1.6	0.1	9	5.2	0.7
Black	5	2.9	0.6	0	0.0	0.0	0	0.0	0.0	1	1.6	0.1	3	1.7	0.4
Hispanic	68	40.0	1.5	5	20.0	0.1	1	25.0	0.01	26	41.3	0.5	59	33.9	1.3
White	75	44.1	2.6	16	64.0	0.5	3	75.0	0.1	30	47.6	1.0	91	52.3	3.4
Other	3	1.8	12.2	0	0.0	0.0	0	0.0	0.0	2	3.2		2	1.1	
Unknown	13	7.6		3	12.0		0	0.0		3	4.8		10	5.7	
SPA															
1	5	2.9	1.4	12	48.0	3.3	0	0.0	0.0	1	1.6	0.3	10	5.7	2.6
2	37	21.8	1.7	9	36.0	0.4	0	0.0	0.0	39	61.9	1.8	73	42.0	3.4
3	61	35.9	3.5	2	8.0	0.1	2	50.0	0.1	16	25.4	0.9	47	27.0	2.9
4	12	7.1	0.9	1	4.0	0.1	0	0.0	0.0	1	1.6	0.1	18	10.3	1.6
5	1	0.6	0.2	1	4.0	0.2	0	0.0	0.0	1	1.6	0.2	8	4.6	1.3
6	6	3.5	0.6	0	0.0	0.0	0	0.0	0.0	1	1.6	0.1	2	1.1	0.2
7	44	25.9	3.2	0	0.0	0.0	2	50.0	0.1	4	6.3	0.3	13	7.5	1.0
8	4	2.4	0.4	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	3	1.7	0.3
Unknown	0	0.0		0	0.0		0	0.0		0	0.0		0	0.0	

*Rates calculated based on less than 19 cases or events are considered unreliable.

**Figure 1. Incidence Rates* of West Nile Virus
LAC, 2004-2012**



**Figure 2. Percent Cases of West Nile Virus by Presentation
LAC, 2012 (N=174)**



*R

**Figure 3. Incidence Rates* of West Nile Virus by Age Group
LAC, 2012 (N=174)**



**Figure 4. West Nile Virus Incidence* by Race/Ethnicity
LAC, 2008-2012**



**Figure 5. Incidence Rates* of West Nile Virus by SPA
LAC, 2012 (N=174)**



**Figure 6. Reported West Nile Virus Cases by Month of Onset
LAC, 2012 (N=174)**



*Rates calculated based on less than 19 cases or events are considered unreliable.

Map 14. West Nile Virus
Rates by Health District, Los Angeles County, 2012*



*Excludes Long Beach and Pasadena Data.

DISEASE OUTBREAK SUMMARIES

THIS PAGE IS INTENTIONALLY LEFT BLANK.

COMMUNITY-ACQUIRED DISEASE OUTBREAKS

ABSTRACT

- In 2012, 227 community-acquired disease outbreaks accounted for 2970 cases of illness (Figure 1).
- Four general disease categories accounted for 81% of all outbreak causes. Gastroenteritis (GE), ectoparasites and respiratory outbreaks contributed 29%, 23% and 10%, respectively. Hand, Foot and Mouth (HFM) outbreak levels increased in 2012 to 18%, almost exclusively in the preschool setting. (Figure 2, Table 2).
- Three outbreak settings accounted for almost all (95%) of the reported outbreaks. Pre-schools, schools, and group/assisted living settings contributed 49%, 26% and 20%, respectively. (Figure 3, Table 2) Outbreaks in pre-school settings were higher than previous years, driven mainly by the increase in HFM outbreaks.

Figure 1
Community Acquired Outbreaks
Number of persons Affected
LAC 2000-2012



DATA

A disease outbreak is an infection/infestation cluster, occurring in time or location, with case numbers above expected for a specified population or location. Depending on the nature of the outbreak, investigation responsibility is maintained by either Los Angeles County Department of Public Health Acute Communicable Disease Control Program (ACDC) or Community Health Services with ACDC providing consultation as needed. The outbreaks reported in this section do not include outbreaks associated with food (see Foodborne Outbreaks section) or regulated facilities specifically licensed to provide medical care (see Healthcare Associated Outbreaks section).

Most outbreaks in 2012 were GE outbreaks caused by either norovirus (22) or of undetermined etiology (41). GE outbreaks also had the higher case counts; norovirus outbreaks had a mean of 46 cases per outbreak and unspecified GE had a 16 cases per outbreak. The single outbreak with the highest number of cases (139) was caused by norovirus. Many of the GE outbreaks of undetermined etiology had characteristics similar to the confirmed norovirus outbreaks, but specimens were not available for testing. These figures highlight the continuing circulation of norovirus and reflect the ease this agent can be transmitted from person-to-person in community settings. Additionally, during late 2012 a new strain of Norovirus (GII.4 Sydney) was seen in Los Angeles; mainly was affecting the older populations in group/assisted living communities (Table 1,2). See also Healthcare Associated Outbreaks section as norovirus was affecting Skilled Nursing facilities during 2012. Interestingly, GE outbreaks in pre-school and school locations decreased from the 2011 levels.

Figure 2
Community-Acquired Outbreaks by Type of Disease* LAC, 2012 (N=227)



*Other includes: ringworm, impetigo, unknown rash, MRSA, mumps, pertussis, rash, invasive strep

Figure 3
Community Outbreaks by Setting
LAC, 2012 (N=227)



* School includes: Elementary (48), Middle (1) and High School (2), and Univerisity (7)
**Other includes: camps, work or home events, shelters,surgery center, spec. ed., restaurants,after school care

Only three of 23 respiratory outbreaks were confirmed Influenza in 2012, often due to a lack of specific laboratory testing. Along with a decrease in reports, the size of respiratory outbreaks in 2012 was also reduced compared to the previous year. In 2011, 49 respiratory outbreaks were reported; averaging 28 cases each with three outbreaks over 100 cases. For 2012, only 23 outbreaks were reported, a much smaller case/outbreak average of 10, and the largest outbreak had 24 cases. It was a very quiet 2012-2013 influenza season and for the year 2012, most outbreaks were reported early in the year associated with the 2011-2012 influenza season.

The outbreak setting often has an effect on type of disease being reported. GE outbreaks were dominant in the group/assisted living sites; the location of record for 53% of all GI outbreaks and 76% of the outbreaks reported from this setting. Nearly all of the confirmed Norovirus outbreaks (82%) were in group/assisted living sites. Ectoparasites continues to be a major cause of outbreaks and also show a location preference; group/assisted living settings tend to report scabies, while schools and pre-schools are affected more often by head lice.

Figure 4
Community Outbreaks by SPA
LAC, 2012 (n=227)



The predominance of outbreaks affecting children in educational settings (preschool to university) is well recognized. In 2012 the most common outbreak settings were again pre-schools and schools accounting for 75% of all outbreaks. (Figure 3, Table 2). In the preschool setting, HFM and pediculosis accounted for 59% of the reports.

Outbreaks were reported from all eight SPAs (Figure 4). SPA 3, San Gabriel (47) and SPA 2, San Fernando (44) had the most outbreaks for the past 3 years.

The graph of community-acquired outbreaks by report month (Figure 5) further illustrates the impact of GE, respiratory, HFM, and ectoparasite outbreaks. These four disease categories dominated the outbreak epidemic curve each month throughout the year. HFM was particularly present during April through July - usually a quieter period for outbreak reports.

Figure 5
Community Outbreaks by Selected Disease and Report Month
LAC, 2012 (n=227)



COMMENTS

Only 1% of the outbreak reports are for disease categories that would be individually reported to the local health department (Tables 1, 2). Outbreaks are most often reported from locations with the ability to recognize an unusual occurrence of disease in a group of individuals and have a procedure in place to report to the local health department. This results in most outbreaks being reported in pre-schools, schools and residential facilities.

Characteristics of community-acquired outbreaks result from interactions among particular age groups, locations, and specific diseases. A profile emerges where children acquire infection or infestation associated with a school setting (85 outbreaks reported in pre-schools, 82 reported in elementary schools – 74% of all outbreaks). Gastroenteritis,

respiratory and pediculosis (head lice), were most common in this young group. While illness is often linked to schools, it must be noted that a school association might be serendipitous to the real etiologic location. Children who share a school setting often have other social interactions that could also account for the infection or infestation (e.g., sleepovers, parties, play dates, after school sports, etc.). But whatever the original source exposure, schools need to be vigilant to prevent further transmission and can be greatly aided by the expertise of public health nurses in this effort. The second age group affected is an older population associated with group and assisted living settings. In this age category, GE and scabies are the most common causes (Table 2). While community transmission of disease most certainly occurs in other settings or locations, they lack the opportunity for such outbreaks to be recognized or reported to Public Health.

Table 1. Community-Acquired Outbreaks by Disease— LAC, 2012

Disease	No. of outbreaks	No. of cases	Cases per outbreak (average)	Cases per outbreak (range)
Varicella	2	11	6	5-6
Streptococcal	5	58	12	6-18
Scabies	3	30	10	2-25
Hand, foot & mouth disease	42	357	7	2-31
Pediculosis	49	296	6	2-25
GE illness-Norovirus	22	1017	46	3-139
GE illness-Shigella	0	0	0	0
GE illness-Salmonella	3	9	3	3
GE illness-Unknown	41	662	16	3-72
Fifth disease	4	40	10	4-17
Conjunctivitis	14	72	5	2-15
Influenza	3	30	10	8-14
Respiratory-Unknown	20	229	11	4-24
Other*	19	150	8	2-30
Total	**227**	**2970**	**13**	**2–139**

* Includes: Unk. rash(5), ringworm (3), impetigo (2), MRSA(1), Pertussis (2), mumps (1), IGAS and other/unspecified (4).

Table 2. Community-Acquired Outbreaks by Disease and Setting — LAC, 2012

Disease	Group Home[a]	School[b]	Preschool or Daycare	Other[c]	TOTAL
Varicella	0	2	0	0	**2**
Streptococcal	0	4	1	0	**5**
Scabies	3	0	0	0	**3**
Hand, foot & mouth disease	1	4	37	0	**42**
Pediculosis	3	14	29	3	**49**
GE illness-Norovirus	18	2	2	0	**22**
GE illness-Shigella	0	0	0	0	**0**
GE illness-Salmonella	2	0	1	0	**3**
GE illness-Unknown	15	6	16	4	**41**
Fifth disease (Parvovirus)	0	3	1	0	**4**
Conjunctivitis	1	2	11	0	**14**
Influenza	1	2	0	0	**3**
Respiratory-Unknown	2	11	7	0	**20**
Other	0	8	7	4	**19**
Total	**46**	**58**	**112**	**11**	**227**

[a] Includes centers for retirement/assisted living (40), Group homes (5) and rehabilitation (1)
[b] Includes elementary (48) middle school (1) high school (2), and universities (7).
[c] Includes home events (1), work events (1) special ed. sites (1), camps (1), restaurant (2), shelters (2) surgery center (1), and after-school site (2).

FOODBORNE OUTBREAKS 2012

DESCRIPTION

Foodborne outbreaks are caused by a variety of bacterial, viral, and parasitic pathogens, as well as toxic substances. To be considered a foodborne outbreak, both the State and the Centers for Disease Control and Prevention (CDC) require the occurrence of two or more cases of a similar illness resulting from the ingestion of a common food.[1]

The surveillance system used by Los Angeles County (LAC) Department of Public Health (DPH) for detection of foodborne outbreaks begins with a Foodborne Illness Report (FBIR). This system monitors complaints from residents, illness reports associated with commercial food facilities, and foodborne exposures uncovered during disease-specific case investigations (e.g., salmonellosis, shigellosis, toxigenic *E. coli* [also: shiga toxin producing *E. coli*, or STEC]). LAC Environmental Health Service's (EHS) Food and Milk Program (F&M) investigates each FBIR by contacting the reporting individual and evaluating the public health importance and need for expanded follow-up. When warranted, a thorough inspection of the facility is conducted. This public health action is often sufficient to prevent additional foodborne illnesses.

LAC DPH Acute Communicable Disease Control (ACDC)'s Food Safety Unit also reviews all FBIRs. Joint investigations are conducted on possible foodborne outbreaks with the greatest public health importance. An epidemiologic investigation will typically be initiated when there are illnesses in multiple households, multiple reports against the same establishment in a short period of time, or there are ill individuals who attended a large event with the potential for others to become ill. The objective of each investigation is to determine the extent of the outbreak, identify a food vehicle or processing error, determine the agent of infection, and take actions to protect the public's health.

RESULTS

The number of FBIRs received in 2012 (2087) was higher than that received in 2011 (1786). Public reporting via the web accounted for 60% (n=1255) of FBIRs this year. F&M contacted each person making the FBIR and performed a site inspection on 26% of FBIR reports that were deemed high priority (n=537). Fifty-six percent of the complaints (n=1173) were referred to district EHS offices (n=1094) and 6% (n=132) were referred to other EHS specialty programs (such as Vehicle Inspection, Street Vending Compliance, Drinking Water, etc.), other LAC departments (e.g., Department of Weights and Measures), or agencies outside LAC (e.g., other local health jurisdictions, state agencies, federal agencies). There were 255 FBIRs (12%) on which F&M did not take action or were duplicates. The categories listed above (i.e., site inspections, referral to district EH offices, and other referrals) sometimes overlap because one FBIR can involve more than one suspected food facility or the findings of an investigation may warrant its referral to another program or agency.

The ACDC Program conducted 27 foodborne outbreak investigations this year most of which were investigated by the Food Safety Unit (96%). Twenty-one of these outbreaks were initiated by FBIR complaints and five FBIRs were initiated through other surveillance activities. Of these 27 investigations, four (15%) were not considered to be foodborne as the evidence collected during the investigations did not support a foodborne source (OB# 173, 251, 277, 294) and two investigations (7%) resulted in the referral of the investigation to neighboring counties/public health jurisdictions (OB#56, 64). Three of the outbreaks not considered to be foodborne were due to norovirus, which can easily be spread person to person in a food setting if one guest is sick when attending. In the other non-foodborne investigation an assessment is made based on the following: 1) no food item was implicated in the case-control study or 2) no significant food violations or ill food handler was identified by the inspection. In some cases there is not enough participation from those affected to conduct a thorough case-control study. Determining whether a food item was the source in these outbreaks can be challenging as well as time and resource consuming.

Figure 1.
Foodborne Outbreaks
Number of Persons Affected
LAC, 2002–2012



The 21 outbreaks determined to be foodborne are listed in Table 1 and summarized below. These outbreaks represent 247 cases of foodborne illness (Figure 1) and 12 hospitalizations. No deaths were identified. Outbreaks occurred throughout the year, with slightly more occurring in the winter months (Figure 2).

Etiology of Foodborne Outbreaks

A meal was epidemiologically implicated in 12 investigations during 2012 (60%) with a specific food item implicated in 11 of these. Implicated food items included poultry (n=2), fish (n=2), cut vegetables (n=2), condiments (n=2), baked goods (n=1), soup (n=1), and dishes with multiple ingredients (n=1). An ill food handler was implicated as the cause of two foodborne outbreaks investigated this year. F&M inspections also identified factors such as temperature violations, improper storage of food items, or improper cleaning of equipment that contributed to occurrence of outbreaks during 2012.

Cooked food items

There were four outbreaks involving cooked food items where a bacterial toxin such as *Clostridium perfringens*, *Bacillus cereus*, or *Clostridium botulinum* was suspected. Two involved a chicken dish (rotisserie chicken and chicken sliders), another involved soup, and the fourth involved Teppanyaki, a variety of meats and vegetables displayed and cooked to order. When foods are held at unsafe temperatures bacteria are allowed to grow and produce toxins. Some *B. cereus* toxins are heat-stable and cooking will not destroy the toxin.

Tuna was another cooked food item identified in one outbreak. Certain fish of the Scrombridae family such as tuna, mackerel, skipjack and bonito may naturally contain amino acid histidine. When stored at improper temperatures (i.e., not properly refrigerated) bacteria grow on the fish and convert the histidine into histamine, a substance involved in many allergic reactions. Histamine, a heat stable compound, is not destroyed by cooking and results in scombroid fish poisoning when ingested in sufficient amounts.

Donuts were another cooked food item identified in one outbreak where the etiologic agent was suspected to be a calicivirus such as norovirus. Humans are the primary reservoir for these viruses and these foods likely became contaminated when prepared by a food-handler lacking proper hygiene and infected with the virus. Cooking at proper temperatures kills the virus, but cooked food items such as breads and pastries that are often served at room temperature can be contaminated by improper handling after cooking.

Uncooked food items

There were four outbreaks involving an uncooked food item where the etiologic agent was suspected to be a calicivirus such as norovirus. These items included chopped onions, cut vegetables, guacamole, and ranch dressing. The onions, vegetables, and guacamole require a fair amount of hand manipulation and it is suspected that a food handler lacking proper hygiene and infected with the virus contaminated these foods. Although the preparation of the ranch dressing did not require as much hand manipulation, it is possible that a food handler could have contaminated the dressing. An ill food handler had laboratory confirmation of norovirus in stool and was implicated as the source of two of these outbreaks.

Tuna as an uncooked item (spicy tuna sushi) was identified as the source of one outbreak. As with the cooked tuna, scombroid fish poisoning occurred. The production of histamine may have been due to poor refrigeration.

An etiological agent was identified in all of the foodborne outbreak investigations this year (N=21) and confirmed in 19% (n=4, Figure 3). A viral agent was responsible for 13 outbreaks, bacterial toxins for four outbreaks, fish toxin for two outbreaks, and a bacterial agent for two outbreaks (Figure 3).

Figure 2.
Foodborne Outbreak Investigations by Month of Onset, 2012



Figure 3
Foodborne Outbreaks by Etiologic Agent Category (Lab Confirmed and Suspect) LAC, 2003–2012



Norovirus Outbreaks

Norovirus was confirmed or suspected in 13 foodborne outbreaks this year (68%), which is the same as that seen in 2011 and a considerable drop from the peak number seen in 2006 (N=25).

The largest laboratory-confirmed foodborne norovirus outbreak this year involved 27 cases from three different parties that were catered by the same restaurant (OB#189). The incubation times were consistent with a point-source outbreak and chopped onions were associated with illness. Three food handlers and three patrons tested positive for norovirus. The source of this outbreak was likely food contaminated with norovirus by an ill food handler. Education on ill employee reporting and on norovirus was provided to the management.

Another laboratory-confirmed norovirus outbreak involved three cases who attended a week-long clothing design event (OB#24). Three attendees tested positive for norovirus. Due to limited participation it was difficult to determine whether the outbreak was point-source or person to person spread.

Bacterial Outbreaks

Shigella sonnei was confirmed in one outbreak this year (OB#165). This outbreak involved 43 cases eating at a private bridge club. This outbreak was reported as an FBIR. Fourteen club members and staff tested positive for *Shigella sonnei.* Ten of the 14 samples underwent PFGE and yielded the same outbreak pattern. One club employee who tested positive was a food handler who was involved in the preparation of the majority of foods identified as being associated with illness (see special report for details).

Salmonella Newport was confirmed in one outbreak this year (OB#154). An outbreak of salmonellosis occurred at a graduation party held at a residence in LAC. This outbreak was reported when district nurses found two confirmed salmonella cases who attended the same graduation party.

A total of nineteen people attended the graduation party. Seven cases participated in the investigation; four of these cases were lab-confirmed. Due to the lack of participation from controls, the source of the outbreak remains unclear. Possible sources include the transmission of *Salmonella* from one person to another at the event or a contaminated home-made or commercial food item.

Other Foodborne Outbreaks

There were two suspect scombroid outbreaks in LAC, one involving 5 cases (OB#201) eating spicy tuna rolls and the other involving 3 cases (OB#209) eating tuna burgers at LAC restaurants. The symptoms and durations of illness reported by cases were consistent with scombroid intoxication and the onset date of illness was consistent with point-source outbreak. The health inspection of the restaurant implicated in OB#201 did not reveal any major health violations, but the vendor of the tuna was unlicensed and suspected of selling tuna scraps that may not have been properly refrigerated. Conversely, the health inspector for the restaurant implicated in OB#209 found major sanitation violations and evidence of mishandling of food that could have resulted in histamine contamination.

There were two foodborne cases of botulism in LAC (OB#44). These cases lived in the same home and both consumed unrefrigerated soup (see 2012 Special Studies Report for details).

State and National Investigation Involving Los Angeles County

LAC assisted state and federal investigators with 15 *Salmonella*, 5 STEC, and 2 *Listeria* cluster investigations that required additional interviews by LAC DPH ACDC staff. Two national *Salmonella* investigations led to the identification of a nationally distributed food item.[2,3] One national *Listeria* investigation involved a pregnant LAC case.[4] The *Listeria* infection resulted in premature birth followed by death soon after. There were also 18 additional *Salmonella* clusters where ACDC provided existing case information to CDC; no additional interviews were required.

Outbreak Locations

Locations for reported foodborne outbreaks included restaurants (9), the workplace (6), a residence (2), a banquet hall, a school, and a bridge club. Service Planning Area (SPA) 2 reported the largest number of outbreaks (37%, Table 2), as was the case in 2010 and 2011.

Table 1. Foodborne Outbreak Investigation 2012 (N=20)

	Agent	Lab Confirmed	OB#	Setting	Cases	Health District	Food Implicated
1	Norovirus	No	288	Restaurant	17	Central	None
2	Norovirus	No	297	Restaurant	18	Central	Guacamole
3	Norovirus	No	299	Restaurant	10	West	None
4	Norovirus	Yes	24	Workplace	3	East Valley	None
5	Norovirus	No	25	Banquet	7	Glendale	None
6	Norovirus	No	49	Workplace	9	Glendale	Donuts
7	Norovirus	No	50	Workplace	7	West	None
8	Norovirus	No	74	Restaurant	9	West	None
9	Norovirus	No	158	School	30	Glendale	None
10	Norovirus	Yes	189	Residence	27	West Valley	Onion
11	Norovirus	No	244	Restaurant	13	Pomona	None
12	Norovirus	No	250	Restaurant	5	East Los Angeles	None
13	Norovirus	No	262	Workplace	8	East Los Angeles	Ranch dressing
14	Bact Toxin	No	29	Workplace	10	Torrance	Chicken Sliders
15	Bact Toxin	No	162	Workplace	7	Bellflower	Rotisserie Chicken
16	Bact Toxin	No	279	Restaurant	7	Glendale	Teppanyaki
17	Scombroid	No	201	Restaurant	5	West Valley	Spicy Tuna
18	Scombroid	No	209	Restaurant	3	West	Albacore Tuna
19	Shigellosis	Yes	165	Bridge Club	43	West	Cut vegetables
20	Botulism	No	44	Residence	2	Central	Soup
21	Salmonellosis	Yes	154	Residence	7	Harbor	None

Table 2. Frequency of Foodborne Outbreaks by Service Planning Area or Location, LAC, 2012 (N=20)

SPA	Frequency	Percent
1	0	0%
2	7	35%
3	1	5%
4	3	15%
5	5	25%
6	0	0%
7	3	15%
8	1	5%

ADDITIONAL RESOURCES

LAC resources:

- Communicable Disease Reporting System
  Hotline: (888) 397-3993
  Fax: (888) 397-3779
- For reporting and infection control procedures consult the LAC DPH ACDC:
  http://publichealth.lacounty.gov/acd/index.htm

CDC:

- Division of Foodborne, Waterborne, and Environmental Diseases (DFWED)–
  http://www.cdc.gov/ncezid/dfwed/
- Outbreak Response and Surveillance Team
  http://www.cdc.gov/foodborneoutbreaks
- FoodNet
  http://www.cdc.gov/foodnet
- Norovirus Information
  http://www.cdc.gov/norovirus/index.html

Other national agencies:

- FDA Center for Food Safety and Applied Nutrition
  http://www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm135675.htm
- Gateway to Government Food Safety Information
  http://www.FoodSafety.gov

REFERENCES

1. Centers for Disease Control and Prevention. Surveillance for foodborne disease outbreaks - United States, 2006. *MMWR.* 2009;58(22):609-615.
2. Centers for Disease Control and Prevention. Multistate Outbreak of Salmonella Bredeney Infections Linked to Peanut Butter Manufactured By Sunland, Inc. 2012; http://www.cdc.gov/salmonella/bredeney-09-12/index.html. Accessed April 25, 2013.
3. Centers for Disease Control and Prevention. Multistate Outbreak of Salmonella Braenderup Infections Associated with Mangoes. 2012; http://www.cdc.gov/salmonella/braenderup-08-12/index.html. Accessed April 25, 2013.
4. Centers for Disease Control and Prevention. Multistate Outbreak of Listeriosis Linked to Imported Frescolina Marte Brand Ricotta Salata Cheese. 2012; http://www.cdc.gov/listeria/outbreaks/cheese-09-12/index.html. Accessed April 25, 2013.

HEALTHCARE-ASSOCIATED OUTBREAKS
GENERAL ACUTE CARE HOSPITALS

DEFINITION

This chapter will discuss healthcare-associated outbreaks and situation events that occurred within the general acute care hospital setting on any patient unit, sub-acute or specialty area within the facility (e.g., surgical suites or procedure rooms). An outbreak in such settings is defined as a cluster of infections related in time and place, or occurring above a baseline or threshold level for a defined area of a facility, including the entire facility, specific unit, or ward. Baseline is relative to what is normally observed in a particular setting.

A situation event is defined as a cluster of infections in the setting of a general acute care hospital that may not clearly meet all outbreak criteria defined above, for which additional information is required to determine if an outbreak has occurred.

Figure 1.
General Acute Care Hospital Outbreaks
and Situation Events
LAC, 2007–2011



ABSTRACT

There were 24 confirmed outbreaks reported in acute care hospitals in 2012 (Figure 1), an increase of 33% from 2011. Sixty-three percent (n=15) occurred in a unit providing intensive or focused specialized care (e.g., neonatal intensive care, bone marrow transplant and cardiac surgery units). Thirteen percent (n=3) occurred in a psychiatric unit located within the acute care hospital (Table 1). Scabies outbreaks (n=3) accounted for 13% of all outbreaks. Sixty-three percent (n=15) of acute care hospital outbreaks were of bacterial etiology (Table 2) from a multidrug-resistant organism (MDRO) such as *Acinetobacter baumannii (A. baumannii)*, carbapenem-resistant *Klebsiella pneumoniae*, (*CRKP*) and *Staphylococcus species* [S. species] (Figure 2). The etiologic agents contributing the largest number of cases in acute care hospital outbreaks were norovirus (64, 28%) followed by scabies (62, 27%) and *S. species* (18, 8%). There were three situation events reported in acute care hospitals in 2012; two were of bacterial etiology and caused by MDROs (Table 4).

Table 1. General Acute Care Hospital Outbreaks by Unit—LAC, 2012

Outbreak Location	No. of Outbreaks
Cardiac Surgery	1
Intensive Care – Adult	3
Intensive Care- Neonatal	6
Liver Transplant	1
Medical/Surgical	1
Orthopaedic Surgery	1
Pediatric	4
Psychiatric	3
Rehabilitation	2
Sub-acute Unit within a Hospital - Adult	1
Telemetry	1
Total	**24**

Table 2. General Acute Care Hospital Outbreaks by Disease/Condition—LAC, 2012

Disease/Condition/ Etiologic Agent	No. of Outbreaks	No. of Cases
A. baumannii	2	8
Aspergillus	2	16
Carbapenem-resistant *Klebsiella pneumoniae*	2	9
Legionellosis	1	2
Norovirus	4	64
Pediculosis	1	3
Pseudomonas aeruginosa	1	3
Respiratory syntial virus	1	5
Scabies	3	62
Staphylococcus species	5	28
Stenotrophomonas maltophilia	1	3
Unknown Gastroenteritis	1	25
Total	**24**	**228**

Table 3. General Acute Care Hospital Situation Events by Unit—LAC, 2012

Outbreak Location	No. of Events
Medical/Surgical	1
OB/GYN	1
Pharmacy	1
Total	**3**

Table 4. General Acute Care Hospital Situation Events by Disease/Condition—LAC, 2012

Disease/Condition/ Etiologic Agent	No. of Events	No. of Cases
lostridium difficile	1	11
Escherichia coli, ESBL	1	2
Non-applicable*	1	3
Total	**3**	**16**

*The patients were diagnosed with Bell's Palsy, etiologic agent not identified.

Figure 2.
Outbreaks of Selected Bacterial Infections
by Year, LAC 2007-2011



COMMENTS

Antibiotic resistant bacteria have had a direct impact on the U. S. healthcare system and the delivery of services. Multidrug-resistant organisms (MDRO) are dynamic by nature and a significant reason for the rise in healthcare costs. These organisms continue to flourish and cause significant morbidity and mortality in hospitalized patients.[1] The CDC notes that "Each year in the United States, at least 2 million people acquire serious infections with bacteria that are resistant to one or more of the antibiotics designed to treat those infections. At least 23,000 people die each year as a direct result of these antibiotic-resistant infections".[2] According to Zimlichman, E. and Henderson, D. et al., "Hospital-acquired infections account for a large proportion of the harms caused by health care and high rates of morbidity, mortality and costs…there are approximately 444,000 of these infections annually among US adult inpatients and …annual costs are $9.8 billion with over a third attributable to SSI"[3].

In 2012, over half the acute care hospital outbreaks reported in Los Angeles County (15/24) were due to an MDRO. *Staphylococcal* species were responsible for three separate outbreaks involving surgical site infections (SSI) post-surgery. In one outbreak, Hospital A reported seven central spinal fluid (CSF) *Staphylococcal* infections among patients who were post ventriculoperitoneal shunt (VP shunt) placement or revision. Three distinct *Staphylococcus* species were identified (*S. aureus* [n=4], *S. epidermidis* [n=2], *S. hominis* [n=1) among the cases and all surgical procedures were performed by Surgeon A. (See Special Studies)

The second SSI outbreak involved eight post hip replacement infections that occurred at Hospital B over a two year period from February 2011-July 2012. In August 2012, the infection preventionist (IP) noted an increase in the hospital-acquired MRSA rate after hip surgery. Seven cases had MRSA infections and one case had *S. aureus* infection. (See Special Studies)

The third SSI outbreak involved five post-cardiac surgery patients diagnosed with *S. epidermidis* endocarditis at Hospital C. All cases had aortic valve replacement (AVR) between January and May 2012, were discharged home and readmitted. Four cases had a second surgery subsequent to the *S. epidermidis* infection. All surgeries were performed by the same surgeon, Surgeon C, who was training at

the facility during the outbreak period (January 1, 2012-August 31, 2012). The surgeon had a contact dermatitis type rash on the hands. (See Special Studies)

Each of these outbreaks was discovered by an astute clinician or IP conducting routine MDRO surveillance. Their subsequent actions illustrate the importance of consistent vigilance surrounding healthcare acquired infections and demonstrate the need for continued surveillance of these pathogens.

REFERENCES

1. Kontra, J, Reduction of Surgical Site Infections by Pre-Operative Eradication of the Staphylococcus Aureus Carrier State: A Paradigm Whose Time has Come. The Journal of Lancaster General Hospital; Spring 2012:Vol. 7-No.1, p.4-7.

2. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Antibiotic Resistance Threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf#page=28.

3. Zimlichman, E, Henderson, D and Tamir, Orly, et al., Original Investigation Healthcare-Associated Infections: A Meta-analysis of Costs and Financial Impact on the US Health Care System, JAMA Intern Med; Published online September 2, 2013,

HEALTHCARE-ASSOCIATED OUTBREAKS
SUB-ACUTE CARE FACILITIES

DEFINITION

Healthcare-associated outbreaks are defined as clusters of infections in healthcare settings related in time and place, or occurring above a baseline or threshold level for a facility, specific unit, or ward. Baseline is defined as what is normally observed in a particular setting.

The sub-acute care facilities include free-standing dialysis centers, skilled nursing facilities (SNF), intermediate care facilities and psychiatric care facilities. SNFs provide continuous skilled nursing care to patients on an extended basis. Intermediate care facilities also provide skilled nursing care and supportive care to patients who have needs of these services but do not require continuous nursing care, but the care is not continuous. Psychiatric facilities provide 24-hour inpatient care for patients with psychiatric care needs.

Figure 1.
Sub-acute Facility Outbreaks
LAC, 2001 – 2012



ABSTRACT

- Total confirmed sub-acute care associated outbreaks increased by 13% in 2012 from 110 to 124 outbreaks in 2011 and 2012 respectively.
- The number of SNF outbreaks increased by 17% from 102 to 119 outbreaks in 2011 and 2012, respectively (Table 1). The rate of SNF outbreaks in 2012 was 31 per 100 facilities compared with 26 in 2011 and 27 in 2010 (Figure 1).
- There were outbreaks in three categories of sub-acute healthcare facilities in 2012 (Table 1).

Table 1. Number of Reported Outbreaks in Sub-acute Healthcare Facilities LAC, 2007–2012

	YEAR					
Type of Facility	**2007**	**2008**	**2009**	**2010**	**2011**	**2012**
Intermediate Care Facilities	3	-	3	-	4	2
Psychiatric Care Facilities	3	2	-	-	3	3
Dialysis Centers	-	-	-	-	1	-
Skilled Nursing Facilities	110	85	166	104	102	119
Total	116	87	169	104	110	124

Intermediate Care Facilities: Two outbreaks were reported in intermediate care facilities in 2012, compared with four outbreaks in 2011. The two investigations included a norovirus outbreak and an unknown gastroenteritis (GI) outbreak.

Psychiatric Facilities: Three outbreaks were reported in psychiatric care facilities in both 2012 and 2011. The three outbreaks in 2012 included one norovirus, one unknown GI and one unknown rash.

Skilled Nursing Facilities: In 2012, there were 119 outbreaks reported by SNFs excluding intermediate and psychiatric care facilities. GI illness accounted for the most frequently reported category of outbreaks, 62 (52%) and involved the greatest number of affected cases, 1405 (71%) compared with 769 (51%) in 2011.

Table 2. All Sub-acute Healthcare Facilities Outbreaks by Disease/Condition LAC, 2012

Disease/Condition	No. of Outbreaks	No. of Cases
Gastroenteritis (GI) • Unspecified (n=24) • Norovirus (n=40) • Clostridium difficile (n=3)	67	1683
Respiratory illness • Unspecified (n=7) • Influenza (n=3) • Respiratory Syncytial Virus (n=1) • Other (n=1)	12	200
Scabies	24	214
Unknown Rash	19	190
Invasive Group A *Streptococcus*	1	3
Legionellosis	1	2
Total	**124**	**2292**

COMMENTS

The total number of outbreaks within skilled nursing facilities (SNFs) increased by 13% in 2012 compared to 2011 with 124 and 110 outbreak reported in respective years. GI outbreaks were the most frequently reported outbreaks and increased from 34 to 67 outbreaks in 2011 and 2012, respectively. GI outbreaks in 2012 comprised of 40 (60%) laboratory- confirmed norovirus, 24 (36%) unknown GI and 3 (4%) *Clostridium difficile* outbreaks. This increase in GI outbreaks was most likely due to the emergence of a new norovirus strain GII.4 Sydney, first identified in Australia in March 2012. This norovirus strain was responsible for over 50% of United States gastroenteritis outbreaks reported to CDC by December 2012[1]. Six GII.4 Sidney strain outbreaks were documented in SNFs from October to December 2012. Of those, SPA (Service Planning Area) 3 had the most documented GII.4 Sidney strain outbreaks 5 (83%). It is likely that the early arrival of the norovirus season with a new genotype as well as directed outreach through the Norovirus Outbreak Prevention Project (NOPP) within SPA 3 from October 1 - December 31, 2012 resulted in increased reporting of outbreaks and better documentation of individual outbreaks.

Twelve respiratory outbreaks were investigated with a total of 200 cases. Of these, three (25%) outbreaks were influenza outbreaks, seven (59%) were respiratory outbreaks of unknown etiologies, one (8%) was a respiratory syncytial virus outbreak and one (8%) was categorized as 'other'. The three confirmed influenza outbreaks occurred in February and April 2012. The influenza outbreaks affected a total of 78 cases, 22 staff and 65 residents. Of the 65 SNF residents with influenza, 12 were hospitalized and one died. Seven of 17 influenza A cases were subtyped H3N2 and the remainder were not subtyped. The respiratory outbreak identified as 'other', involved ten cases, four of which were laboratory confirmed cases. Other pathogens responsible for respiratory outbreaks included: two cases had sputum cultures-

[1] CDC. Emergence of New Norovirus Strain GII.4 Sydney- United States, 2012. MMWR 2013; 62.

positive for *Pseudonomas aeruginosa*, two positive for human metapneumovirus with one case also positive for rhinovirus. There were 24 scabies outbreaks (19%) with a total of 214 cases in 2012 compared with 35 outbreaks in 2011, representing a 31% decline rate. Similarly, the number of unknown rash outbreaks decreased by 37% from 30 in 2011 to 19 in 2012.

Two SNF outbreak investigations conducted by ACDC involved an invasive group A *Streptococcus* (IGAS) and a legionellosis investigation. The IGAS investigation involved two blood culture- confirmed IGAS cases and one probable case. A site visit revealed several breaches in infection control including improper hand washing and infection control policies that were not standardized to CDC guidelines. The legionellosis investigation involved two cases of nosocomial *Legionella* disease occurring in a facility within a five month period. Enhanced surveillance of all nosocomial pneumonia cases did not reveal any additional cases in the facility. The source of *L. pneumophila* was not identified during the investigation.

Twenty LAC DPH districts investigated at least one sub-acute care facility outbreak during 2012. The greatest proportion of outbreaks was investigated by Monrovia (16, 13%), followed by Pomona (15, 12%), Glendale (12, 10%) and West Valley (12, 10%) health districts. The increase in GI and norovirus outbreaks in Monrovia and Pomona health districts was likely due to norovirus disease outreach conducted by NOPP (Norovirus Outbreak Prevention Project) described in detail below. Facilities in SPAs 3 reported the most SNF outbreaks in 2012 (39, 31%) followed by SPA 2 (27, 22%) and SPA 4 (15, 12%).

PREVENTION

The majority of outbreaks in sub-acute care facilities are caused by agents that are spread via person-to-person contact. Thus, appropriate hand hygiene practice by staff and residents is a crucial infection control measure. Influenza vaccination for SNF staff and residents as well as proper handwashing, administrative controls, utilization of appropriate antiviral prophylaxis for facility residents and staff and isolation where necessary are essential in the prevention of seasonal influenza.

During the spring of 2012, a NOPP (Norovirus Outbreak Prevention Project) working group was convened with public health representation from the Environmental Health Program, Health Facilities Licensing and Certification Program, Acute Communicable Disease Control Program, and Community Health Services. The goals of the Working Group were to develop a “Norovirus Outbreak Prevention Toolkit” and to provide targeted norovirus outbreak prevention training to SPA 3 SNF administrators, nursing directors and line staff with the objective of decreasing the number and size of SNF- associated norovirus and other gastroenteritis outbreaks. The “Norovirus Outbreak Prevention Toolkit” was completed by September 2012. SNF administrator and nursing director training was completed by the first week in October and SNF line staff training was completed by mid- December 2012. The NOPP toolkit is posted on the Acute Communicable Disease Control Program
(ACDC) web site at http://publichealth.lacounty.gov/acd/docs/Norovirus/NoroToolkit2012.pdf.

Two training sessions for SPA 3 SNF Directors of Nursing (DON) and administrators were completed on September 11 and October 2, 2012. In total, 165 SNF DONs and administrators completed two hours training from 65 of the 78 total SNFs in SPA 3. An ACDC physician gave a one hour presentation titled, “Prevention of Norovirus Outbreaks in Subacute Healthcare Facilities” to the Association of Skilled Nursing Facilities on September 20, 2012, to approximately 300 SNF administrators from Southern California. SPA 3 public health nurses (PHNs) completed NOPP training at 60 of 78 SNFs by December 15, 2012; 18 SNFs declined multiple offers for training by district PHNs. In total 2,264 line staff, consisting of certified nursing assistants, licensed vocation nurses, and housekeeping staff attended these presentations. Public health nurses from SPA 3 who provided SNF training reported positive experiences and appreciative SNF staff. SNF- associated gastroenteritis outbreaks in the upcoming fall and winter of 2013- 2014 will be followed closely. It is hopeful that decreases in outbreak reports and size of outbreaks will be the result of the intervention in the upcoming season.

Acute Communicable Disease Control Program

Special Studies Report

2012

Los Angeles County
Department of Public Health

Public Health
Laurene Mascola, MD, MPH
Chief, Acute Communicable Disease Control Program

THIS PAGE IS INTENTIONALLY LEFT BLANK.

ACDC SPECIAL STUDIES REPORT 2012

TABLE OF CONTENTS

Disease Surveillance, Trends, & Summaries:

Infectious Disease Incidents/Clusters/Outbreaks:

BOTULISM CASE REPORT SUMMARY
LOS ANGELES COUNTY, 2012

David Dassey, MD, MPH

Four cases of botulism were confirmed and reported in 2012; all cases survived. One additional report of suspected botulism was not confirmed.

Two of the cases comprised a foodborne botulism outbreak. A cohabiting couple ingested soup that had not been refrigerated for over a week. One case was hospitalized for several days and received botulinum antitoxin. The other case was stable and was hospitalized for only one day for observation. Tests of several clinical specimens were negative for botulinum toxin and organisms for both cases; however the occurrence of clinically compatible botulism in two persons who had consumed a risky food item was sufficient to meet the case definition of a foodborne botulism outbreak. The investigation identified conflicting label instructions for food storage; this was brought to the attention of the federal Food and Drug Administration and the soup manufacturer, which took immediate steps to correct the labeling problem on its products nationwide. See the special report for details.

One case was classified as wound botulism. The case patient was an injection drug user with cellulitis; both serum and wound culture demonstrated botulinum toxin type A. The patient received antitoxin and recovered.

The fourth case also occurred in an injection drug user but was classified as a case of "other" botulism. Botulinum toxin type A was detected in the patient's serum obtained prior to treatment with antitoxin. No wound culture was obtained, but a stool sample also showed evidence of toxin type A, which would not happen in wound botulism. Before the patient could be questioned further about his recent food consumption, he left the hospital against medical advice. Lacking a history of exposure to a botulism-prone food item, the case could not be classified definitively as foodborne botulism.

The unconfirmed botulism suspect was an injection drug user who presented with a clinical picture similar to botulism, but additional tests confirmed myasthenia gravis. He did not receive antitoxin and no further botulism tests were conducted.

There were 14 cases of infant botulism confirmed by the California Department of Public Health, Infant Botulism Treatment and Prevention Program[1]; ten were due to type A and four were due to type B toxin. Seven cases were Hispanic, six were white, non-Hispanic, and one was Asian. There were four female cases and ten male cases, with ages ranging from 48 to 240 days (mean, 136 days) at time of onset. All survived.

[1] Infant Botulism Treatment and Prevention Program. Division of Communicable Disease Control, California Department of Public Health. http://www.infantbotulism.org/.

FACILITY-LEVEL PREDICTORS OF *CLOSTRIDIUM DIFFICILE* INFECTION RATES IN LOS ANGELES COUNTY HOSPITALS, 2010-2012

Kelsey OYong, MPH, Patricia Marquez, MPH, Dawn Terashita, MD, MPH

BACKGROUND

Clostridium difficile is an anaerobic, spore-forming bacterium that lives naturally in the intestine of 3% of healthy adults.[1] However, with disruption of the natural gut flora, through use of antimicrobials or illness, *C. difficile* is able to infect the host. During infection, *C. difficile* produces toxins which cause watery diarrhea, fever, abdominal pain, cramping, and dehydration, leading to higher costs and length of hospital stay.[2,3,4] The incidence and mortality of *C. difficile* infection (CDI) have increased in recent years nationally. An emergent resistant strain of *C. difficile*, NAP1/ BI/027, has been associated with many outbreaks and cases of severe illness, and may account for this surge in CDI rates.[5]

In 2008, California mandated hospital reporting of CDI to the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN). NHSN is a free internet-based surveillance system that collects data from healthcare facilities on infections and other adverse events. California hospitals began reporting CDI data to NHSN on April 1, 2010 using the Lab ID module, a component of NHSN used by facilities to monitor and analyze CDI and multi-drug resistant organism infections. In Los Angeles County (LAC), 100 (100%) hospitals report to NHSN; all of these hospitals have voluntarily conferred rights to Los Angeles County Department of Public Health (LAC DPH) to access their NHSN data.

Population-based CDI rates in LAC have not been previously determined. Additionally, few studies have examined facility-level predictors of CDI rates. High levels of CDI have been associated with hospitals that are non-teaching and without emergency departments or trauma services.[6,7] CDI testing method is another factor that affects a facility's CDI rates and is not well understood. Several different testing methods are available with varying degrees of sensitivity and specificity, which may impact CDI rates.[8] The objective of this report is to describe the first two years of facility-level CDI data collected in NHSN, from April 2010 to March 2012, by time period, hospital-level attributes, and testing method.

METHODS

CDI counts and total CDI patient-days were collected using NHSN. Patient-days are defined as the sum of the daily count of the number of patients per location. Hospitals reporting less than ten months per reporting year of CDI summary data were excluded. Hospital attributes were determined using surveys conducted by the LAC DPH Hospital Outreach Unit (HOU). The analyzed attributes were: status as a long-term acute care (LTAC) facility, presence of a residency program, presence of an emergency department, and status as a trauma center. Rate calculations for the latter three attributes excluded LTACs. The Centers for Medicare and Medicaid Services certifies a hospital as LTAC if its average length of stay among patients is greater than or equal to 25 days.[9] *C. difficile* sample testing methods were determined using the NHSN user survey, which was self-reported by hospitals. The testing methods were not mutually exclusive; some hospital laboratories employed more than one method. The CDI annual rates were calculated with SAS 9.3.

Cases were defined based on the NHSN LabID component criteria for onset type. Hospital-associated (HA) CDIs include both hospital-onset cases (HO CDI) and community-onset-healthcare-facility-associated cases (COHCFA CDI). HO CDIs are defined as events occurring more than three days after admission to the facility. COHCFA CDIs are defined as events occurring in patients who were discharged from the facility four weeks or less prior to the date of stool specimen collection. Community-onset (CO) CDIs were defined as events occurring as an outpatient or an inpatient equal or less than three days after admission to the facility. CDI rates were calculated as cases per 10,000 patient-days, as defined and collected in NHSN. Duplicate CDI specimens were excluded following the NHSN definition for duplicate *C. difficile*-positive test: any *C. difficile* toxin-positive laboratory result from the same patient and NHSN-

mapped location within the hospital, following a previous *C. difficile* toxin-positive laboratory result within the past two weeks.

RESULTS

In the first year of reporting, from April 2010 to March 2011, complete NHSN CDI data were available for all 100 hospitals. In the second year of reporting, April 2011 to March 2012, complete NHSN CDI data were available for 99 hospitals. The breakdown of reporting hospitals by attribute is shown in Table 1. For the reporting year 2010-2011, 8516 CDIs were reported to NHSN by LAC hospitals. The second year of reporting, 2011-2012, yielded 9474 CDIs (Figure 2). The numbers of CDIs by onset type for the two reporting years are shown in Table 2. Figure 1 displays the median CDI rates by type for the two reporting years. For the 2010-2011 time period, LAC hospitals reported an HA CDI rate of 9.8 events per 10,000 patient-days and an HO CDI rate of 7.6 events per 10,000 patient-days. During the 2011-2012 time period, LAC hospitals reported an HA CDI rate of 10.9 events per 10,000 patient-days and an HO CDI rate of 8.4 events per 10,000 patient-days. The HA CDI rates by status as a LTAC, presence of a residency program or an emergency department, and status as a trauma center are displayed in figures 2-5. Of note, the HA CDI rate in LTACs was 23.8 and 22.2 events per 10,000 patient-days for 2010-2011 and 2011-2012, respectively; for non-LTACs, the HA CDI rate was 9.6 and 10.5 events per 10,000 patient-days for the same time periods. Table 3 displays the HA CDI rates for 2010-2012 by *C. difficile* sample testing method. For both reporting years, the HA CDI rate was highest in those LAC hospitals using nucleic acid amplification, including PCR, testing.

Table 1. Number of LAC hospitals, by attributes, 2010-2012.

	2010-2011	**2011-2012**
LTAC	8	9
Non-LTAC	92	90
Residency program	19	20
No residency program	81	79
ED	77	77
No ED	23	22
Trauma center	15	15
No trauma center	85	84

Table 2. Number of *Clostridium difficile* infections reported to NHSN, by onset type, Los Angeles County, 2010-2012

CDI Type	**No. infections, 2010-2011**	**No. infections, 2011-2012**
HA	5574	6058
HO	4332	4684
COHCFA	1242	1374
CO	2942	3416

HA – hospital associated HO – hospital onset CO – community onset
COHCFA – community onset, healthcare facility associated (see text for details)

Figure 1. Median *Clostridium difficile* rates reported to NHSN, by disease onset type, Los Angeles County, 2010-2012



Figure 2. Median hospital-associated *Clostridium difficile* rates by LTAC status, Los Angeles County, 2010-2012



Figure 3. Median hospital-associated *Clostridium difficile* rates by ED status, Los Angeles County, 2010-2012



Figure 4. Median hospital-associated *Clostridium difficile* rates by status as a trauma center, Los Angeles County, 2010-2012





Table 3. Median hospital-associated *Clostridium difficile* rates by sample testing method (per 10,000 patient-days), Los Angeles County, 2010-2012

Year	Testing method					
	Stool Culture	Cytotoxin assay	Enzyme immunoassay for toxin	Nucleic acid amplification	Stool antigen	Other
2010	8.0	6.5	8.9	10.9	8.7	10.5
2011	7.1	8.0	6.6	14.9	7.3	10.9

DISCUSSION

This is the first report of CDI rates in LAC using NHSN data and hospital attributes. The CDI rates in LAC are similar to, yet higher than state and national trends. Compared to the California 2010-2011 state HA rate of 9.4 events per 10,000 patient-days, LAC hospitals reported higher rates in 2010-2011 and 2011-2012 (9.8 and 10.9 events per 10,000 patient-days, respectively). Similarly, the 2010-2011 and 2011-2012 LAC HO rates (7.6 and 8.4 events per 10,000 patient-days, respectively) were higher than both the 2010-2011 state HO rate, 7.0 events per 10,000 patient-days, and the 2010 national HO rate of 7.4 events per 10,000 patient-days.[10,11]

Notably, HA CDI rates were higher in hospitals that had residency programs and in hospitals with an emergency department for both time periods. These findings are in contrast to prior studies on hospital attributes associated with high CDI rates; however, our analyses were specific to NHSN-defined hospital-associated infections, rather than overall rates.[6,7] We removed LTACs from the rate comparison of facilities by presence of a residency program, presence of an emergency department, and status as a trauma center because the rates of HA CDI among LTACs was much higher than general acute care facilities. LTACs had an HA CDI rate of over two fold that of non-LTAC hospitals in LAC. LTACs represent a specific role on the continuum of care, as many patients are transferred to LTACs following stays in critical or intensive care units of general acute care hospitals, before being sent home. CDI rates between LTACs and non-LTACs vary greatly for a number of reasons, including longer average length of stays in

LTACs. In California, the average length of stay for patients in LTACs was over six times longer than non-LTACs.[10] Further, the patient populations are quite different for LTACs and non-LTACs. LTAC patients are generally medically complex, with a higher numbers and severity of comorbidities. LTAC patients are on average, older in age, a risk factor in CDI.[12,13] Targeted interventions for LTAC patient population is needed, as these facilities access services in all aspects of patient care.

Differences in CDI rates by various testing methods have been reported.[14] In some cases, the CDI rate doubled after implementation of polymerase chain reaction (PCR) testing replaced immunoassay methods.[14] Several hospitals reported using more than one testing method, rendering comparisons between the methods difficult. A limitation of this study was that it was not possible to determine if the testing methods changed within a study year or how often multiple tests were employed and used in conjunction with each other.

Collaboration across the continuum of care is imperative in decreasing CDI rates. A regional approach to CDI reduction, including continued surveillance using NHSN and further strengthening LAC DPH relationships with acute care and outpatient facilities, may assist in decreasing rates of this costly and preventable infection.

REFERENCES

[1] Bartlett, JG. 1994. *Clostridium difficile*: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis. 18(S4):S265-272.
[2] Kyne, L, Hamel, MB, Polavaram, R, Kelly, CP. 2002. Health care costs and mortality associated with nosocomial diarrhea due to *Clostridium difficile*. Clin Infect Dis. 34 (3):346-353.
[3] http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf
[4] http://www.cdph.ca.gov/programs/hai/Documents/Healthcare-Associated-Clostridium-difficile-Infections-April-2010—March-2011.pdf
[5] Warny, M, Pepin, J, Fang, A, Killgore, G, Thompson, A, Brazier, J, Frost, E, McDonald, LC. 2005. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. The Lancet 355(9491):1079-1084.
[6] Gilca, R, Hubert, B, Fortin, E, Gaulin, C, Dionne, M. 2006. Epidemiological patterns and hospital characteristics associated with increased incidence of *Clostridium difficile* infection in Quebec, Canada, 1998-2006. ICHE 31(9):939-947.
[7] Ricciardi, R, Harriman, K, Baxter, NN, Hartman, LK, Town, RJ, Virnig, BA. 2008. Predictors of *Clostridium difficile* colitis infections in hospitals. Epidemiol Infect 136(7):913-921.
[8] Alcala, L, Sanchez-Cambronero, L, Catalan, MP, Sanchez-Somolinos, M, Pelaez, M, Marin, M, Bouza, E. 2008. Comparison of three commercial methods for rapid detection of *Clostridium difficile* toxins A and B from fecal specimens. J. Clin. Microbiol. 46(110:3833-3835.
[9] Centers for Medicare and Medicaid Services. 2012. CMS Publication No. 11347. http://www.medicare.gov/Pubs/pdf/11347.pdf, accessed on 1/7/13.
[10] California Department of Public Health. 2012. Healthcare-associated *Clostridium difficile* infections in California general acute care hospitals, April 1, 2010 through March 31, 2011. http://www.cdph.ca.gov/programs/hai/Documents/Healthcare-Associated-Clostridium-difficile-Infections-April-2010%E2%80%94March-2011.pdf, accessed on 1/10/13.
[11] CDC. 2012. Vital signs: preventing *Clostridium difficile* infections. MMWR 61(9):157-162.
[12] Munoz-Price, LS. 2009. Long-term acute care hospitals. Clin Infect Dis. 49:438-443.
[13] Bignardi, GE. 1998. Risk factors for *Clostridium difficile* infection. Journal of Hospital Infection 40(1):1-15.
[14] Fong, KS, Fatica, C, Hall, G, Procop, G, Schindler, S, Gordon, SM, Fraser, TG. 2011. Impact of PCR testing for *Clostridium difficile* on incident rates and potential on public reporting: Is the playing field level? ICHE 32(9): 932-933.

SHIGA TOXIN-PRODUCING *ESCHERICHIA COLI* (STEC) IN LOS ANGELES COUNTY, 2006-2011: A COMPARISON OF NON-O157:H7 SEROTYPES WITH SEROTYPE O157:H7

Curtis Croker, MPH; Icela Rosas, MPH; Leticia Martinez, RN, PHN, MPH; and
Roshan Reporter, MD MPH

BACKGROUND

Shiga toxin-producing *Escherichia coli* (STEC) are a group of bacterial pathogens that cause severe illness worldwide. The Centers of Disease Control and Prevention estimates that STEC infections cause more than 265,000 illnesses each year in the United States (US), with more than 3,600 hospitalizations and 30 deaths [Scallan 2011]. Persons with STEC infection often have diarrhea, sometimes bloody, along with abdominal cramps and vomiting. Approximately 5%-10% of cases develop hemolytic-uremic syndrome (HUS), which is associated with high case mortality (3%-7%) [Griffin 2003].

STEC infection can be acquired through contaminated food or water, and through direct contact with infected animals or humans. In 1995, Karch et al. demonstrated that STEC (serotype O157) is shed in the feces of persons with STEC infection long after their symptoms have abated, which indicates the potential for person-to-person transmission of this organism [Karch 1995]. In response to such findings, California mandated reporting of all suspect serotype O157:H7 STEC cases as well as all HUS cases from health care providers and laboratories to their local health department in 1995 [State Report 2009]. To prevent person-to-person spread of STEC in Los Angeles County (LAC), public health follow-up of all confirmed cases is carried out. Follow-up involves source investigation, education, and identification of any case or household contact from a sensitive occupation or situation (SOS) and their removal until cleared of infection.

In 2006, Johnson et al. demonstrated that other STEC serotypes (non-O157:H7) also have the potential to cause considerable morbidity and mortality [Johnson 2006]. Findings like this prompted California to broaden the STEC reporting requirements in 2006 to include serotypes other than O157:H7 (non-O157:H7). Additional studies of non-O157:H7 serotypes by Hedican et al. demonstrated that this group generally causes less severe illness than serotype O157:H7 [Hedican 2009]. However, Nitschke et al. in 2012 [Nitschke 2012] demonstrated that serotype O104:H4 is capable of causing severe illness, comparable to that for O157, with cases excreting STEC organism for a considerable amount of time after symptoms subsided.

Our current study examines trends in STEC cases reported to the Los Angeles County (LAC) Department of Public Health (DPH) over a six year study period. We compared demographics, duration of illness and shedding times of STEC cases by serotype (non-O157:H7 serotypes vs serotype O157:H7).

METHODS

A study period from 2006 to 2011 was selected for this review. A study data set containing epidemiological and laboratory information on all culture confirmed LAC STEC cases was constructed. Cases that were shiga toxin positive but culture negative and culture negative HUS cases were excluded even though these meet the current surveillance definition for a case of STEC. The epidemiological information consisted of case demographics, symptoms and illness duration, SOS status, hospitalization status, and outcome. Information was obtained by public health nurses (PHNs), who interview all reported cases using a standardized case interview form.

The laboratory information included STEC culture and serotype results and date the results were finalized. This information was obtained from the LAC Public Health Laboratory (PHL) data system which contains information on all STEC isolates or broths submitted to PHL for testing. Common STEC serotypes can be identified by the LAC PHL; less common serotypes are sent to the California DPH

Microbial Diseases Laboratory or to the Centers for Disease Control National Laboratory for identification. Final results are reported back to LAC PHL and recorded into the laboratory data system.

The study data set was used to assess trends in STEC cases, demographics, illness severity and duration of shedding by serotype (non-O157:H7 serotypes vs serotype O157:H7). STEC 0157:NM was included as a non-O157:H7 serotype. Communicability by serotype was assessed by reviewing the following: 1) the number of stool specimens collected from SOS cases until clearance of infection; 2) the median and average time for clearance of SOS cases, defined as the time from date of collection of the first positive test to date of collection on the first of two negative tests. Clearance of infection for SOS cases was defined as having two consecutive negative stool cultures collected at least 24 hours apart.
Statistical analyses were conducted using Statistical Analysis Software (SAS®) version 9.2. Categorical variables were analyzed using Fisher's exact test. Continuous variables were analyzed using a Student's t-test (data distribution that was normal) and Kruskal-Wallis test (data distribution that was not normal). Only two-sided p-values ≥0.05 were considered to be statistically significant.

RESULTS

Trend in STEC Cases

From 2006 to 2011 there were a total of 270 laboratory confirmed STEC cases reported to the LAC DPH. Reported cases followed an upward trend over the study period; cases increased an average of 13.5 cases per year, from 18 cases in 2006 to 86 cases in 2011. The crude STEC incident rate per million population over the study period was 4.8, increasing from 1.9 in 2006 to 9.3 in 2011 (data not shown). Non-O157:H7 cases comprised 66% of reported STEC cases over the study period (n=179). Non-O157:H7 cases increased every year of the study period, from six cases in 2006 to 65 cases in 2011, with the increase more pronounced after 2009 (Figure 1). Reports of O157:H7 cases remained fairly consistent over the study period, ranging from 12 to 21 cases per year (median 14.5) with no apparent temporal trend.



Demographics

The median age of reported STEC cases was 6.5 years (range 6 months to 95 years). The median age of non-O157:H7 cases was younger than that identified among O157:H7 cases (3 vs 14 years, p<0.05). In addition, a larger proportion of non-O157:H7 cases were under the age of five years as compared to O157:H7 cases (54% vs 38%, p<0.05) (Figure 2). There were some differences in proportion by serotype for other age groups as well, but the numbers of cases involved were much smaller.



STEC cases reported over the study period in LAC were primarly Hispanic (49%), followed by white (39%), Asian (7%) and black (5%). Whites had the highest crude incidence rate over the study period (6.3), followed by Hispanics (4.8), blacks (2.8) and Asians (2.5) per million population. However, whites and Hispanics had equivalent incident rates in the last year surveyed (both at 10.9 per million popuation in 2011).

Non-O157:H7 cases were more likely to be Hispanic (59% vs 29%, p<0.05) and less likely to be white (32% vs 54%, p<0.05) or black (2% vs 11%, p<0.05) as compared to O157:H7 cases (Figure 3). The

crude incident rate for non-O157:H7 over the study period was similar for Hispanics (3.9) and whites (3.4) per million population, but the rate for Hispanics surpassed whites in the last year surveyed (9.3 vs 6.4, 2011).



STEC cases occurring after 2009 (n=154) were more likely to be Hispanic than cases reported from 2006 to 2009 (58% vs 35%, p<0.05). Cases occurring in the under five year age group were more likely to be Hispanic than those age five years and older (73% vs 26%, p< 0.05).

Symptoms and Duration

Symptoms reported by STEC cases in LAC over the study period included diarrhea (91%), bloody diarrhea (50%), cramps (69%), vomiting (32%), fever (33%) and headache (23%). Non-O157:H7 cases were less likely to report bloody diarrhea than O157:H7 cases (35% vs 81%, p<0.05) (Figure 4). Other symptoms such as vomiting, fever, headache and cramps were reported by O157:H7 cases; however, these differences were not statistically significant. The average duration of illness reported by non-O157:H7 cases was comparable to that reported by O157:H7 cases (10 vs 9 days, p= 0.22).



Illness Severity

Seventeen-percent of reported STEC cases were hospitalized, with 3% of STEC cases resulting in HUS and 3% requiring dialysis. Two deaths were reported (1%). Non-O157:H7 cases were less likely to be hospitalized (9% vs 34%, p<0.05), less likely to result in HUS (0% vs 9%, p<0.05) and less likely to require a dialysis procedure (1% vs 7%, p<0.05) (Figure 5). The case mortality rate appeared comparable, with one death in each group. The non-O157:H7 case that died was a 66-year-old Hispanic, with other underlying health conditions, infected with serotype O118:H16. The O157:H7 case that died was a 57 year old White male with history of hypertension who developed HUS during the course of his infection.



Shedding Time

Public health follow-up and clearance testing was performed on 43 STEC cases in LAC over the study period (16%). The mean age for cases requiring clearance (7.9 years) was younger than those that did not require clearance (19.7 years). Forty-percent of STEC cases that required clearance (n=17) tested

negative on the first set of clearance specimens collected. However, 19% of cases (n=8) required more than six specimens to be collected before clearance of infection was validated (range 6-9 specimens).
Of the 43 STEC cases requiring clearance, 28 were a non-O157:H7 serotype and 15 were serotype O157:H7. The percent of STEC cases that tested negative on the first set of clearance specimens collected did not differ by serotype (40% for non-O157:H7 and 39% of O157:H7) (Figure 6). However, non-O157:H7 cases made up the entirety of the cases requiring more than six specimens to be collected before clearance of infection was validated (29% of non-O157:H7 vs 0% for O157:H7). On average, more specimens were required to be collected for clearance of a non-O157:H7 case (average 5.8 specimens) than for clearance of an O157:H7 case (average 4.8 specimens); however, the results were not statistically significant (p=0.15).



The median number of days to clear a STEC case was 26 days (range 6 to 97 days, average 32 days). Non-O157:H7 cases have a median clearance time of 32 days, with the distribution of times appearing very bimodal; a cluster of times around 15 days and another around 53 days (Figure 7). The median clearance time for O157:H7 cases was 23 days (range 11 to 95 days, average 26), with the distribution of times skewed toward a shorter clearance time.

STEC cases under the age of ten years had a longer median clearance time (33 days, n=34) than cases ten years of age and older (27 days, n=9). Non-O157:H7 cases under the age of ten years had an even longer clearance time (37 days, n=24).



Risk Factors

PHNs interviewed all STEC cases to obtain risk factors such as travel history and food history for the seven days prior to illness. Risk factors where at least 5% of cases responded "yes" (Table 1)**.** Of interest, non-O157:H7 cases were more likely to have traveled outside of the US during their incubation period than O157:H7 cases (13% vs 1%, p<0.05). Travel destinations for the non-O157:H7 cases (n=23) included: Mexico (n=12), Latin America (n=7), and Europe or Asia (n=4). Other risk factors, such as recent farm exposure, were only reported by 5% of STEC cases, with little difference by serotype.

There was no significant difference observed in selected food histories by serotype (Table 1). Forty-three percent of cases report consuming ground beef: 38% for non-O157:H7 serotypes and 43% for serotype O157:H7 (p=0.12). Forty-one percent of cases reported eating lettuce with little difference by serotype. STEC cases also reported consuming steak (25%) and dried meats (7%), with little difference by serotype. Other food items reported by fewer than 5%

Table 1. Risk Factors for STEC Cases by Serotype

		Total		Non-O157:H7		O157:H7		Comparison
	N	n	%	n	%	n	%	p-value
All	270	270	100%	179	100%	91	100%	-
Travel History								
Travel outside of U.S.	254	14	6%	23	**13%**	1	**1%**	**<0.05**
Visit a Farm	261	12	5%	6	4%	6	7%	0.41
Food History								
Ground Beef	251	109	43%	65	38%	44	49%	0.12
Undercooked	241	17	7%	8	5%	9	10%	0.26
Lettuce	257	106	41%	66	39%	40	45%	0.38
Steak	248	61	25%	40	24%	21	24%	0.84
~~Dried Meats~~	~~229~~	17	~~7%~~	8	~~5%~~	9	~~10%~~	~~0.18~~

of cases included raw steak, raw milk, berries, and alfalfa sprouts.

Non-O157:H7 Serotypes

The non-O157:H7 organisms identified over the study period are comprised of 36 different serotypes. The more commonly isolated serotypes include O103:H2 (18%, n=32), O111:NM (18%, n=32) and O26:H11 (16%, n=29) (Table 2). One non-O157:H7 case was identified with two different STEC serotypes. This case was exposed while traveling in Mexico and was confirmed with O4:H11 and O186 (flagellar antigen undetermined). There was one case with serotype O1O4:H4 (a serotype associated with high morbidity) identified during the study period with exposure occurring while traveling in Russia. This case was not considered part of the large outbreak of O1O4:H4 in Germany in 2011.

Table 2. Frequency of Non-O157:H7 STEC Serotypes (N=179) Los Angeles County, 2006-2011

	n	%
O103:H2	32	18%
O111:NM	32	18%
O26:H11	29	16%
O157:NM	12	7%
O118:H16	9	5%
O26:NM	7	4%
O69:H11	3	2%
O103:NM	3	2%
Other Non-O157:H7 serotype	34	13%
Other Non-O157:H7 incomplete serotype	18	7%

DISCUSSION

The recent increase in non-O157:H7 reports in LAC is believed to be due to several factors, which include: 1) increased testing by reference laboratories with the enzyme immunoassay (EIA) used for the detection of shiga toxin; 2) improved compliance with reporting by both providers and laboratories, especially in light of increased electronic laboratory reporting in LAC during the study period; and 3) possibly higher incidence of non-O157:H7 cases.

The overall incidence rate for reported STEC cases in LAC identified in this study (4.8 per million population) is slightly lower than that identified in a recent STEC report for California cases occurring from 2001 through 2008 (7 per million population) [State Report 2009]. Whites had the highest incidence rate in LAC, followed by Hispanics, but rates were equivalent for both whites and Hispanics in the last year surveyed.

The demographics of LAC STEC cases differ by serotype, with a higher prevalence of younger Hispanics identified among non-O157:H7 serotypes as compared to serotype O157:H7. The incidence rates for non-O157:H7 appear comparable between whites and Hispanics over the study period; however, the crude incidence rate for Hispanics surpassed whites in the last year surveyed. Possible explanations for this demographic difference by serotype include consumption of a contaminated food item imported from Latin America or other exposure for this group that travels more frequently to Central and South America. Our study also indicates that non-O157:H7 serotypes in LAC cause less severe illness than serotype O157:H7, involving less severe symptoms and fewer hospitalizations. This finding appears consistent with other studies comparing STEC serotypes [Hedican 2009]. There was one death reported among non-O157:H7 serotypes and one among serotype O157:H7, but these small numbers make it difficult to generalize this finding. Our study did not find any significant difference in the duration of symptoms by serotypes.

A majority of the non-O157:H7 serotypes (53%) identified in this LAC study were serotypes O103, 0111, and O26. These serotypes are among the nine most common serotypes identified in the US [Johnson 2009]. One LAC serotype not seen on this national list is serotype 0118:H16, which was identified in 5% of non-O157:H7 cases in LAC and associated with one death. This serotype is more commonly identified in Spain, Germany and Belgium.

Our review of STEC cases requiring public health clearance indicates that the shedding time for persons infected with non-O157:H7 serotypes are comparable to that for persons infected with serotype O157:H7. Non-O157:H7 cases requiring clearance actually required more stool specimens to be collected, on average, before clearance of infection was verified, and they were identified with slightly longer clearance times than O157:H7 cases. The average clearance time for STEC cases identified in our study of 32 days

is comparable to the average shedding time of 34 days identified for serotype O104:H4 (not treated with antibiotics) [Nitschke 2012].
However, Karch et al. [Karch 1996] identified a median shedding duration of 13 days for children under the age of ten years, with O157:FAU (flagellar antigen unspecified) infection having diarrhea or hemorrhagic colitis and 21 days in cases that developed HUS. In comparison, our study identified a longer median shedding time for all STEC cases (26 days), as well as those age under ten years of age (33 days); 37 days for non-O157:H7 cases. Karch also found that 68% of O157:FAU cases had cleared infection (three consecutive negative stools) after the first positive culture, which is a much higher proportion than that identified among our study population (40%, two consecutive negative stools). The reason for this difference is unclear, but it may reflect improved testing capabilities of laboratories to detect fewer organisms. STEC cases under the age of ten years in our study had a longer median shedding time than those older than 10 years, which is consistent with other studies.

In comparing STEC shedding times to other potentially foodborne pathogens that require public health follow-up, Bushwald et al. found that the median duration for non-typhi salmonella excretion was approximately five weeks, which is slightly longer than the median clearance time of 26 days identified in our study of STEC cases [Bushwald 1984].

LIMITATIONS

The STEC cases reported to LAC DPH and utilized for this analysis may not be representative of all STEC infections that actually occurred in LAC. For example, shiga toxin positive cases that were not culture confirmed were not analyzed here. Some STEC cases may not be reported, such as milder cases that do not seek medical attention. Scallan et al. estimate that only one in 26 cases of serotype O157 are reported to the public health department and only one in 107 cases of non-O157 are reported [Scallan 2011]. Thus, the results of our study may underestimate the burden of STEC in LAC and may overestimate the severity of illness. Also, the findings of this review may not be generalized to other regions of California, other states in the US or regions of the world where the distribution of non-O157:H7 serotypes may differ from that identified in LAC.

STEC cases requiring public health clearance are likely to be associated with retail food preparation or daycare and may be of lower economic status. This must be kept in mind when interpreting the shedding time results and generalizing to all STEC cases reported, as well as all STEC cases occurring in the county.

The non-O157:H7 serotypes grouped for this analysis are quite varied, and some may argue that it is not proper to place all non-O157:H7 serotypes into one category for analysis. There may be a few non-O157:H7 serotypes that cause severe illness, such as O104:H4, but are lost in the vast majority of non-O157:H7 serotypes that appear to be less severe than serotype 0157:H7.

STEC 0157:NM was included as a non-O157:H7 serotype. This serotype accounted for 12 of the 179 non-O157:H7 cases (7%). Some might argue that the serotype stratification should be between O157 and non-O157; however, this would probably not change the results of this study significantly.

Using clearance times as a proxy for shedding times may lead to biased estimates. Cases may have been shedding the bacteria days before they first tested positive, which would make our clearance time calculations shorter than the actual shedding time by perhaps a few days. In addition, cases may cease shedding the bacteria days before they are actually tested and cleared of infection, which may make our clearance time calculations longer than the actual shedding time.

The use of antibiotics by STEC cases may have influenced the shedding times reported in this study. Two of the non-O157:H7 cases that required public health follow-up (7%) reported taking antibiotics. None of the O157:H7 cases reported receiving antibiotic treatment.

The epidemiological form used during the study period did not specifically ask for travel history. However, this information was usually obtained during the course of reviewing any exposures within the seven day

prior to onset of illness. But it is possible that some responses to travel questions were not recorded, which would underestimate the number of cases that actually did travel. The updated STEC epidemiological form specifically asks about travel history.

CONCLUSION

The results of this study suggest that non-O157:H7 serotypes in LAC are more likely to occur among young Hispanics than serotype O157:H7. Non-O157:H7 serotypes appear to cause less severe illness than O157:H7; however, the morbidity of these serotypes was still found to be appreciable. Non-O157:H7 serotypes also appear to be just as communicable as O157:H7, with similar clearance times and number of stools needed for clearance. These results indicate that public health control measures, including clearance of SOS cases, are necessary for all for STEC cases, regardless of STEC serotype.

ACKNOWLEDGEMENTS

Special thanks to LAC DPH Acute Communicable Disease Control Program staff members—Rita Bagby with the Food Safety Unit, and Alison Itano and Michael Tormey in the Data Support Group for their comments and advice.

REFERENCES

1. Scallan E, et al. Foodborne illness acquired in the United States---major pathogens. Emerging infectious disease 2011: 17(1): 7-15.

2. Mead P, et al. *Escherichia coli* O157:H7 and other enterohemorrhagic *E. coli*. Infections of the gastrointestinal tract. 2nd ed: Philadelphia: Lipincott Williams & Wilkins, 2003:627-42.

3. Griffin P, Mead P, Sivapalasingam S. Escherichia coli O157:H7 and other Enterohemorrhagic *E. coli*. In: Blaser MJ, Smith PD, Ravdin JI, et al., eds. Infections of the gastrointestinal tract. 2nd ed: Philadelphia: Lippincott Williams & Wilkins, 2003:627–42.

4. Hedican E, et al. Characteristics of O157 versus Non-O157 Shiga Toxin–Producing *Escherichia coli* Infections in Minnesota, 2000–2006. CID 2009:49 (1 August).

5. Epidemiological Summaries of Selected General, Communicable Diseases in California, 2001-2008.
Web Page: http://www.cdph.ca.gov/programs/sss/documents/Epi-Summaries-CA-2001-2008-083111.pdf

6. Karch H, et al. Long-term shedding and clonal turnover of enterohemorrhagic Escherichia coli O157 in Diarrheal Diseases. Journal of clinical microbiology, June 1995, p. 1602–1605, Vol. 33, No. 60095-1137/95.

7. Johnson K, et al. The emerging clinical importance of non-O157 Shiga Toxin–producing *Escherichia coli*. Emerging infections, CID 2006:43 (15 December).

8. Nitschke M, et al. Association between Azithromycin therapy and duration of bacterial shedding among patients with Shiga Toxin–producing Enteroaggregative Escherichia coli O104:H4. JAMA. 2012; 307(10):1046-1052. doi: 10.1001/jama.2012.264.

9. Buchwald D, et al. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev Infect Dis. 1984 May-Jun; 6(3):345-56.

VARICELLA SURVEILLANCE IN THE ANTELOPE VALLEY, 2006-2011

Karen Kuguru, MPA and Rachel Civen, MD, MPH

BACKGROUND

In September 1994, the Los Angeles County Department of Public Health (DPH) entered into a cooperative agreement with the Centers for Disease Control and Prevention (CDC) to establish active surveillance for varicella in Antelope Valley (AV), California. The active surveillance project became known as Varicella Active Surveillance Project (VASP). Information on disease incidence, clinical presentation and varicella vaccine coverage levels by age group and the impact of increasing vaccine coverage has been collected since 1995.

From 1995 to 2000, VASP demonstrated that varicella incidence declined by 71% with the successful implementation of the childhood varicella vaccination program recommending routine varicella vaccination between 12-18 months of age (1). Starting in 2001, VASP data showed that varicella cases and outbreaks involving previously vaccinated varicella cases or "breakthrough" varicella were increasing (2,3). By comparing contact registries of vaccinated and unvaccinated varicella cases and secondary cases within households, VASP data demonstrated that varicella zoster virus (VZV) could be transmitted by varicella cases with a previous vaccination. However, breakthrough varicella cases were less transmissible than unvaccinated cases by approximately 50% (4). In 2006, the Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics updated the 1996 and 1999 recommendations to implement a routine 2-dose varicella vaccination program for children, with the first dose administered at 12-15 months and the second dose at 4-6 years or a second dose catch-up varicella vaccination for children, adolescents, and adults who previously had received one dose (5). In the fall of 2012, the AV VASP ended. The 2011 surveillance report represents the 16th and final year of varicella active surveillance in AV. This report summarizes five years of varicella surveillance data since the second dose recommendation in 2006.

SURVEILLANCE METHODS

Nearly 100% of all identified reporting sites participated in the surveillance project, including public and private schools and day care centers with enrollments of 12 or more children; public health clinics, hospitals, emergency rooms, private practice physicians and health maintenance organizations offices; correctional facilities; and miscellaneous others likely to identify and report cases of varicella. All sites submitted varicella surveillance logs to VASP on a biweekly basis. Electronic reporting was completed by two health maintenance organizations (HMO) on a weekly basis and one acute care facility on a monthly basis using diagnostic codes for varicella. Forty-five vaccine providers submitted varicella vaccine doses administered and age of recipient on a monthly basis. Additionally, Merck, the manufacturer of varicella vaccines Varivax® and ProQuad®, reported the total doses of varicella vaccines sold to healthcare providers in the AV.

Case Definitions:

A case of varicella was defined as illness with acute onset of a diffuse papulovesicular rash without other known cause that was diagnosed or reported by a licensed healthcare provider, school nurse, or parent. VASP project staff completed case reports by interviewing the parent or guardian of varicella cases <18 years old or interviewed the case himself if ≥18 years old; if interview was not obtained, a medical chart review was completed. A *verified varicella case* met the above case definition, had a completed case report, and resided in the AV. A *probable varicella case* did not have a completed case report either because there was no medical record or an interview could not be completed. Probable cases were excluded from the analysis.

A *breakthrough varicella case* was defined as a verified varicella case with a documented varicella vaccine at least six months prior to disease onset. A *varicella outbreak* was defined as five or more verified varicella cases within one incubation period (21 days) linked to a common setting, such as a school.

Receipt of varicella vaccine was confirmed in one of three ways: 1) VASP staff obtained immunization records during the telephone interview, 2) medical office staff provided vaccine records for suspect varicella cases, or 3) the school the child attended provided vaccination documentation. If varicella vaccination could not be documented as stated, parental recall was utilized. Susceptible household contacts of varicella cases were re-interviewed four weeks after the initial contact to identify additional cases.

Skin scrapings for laboratory confirmation were obtained by VASP staff or medical providers on a portion of suspected varicella cases. Polymerase chain reaction (PCR)-based testing was completed at the National Varicella Zoster Virus Laboratory in Atlanta, Georgia (6).

From 1995 to 2002, varicella data were entered into a Turbo Pascal® based database designed by project staff; beginning in 2003, all data were entered into Microsoft Access® and data analysis was performed using SAS®. To calculate incidence rates, verified varicella cases were used in the numerator and census estimates for AV stratified by age and race/ethnicity were used as denominators. For each surveillance year, completeness of varicella reporting was estimated using a two-source capture-recapture method. Aggressive manual and computer verification of data was used to ensure data quality.

RESULTS

Varicella vaccine doses administered (*Varivax*® and *ProQuad*®) were obtained from 45 vaccine providers in AV. In 2011, the total number of varicella vaccine doses administered by surveillance sites increased 18% with 17,729 and 15,004 doses reported in 2011 and 2010, respectively. The total doses in 2011 represent an increase of 123% from the 7,937 doses reported in 2006 (Figure 1).

Figure 1. Total number of varicella vaccine doses administered by Antelope Valley vaccine providers, VASP, 2006-2011



From 2006 to 2011, vaccine doses administered in the AV increased across most age-groups. Vaccine doses administered increased in the following age groups: 12 to 24 months of age, from 4165 to 4193, 3-4 years of age from 643 to 4194, 5-9 years of age from 387 to 1063, 10-12 year olds from 760 to 3782, and in adolescents 13-19 years of age from 471 to 3309 doses. Varicella vaccine doses administered decreased from 515 to 447 doses among two year olds and also in persons >19 years old from 275 to 41 doses during the respective years (data not shown).

Since the introduction of the two dose varicella vaccine regimen, the overall varicella incidence rate for the AV continued to decline from 1.1 to 0.2 cases per 1,000 population in 2006 and 2011, respectively. In 2011, the highest varicella incidence was among infants <1 year old (who are ineligible for vaccination) with 0.8 cases per 1,000, followed by those 5-9 years old, 0.7 cases per 1,000. Most age-groups of children showed declines in incidence from 2006-2011, including infants <1 year of age with rates declining from 3.2 to 0.8 cases per 1,000, in respective years. The most significant declines was in the 5-9 year old age group with incidence declining from 6.2 to 0.8 cases per 1000 in 2006 and 2011, respectively (Figure 2).

From 2006 through 2010, outbreaks decreased from 11 to 1 in the respective years. There were no outbreaks reported in 2011. In 2010, only one outbreak was identified compared to two and four in 2009 and 2008, respectively. In 2010, the proportion of outbreak related cases (ORC) that were classified as breakthrough was 100% compared to 50% of cases in 2009 and 67% of cases in 2008 (data not shown).

Figure 2. Varicella cases by incidence rates and age-groups, Antelope Valley, CA, 2006 to 2011



The total number of varicella cases during the study period was 1,260 ranging from 395 in 2006 to 79 in 2011. The proportion of these that were breakthrough (BT) varicella cases steadily increased since 2000, from 16.8% of cases in 2000 to a high of 66.4% of cases in 2008; in 2011, the proportion of BT cases was 61%. Since 2006, 106 BT cases who received two doses of varicella vaccine were documented (Table 1). Laboratory testing was completed on 15 (17%) 2-dose BT cases; five cases were PCR-positive with wild type VZV. The annual proportion of breakthrough cases with two doses of vaccine rose from just 1% in 2006 to 56% in 2011.

Table 1. Varicella Breakthrough Cases and vaccination status Antelope Valley, VASP, 2006-2011

Age at Breakthrough (years)	2006 N=235	2007 N=175	2008 N=144	2009 N=108	2010 N=57	2011 N=48
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
1-4	26 (11.1)	25 (14.3)	19 (13.2)	28 (25.9)	12 (21.1)	9 (18.8)
5-9	139 (59.1)	94 (53.7)	65 (45.1)	36 (33.3)	18 (31.6)	19 (39.6)
10-14	66 (28.1)	55 (31.4)	58 (40.3)	42 (38.9)	22 (38.6)	13 (27.1)
15-19	3 (1.3)	1 (0.6)	2 (1.4)	2 (1.9)	5 (8.8)	6 (12.5)
>20	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.0)
1st Dose Vaccine Only	233 (99.0)	165 (94.3)	126 (87.5)	78 (72.0)	38 (66.7)	21 (43.8)
Both 1st and 2nd Dose	2 (1.0)	10 (5.7)	18 (12.5)	30 (28.0)	19 (33.3)	27 (56.3)

The clinical presentation of varicella continued to be mild between 2006 and 2011. In 2006 and 2011, 60% and 50% of varicella cases reported < 50 lesions during respective years. In 2006, only 3% of cases reported >500 lesions, whereas no cases were documented with this many lesions in 2011. Since 2008, there have been no reports of hospitalized varicella cases. In addition to decreasing clinical severity, work and school absenteeism have declined by over 90% from 2220 days to only 238 days in 2006 and 2011, respectively.

Information on the likely exposure source for varicella cases has been tracked since 1996. An increasing proportion of varicella cases could not identify a source of infection, increasing from 9% in 1996 to16% in 2006 and 77% in 2011 (Table 2). Reports of school exposure declined from 25% of verified cases in 2006 to no reports of school exposures in 2011. The proportion of cases reporting household exposure to varicella zoster virus (VZV) (either another varicella case or a herpes zoster [HZ] case) has decreased from 42% in

1996 to 29% and 18% in 2006 and 2011, respectively. History of recent exposure to a HZ case within the varicella case's household ranged from 3% to 5% of all exposures since 2003. HZ will most likely continue to be an important source of exposure for VZV, which could possibly prevent the elimination of varicella despite increases in childhood varicella vaccination coverage.

Table 2. Suspected Source of Varicella Infection by Year, Antelope Valley, VASP, 2006-2011

Suspected Source of Infection	2006 N (%)	2007 N (%)	2008 N (%)	2009 N (%)	2010 N (%)	2011 N (%)
Exposure to a varicella case						
Household	64(16.2)	31(10.5)	23(10.6)	19(10.9)	12(12.0)	10(12.7)
School	98(24.8)	91(30.8)	32(14.8)	6(3.4)	11(11.0)	0(0.0)
Church/ Neighborhood	15(3.8)	5(1.8)	3(1.3)	1(0.6)	0(0.0)	0(0.0)
Childcare	2(0.5)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
Other	14(3.5)	6(2.0)	17(7.9)	1(0.6)	2(2.0)	4(5.1)
Exposure to a herpes zoster case						
Household	16(4.0)	6(2.0)	4(1.9)	9(5.1)	3(3.0)	4(5.1)
School	0(0.0)	0(0.0)	0(0.0	0(0.0)	0(0.0)	0(0.0)
Church/ Neighborhood	2(0.5)	0(0.0)	0(0.0	0(0.0	0(0.0)	0(0.0)
Childcare	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
Other	0(0.0)	6(2.0)	1(0.5)	2(1.0)	0(0.0)	0(0.0)
Unknown Exposure	184(46.5)	150(50.9)	136(63.0)	137(78.4)	72(72.0)	61(77.1)
Total	395(100)	295(100)	216(100)	175(100)	100(100)	79(100)

CONCLUSIONS

Declines in varicella incidence, clinical severity, and outbreaks have continued since the adoption of a routine two-dose varicella vaccine program. Incidence declines were notable in all age groups, even in those who were not eligible or recommended for varicella vaccination. Success of the two-dose program is also supported by the doubling of the number of varicella vaccine doses provided by AV healthcare providers from 2006 to 2011. The trend of increasing proportion of documented BT varicella cases should continue with high rates of one and two dose vaccination coverage and declining community transmission of varicella. In 2011, over 60 % of varicella cases had a history of previous vaccination and more than half of these cases had two verified varicella vaccines. It is unclear the role that varicella cases with a history of two dose vaccine will have in sustaining community transmission of varicella. It is clear that efforts to promote catch-up vaccination among older susceptible individuals should continue. Although the AV VASP closed in September 2012, national two-dose varicella vaccine coverage and case based state surveillance data are needed to more fully understand the impact of routine two-dose varicella vaccine.

REFERENCES

1. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002;287(5):606-11.
2. Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites-United State, 1995-2005. JID 2008;197: S71-75.
3. Civen R, Lopez AS, Zhang J, et al. Varicella outbreak epidemiology in an active surveillance site, 1995-2005. JID 2008; 197: S114-119.
4. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumann AO. JAMA 2004; 292 (6):606-611.

5. Marin M, Guris, Chaves SS, Schmid S, Seward; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. MMWR Recomm Rep. 2007; 56 (RR-4):1-40.
6. Leung J, Harpaz R, Baughman A, et al. Evaluation of Laboratory Methods for Diagnosis of Varicella Clinical Infectious Disease 2010; 51 (1):23-32.

CHARACTERISTICS BETWEEN PEAK AND OFF-PEAK WEST NILE VIRUS SURVEILLANCE LOS ANGELES COUNTY, 2004-2012

Van Ngo, MPH and Rachel Civen, MD, MPH

BACKGROUND

Since West Nile virus (WNV) was first detected in North America in New York City in 1999, the infection has spread throughout the continental United States (US), and is now the leading cause of arboviral encephalitis in the US. WNV is a flavivirus closely related to the viruses that cause Japanese encephalitis and Saint Louis encephalitis. Usually transmitted by mosquitoes between bird reservoir hosts, humans are incidentally infected with the virus when bitten by an infected mosquito. Additional, but less frequent, documented routes of transmission include transplantation of WNV-infected organs, blood transfusions, transplacental (mother-to-child) transmission, occupational exposure, and breast milk (1,2).

Most infected persons are asymptomatic but about 20% will develop WN fever with symptoms that include fever, headache, rash, muscle weakness, fatigue, nausea and vomiting, and occasionally lymph node swelling. WN fever symptoms can last from a few days to months. Less than 1% will develop more severe illness, manifesting as WNV neuro-invasive disease (NID), including meningitis, encephalitis, and acute flaccid paralysis. WNV-associated meningitis usually involves fever, headache, and stiff neck, and has a good prognosis. WNV-associated encephalitis is commonly associated with fever, altered mental status, headache, and seizures, and can be fatal. It usually necessitates a high level of specialized medical care and is associated with prolonged, even permanent, disability (1,2).

Los Angeles County (LAC) first detected WNV-infection in dead birds, mosquitoes, and sentinel chicken flocks in 2003 and documented its first human case later that year. In 2004, LAC reported 309 human cases and California (CA) reported the greatest number of any state, 779 cases; 2539 confirmed human WNV cases were reported nationally to the Centers for Disease Control and Prevention (CDC). Since then, LAC has documented WNV infection every year in mosquitoes, birds, humans, and other mammals (i.e. horses, squirrels). Surveillance of human WNV infections documented three peaks of activity occurring every four years, once in 2004, then in 2008 (n=170), and most recently in 2012 (n=174). In other non-peak years, human cases have ranged from four in 2010 to 63 in 2011 and included the two years with the lowest case counts, 2006 and 2010, with four cases each. The objective of this report is to compare the demographic and clinical characteristics as well as the climatic variations between peak human WNV activity (2004, 2008, and 2012) with those in years of low WNV activity.

METHODS

All suspect human cases of WNV disease and asymptomatic blood donors are reportable to the LAC Department of Public Health (DPH) within one working day. Cases included in this analysis comprised of both symptomatic infections and asymptomatic blood donors who were residents of LAC, and had onset of illness or a date of blood donation between January 1, 2004 and December 31, 2012. Symptomatic human cases were defined as those who had diagnosed febrile illness or NID in addition to supportive laboratory evidence of WNV infection. Patients with febrile symptoms alone were classified with WN fever. Patients with a clinical diagnosis of meningitis, encephalitis, or acute flaccid paralysis were classified with NID. Supportive laboratory evidence of WNV infection included a single acute cerebrospinal fluid (CSF) or serum serology that was positive for WNV IgM by capture enzyme-linked immunosorbent assay (ELISA) or immuno-fluorescent antibody (IFA) slide test kit. Asymptomatic donors had a single reactive nucleic acid-amplification test (NAT) with a signal-to-cutoff score of equal or greater than 17 (3).

Peak years were defined as the three surveillance years in which LAC documented the highest number of confirmed cases— 2004, 2008, and 2012. Off-peak years were defined as the remaining six surveillance years 2005-2007 and 2009-2011. Public health staff completed a standardized WNV case report form by

reviewing medical records and by conducting a telephone interview with the case or family member. The reporting form included variables for age, gender, residence, race/ethnicity, hospitalization, outcome, and major diagnoses. Climactic data (maximum monthly temperature and total monthly precipitation) were obtained from measurements documented at a weather station located in Pomona, CA, a city in the San Gabriel Valley area (4). Means and frequencies were calculated using SAS version 9.3. Mean climactic values were evaluated by the student t-test.

RESULTS

Eight hundred forty six human cases of WNV were documented between 2004 and 2012 in LAC. Six hundred fifty two (77%) of WNV cases occurred during the peak years of 2004, 2008, and 2012 compared to 194 cases in off-peak years. WNV seasons were longer in peak versus off-peak years. In peak years, cases occurred from June through November with a mean duration of 21.7 weeks compared to a mean of 12.8 weeks in off-peak years. Off- peak seasons lasted from June through October, with the exception of 2009, which began in May and ended in September. The latest documented WNV case in LAC had an onset of November 25 (MMWR Week 48), occurring in 2012. The weekly number of cases occurring during the most active periods of peak years was as high as 40 per week. In off-peak years, the weekly number of cases did not reach over 10 per week, with the exception of 2011 when 12 and 13 cases occurred during MMWR Weeks 36 and 37, respectively.

The demographic characteristics of cases did not vary considerably between peak and off-peak years. The median ages were 56 and 57 years old for peak and off-peak years, respectively. There were approximately twice as many male cases in both peak and off-peak years. And the large majority of cases were white or Latino (49% and 36%, respectively, in peak years vs. 59% and 32% in off-peak years). There were not more than 5% each of cases that were Asian, black, or other in both peak and off-peak years.

Across the entire surveillance period, 279 cases classified with WN fever, 480 with NID and 87were asymptomatic blood donors. The mean annual proportions of asymptomatic blood donors and cases with NID presentation were slightly higher in off-peak years than in peak years, separated by a difference of 2 and 3%, respectively (Table 1). Over all years, the mean proportion of asymptomatic donors was 14% per year and of NID cases was 58% per year. In contrast, the mean proportion of those with WN fever was higher in peak years, 32% per year compared to 27% per year in off-peak years. The mean percentage of hospitalizations among symptomatic cases was also slightly higher in peak compared to off- peak years, 77% versus 73%, respectively. Fatality rates among symptomatic cases were similar in peak and off-peak years, 4.3% overall.

Table 1. Clinical Presentation and Severity of WNV Cases in Peak and Off-Peak Years, 2004-2012

Years	Hospitalizations* Mean Annual %, Annual Range %	Fatalities* Mean Annual %, Annual Range %	Neuroinvasive Disease Mean Annual %, Annual Range %	WN Fever Mean Annual %, Annual Range %	Asympt. Donor Mean Annual %, Annual Range %
Peak	77, 63-85	4.3, 4-5	58, 44-68	32, 23-48	10, 7-13
Off-Peak	73, 38-86	4.3, 0-14	60, 31-75	27, 19-50	13, 0-20
All	75, 38-86	4.3, 0-14	58, 31-75	29, 19-50	14, 7-19

*Excludes asymptomatic blood donors

Gender, age, and race/ethnicity demographics were analyzed by the various presentations of WNV (NID, WN fever, and asymptomatic donor). With the exception of WN fever cases during off-peak years, the male to female ratio for all diagnoses of WNV, including asymptomatic donors, remained nearly 2:1 throughout peak and off-peak years. For WN Fever, the male to female ratio was 1.7:1 in peak years versus 1.4:1 in off-peak years. Median age of cases were similar between peak and off-peak years, but increased from 49 to 52 to 61 years old (for all years) as severity of presentation increased from asymptomatic to WN fever to NID, respectively. Whites accounted for higher proportions of WN fever and positive asymptomatic donations during off-peak years than peak years (71% vs. 54% for WN fever and 58% vs. 34% for asymptomatic donors). However, the opposite occurred among Latinos (Figure 1). Twenty-three percent of asymptomatic donors and 21% of WN fever cases was Latino in off-peak years compared to 28% and 35% in peak years, respectively. The proportion of whites and Latinos were distributed similarly between peak and off-peak years for NID cases. The proportions of Asians, blacks, and other were too small for evaluation.

Figure 1. Distribution of race/ethnicity by WNV clinical presentations in peak and off-peak years, 2004-20012



Nearly all NID patients were hospitalized, during both peak (96%) and off-peak years (99%), 97% overall. Those presenting with WN fever were hospitalized at a higher proportion during peak years compared to off-peak years, 40% vs. 29%, respectively. Fatalities occurred mainly among those with NID diagnosis and the proportion was similar across peak and off-peak years, 7% overall. A few fatalities occurred among those with WN fever diagnosis, 1% overall (data not shown).

Cases have been documented in all health districts during the three peak years of WNV, with the highest number of cases occurring in health districts in the San Fernando (SF) Valley and San Gabriel Valley regions (Figure 2), particularly in the West Valley Health District (n=68). In off-peak years, West Valley remained active, with the highest total case count (n=48). And no cases occurred during the six years in the South, Southeast, and East LA Health Districts. The mean maximum monthly temperatures documented in Pomona during peak and off-peak years were nearly identical. However, during the main months of WNV activity (June through October), temperatures were cooler in peak years than off-peak years (100° Fahrenheit (F) vs. 101°F) (Table 2). On the contrary, mean maximum temperatures in the preceding 5 months of January through May were warmer in peak years than off-peak years (89.5°F vs. 87.6°F). Mean monthly precipitation was higher in peak years than off-peak years, for both the total year



Figure 2. Total Number of Human WNV Cases by Health District, LAC*, Peak vs. Off-Peak Years, 2004-2012

(1.61" vs. 1.17") as well as during June through October (0.65" vs. 0.17"). However, there was less precipitation in peak years during January through May (1.17" vs. 1.97"). None of these temperature and precipitation differences were statistically significant.

Table 2. Temperature and Precipitation, Pomona, California, 2004-2012

	Total Year		Jun-Oct		Jan-May	
	Peak	Off-peak	Peak	Off-peak	Peak	Off-peak
Mean Maximum Monthly Temperature (°F)	92.5	92.3	100	101	89.5	87.6
Mean Total Monthly Precipitation (inches)	1.61	1.17	0.65	0.17	1.17	1.97

DISCUSSION

Since its arrival in 2003 to LAC, surveillance has documented a cyclic pattern of WNV activity with peaks of human infection occurring every four years – in 2004, 2008, and 2012 – and the fewest cases being documented two years after - in 2006 and 2010. Peak years were characterized by differences in demographic and environmental trends. In LAC, cases occurred each year from June through October, with the season extending into November in some peak years. However, peak years had much longer seasons, with cases reported over an average of 21.7 weeks compared to 12.8 weeks in off-peak years. In comparison, in Dallas County, Texas, during the 2012 outbreak season when 393 human infections were reported, cases occurred over only 13 weeks (5). During peak years in LAC the number of cases occurring per week were much higher than off-peak years, which numbered less than 10 cases per week compared to up to 40 per week in peak years.

The high number of cases in peak years appears to be driven by increased reports of severe WN fever, cases severe enough to require hospitalization. In these years, a higher proportion of males and Latinos were represented among WN fever cases, indicating that in off-peak years, WN fever may be mild enough that issues in accessing healthcare may be a barrier in diagnosing the infection. NID, on the other hand, is consistently represented among gender and race/ethnicity groups between peak and off-peak years, likely a result of NID infection necessitating nearly universal hospitalization.

The monitoring of asymptomatic blood donors has been utilized as a method of detecting the underlying rate of WNV infection in a population (6,7). However, our surveillance documented slightly more asymptomatic infections in off-peak years as with NID, likely representing a more stable source of diagnosis in comparison to WN fever infections. Interestingly, our asymptomatic donors were mostly white, which is consistent with the demographics of blood donor populations; even in regions with higher proportions of minorities in the population, whites tend to over-represent the blood donor population (8). However, asymptomatic donors were overwhelmingly male in both peak and off-peak years, whereas, white blood donors in the general donor population are equally male and female (8). Although the development of NID occurs more frequently among males, the risk for initial infection with WNV has not been found to be significantly higher among males (9).

Our data corroborates what is known about the presentation of NID. The surveillance of NID is a robust method of following WNV as its rate remains relatively stable across gender and race/ethnicity subgroups as well as through peak and off –peak years. That the average age of the LAC WNV case population increases with the severity of WNV infection supports the fact that those over the age of 50 years are at increased risk for NID disease (9).

Human WNV activity in LAC remained high in the SF Valley area between peak and off-peak years. Several studies on WNV geographic distribution have shown that incidence rates are substantially affected by variables that are relatively static over long periods of time such as land use, population density, and even climate normals as opposed to yearly weather fluctuations (10,11). These stable factors are likely a major contributor to the maintenance of WNV activity in the SF Valley. In addition, there are likely local breeding habitats unique to the region that continually maintain vector and/or host populations 10,11,12). Indeed, our analysis of temperature and precipitation data from Pomona, located in an area with high WNV activity, showed no significant differences between peak and off-peak years.

This analysis is limited by possible underreporting of cases when diagnostic tests for WNV are not ordered for a patient and also when suspected or known WN infections were not reported to the public health department. This is particularly true for patients with mild WN infections, such as WN fever, who may not even seek or have access to medical care. In addition, awareness of WNV among both patients and healthcare providers may vary from year to year due to media interest or fatigue, driving the WNV testing rate up or down. A major limitation in the climactic analysis was that maximum monthly temperature and precipitation data from a single weather station in Pomona was used to represent climate for all regions of LAC. Climate data obtained from the geographic location of each WNV case would describe the variation between peak and off-peak years more accurately. We also assumed that the reported residence of each case was the likely site of acquisition of WNV infection. Patterns in WNV

incidence are difficult to generalize from one geographic area to another due to the environmental and behavioral factors of vectors and hosts that occur on smaller scales and even by individual human behavior (10,11,12). Thus, more complicated modeling of weather, geographic, mosquito population, susceptible bird population, and human behavior data would provide better descriptions of the activity occurring in LAC.

The distinct cyclical pattern of human WNV activity in LAC from 2004-2012 allows us an opportunity to neatly assess characteristics between peak years and off-peak years. Though major limitations prevent concrete conclusions, patterns have emerged in the demographics of human WNV cases and environmental characteristics of peak years in comparison to off-peak years. Because WNV activity can be highly specific to geographic areas, it is important to review data specific to Los Angeles County as it may begin to elucidate ways that LAC DPH can target mosquito abatement services and health education.

REFERENCES

1. Rossi SL, Ross TM, and Evans JD. West Nile Virus. Clin Lab Med. 2010; 30: 47-65.
2. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006; 57:181-94.
3. California Department of Public Health, Mosquito and Vector Control Association of California, and University of California. California mosquito-borne virus surveillance and response plan. May 2012:46-47.
4. http://weather-warehouse.com/index.html. Accessed: May 1, 2013.
5. http://www.dshs.state.tx.us/ Accessed: March 25, 2013
6. Busch MP, Wright DJ, Custer B, Tobler LH, Stramer SL et al. West Nile Virus infections projected from blood donor screening data, United States, 2003. Emerging Infectious Diseases. Mar2006 ; 12 (3): 395-402.
7. Garza Rodriguez M, Rodriguez Rodriguez DR, Blitvich BJ, Reyes Lopez MA, Fernandez-salas I, Ramos Jimenez J et al. Serologic surveillance for West Nile Virus and other flaviviruses in febrile patients, encephalitic patients, and asymptomatic blood donors in northern Mexico. Vector-borne and Zoonotic Diseases. 2010; 10 (2): 151-157.
8. Murphy EL, Shaz B, Hillyer C, Carey P, Custer B et al. Minority and foreign-born representation among USA blood donors: demographics and donation frequency for 2006. Transfusion. Oct 2009; 49(10): 2221–2228.
9. Lindsey NP, Staples JE, Lehman JA, and Fischer M. Surveillance for human West Nile Virus disease, Unites States, 1999-2008. Morbidity and Mortality Weekly Report. 2 Apr 2010;59 (ss02): 1-17.
10. Wimberly MC, Hildreth MC, Boyte SP, Lindquist E, and Kightlinger L. Ecological niche of the 2003 West Nile Virus epidemic in northern Great Plains of the United States. PloS ONE. Dec 2008; 3(12, e3744): 1-7.
11. Liu A, Lee V, Galusha D, Slade MD, Diuk-Wasser M, et al. Risk factors for human infection with West Nile Virus in Connecticut: a multi-year analysis. International Journal of Geographics. 27 Nov 2009, 8:67.
12. Ruiz MO, Chaves LF, Hamer GL, Sun T, and Brown WM et al. Local impact of temperature and precipitation on West Nile Virus infection in Culex species mosquitoes I northeast Illinois, USA. Parasites and Vectors. 2010; 3:19.

SUMMARY AND HIGHLIGHTS OF THE 2012-2013 INFLUENZA SEASON IN LOS ANGELES COUNTY

Wendy Manuel, MPH

OVERVIEW

The 2012-2013 influenza season in Los Angeles County (LAC) was moderately severe with an increased number of confirmed fatal cases. LAC experienced the highest number of deaths since the 2009-2010 H1N1 pandemic, primarily in the older population. The highest percent positive cases of influenza tests from our sentinel laboratories in LAC occurred during the same week that influenza-like illness (ILI) visits in emergency departments peaked (Figure 1). Overall activity reached a highpoint during the last week of January/beginning of February with 13 respiratory community outbreaks confirmed and 13 influenza attributed fatalities, including one pediatric death (Table 1). Locally and nationally type A dominated, specifically the H3N2 strain (1,2).

Table 1. Surveillance Summary for LA County (2012-2013)
Peak Activity MMWR Week 5

LA County Surveillance Summary	Influenza Peak Week 5 1/27/13-2/2/13	2012-13 Season Summary 9/30/12-7/20/13
Positive Flu Tests/Total Tests (Percent Positive Flu Tests)	552/1,904 (29.0%)	3163/28,642 (11.0%)
Percent Flu A/B	79%/21%	68%/32%
Community Respiratory Outbreaks (Influenza, Confirmed†)	13 (2)	62 (9)
Flu Deaths, Confirmed†† (Pediatric Deaths, Confirmed††)	13 (1)	69 (7)

†Confirmed influenza outbreak is defined by 2 or more positive lab tests for Influenza
††Confirmed influenza death is defined by a positive lab test, compatible symptoms, and clear progression from illness to death

Figure 1. Percent Positive Emergency Department Visits for Influenza-Like Illness, LA County (2007-2013)



SURVEILLANCE IN LAC

Respiratory illness and responsible pathogens are tracked in LAC from nine sentinel laboratory sites geographically spread across the county that report weekly data on influenza test rates at their facilities. In addition some sites return reports on the following respiratory viruses: respiratory syncytial virus (RSV), rhino/enterovirus, parainfluenza, human metapneumovirus, and coronavirus. Figure 2 shows the percent positive lab results for the various respiratory viruses by MMWR week. Los Angeles County Department of Public Health (LAC DPH) also monitors syndromic surveillance of ILI from participating emergency departments (ED) throughout the county. ILI symptoms include: fever, sore throat or cough, runny nose, sneezing, and congestion. The percent positive of ILI visits over total ED visits is monitored as an additional measure of regional influenza activity. Figure 1 compares percent positive ILI visits to participating EDs over the past 6 influenza seasons.

LAC DPH requires that all influenza related deaths be reported; therefore, data collection differs in fatal cases from routine surveillance. Data collection of fatal influenza cases has changed over the past decade. In 2003, the California Department of Public Health (CDPH) began requiring reports of fatal pediatric cases attributed to influenza. A few years later in 2009 with the emergence of the type A pH1N1 pandemic strain, LAC DPH required that all intensive care and fatal cases of influenza be reported in order to monitor the rapidly changing status of the pandemic. Once the emergency situation was over, data collection was revised and as of October 2010 intensive care cases were no longer reportable however all influenza related fatalities remained reportable to LAC DPH within seven days of identification. Currently CDPH only collects influenza fatality data for those 0-64 years old, however LAC tracks fatalities of all age groups in order to monitor a more comprehensive scope of the impact of influenza in our region. These longitudinal findings allow us to track changes in severity from season to season and help identify high risk groups that would benefit from future prevention methods aimed at decreasing morbidity. Additional information about surveillance methods can be found at the LAC DPH website (3).

**Figure 2. Respiratory Viruses LA County 2012-2013,
Percent Positive Cases by MMWR Week**



INCREASED FATALITIES: 4 YEAR COMPARISON

During the 2012-13 influenza season LAC experienced a substantial increase in fatalities attributed to influenza compared with the previous two seasons. The past three influenza seasons have been predominated by type A influenza (H3N2) however for the 2012-13 season a different strain emerged antigenically characterized as A/Victoria/361/2011, whereas the previous two seasons were primarily of the Perth lineage, A/Perth/16/2009. Despite the Victoria strain being included in the 2012-13 seasonal

influenza vaccine, LAC identified the highest number of influenza deaths since the H1N1 pandemic (pH1N1) season reflecting a moderately severe season. Consistent with last season, those 65 years of age and older comprised the majority (52%) of deaths (Table 2). The CDC found a low vaccination efficacy rate for those over 65 years old which suggests a failure to mount a sufficient immune response (4). In contrast, table 2 shows the atypically high percentage of deaths in those under 65 years old (77%) that were most affected during the 2009 pandemic year relative to those 65 and up. During pandemic influenza seasons mortality rates skew disproportionately towards the young (5). Pandemic mortality burden is contrary to normal seasonal influenza years, where 90% of deaths nationally occur in those over 65 years old (6). Comparing the past four influenza seasons, with each consecutive season since pH1N1 the majority of fatal cases shifts back to the typical seasonal influenza trend that disparately affects the elderly. This measure of morbidity burden shift to an older age group progressively increases each year as we move farther away from the pandemic. Comorbid factors related to influenza fatalities remain similar to previous years, with high blood pressure, overweight/obesity, and heart disease continuing to be the top 3 risk factors. Overweight/obesity is a relatively new risk factor for influenza mortality first identified during the 2009 pH1N1 season, however in LAC it was the second most common comorbidity found in 42% of adult influenza deaths (Table 3).

Table 2. Demographic Characteristics of Influenza Fatalities by Flu Season 2009-2013

		2012-13 N (%)	2011-12 N (%)	2010-11 N (%)	2009-10† N (%)
Age (years)	Median	**68**	64	45	48
	Range	**0-100**	0-104	0-92	0-94
	0-5	**5 (7)**	2 (8)	4 (9)	3 (2)
	6-17	**2 (3)**	2 (8)	2 (5)	10 (8)
	18-40	**4 (6)**	2 (8)	14 (33)	37 (29)
	41-64	**22 (32)**	6 (25)	19 (44)	60 (47)
	65+	**36 (52)**	12 (50)	4 (9)	17 (13)
Gender	Female	**35 (51)**	14 (58)	23 (53)	70 (55)
	Male	**34 (49)**	10 (42)	20 (47)	57 (45)
Race	Hispanic	**28 (42)**	12 (50)	26 (60)	56 (49)
	White Non-Hispanic	**25 (37)**	5 (21)	9 (21)	39 (34)
	Black	**8 (12)**	4 (17)	4 (9)	11 (9)
	Asian/Pacifc Islander	**6 (9)**	3 (12)	4 (9)	9 (8)
SPA‡	1: Antelope Valley	**3 (4)**	0 (0)	1 (2)	6 (5)
	2: San Fernando	**18 (26)**	4 (17)	16 (37)	25 (21)
	3: San Gabriel	**8 (12)**	2 (8)	4 (9)	32 (26)
	4: Metro	**12 (17)**	5 (21)	3 (7)	14 (12)
	5: West	**8 (12)**	2 (8)	1 (2)	8 (7)
	6: South	**7 (10)**	3 (13)	6 (14)	6 (5)
	7: East	**6 (9)**	4 (17)	8 (19)	24 (20)
	8: South Bay	**7 (10)**	4 (17)	4 (9)	8 (7)
Total Fatalities		**69**	**24**	**43**	**127**

†2009-10 season is missing race data for n=12 and SPA data for n=4

‡ Service Planning Areas in LA County, http://publichealth.lacounty.gov/chs/SPAMain/ServicePlanningAreas.htm

Table 3. Top 10 Underlying Medical Conditions, Confirmed Adult Influenza Fatalities LA County 2009-201				
Sorted by % for 2012-13 Season	2012-13 N (%)	2011-12 N (%)	2010-11 N (%)	2009-10 N (%)
Hypertension	**32 (52)**	13 (65)	17 (47)	34 (27)
Overweight or obese	**26 (42)**	9 (45)	31 (86)	69 (54)
Heart Disease	**23 (38)**	12 (60)	6 (17)	40 (31)
Diabetes	**19 (31)**	7 (35)	10 (28)	44 (35)
Lung Disease	**11 (18)**	3 (15)	6 (17)	42 (33)
Immunosuppression	**9 (15)**	7 (35)	5 (14)	30 (24)
History of tobacco use	**8 (13)**	8 (40)	9 (25)	12 (9)
History of drug or alcohol abuse	**5 (8)**	4 (20)	3 (8)	7 (5)
Asthma	**5 (8)**	3 (15)	3(8)	9 (7)
Pregnancy	**0**	0	1 (3)	4 (3)
Total Adult Fatalities	**62**	**20**	**37**	**114**

Notes: Overlapping conditions and complications may total over 100%, data not available for all categories, data taken from self-reported medical records

H3N2 TYPE A DOMINATED THIS SEASON

Nationally and locally type A, H3N2 subtype dominated this influenza season. 68% of positive influenza lab tests from sentinel sites returned type A results. Type A was the major strain responsible for influenza mortality in LAC found in 79% of fatal cases (Figure 3). Out of 69 fatal cases, 52 were type A and of those, 23 (32%) were further subtyped H3N2. The pandemic H1N1 strain that emerged during the 2009-10 pandemic season was still circulating during the 2012-2013 season but in low numbers (7% of fatalities). Figure 4 provides an overview of percent positive reports by our sentinel sites by MMWR week (weeks are counted starting at the beginning of the calendar year where week 1 is the first week of January). Consistent with ILI activity from reporting EDs in LAC (Figure 1), LAC sentinel laboratories also reported peak positive influenza tests at the end of January (week 5). The majority of positive influenza during the 2012-2013 season was type A, however type B was simultaneously circulating and showed increased activity over type A later in the season starting in March through the beginning of May until overall influenza activity in LAC dropped. Table 4 shows the waning effect of pH1N1 mortality over time as the rate of fatal pH1N1 cases continue to decrease by about half each consecutive year from 2009-2010.

Figure 3. Percent Positive Influenza Type Nationwide and LA County 2012-2013





Table 4. Viruses Associated with Confirmed Influenza Fatalities 2009-2013

	2012-13† N (%)	2011-12 N (%)	2010-11‡ N (%)	2009-10 N (%)
A no type	29 (42)	14 (58)	15 (35)	19 (16)
A H1N1p	5 (6)	5 (21)	18 (42)	104 (82)
A H3N2	23 (32)	1 (4)	3 (7)	0
B no type	14 (20)	4 (17)	7 (16)	3 (2)
Total	**69**	**24**	**43**	**127**

†One case tested positive for H1N1p & H3N2, and one tested positive for Flu A&B, both counted twice
‡Two cases tested positive Flu A&B counted twice

RESPIRATORY COMMUNITY OUTBREAKS

A total of 50 respiratory outbreaks were confirmed, of those nine were attributed to influenza having at least two positive lab tests (3 A, 4 B, and 2 A& B mixed). Consistent with previous influenza seasons, the majority (over 80%) of 2012-13 outbreaks in LAC were school based (Table 4). This steady trend emphasizes the continued need to monitor influenza activity in school settings and encourage parents to vaccinate their children. Outbreak locations were mapped across service planning areas with most occurring in the San Fernando, Metropolitan, and San Gabriel areas.

Table 5. Characteristics of Confirmed Community Respiratory Outbreaks in LA County 2009-2013				
Characteristic	2012-13 N (%)	2011-12 N (%)	2010-11 N (%)	2009-10 N (%)
Total†	**50**	**27**	**53**	**432**
Location				
School or Pre-School	**41 (82)**	22 (81)	46 (87)	376 (87)
Assisted Living	**6 (12)**	2 (7)	3 (6)	20 (5)
Daycare/child care	**3 (6)**	3 (11)	3 (6)	6 (1)
Juvenile Detention/Jail	**0**	0	0	13 (3)
Hospital	**0**	0	0	8 (2)
Other	**0**	0	1 (1)	9 (2)
Etiology				
Influenza††	**9 (18)**	3 (11)	14 (26)	82 (19)
Streptococcal	**1 (2)**	5 (19)	3 (6)	0
Other respiratory	**40 (80)**	19 (70)	36 (68)	350 (81)

†Totals from previous seasons have been updated

††Confirmed influenza outbreaks must include at least 2 positive lab tests

CONCLUSION

Influenza disease causes significant morbidity and mortality every year. Estimating overall influenza burden is difficult since only a small portion of those who are sick seek treatment and of those not all are tested. Therefore only a small percentage of the population who actually suffer from the disease are counted towards morbidity values. With those limitations in mind, LAC DPH tracks specific measures of influenza in the county from year to year to compare between seasons. The level of activity in LAC during the 2012-2013 influenza season was more severe compared with the previous two seasons as the county suffered the highest number of fatalities since the H1N1 pandemic in 2009-2010. The elderly were disproportionately affected as well as those with underlying medical conditions. Type A H3N2 was the dominant strain both nationally and locally, however type B and A pH1N1 were also present and contributed to morbidity and mortality. As the remarkable effects of the H1N1 pandemic diminish over time, regular seasonal influenza patterns return to normal where activity peaks from December to February and the elderly are most susceptible. The 2009-2010 influenza season is used as a marker to compare other seasons since it was a unique event with lasting effects on our population. Four influenza pandemics have occurred in the past century and because influenza viruses can mutate and adapt to new hosts, public health officials need to diligently monitor for new strains in the event that another pandemic situation emerges.

REFERENCES

1. LACDPH ACDC. Influenza Watch Los Angeles County Season Summary 2012-13
2. CDC. Influenza Activity-United States, 2012-13 Season and Composition of the 2013-14 Influenza Vaccine
3. Department of Public Health - Acute Communicable Disease Control
4..CDC. Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness-United States, February 2013.
5. Nguyen AM, Noymer A (2013) Influenza Mortality in the United States, 2009 Pandemic: Burden, Timing and Age Distribution. PLoS ONE 8(5): e64198. doi:10.1371/journal.pone.0064198
6. CDC. Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 – April 10, 2010.

HEALTHCARE ASSOCIATED INFECTION OUTBREAK INVESTIGATIONS IN AMBULATORY CARE SETTINGS, LOS ANGELES COUNTY, 2000 – 2012

Kelsey OYong, MPH; Laura Coelho; and Dawn Terashita, MD, MPH

BACKGROUND

Healthcare services are increasingly delivered in outpatient, ambulatory care settings (ACSs) rather than inpatient, acute care settings. Nationwide, there are nearly 1.2 billion outpatient visits per year.[1] ACSs encompass a broad array of facilities, such as primary care clinics, ambulatory surgery centers, pain clinics, oncology clinics, imaging facilities, dialysis centers, urgent care centers, and other specialized facilities. The types of procedures performed in ACSs are also diverse, including podiatry (e.g., nail clipping, wound care, podiatric surgery), surgery, endoscopy (e.g., gastrointestinal, urological, arthroscopic), pain injections, and more.

Ambulatory surgery centers, a subset of ACSs, have seen an astounding growth. In 1985, the number of ambulatory surgery centers participating in Medicare was 336; the number boomed to approximately 5368 in 2011.[2,3] Sixty-three percent of all surgeries in 2005 were outpatient, compared with 51 percent in 1990 and only 16 percent in 1980.[4] Explanations for this shift in delivery of healthcare services include lower costs, increased patient satisfaction, and convenient scheduling[5]; however, there are also a number of concerns.

Often, the procedures performed in ACSs are invasive, putting patients at high risk of infection. Further, many procedures currently performed in ACSs were previously performed in hospitals where infection control oversight is regulated. Despite the surge in ambulatory care, there has not been a corresponding increase in infection control oversight in ACSs, and there are insufficient data on the rates of infections resulting from procedures performed in ACSs. In fact, only 20 ambulatory surgery centers reported data to the National Healthcare Safety Network (NHSN) for 2006 through 2008, compared to 1545 hospitals that reported data during the same period.[6]

At the same time, the amount of literature demonstrating a need for infection control oversight in ACSs is growing. For example, from 2001 through 2011, at least 18 outbreaks of viral hepatitis were associated with unsafe injection practices in ACSs, such as physician offices or ambulatory surgery centers.[7] Additionally, an infection control audit performed by the Centers for Medicare and Medicaid Services (CMS) in 2008 found that 46 of 68 ambulatory surgery centers surveyed had at least one lapse in infection control; 12 had lapses identified in three or more of five infection control categories.[8] As such, CMS now requires adherence to its Infection Control Surveyor Worksheet for participation in CMS.[9] However, many ACSs do not fall into the category of licensed surgery or dialysis center or do not participate in CMS, and are thus not held to the same infection controls standards.

Recognizing the infection control concerns associated with ACSs, the Los Angeles County (LAC) Department of Public Health (DPH) Acute Communicable Disease Control Program (ACDC) conducted an analysis to characterize healthcare associated infection (HAI) outbreaks in LAC in ACSs.

METHODS

Adapting the CMS definition for ambulatory surgery centers, ACDC defined an ACS as a distinct healthcare entity, either hospital-based or non-hospital-based, that operates exclusively on an outpatient basis for patients who do not require hospitalization and who are expected to stay less than 24 hours.[10] ACSs affiliated with a hospital are under the common ownership, licensure, or control of a hospital.[11] Ophthalmology offices, hospital clinics, urology offices, radiology offices, pain clinics, orthopedist offices, oncology offices, OB/GYN clinics, and medical spas were grouped together into offices/clinics.

LAC DPH relies on passive surveillance, the receipt of reports of infections from hospitals, laboratories, clinics, and other healthcare facilities and professionals required to submit such reports as defined by

regulation. In California, all outbreaks, confirmed or suspected, are mandated under Title 17 of the California Code of Regulations § 2500 to be reported to the local health department. At LAC DPH, reported outbreaks are documented in the LAC DPH Disease Control Outbreak Log. For this analysis, ACDC reviewed the LAC DPH Disease Control Outbreak Log database, LAC DPH Special Studies Reports where many outbreak investigations are described for ACDC's annual report, and personal correspondence with LAC DPH employees involved in investigations of reported suspected and confirmed HAI outbreaks in ACSs that occurred from January 2000 through November 2012.

These suspected and confirmed HAI outbreaks in ACSs were classified by public health activities undertaken by ACDC, infection control breaches, duration of investigation, and number and outcome of cases. Data were analyzed using SAS 9.3.

Public health activities were separated into 15 categories, including site visit(s), medical record review, epidemiologic studies, patient notification, active surveillance, recommendations to facility, sample collection, laboratory analysis, and environmental investigation. Epidemiologic analyses included case control, retrospective cohort, prospective cohort, and comparison studies. Patient notification refers to the process of informing patients about potential exposures through mailed notification letters or postage of a letter in the facility. Active surveillance, as opposed to passive surveillance, is surveillance in which ACDC proactively solicited infection reporting (e.g., analyzed current patient medical records from facilities for case finding or surveying patients to identify additional cases). Sample collection involved the ascertainment of biological specimens from patients (e.g., from blood, wound, urine), environmental samples (e.g., water, air), medication samples, and samples from equipment (swabs from inside or outside of equipment). Laboratory analyses included genetic typing, pulsed-field gel electrophoresis for DNA fingerprinting, and genomic sequencing. Laboratory analysis was conducted by either LAC DPH Public Health Laboratory or sent to the Centers for Disease Control and Prevention (CDC) laboratory or California Department of Public Health (CDPH) laboratory for testing. Environmental investigations were conducted in conjunction with LAC DPH Environmental Health Division and involved evaluating facility layouts, monitoring staff compliance with environmental infection control standards, and collecting and laboratory testing air, water, or equipment samples.

Infection control characteristics were classified into ten categories, including breaches in hand hygiene, use of personal protective equipment (PPE), injection safety, medication documentation, equipment processing and sterilization, written infection control policies and procedures, and staff credentials.

RESULTS

Characterization of Outbreak Investigations

Twenty-eight investigations of suspected or confirmed HAI outbreaks in ACSs in LAC met the inclusion criteria. The majority of identified outbreak investigations were in facilities not affiliated with a hospital (71.4%). The most common settings for outbreak investigations were ambulatory surgery centers (21.4%) and dialysis centers (21.4%). The distribution of settings by outbreak investigations is shown in Table 1.

Table 1: Distribution of outbreaks by hospital affiliation and setting type

Setting type	Number of outbreak investigations (% of total)	Total number of cases (% of total)
Hospital Affiliation		
Yes	8 (28.6)	42 (25.0)
No	20 (71.4)	126 (75.0)
Setting type		
Office/ clinic	11 (39.3)	53 (31.5)
Ambulatory surgery center	6 (21.4)	26 (15.5)
Dialysis center	6 (21.4)	70 (41.7)
Contracted home health agency	5 (17.9)	19 (11.3)

Outbreaks were reported 0 to 1160 days after exposure of the first case (median: 69 days). The total case count was 168 (mean: 6; range: 0–36); 59 cases were hospitalized and five cases died. The types of implicated agents included bacterial, viral, fungal, ectoparasitic, toxin, and chemical. Bacterial agents were implicated in 50% of identified outbreak investigations. One investigation found no cases and did not implicate an agent. The distribution of agent types by outbreak investigations is shown in Table 2.

Table 2: Types of implicated agents

Agent type	Number of outbreak investigations (% of total)	Examples
Bacterial	14 (50)	*Enterobacter*, *Klebsiella*, *Pseudomonas*, *Stenotrophomonas*, *Staphylococcus*, *Mycobacterium*
Viral	6 (21.4)	Hepatitis B, Hepatitis C
Fungal	3 (10.7)	*Fusarium*
Ectoparasitic	1 (3.6)	Scabies
Toxin	1 (3.6)	
Multiple	1 (3.6)	Adenovirus and *Streptococcus*
Unknown	1 (3.6)	
Not applicable	1 (3.6)	

Public Health Activities

Investigations lasted a median of 36 days (range: 7–94 days). The mean number of control activities undertaken by ACDC during the investigations was 6.8. The most common actions taken by ACDC were: conducting one or more site visits (78.6% of investigations); providing written recommendations to the facility (78.6%); medical record reviews of cases and other patients (75%); formal interviews of facility staff (64.3%); and laboratory analysis (60.7%). ACDC also often consulted CDC (50.0%) and CDPH (35.7%) during investigations. Other partners consulted included the Food and Drug Administration, the Medical Board of California, the California Board of Pharmacy, and internally, LAC Public Health Laboratory (PHL) and LAC Environmental Health Division. Non-case patients were notified of possible risk in 7.1% of investigations. In one investigation, nearly 2,300 patients were notified of possible exposure. Public health activities performed by LAC DPH are summarized in Table 3.

Table 3: Public health activities conducted during outbreak investigations

Public health activity	Number of outbreak investigations (% of total)
Site visit	22 (78.6)
Medical record review	21 (75.0)
Formal staff interviews	18 (64.3)
Epidemiologic study[±]	9 (32.1)
Sample collection	13 (46.4)
Environmental sample[¥]	9 (32.1)
Biological specimen	6 (21.4)
Medication sample	4 (14.3)
Laboratory analysis	17 (60.7)
LAC PHL	14 (50.0)
CDC	9 (32.1)
Environmental health investigation	7 (25.0)
Patient interviews	6 (21.4)
Patient notification	2 (7.1)
Active surveillance	8 (28.6)
Sought outside consultation	17 (60.7)
CDC	14 (50.0)
CDPH	10 (35.7)

Review of facility policies and procedures	15 (53.6)
Written recommendations to facility	22 (78.6)
Special report published by ACDC	10 (35.7)
Other publications×	5 (17.9)

±Epidemiologic study includes case control (5), retrospective cohort (2), prospective cohort (1), and comparison (1)
¥Environmental samples include air, water, and equipment isolates
×Other publications include CDC's Morbidity and Mortality Weekly Reports, the American Journal of Infection Control, Emerging Infectious Diseases, and an abstract for the Society for Healthcare Epidemiology of America (SHEA) conference

Infection Control Breaches

Of the 28 outbreak investigations included, 22 (78.6%) cited at least one infection control breach. The mean number of infection control breaches identified by LAC DPH during the outbreak investigations was 2.4 (range: 0 – 8). The most common breaches recorded were associated with injection safety (35.7%), equipment processing and sterilization (35.7%), medication documentation (25.0%), and environmental cleaning (21.4%). Injection safety violations included reuse of single-dose medication and not using aseptic technique to enter multi-dose vials. Breaches in equipment processing and sterilization included incomplete disinfection of reusable dialyzers following dialysis and use of incorrect cleanser and disinfection method for endoscopes. Infection control breaches are summarized in Table 4.

Table 4: Infection control breaches noted in outbreak investigations

Infection control breach	Number of outbreak investigations (% of total)
Hand hygiene	5 (17.9)
Personal protective equipment (PPE)	3 (10.7)
Proper glove use	2 (7.1)
Injection safety	10 (35.7)
Injection preparation technique and environment	7 (25.0)
Single-use medication policies	2 (7.1)
Logging exposure events	2 (7.1)
Single-use equipment (e.g., blood glucose meters)	4 (14.3)
Medication documentation	7 (25.0)
Dosage or lot number	3 (10.7)
Open date or expiration date	5 (17.9)
Equipment processing and sterilization	10 (35.7)
Log of equipment maintenance	2 (7.1)
Documentation or manuals for equipment	2 (7.1)
Documentation of infection control policies and procedures	5 (17.9)
Knowledge and adherence to policies and procedures	4 (14.3)
Credentials of staff	5 (17.9)
Environmental cleaning	6 (21.4)

Outbreak investigations in which infection control breaches were identified required significantly more public health activities than those that did not find infection control breaches (7.5 actions versus 3.7 actions; $p<0.05$). When a site visit was part of the outbreak investigation, significantly more infection control breaches were identified than when there was no site visit conducted (3.0 breaches versus 0.2 breaches; $p <0.0001$).

Suspected Sources of Outbreaks

Lapses in infection control were suspected as the source for 16 (57.1%) of the outbreak investigations reviewed. Suspected causes included single-use medication used on multiple patients, reuse of finger stick blood glucose meters on multiple patients, deficiencies in dialyzer reprocessing, and improper equipment cleaning and disinfection. Two outbreak investigations identified externally contaminated medication as the suspected source (7.1%). Nine investigations did not identify a source of the outbreak (32.1%). One investigation found no cases and thus identified no source.

DISCUSSION

ACDC documented considerable morbidity and mortality associated with the 28 suspected and confirmed HAI outbreak investigations in ACSs included in this review. Cumulatively, over one-third of cases associated with these investigations were hospitalized; there was a 3% mortality rate among the cases. The analysis revealed diversity in types of ACSs and outbreak settings in LAC. A dozen different types of outbreak settings were identified, ranging from complex surgery centers with multiple operating rooms to small medical spas and pain clinics, all performing a variety of services. Additionally, the review demonstrates that outbreak investigations require substantial public health resources. The 28 investigations required many public health activities including site visits, laboratory analysis, and patient notification; our investigations lasted, on average, over one month. Interestingly, outbreak investigations that uncovered infection control breaches were associated with a greater number of public health activities than those without infection control breaches.

The most common infection control lapses identified in this analysis are consistent with those found by a national audit of ambulatory surgery centers nationwide.[8] Notably, injection safety violations and equipment cleaning issues were most frequent, both of which are preventable through taking Standard Precautions and practicing basic infection control. These findings highlight a need for better reporting from ACSs as well as more infection control oversight of ACSs.

There were some limitations to this analysis. This retrospective review relied on the availability and completeness of investigation documents. It is possible that some investigations were not documented in the LAC DPH Disease Control Outbreak Log or recalled by ACDC personnel and were not included in this review. Another limitation is delayed reporting to LAC DPH. Surveillance of HAIs in ACSs is passive in LAC, relying on facilities to recognize and report outbreaks and reportable conditions to LAC DPH. Among the 28 investigations included in this review, the median time between exposure of first case and report to LAC DPH was 69 days, with some situations reported years following the first exposure. Delayed reporting may be due in part to difficulty in tracking infections in outpatient populations; ACSs may have minimal patient follow-up. The difficulty in tracking infections also reduces the ability of public health officials to attribute infections to ACSs, especially if the infection is identified in an acute care setting after exposure at an ACS. In many cases, ACSs were unaware of the reporting requirements for outbreaks and other notifiable conditions. As a result of reporting issues, the findings of this review may be an underestimation of the true morbidity and mortality associated with HAIs in ACSs in LAC.

The difficulty in tracking infections in ACSs is concerning, especially in the case of acute communicable diseases, because delayed reporting can have serious consequences for public health intervention and patient safety. To improve reporting, ACSs should be encouraged to utilize NHSN reporting tools when applicable. NHSN is a useful system for both active and passive surveillance of HAIs and can be applied to ambulatory settings. NHSN recently launched a module for dialysis facilities to track infections; ambulatory surgery centers can already report infections to NHSN in the same way as hospitals.[6]

In addition to enhanced reporting, there are several potential opportunities to improve infection control practices and guidelines in ACSs through more oversight. While more research is needed to identify common infection control errors in ACSs and how to prevent them, state policies for oversight through licensure, incorporating training requirements, infection control standards, and regular inspection may be an approach for reducing HAIs in ACSs. As an example, the New York State Department of Health requires all office-based surgery practices to be accredited, mandates infection control training for every licensed healthcare provider, and requires providers in these facilities to report adverse events within one day.[12] Furthermore, much like following the CMS Infection Control Surveyor Worksheet is mandatory for CMS participation, requiring site visits, infection prevention programs and adherence to nationally recognized infection control guidelines for licensure may be appropriate for ACSs.[9] In our analysis, we found that site visits made by ACDC were helpful in identifying infection control breaches during the investigation process, as opposed to when no site visits are made. With regular inspection, infection control violations can be detected and addressed. The CDC and Healthcare Infection Control Practices Advisory Committee (HICPAC) created the *Guide to infection prevention in outpatient settings: Minimum*

expectations for safe care, which is intended to provide infection control and prevention recommendations to ACSs. Included in the recommendations are the development of an infection prevention program in the facility, specific infection prevention education and training of healthcare personnel, surveillance of HAIs, and adherence to Standard Precautions.[13] This document should serve as a guide to ACSs in LAC for infection prevention practices.

CONCLUSION

HAI outbreaks in ACSs occur frequently, in diverse settings, and require substantial public health resources. The reviewed outbreak investigations were associated with considerable morbidity and mortality, as more than one-third of affected patients were hospitalized. Infection control standards and appropriate event reporting should be promoted, enhanced, and enforced in ACSs to ensure patient safety.

REFERENCES

1. Perz, J. "Infection Prevention, Surveillance, and Oversight for Ambulatory Care Settings." IDWeek. 18 Oct 2012.
2. Centers for Medicare and Medicaid Services (CMS). Data Compendium, 2002 Edition. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/DataCompendium/2011_Data_Compendium.html, accessed 3/6/13.
3. Kuehn, BM. 2012. Medical News & Perspective: Unsafe Injection Practices Plague US outpatient Facilities, Harm Patients. JAMA 308(23):2551-2552.
4. Russo, A, Elixhauser, A, Steiner, C, Wier, L. 2010. Hospital-based ambulatory surgery, 2007. Healthcare Cost and Utilization Project (HCUP) Statistical Brief #86. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb86.jsp, accessed 3/1/13.
5. Barie, PS. Editorial: Infection Control Practices in Ambulatory Surgical Centers. 2010. Infection Control Practices in Ambulatory Surgical Centers. JAMA 303(22):2295-2297.
6. Edwards, JR, Peterson, KD, Banergee, S, Allen-Bridson, K, Morrell, G, Dudeck, MA, Pollock, DA, Horan, TC. 2009. National Healthcare Safety Network (NHSN) report: Data summary for 2006 through 2008, issued December 2009. Am J Infect Control 37:783-805.
7. United States Government Accountability Office (GAO). Patient Safety: HHS Has Taken Steps to Address Unsafe Injection Practices, but More Action Is Needed. Report to the Ranking Member, Subcommittee on Health, Committee on Energy and Commerce, House of Representatives. GAO-12-712. July 2012
8. Schaefer, MK, Jhung, M, Dahl, M, Schillie, S, Simpson, C, Llata, E, Link-Gelles, R, Sinkowitz-Cochran, R, Patel, P, Bolyard, E, Sehulster, L, Srinivasan, A, Perz, JF. 2010. Infection control assessment of ambulatory surgical centers. JAMA 303(22):2273-2279.
9. CMS. 2010. Ambulatory Surgical Center Infection Control Surveyor Worksheet. http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/som107_exhibit_351.pdf, accessed 5/31/13.
10. CMS. 42 C.F.R. §416.2 http://www.cms.gov/RegulationsandGuidance/Legislation/CFCsAndCoPs/Downloads/CMS3217F.pdf, accessed 3/1/13.
11. CMS. Ambulatory Surgical Center Fee Schedule. Medicare Learning Network. http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/AmbSurgCtrFeepymtfctsht508-09.pdf, accessed 5/31/13.
12. New York State Department of Health. 2008. New York State Public Health Law Section 230-d Office-Based Surgery. http://www.health.ny.gov/professionals/office-based_surgery/law/230-d.htm, accessed 3/13/13.
13. Centers for Disease Control and Prevention (CDC). Guide to infection prevention in outpatient settings: Minimum expectations for safe care. http://www.cdc.gov/hai/pdfs/guidelines/ambulatory-care-04-2011.pdf, accessed 5/21/13.

OUTBREAK OF FUNGAL ENDOPHTHALMITIS ASSOCIATED WITH AN OUT-OF-STATE COMPOUNDING PHARMACY

Moon Kim, MD, MPH; Clara Tyson, RN, MSN; and Christina Mikosz, MD, MPH

BACKGROUND

On March 6, 2012, the Acute Communicable Disease Control Program (ACDC) of the Los Angeles County (LAC) Department of Public Health (DPH) received a report from the California Department of Public Health (CDPH) about a cluster of clinically diagnosed fungal endophthalmitis cases in nine patients. All nine case-patients had undergone vitrectomy with retinal membrane peeling by any one of five retinal surgeons at a single ambulatory surgery center, Facility A. Case-patients underwent surgeries from October 31, 2011 through December 27, 2011. All nine case-patients were exposed to Brilliant Blue-G (BBG), a dye used during the retinal surgery. The BBG used during the surgeries was purchased from Franck's Compounding Lab (FCL) in Ocala, Florida. Signs of post-operative infection were noted starting in mid-November 2011.

Cases of fungal endophthalmitis associated with BBG were subsequently identified in other multiple states. The multistate investigation, including national case findings, specialized laboratory tests and collaboration with the United State (US) Food and Drug Administration (FDA) to develop recommendations to prevent infections, was led and coordinated by the Centers for Disease Control and Prevention (CDC).

During the course of investigating the initial infections associated with BBG, CDC identified clusters of fungal endophthalmitis in patients who had been administered intraocular injections of triamcinolone acetonide ("triamcinolone"), which was also compounded at FCL. On March 31, 2012, FCL issued a press release stating that they had recalled triamcinolone.

On April 2, 2012, ACDC was notified by the CDC of a cluster of three cases of fungal endophthalmitis after intraocular injections with triamcinolone at an outpatient ophthalmology clinic, Office B. Office B had purchased the triamcinolone from FCL.

ACDC investigated both of these facilities to confirm the presence of the outbreak, by interviewing staff, reviewing medical records, conduct case findings, and in conjunction with the CDC, determine source of infection and recommend measures to control the outbreak. ACDC was regularly in consultation with the CDPH and the CDC throughout this multistate outbreak investigation.

Investigation of FCL was conducted by the US FDA and the State of Florida Department of Health Services.

METHODS

Case Finding

A probable case was defined as ophthalmologist-diagnosed fungal endophthalmitis occurring in a patient who underwent an invasive ophthalmic procedure, including but not limited to vitrectomy, corneal surgery, or intravitreal injections on or after August 23, 2011, the production date of the BBG stock used on the Facility A patients. Confirmed cases met criteria for probable infection and also had fungi identified from the affected eye by culture, genetic sequencing, or histopathology. Each infected eye was counted separately as a case.

To identify cases, we first reviewed medical records from Facility A patients who received BBG from FCL and received a clinical diagnosis of fungal endophthalmitis. ACDC worked with Facility A to identify all patients who received BBG since Facility A first began purchasing BBG from FCL to determine if there were any other cases of fungal endophthalmitis. Billing codes were reviewed by Office B to identify

patients who had received triamcinolone intraocular injections. All patients who had received injections of triamcinolone subsequently recalled by FCL were identified and their medical records were reviewed.

Active Surveillance:

To identify other cases of fungal endophthalmitis related to BBG, ACDC contacted large retinal surgery practices in LAC to inquire about the use of sterile products from FCL.

Notifications and Recalls:

Local alerts and national notifications to ophthalmologists, retinal specialists, and clinicians were distributed by LAC DPH, CDC and CDPH. The FDA also posted recalls, safety alerts, and MedWatch (The FDA Safety Information and Adverse Events Reporting Program) alerts. National ophthalmology and retinal surgery organizations sent notices to their members. FCL sent recall notices to physicians. The California State Board of Pharmacy was also notified by LAC DPH.

Site Visits

1. Facility A: On March 7 and 8, 2012, site visits were conducted at Facility A by an ACDC team of medical, nursing, and epidemiology staff to meet with the Director of Nursing, President, and Medical Director; for a tour of the facility, to review pharmacy invoices, medication storage, infection control policies, and medical records. Subsequent site visits occurred to complete medical record review.

2. Office B: On April 4, 2012, an initial site visit was conducted by an ACDC physician and nurse to meet with the owner and ophthalmologist, to review pharmacy invoices, and review medical records. Medical records of patients who had received recalled triamcinolone from FCL were reviewed. Subsequent site visits occurred to complete medical record review.

Case-Control Studies

1. Facility A: On March 14 and 15, 2012, ACDC returned to Facility A to conduct a case-control study to determine risk factors associated with illness. Cases were defined as patients that underwent vitrectomy during the investigated time period at the Facility A from October 13, 2011 through January 12, 2012 (the dates BBG from FCL were used at Facility A) and who were subsequently clinically diagnosed with fungal endophthalmitis. Controls were patients who underwent vitrectomies during the same time period and were well at the time of the study. Two matched controls per case were selected from among other patients who also underwent vitrectomies in the same operating room on the date of each case's procedure; thirteen other controls that underwent vitrectomies from October 13, 2011 through January 12, 2012 were selected randomly. Using a standardized questionnaire, clinical and laboratory data were abstracted from medical records; SAS® version 9.2 was used for statistical analysis. A national case-control study is also being conducted by the CDC.

2. Office B: On May 18, 2013, ACDC abstracted data from medical records using a standardized questionnaire for a national case-control study being conducted by the CDC.

Laboratory Testing

Available case specimens (e.g., vitreous fluid, intraocular lens) that showed fungal hyphae by histopathology or fungal growth on culture were sent to the LAC DPH Laboratory for further fungal identification and then forwarded to the Antifungal and Fungal Reference Unit of CDC's Mycotic Diseases Branch for additional molecular testing. Polymerase Chain Reaction (PCR) was performed by CDC on available case specimens (e.g., vitreous fluid, intraocular lenses, and natural lens) that had no evidence of fungal hyphae on histopathology and no fungal growth on culture. ACDC worked with local hospitals and the LAC DPH Laboratory to coordinate specimen collection and transport.

All testing of BBG and triamcinolone products from FCL was conducted by the FDA.

RESULTS

Facility A reported first ordering BBG from FCL on September 12, 2011. On December 8, 2011, Facility A noticed that the expiration dates printed on the BBG vials received from FCL had differed from dates printed on the box they came in. They reported this inconsistency to FCL and they were advised to return any used vials to FCL. In December 2011, Facility A noticed a few patients who had retinal surgery during November/December 2011 had developed extended post-operative inflammation and severe vitritis. Facility A stopped using BBG from FCL on January 12, 2012 and returned remaining vials of BBG to FCL. Lot numbers of the BBG were not recorded on patient's medical records; however, Facility A's central supply department kept records of shipments. On February 21, 2012, Facility A received a laboratory results sent by FCL showing that a 5mL BBG sample (labeled as Sample #W-1-1316 and received by the laboratory on January 16, 2012) was positive for *Fusarium* species (report date February 14, 2012). Facility A then notified the CDC, CDPH, FDA, and the Florida State Board of Pharmacy.

Case Finding

1. Facility A: A total of nine cases (in nine patients) were identified (two confirmed and seven probable) with no bilateral infections. A total of 28 patients had exposure to BBG from October 13, 2011 through January 12, 2012 out of a total of 122 vitrectomies performed during this time period. Cases underwent their initial surgeries from October 31, 2011 through December 27, 2011. Two cases had hyphae by histopathology on ocular specimens. Fungal cultures had not been obtained. Six cases had ocular specimens sent to the CDC for PCR; no fungal DNA was amplified by PCR from these specimens. The onset of symptoms in the first case was November 14, 2011. Mean incubation period from procedure date to endophthalmitis onset was 13.3 days (range from 3-36 days).

2. Office B: A total of 14 cases (in 12 patients) were identified (eight confirmed and six probable). Case patients received intravitreal injections of triamcinolone from December 21, 2011 through February 29, 2012. A total of 15 patients received recalled triamcinolone during this time period, three with bilateral injections and three receiving multiple injections in the same eye. Two patients who received bilateral injections with recalled triamcinolone subsequently developed infections in each of those eyes. Three cases had evidence of fungal hyphae on histopathology without culture confirmation. One case had growth of *Bipolaris* species on culture but no hyphae observed on histopathology. Four had both fungal hyphae on histopathology and growth of *Bipolaris* species in culture. Seven specimens were sent to the CDC for PCR; no fungal DNA was amplified by PCR from these specimens. Incubation period (date of triamcinolone injection to date of vision changes or clinical diagnosis of endophthalmitis) ranged from seven days to ten months. To date, three patients of the 15 total patients exposed to recalled triamcinolone have not shown evidence of infection.

All nine cases exposed to BBG required repeat surgery or surgeries. Seven received antifungal treatment.

All 12 case-patients exposed to triamcinolone required repeat surgery or surgeries. All cases received antifungal treatment.

Active surveillance:

No additional cases associated with products from FCL were identified after calling 15 retinal surgery centers in LAC.

Notifications and Recalls:

- On March 7, 2012 the LAC DPH posted a report regarding the BBG-associated fungal endophthalmitis cases to the CDC's Epidemic Information Exchange (*Epi-X*).

- Both the American Society of Retinal Surgeons and the American Academy of Ophthalmologists issued multiple warnings to its members about BBG.

- FCL sent a letter recalling its BBG on March 9, 2012 to ordering physicians.[1] The FDA publicly issued this letter as a press release on March 16, 2012, then issued a follow-up notice on its MedWatch site on March 19, 2012.[2, 3]

- On March 31, 2012, a single lot of triamcinolone was recalled by FCL.[4] An additional lot of triamcinolone was recalled on May 2, 2012.[5]

- On April 13, 2012 the LAC DPH notified the California State Board of Pharmacy regarding the second ophthalmic product, triamcinolone, associated with a cluster of fungal endophthalmitis cases in LAC.

- FDA issued a second warning to physicians regarding drugs from FCL on April 20, 2012 and May 4, 2012.[6, 7]

- On April 16, 2012, the LAC DPH issued an alert to healthcare providers, hospital laboratories, clinical laboratories, and pharmacies.[8] The alert described the outbreak of fungal endophthalmitis associated with the use of two separate products purchased from FCL and advised healthcare workers to immediately discontinue use of those products and report, to LAC DPH, any cases of endophthalmitis or clusters of any other bacterial or fungal infections following use of sterile compounded products from FCL.

- On April 19, 2012, the California State Board of Pharmacy served FCL with an Order to Cease and Desist, prohibiting it from shipping any sterile injectable compounded products into California.

- On May 4, 2012, the CDC and multiple state/local health departments published a brief report of the outbreak and recommended that clinicians and patients avoid use of compounded products labeled as sterile from FCL.[9]

- On May 25, 2012, FDA announced an expanded recall of all sterile compounded drugs from Franck's distributed from November 21, 2011 through May 21, 2012.[10,11]

- On July 9, 2012, the FDA issued a warning letter to FCL describing its inspection and charges.[12]

- Through disciplinary action of the California Board of Pharmacy, both of Franck's compounding pharmacy licenses issued by the state of California were voluntarily surrendered.[13]

Case-Control Study

Nine BBG-exposed cases and 33 controls were included in the LAC case-control study. The mean age of cases was 72.3 years and the mean age of controls was 61.8 years. Cases and controls did not differ significantly by gender, past history of diabetes, hypertension or recent past history of eye surgery; preoperative or intraoperative medicines including eye drops; or operating staff. However, cases had significantly higher odds of being exposed to BBG than controls (odds ratio: ∞; $P < 0.001$).

National case data is under review by the CDC; at the time of this report, those results were not available.

Laboratory Testing

All available fungal isolates from confirmed nationwide cases associated with BBG exposure were identified by culture or genetic sequencing as the mold *Fusarium incarnatum-equiseti* species complex. Culture of unopened bottles and intact (unused, pharmacy-prepared) syringes of BBG dye collected by FDA yielded multiple bacterial and fungal species, including *Fusarium incarnatum-equiseti* species complex.[9] *Fusarium incarnatum-equiseti* species complex isolates from BBG tested were shown by multilocus DNA sequencing at CDC to be indistinguishable from cases in the national outbreak.

All available fungal isolates from confirmed cases nationwide occurring after intravitreal injection of triamcinolone-containing products were identified as *Bipolaris hawaiiensis*.[9] Bipolaris *hawaiiensis* was identified by DNA sequencing of multiple isolates from triamcinolone-exposed case isolates across multiple states.

CONCLUSIONS

In LAC, a total of 23 cases of fungal endophthalmitis associated with products compounded by FCL were identified (ten confirmed and 13 probable) in 21 patients. Nine cases were associated with BBG exposure (two confirmed, seven probable) and 14 cases (in 12 patients, two of which had bilateral eye infections) were associated with triamcinolone exposure (eight confirmed, six probable). Both the BBG and triamcinolone administered to these cases were compounded at FCL.

Confirmed national cases associated with BBG exposure were identified by culture or genetic sequencing as the mold *Fusarium incarnatum-equiseti* species complex. BBG from FCL was also found to have *Fusarium incarnatum-equiseti species complex* that was indistinguishable from cases in the national outbreak by DNA sequencing.

Bipolaris hawaiiensis was identified by DNA sequencing of multiple isolates from triamcinolone-exposed cases across multiple states, suggesting a common source.

Alerts and recalls of products from FCL were distributed locally and nationally by LAC DPH, CDC, and FDA. Investigation of FCL was performed by the FDA[12] and Florida Department of Health.

REFERENCES

1. Franck's Compounding Lab Notice of Recall for Brilliant Blue G. FDA. 3/9/12 http://www.fda.gov/Safety/Recalls/ucm296326.htm (accessed February 14, 2013)

2. FDA Warns Physicians about Using Brilliant Blue G for Eye Surgery. FDA. Posted 3/19/12 and updated 4/20/12. http://www.fda.gov/Drugs/DrugSafety/ucm296410.htm (accessed February 14, 2013)

3. FDA Safety Information: Brilliant Blue G Compounded by Franck's: Recall of Unapproved Drug-Ongoing Investigation of Fungal Endophthalmitis Cases. FDA. Posted 3/19/12. Updated 4/20/12 and 5/4/12. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm296383.htm (accessed February 14, 2013)

4. Franck's Compounding Lab Notice of Recall for triamcinolone. FDA. 3/31/12 http://www.fda.gov/Safety/Recalls/ucm300712.htm (accessed February 14, 2013)

5. Franck's Compounding Lab Notice of Recall-Triamcinolone acetonide P.F. FDA. 5/2/12 http://www.fda.gov/Safety/Recalls/ucm302899.htm (accessed February 14, 2013)

6. FDA Safety Information: Certain Compounded Drugs from Franck's: FDA Issues Second Warning to Physicians. FDA. Posted 4/20/12 and updated 5/4/12.

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm301137.htm (accessed February 14, 2013)

7. Updated: FDA Issues Second Warning to Physicians about Certain Compounded Drugs from Franck's. FDA. 4/20/12 http://www.fda.gov/Drugs/DrugSafety/ucm301027.htm (accessed February 14, 2013)

8. Los Angeles County Department of Health, Health Alert-Fungal endophthalmitis following use of products from Franck's Compounding Pharmacy. LAC DPH. 4/16/12. http://publichealth.lacounty.gov/acd/docs/HANfungalOB.pdf (accessed February 14, 2013)

9. Centers for Disease Control and Prevention. Notes from the Field: Multistate Outbreak of Postprocedural Fungal Endophthalmitis Associated with a Single Compounding Pharmacy—United States, March–April 2012. MMWR 2012; 61(17); 310-311.

10. FDA Safety Information: Franck's Compounding Pharmacy Sterile Preparations: Reports of Fungal Endophthalmitis, Expanded Recall. FDA. 5/24/12 http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305592.htm (accessed February 14, 2013)

11. FDA Recall Notice posting: All Sterile Human and Veterinary Prescriptions Distributed by Franck's Pharmacy from November 21, 2011 to May 21, 2012. FDA. 5/25/12 http://www.fda.gov/Safety/Recalls/ucm305509.htm (accessed February 14, 2013)

12. FDA warning letter to Franck's Lab Inc., d.b.a. Franck's Compounding Lab 7/9/12. FDA. 7/9/12 http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm312645.htm (accessed February 14, 2013)

13. California Board of Pharmacy, Decision effective 12/28/2012 http://www.pharmacy.ca.gov/enforcement/fy1112/ac114308.pdf

OUTBREAK OF *MYCOBACTERIUM FORTUITUM* SURGICAL SITE INFECTIONS AT A PLASTIC SURGERY AMBULATORY CENTER

Clara Tyson, RN, MSN; Moon Kim, MD, MPH; Christina Mikosz, MD, MPH;
Monica Luarca, MPH; Lorna Eusebio; Cole Landowski, MS; and Hector Rivas, BS

BACKGROUND

Mycobacterium fortuitum is a rapidly-growing mycobacterium (RGM) that is commonly found in water and soil. RGM as a group (consisting of *M. fortuitum*, *Mycobacterium abscessus*, and *Mycobacterium chelonae*, including their subspecies) are increasingly linked to localized infections of skin and soft tissue following a variety of procedures (1), including but not limited to cardiothoracic surgery, mesotherapy, liposuction, abdominoplasty, and Mohs micrographic surgery. In particular, RGM, especially *M. fortuitum*, have been increasingly associated with plastic/reconstructive procedures such as breast augmentation, in some cases leading to outbreaks (2-4). While a specific route of transmission was postulated in some RGM outbreaks, such as a contaminated skin-marking medication shared among multiple patients (5), contaminated solutions or instrumentation (6,7), or body colonization of a staff member (8), no source of RGM is identified in most outbreaks. However, due to their ubiquitous nature, tap water and the surgical or hospital environment (9) are likely sources.

On October 20, 2011, the Los Angeles County Department of Public Health (LAC DPH) Acute Communicable Disease Control Program (ACDC) was notified by an ambulatory plastic surgery center (Facility A) of an ongoing cluster of five *M. fortuitum* surgical site infections among patients who underwent breast augmentation and/or abdominoplasty procedures at their facility; the first two cases underwent surgery during December 2010, and the subsequent three cases had surgery in January 2011, June 2011, and August 2011, respectively. All patients had uneventful surgeries but returned for follow-up within two months with infected wounds that grew *Mycobacterium fortuitum* by culture.

ACDC conducted an initial investigation in October 2011 and consulted with the California Department of Public Health and the Centers for Disease Control and Prevention (CDC) throughout the investigation to discuss methods, findings, and recommendations.

After the initial three cases were identified by the surgeon, Facility A hired a private infection control firm in May 2011, and implemented several infection control measures including installation of filters on scrub and utility sinks, changes in patient cleansing procedures both preoperatively and intraoperatively, changes in surgeon and operating room (OR) staff preoperative scrub technique, collection of multiple cultures of staff, and other measures. However, two additional cases of *M. fortuitum* infection occurred after initiating these infection control actions, prompting the surgeon to contact ACDC in October 2011.

Subsequently, in August and October 2012, two additional case-patients were diagnosed with *M. fortuitum* wound infections following breast surgery in June 2012 and July 2012, approximately one year after the first cluster of five case-patients were identified and reported. Both of the latest case-patients underwent uneventful surgeries and presented for follow-up at two and three months post-surgery with initial onset of wound infection.

METHODS

CASE FINDING

A case was defined as a patient who developed an *M. fortuitum* surgical site infection more than 30 days following breast or abdominoplasty surgery at Facility A from December 2010 to present.

At the onset of the investigation in October 2011, ACDC asked Facility A staff to identify all primary/secondary breast augmentation and abdominoplasty patients who underwent surgery between December 1, 2010, and September 1, 2011 who did not return for follow-up within three months of their

procedures. Facility A contacted patients by email and telephone to discuss each patient's post-operative course and to schedule follow-up visits whenever possible. ACDC also consulted with the LAC DPH Tuberculosis Control Program and reviewed their surveillance data of nontuberculous mycobacteria isolated from non-pulmonary sites dating back to January 1, 2010. ACDC also reviewed medical records of four additional patients listed in a recovery room infection log as having developed post-operative infections between September 2010 and October 2011.

CASE-CONTROL STUDY

A case-control study was conducted to identify exposures epidemiologically associated with *M. fortuitum* infection during the investigation of the initial cluster of five cases. For this study, cases were defined as described earlier; control subjects were breast augmentation and abdominoplasty patients selected randomly from noncase months between December 2010 and August 2011. Using a standardized chart abstraction form, data from all case and control subjects was collected regarding surgical patient order in a given day, surgery day of week, length of surgery, medications used pre- and intraoperatively, placement of drains for post-operative management, post-operative destination, county of residence, anatomic surgical site location, and stay at a nearby independent post-operative recovery center (Facility X).

SITE VISITS

An initial site visit to Facility A was made on October 21, 2011, by ACDC medical, nursing, and epidemiology staff. Infection-control deficiencies and corrective actions were verbally discussed with the surgeon involved in the five initial cases and his staff, and environmental samples were collected for mycobacterial testing.

On October 26, 2011, ACDC staff observed a secondary breast augmentation surgery, collected additional environmental samples, and reviewed medical records. Cleaning, disinfection, and sterilization procedures/policies were also reviewed. Recommendations to correct infection-control deficiencies were provided to Facility A both verbally and in writing following the first two site visits.

An environmental health inspection was conducted on November 4, 2011, to evaluate air flow, collect environmental samples, and further medical record review was completed by ACDC.

On November 9, 2012, ACDC returned to Facility A for a site visit due to the identification of two additional cases. Medical records of the case-patients were reviewed and a tour of the clinic area and building of the facility area were conducted. On November 13, 2012, ACDC observed a secondary breast surgery, and collected additional environmental samples in addition to personnel samples for mycobacterial testing.

LABORATORY TESTING

Environmental samples collected on October 21 and 26, 2011, by LACDPH from Facility A included:

- filters from the scrub sink and utility room sink
- faucet aerator from recovery room sink
- water (both with and without filter) from the scrub sink and utility room sink
- irrigation solutions and swabs of irrigation solution bottles used during an observed secondary augmentation surgery
- Marcaine™ solution and swab of the medication vial opened with bottle opener and used during observed surgery
- bottle opener used in the OR
- autoclave water, including prepackaged distilled water, autoclave reservoir water, autoclave wastewater, and swabs of reservoir and wastewater ports
- surgical marking pens
- disinfectant solution from instrument soaking trays in multiple exam rooms
- swabs of OR microwave
- sealed, microwaved 500 ml container of sterile saline solution

- open vial of single-dose lidocaine from OR
- open, expired bottle of tricholoracetic acid (TCA) 35% in OR
- Gentian Violet and Methylene Blue solutions from OR
- open bottles of single-use sterile saline from exam rooms
- building HVAC (heating, ventilation, and air conditioning) system pre-filter and swab of condensation drainage line, and
- air samples collected from the OR, utility room, and OR suite hallway via an Andersen sampler.

On November 13, 2012, a total of 36 environmental samples and 15 personnel samples were collected. Environmental samples included:

- water from sinks in exam rooms (1, 2, 3, and 4), fish aquarium in the medical office above Facility A, and cooling tower located on the roof of the building
- water (both with and without filter, where applicable) from kitchen sink, utility room, scrub sink, and OR recovery room
- office kitchen refrigerator water and ice
- staff bathroom sink and toilet tank water, and
- swabs of utility sink faucet, recovery room sink faucet, inner surfaces of utility room freezers, inner walls of the fish aquarium, inner surface of the cooling tower, and spigots from bathroom sink and exam rooms 1, 2, 3 and 4.

Personnel samples included:

- sponge wipes of nares, eyebrows, and hands/nails of the OR circulating nurse #1 and #2, scrub technician, anesthesiologist, and surgeon.

The LAC DPH's Public Health Lab (PHL) performed acid-fast bacilli (AFB) testing on environmental samples collected during the site visits, including culture and high pressure liquid chromatography (HPLC). AFB testing on environmental samples collected on November 4, 2011, was performed by CDC; methods included culture, HPLC, and genetic sequencing.

CDC also performed pulsed field gel electrophoresis (PFGE) of the four available patient isolates, those from four patients that underwent surgery in June and August 2011, and June and July 2012, respectively.

ACDC also reviewed the final environmental testing results performed by a private laboratory prior to the initiation of our investigation of this outbreak.

RESULTS

CASE FINDING

Between December 1, 2010, and September 1, 2011, a total of 20 abdominoplasties, 86 primary breast augmentations, and 45 secondary breast augmentations were performed.

A total of seven cases meeting the case definition were identified: Six of the seven cases were infections following a breast procedure and one case was an infection following an abdominoplasty procedure. All had surgical site specimens that were AFB smear-negative but had growth of *M. fortuitum* on culture. The abdominoplasty case also underwent a concurrent secondary breast augmentation procedure, but only the abdominoplasty wound was infected with *M. fortuitum*. Six of seven case-patients were female, with a mean age of 37 years (range 23-49 years). The mean incubation period from date of the initial surgery to date of symptom (wound swelling without fever) onset was 53 days (range 27-82 days).

All case-patients required treatment with antibiotics; four breast augmentation case-patients also required surgical implant removal to manage their infections. None were hospitalized. Figure A is an epidemic curve depicting the dates of diagnosis of all seven case-patients associated with this outbreak.

Thirty-eight abdominoplasty and primary/secondary breast augmentation patients were identified as not having returned for follow-up within three months of surgery from December 1, 2010 to September 1, 2011. Facility A was able to reach 18 of these patients for clinic follow-up; none had experienced any signs of infection post-operatively.

No other cases were identified via review of the LAC DPH Tuberculosis Control surveillance data for AFB wound site or medical record review of patients named on an internal infection control log.

FIGURE A. Epidemic curve depicting symptom onset dates of post-surgical *M. fortuitum* infections at Facility A from Jan 2011 to October 2012



CASE-CONTROL STUDY

The initial cluster of five case-patients and 29 identified control subjects were included in the case-control study. There were no statistically significant differences between case-patients and control subjects with regards to surgical patient order in a given day, surgery day of week, length of surgery, medications used pre- and intraoperatively, placement of drains for post-operative management, county of residence, and anatomic surgical site location (Figure B). A significant difference between case-patients and control subjects was observed regarding post-operative stay at Facility X, but this likely represents a statistical anomaly due to the small number of case-patients in the analysis; additionally, this facility is used by multiple surgeons from multiple facilities who have not experienced known clusters of mycobacterial post-operative infections, making Facility X a less plausible source of *M. fortuitum* transmission for this outbreak.

FIGURE B. Case-control study results – Initial Cluster of Five Case-Patients

	Cases (N=5)			Controls (N=29)				
	%	n	N	%	n	N	Attack Rate	p-value
Post op stay at Facility X	80%	4	5	10%	3	29	**57%**	**0.003**
Out-of-county resident	60%	3	5	48%	14	29	18%	0.64
Drains placed	80%	4	5	24%	7	29	36%	0.05
Pain pump used	20%	1	5	7%	2	29	33%	0.92
Bilateral procedure	100%	5	5	90%	26	29	16%	1.00
Marcaine™ used locally	100%	5	5	97%	28	29	15%	1.00
Irrigation solution used	100%	5	5	90%	26	29	16%	1.00
R&R with caps	60%	3	5	28%	8	29	27%	0.36
Day of Week								
Monday	0%	0	5	10%	3	29	0%	1.00
Tuesday	0%	0	5	38%	11	29	0%	0.71
Wednesday	40%	2	5	21%	6	29	25%	0.46
Thursday	60%	3	5	31%	9	29	25%	0.25
Surgery Length								
1 hour	20%	1	5	66%	19	29	5%	0.16
2 hours	60%	3	5	28%	8	29	27%	0.36
2.5 hours	20%	1	5	7%	2	29	33%	0.92
Case Order								
First	40%	2	5	48%	14	29	13%	1.00
Second	20%	1	5	31%	9	29	10%	1.00
Third	20%	1	5	17%	5	29	17%	1.00
Fourth	20%	1	5	3%	1	29	50%	0.67

SITE VISITS

On October 21, 2011, ACDC personnel conducted a site visit to review medical records of the five known cases. A walk-through of the facility was also performed. Facility A is an ambulatory surgery center housed within a medical office building. Patient care areas consist of four exam rooms, with a separate operating suite containing a single OR with adjacent recovery room and a utility room with a sink and two autoclaves. These areas are shared by three physicians: the plastic surgeon who operated on all seven case patients (Surgeon A), a dermatologist who uses the exam rooms and occasionally also does procedures in the OR, and a second plastic surgeon who performs only a few surgeries per month at this facility. All three physicians hold active medical licenses in the state of California. The surgical team for each of the seven cases consisted of Surgeon A, an anesthesiologist, scrub tech, and circulating nurse; the recovery room was staffed by a different nurse than that in the OR. The four office Registered Nurses (RN) each held a current RN License issued by the California Board of Registered Nurses. The scrub tech also held a current surgical technologist certificate issued by the National Board of Surgical Technology and Surgical Assisting.

ACDC reviewed the office's infection control policies and procedures manual, employee training log, nursing staff meeting minutes, quality improvement studies, and infection control log maintained by the supervising RN.

The facility was overall clean and orderly, but several infection control deficiencies were observed in the patient examination rooms, including:

- opened single-use medication vials

- undated, opened sterile water and sterile saline bottles
- expired multi-use medication vials
- multi-use medication vials without a written open-date, and
- drawers containing syringes pre-filled with medication with no labeling of the syringe contents, expiration dates, or medication dosages.

In the operating room, the following infection control deficiencies were observed:

- opened, single-use vial of lidocaine
- expired, unopened multi-use Marcaine™ vials
- can/bottle opener used to remove medication vial cap and rubber stopper prior to pouring contents into sterile bowl, and
- microwave used to warm sterile saline and irrigation solutions used during surgery.

On October 26, 2011, ACDC staff returned for additional medical record review. A secondary augmentation surgery was also observed during this visit. The following infection control deficiencies were observed.

- During surgery the circulating nurse opened a sterile Marcaine™ vial by completely removing the vial top (including both the rubber stopper and glass vial neck) with a common household bottle opener, then poured the vial contents into a sterile bowl. The OR staff stated this was their standard procedure for Marcaine™ preparation.
- Sterile saline bags for infusion and sterile saline bottles for irrigation were heated in a microwave located just outside the OR that was dedicated to heating OR solutions only. A review of staff meeting documents found that prior to January 2011, the kitchen microwave used for heating of food was also used to heat the OR solutions.
- Movement of personnel in OR was not kept to a minimum (circulator nurse walked in and out of OR on a cell phone).

In addition, irrigation solution was mixed in bulk at the start of surgery, but exact volumes used during surgery and location of irrigation administration (e.g., left breast or right breast) were not recorded in the medical record. Exact dose of Marcaine™ administered and location administered was also not documented in the medical record.

Fourteen environmental specimens, including the bottle opener used to open medication vials, were collected during the October 26, 2011 visit and submitted to LAC PHL for culture. Recommendations for rectifying infection control breaches were discussed verbally that day and also in writing in a follow-up email.

ACDC visited Facility A on November 4, 2011, with an LAC DPH Environmental Health (EH) Industrial Hygienist for air flow testing, medical record review, and case finding. Seventeen environmental samples were collected and submitted to CDC for testing. Autoclave records including biologic monitoring were reviewed dating back to December 2010; no system deficiencies were noted during this time period.

ACDC returned to Facility A on November 9, 2012, in response to the report of the two additional cases. Medical records of the case patients were reviewed, in addition to inspection of the exam rooms, OR, and utility room where the autoclave and sterilizer are located. On November 13, 2012, ACDC observed a secondary breast augmentation surgery. Overall, the clinic was very clean and had implemented the recommendations provided during the site visits approximately one year prior, except for the observation of opened single-dose vials in patient exam rooms.

Steam exhausted from the autoclave during a cycle was observed accumulating in the utility room which is located directly across from the OR door. The exhaust fan is not always turned on in the utility room. Condensation of steam was also noted on the lower shelf items when the autoclave water was being drained into a basin placed on a step stool and on the upper shelf items during the autoclave cycle, when steam is continually exhausted directly above the autoclave.

In the OR, the staff were observed to use correct aseptic technique in the transferring of medication from a vial to a sterile field in the preparation of irrigation solution. The use of a cabinet with temperature controls specifically designed for warming irrigation and intravenous fluids was observed in the OR and the microwave used for heating up solutions during the site visits in October and November 2011 was removed.

ENVIRONMENTAL HEALTH INSPECTION

Air flow testing conducted by an LAC DPH EH Industrial Hygienist during the November 4, 2011, visit suggested that there was suboptimal air circulation in the OR. Specific findings included:

- placement of supply and return air registers in the OR were too close in proximity to each other, resulting in stagnant air over the operating table; this was confirmed via smoke tubes, which demonstrated that air in the OR tended to remain suspended over the operating table
- low air flow at both the supply and return air registers in the OR, based on smoke tube testing, and
- no positive- or negative-pressure air flow in the OR, as demonstrated by smoke tube testing, also suggesting stagnant air in the OR.

The Industrial Hygienist returned to Facility A on November 28, 2011, to conduct microbiologic air sampling of the OR, utility room, and OR suite hallway with a standard Andersen sampler. During this visit the air flow in the OR had improved and the room was now under positive pressure. The Industrial Hygienist felt that under ideal conditions, an OR should have high-efficiency particulate air (HEPA)-filtered air supplied at the ceiling and exhausted near the floor, which was not observed in the OR at Facility A. However, in light of the negative microbiologic results suggesting contaminated air was not likely to be the source of patient infections, Industrial Hygiene did not ultimately feel that an improved air supply within the OR was absolutely necessary.

LABORATORY TESTING

PFGE of *M. fortuitum* isolates from the two case-patients who underwent surgery in June and August 2011, respectively, was indistinguishable suggesting that their *M. fortuitum* isolates may have originated from a common source. The *M. fortuitum* isolates from the two case-patients who underwent surgery in June and July 2012 were also submitted to the CDC for PFGE testing. Their patterns are indistinguishable from each other and also from the two 2011 (June and August) cases previously tested by PFGE.

All environmental and office personnel samples collected throughout the investigation were *M. fortuitum* culture-negative, except for a swab taken on November 13, 2012, from inside the aquarium in the medical office located directly above the surgery suite. Growth from this swab was identified as *M. fortuitum*; an isolate was subsequently sent to the CDC for PFGE to compare its relatedness to the four case-patient isolates. The final result of the aquarium isolate indicated no relation to the four case-patients based on standard PFGE interpretation criteria (Figure C).

FIGURE C. CDC PFGE testing of four case-patient and aquarium *M. fortuitum* isolates.



Additionally, ACDC learned that a specimen from the building HVAC system that was submitted to an outside laboratory independent of our investigation was AFB positive by culture. The specimen was forwarded to the LAC DPH PHL for further testing; *M. chelonae* was identified by HPLC.

Environmental samples collected by Facility A staff and tested at an outside laboratory prior to ACDC's investigation included water from the autoclave and OR sink, an air vent in the OR, swabs from the utility and OR sinks, a plastic basin believed to have been used for instrument cleaning, skin swabs of several staff members, and water collected from a staff member's home swimming pool. ACDC reviewed all microbiologic results: with the exception of *M. chelonae* isolated from water from the OR (scrub) sink, all testing from the surgery suite and office in Facility A was negative for RGM species.

RECOMMENDATIONS

1. Continue to immediately notify LAC DPH of any new cases of post-operative infections with acid-fast bacilli (AFB) or culture-confirmed mycobacteria.
2. Discontinue use of the can/bottle opener. Ensure strict use of aseptic technique in the transferring of medication from a vial to the sterile field in the operating room. The medication vial cap and rubber stopper should not be removed from vials for the purpose of pouring medication as the edge of the vial can become contaminated. Sterile transfer devices should be used to dispense medications to the sterile field; alternatively, the medication should be drawn from the vial into a sterile syringe with the use of a sterile needle.
3. Infusions and irrigation solutions should not be heated in microwave ovens. Temperatures cannot be controlled in a finite way in microwave ovens and therefore medical products are subjected to uncontrolled conditions. Not only is product degradation a concern but so is degradation of the container. An appropriate temperature controlled fluid warming cabinet should be used, which Facility A has now obtained. Follow the manufacturer's recommendations for the appropriate temperature for solution warming.
4. Single dose (single-use) medication vials or bottles of solution should be used for only one patient then discarded. The safest practice is to enter a single-dose or single-use vial only once so as to prevent inadvertent contamination of the vial and infection transmission. Single-dose or single-use vials should be used for a single patient for a single case/procedure/injection.
5. Label all pre-filled medication syringes with the name of the medication, date filled, concentration and dosage of the medication, and expiration date.
6. Date multi-dose vials when they are first opened and then discard within 28 days unless the manufacturer specifies a different (shorter or longer) date for that opened vial. *Note: This is different from the expiration date printed on the vial.*
7. Discard expired medication vials.
8. Keep accurate documentation in the peri-operative notes regarding amount of medications and irrigation solutions administered to the patient and the location site given.
9. Ensure training of staff in infection control practices and routinely review staff's use of proper aseptic technique.
10. Work with the building management to prevent further leaks from the aquarium located above Facility A and fix any pipes that have leaked into any office space.
11. Keep the exhaust fan in the utility room turned on at all times. Minimize traffic in the hallway between the utility room and the OR, and minimize opening the OR door when surgery is in progress. Minimize traffic in and out of the OR during surgery
12. Change patient surgical skin preparation in the operating room to iodine-based formulations, such as providone-iodine (unless contraindicated), rather than a chlorhexidine-based product, such as Chloraprep®. Iodine-and alcohol-based compounds are more reliably mycobactericidal than chlorhexadine.
13. Discontinue home laundering of OR attire. Use a facility-approved and monitored commercial healthcare laundry company, which abides by Occupational Safety and Health Administration and CDC guidelines to ensure OR attire are free from microbial contaminants. Follow the standards developed by the Association of Surgical Technologists regarding OR attire and laundering (10).
14. Discontinue practice of wearing OR attire (e.g., scrubs) outside the surgical area, When leaving the OR area, remove and dispose of shoe/hair covering.
15. Hair coverings in the OR should cover facial hair, sideburns, and the nape for the neck.
16. Remove the items stored in storage bins on the shelves located directly underneath the autoclave and on the shelf above the autoclave.

CONCLUSIONS

In summary, a total of seven case-patients were identified at Facility A with *M. fortuitum* surgical site infections following breast or abdominoplasty surgery performed between December 2010 and July 2012. Of the seven cases, isolates were available for four patients, surgery in June 2011, August 2011, August 2012, and October 2012, respectively. These isolates were submitted to the CDC for PFGE, which indicated that these four case-patient isolates were indistinguishable from each other, despite nearly one year between the two clusters, suggesting that these infections originated from a common exposure.

RGM are ubiquitous environmental organisms that can be readily isolated from soil and water, and the recovery of *M. chelonae* and *M. mucogenicum* from several water-associated specimens collected during this investigation underscores this. However, RGM are not typical skin flora; soft tissue infections by these organisms are typically associated with trauma and/or a foreign material breaching the integrity of the skin. The common source was most likely an environmental source at Facility A, as the likelihood of infection with the same genetically-indistinguishable organism by exposure to water/soil at home or in another setting not held in common by four cases is extremely low. The ubiquitous nature of RGM highlights the importance of strict adherence to appropriate sterilization procedures and aseptic technique at all stages of an invasive procedure.

REFERENCES

1. Wallace RJ et al. Nosocomial outbreaks/pseudooutbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol. 1998;52:453-90.
2. Clegg HW, Foster MT, Sanders Jr WE, et al. Infection due to organisms of the Mycobacterium fortuitum complex after augmentation mammaplasty: Clinical and epidemiologic features J Infect Dis 1983: 147:427-33.
3. Padoveze MC, Fortaleza CM, Freire MP, et al. Outbreak of surgical infection caused by non-tuberculous mycobacteria in breast implants in Brazil J Hosp Infect 2007 67:161-7.
4. Furuya EY, Paez A, Srinivasan A, et al. Outbreak of Mycobacterium abscessus wound infections among "lipotourists" from the United States who underwent abdominoplasty in the Dominican Republic Clin Infect Dis 2008 46:1181-8.
5. Safranek TJ et al. Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution. N Engl J Med. 1987 Jul 23;317(4):197-201.
6. Meyers H, Brown-Elliott B, Moore D, et al. An Outbreak of Mycobacterium chelonae Infection Following Liposuction Clin Infect Dis 2002; 34:1500-7.
7. De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006 42:1756-62.
8. Rahav G et al. An outbreak of Mycobacterium jacuzzii infection following insertion of breast implants. Clin Infect Dis. 2006 Oct 1;43(7):823-30. Epub 2006 Aug 28.
9. Macadam SA et al. Nontuberculous mycobacterial breast implant infections. Plast Reconstr Surg. 2007 Jan;119(1):337-44.
10. Association of Surgical Technologist, AST Recommended Standards of Practice for Laundering of Scrub Attire, April 13, 2008
http://www.ast.org/pdf/Standards_of_Practice/RSOP_Laundering_Scrub_Attire pdf

OUTBREAK INVESTIGATION OF VENTRICULOPERITONEAL SHUNT INFECTIONS AMONG NEUROSURGERY PATIENTS, LOS ANGELES 2012

Patricia Marquez, MPH; L'Tanya, RN, MPH; and Dawn Terashita, MD, MPH

BACKGROUND

Ventriculoperitoneal (VP) shunts are one of the main methods to treat hydrocephalus, either excess production or reduced drainage of cerebrospinal fluid (CSF), which can cause increased pressure against the brain and subsequent neurological issues. VP shunts drain the excess fluid from the brain through a catheter into the abdominal cavity where it is reabsorbed by the body. Infections related to VP shunt insertions and revisions occur in 5-27% of patients, and most often are caused by *Staphylococcus epidermidis (S. epidermidis)* and *S. aureus*.[1,2] Risk factors for infection include premature birth, prolonged hospital stay, previous shunt infection and the conversion of an external ventricular drain to a VP shunt.[3] Many of these infections are hypothesized to be caused by the patient's own skin flora, as organisms such as staphylococci produce a biofilm that adheres to the inside of the shunt tubing.[3]

In March 2012, the infection preventionist (IP) of Hospital A notified the Los Angeles County Department of Public Health (LAC DPH) Acute Communicable Disease Control (ACDC) of four patients with *S. aureus* infections related to their recent VP shunt surgery; three were CSF infections and one a wound infection. All patients had a VP shunt placement (1) or revision (3) prior to positive culture, and all surgical procedures were performed by Surgeon A. An investigation was initiated to identify additional patients, determine the source of infection, and prevent additional cases.

METHODS

A case was defined as a patient post VP shunt surgery (insertion or revision) who was CSF or surgical wound culture positive with any staphylococcal species between January 1, 2012 and May 30, 2012. Infection control staff was instructed to notify ACDC of any new patient meeting the case definition throughout the investigation.

ACDC conducted a comprehensive review of case medical records, including clinical, surgical and microbiologic records. The monthly neurosurgery unit's *S. aureus* background rate, as well as the monthly count of neurosurgeon-specific *S. aureus* infections from January-December 2011 were reviewed. In addition ACDC requested a monthly log of total procedures and VP shunt procedures performed in operating room (OR) 7, the main room for VP shunt surgeries, from October 2011-March 2012.

ACDC staff made multiple site visits to examine the hospital environment and obtain additional information. All available case isolates were sent to the LAC Public Health Laboratory (PHL) for pulsed field gel electrophoresis (PFGE) testing.

RESULTS

A total of seven patients met the case definition. Four cases were culture positive for *S. aureus*, two cases had *S. epidermidis*, and one case was *S. hominis* positive. Two cases were female. Ages ranged from two months to 18 years, with a median age of three years. All cases had complex underlying medical problems. Three cases had multiple shunt revisions since birth and four cases had first-time shunt insertions. There were no deaths.

Background Surveillance

From January 2011 to December 2011 the monthly rate of patients in the neurosurgical unit positive with *S. aureus* at any site ranged from 4.42 to 22.1 per 1000 patient days; the CSF *S. aureus* infection rate in this same unit ranged from 0 to 1.12 per 1000 patient days during the same time period. Only two surgeons, Surgeon A and Surgeon B, perform VP shunt procedures in Facility A. Surgeon A performed

57% (n=100) of all VP shunt procedures during the background period; two CSF infections occurred in these patients, with a mean monthly infection rate of 2.0 infections per 100 procedures (range 0.0 - 12.5 infections per 100 procedures). Surgeon B performed 43% (n=74) of VP shunt procedures; none of Surgeon B's patients experienced any CSF infections during the same time period.

Epidemiologic Analysis

The main OR nursing note, brief operative note, the OR floor plan, staffing roster and related documents were reviewed for all cases. All cases received single dose pre-operative, weight-dependent antibiotic prophylaxis with vancomycin whether the procedure was elective or emergent. Six cases had their VP shunt surgery performed in OR 7; this OR is also used for other neurosurgical procedures. The seventh case had surgery performed in OR 1.

The OR 7 procedure count from October 2011 to March 2012 was reviewed; VP shunt surgeries account for nearly a quarter of total procedures performed (range 17-28%). Per communications with facility IPs, increases in infections from other procedures performed in this OR were not noted.

The operative record for each case was reviewed to identify common OR surgical staff, including the attending neurosurgeon, neurosurgery fellows and residents, anesthesiologist, nurses and scrub technicians. All cases had VP shunt surgery performed by the same neurosurgeon; however, the neurosurgery fellow, neurosurgery resident, anesthesiologist and other surgical staff varied in each procedure. The pooled mean VP shunt procedure infection rate for Surgeon A during the outbreak period January - May 2012 was 16.9 per 100 procedures (monthly range 7.7 – 30 per 100 procedures).

Molecular Epidemiology

PFGE was performed by the LAC PHL on three available *S. aureus* isolates and two *S. epidermidis* isolates. The three outbreak isolates of *S. aureus* had greater than seven band differences and were considered unrelated. The two *S. epidermidis* outbreak isolates also differed by greater than seven bands and were considered unrelated. PFGE was not performed on the single *S. hominis* isolate.

Surgical Procedure Review

A surgical practice shared by both neurosurgeons, and performed for over 15 years in the facility, is the use of a dilute iodine tincture solution to flush the shunt valve and ventricular and peritoneal catheters prior to insertion; gloved hands are also submerged into the iodine tincture solution. The solution is also used to irrigate the cranial incision prior to suture at the end of the procedure. No other neurosurgeons follow this practice at Facility A.

Site Investigation

ACDC conducted multiple site investigations during the outbreak. On April 30, 2012, we observed a VP shunt surgery performed by Surgeon A. The surgical team was double-gloved throughout the procedure and no lapses in infection control practice were identified. Hair clipping was performed by the neurosurgery resident in the prep room prior to surgery and surgical skin preparation was performed by the neurosurgery resident or fellow and supervised by the attending neurosurgeon. Interviews with Surgeon A, the neurosurgery fellow, the neurosurgery resident and the OR charge nurse were also conducted. No deficiencies were noted.

Control Measures

Upon identification of the cluster the facility notified DPH, the neurosurgical team, and the chief infectious disease physician. Facility neurosurgery staff described their infection control measures, which exceeded standards of practice in similar facilities. Most infection control measures were implemented prior to the outbreak. Ongoing measures included administration of prophylactic vancomycin to all surgical patients, the use of DuraPrep™ for skin preparation prior to surgical incision, hair clipping performed in the OR

immediately prior to surgery, double gloving of all surgical team members, double hat (bouffant and hood) for surgeons and limiting OR traffic during surgery.

DISCUSSION

Review of the literature denotes VP shunt infection rates of 5%-27%; the background rate of VP shunt infection among Surgeon A's patients prior to the outbreak period was lower, with a mean rate of infection of 2.0 per 100 procedures (monthly range 0 to 12.5 infections per 100 procedures).[1,4] ACDC analysis of the VP shunt infections in Facility A from January 2011 to April 2012 indicates that all CSF infections that occurred in this time period were in Surgeon A's patients. Surgeon A's mean infection rate during the five month outbreak period was 16.9 per 100 procedures, slightly higher than the national rates reported in the literature.

Relevant infection control policies/procedures were reviewed and determined to be within community standards of practice. The facility is compliant with the 1999 Centers for Disease Control and Prevention and the Hospital Infection Control Practices Advisory Committee's Guideline for Prevention of Surgical Site Infection (e.g., hair clipping, antibiotic prophylaxis, antimicrobial sutures and double-gloving). We were told that two cases had large volumes of CSF which could affect the patient's response to the antibiotic prophylaxis at the time of surgery.

There was no apparent point-source for the outbreak, as *S. epidermidis* and *S. aureus* are frequently identified in shunt infections and usually originate from the patient's own skin flora. DNA fingerprinting of available isolates by PFGE indicated that all were unrelated.

All infections during and prior to this outbreak occurred in Surgeon A's patients; none occurred in Surgeon B's patients. We were unable to conclusively determine the route of infection in these seven cases. However, the epidemiologic investigation identified Surgeon A as the only link between the seven cases. During the investigation it was revealed that a dilute iodine tincture solution was regularly used to flush sterile implantable medical devices and catheters prior to insertion, a practice conducted by both surgeons over 15 years and implemented purportedly to decrease the patient's risk of infection after surgery. This practice is an off-label and an unapproved use of the product. Although it is unlikely that the use of iodine tincture during surgery was the cause of the outbreak, DPH recommended all neurosurgeons in Facility A discontinue the practice and to strictly adhere to the manufacturer's recommendations and guidelines for shunt preparation before insertion.

REFERENCES

1. McGirt MJ, Zaas A, Fuchs HE, et al. Risk Factors for Pediatric Ventriculoperitoneal Shunt Infection and Predictors of Infectious Pathogens. CID. 2003; 36:858–62.
2. Wang KW, Chang WN, Shih TY, et al. Infection of Cerebral Spinal Fluid Shunts: Causative Pathogens, Clinical Features and Outcomes. Jpn J. Infect. Dis. 2004;57:44-48.
3. Stevens NT, Greene CM, O'Gara JP, et al. Ventriculoperitoneal shunt-related infections caused by *Staphylococcus epidermidis*: pathogenesis and implications for treatment. Br J of Neurosurg. 2012;26(6):792-797.
4. Hayashi T, Shirane R, Yokosawa M, et al. Efficacy of Intraoperative Irrigation with Saline for Preventing Shunt Infection. J Neurosurg Pediatrics. 2010;6:273-76.

OUTBREAK OF INFECTIONS CAUSED BY *SHIGELLA SONNEI* WITH DECREASED SUSCEPTIBILITY TO AZITHROMYCIN

Roshan Reporter, MD, MPH and Marifi Pulido, PhD

SUMMARY

In May 2012, the Los Angeles County Department of Public Health's (LAC DPH) Acute Communicable Disease Control Unit (ACDC) and Environmental Health Services (EHS), Food and Milk Program (F&M), investigated an outbreak of shigellosis associated with a private bridge club. This investigation documented the first known outbreak-transmitted *Shigella sonnei* with decreased susceptibility to azithromycin in the United States (US).

BACKGROUND

On Tuesday, May 29, 2012, LAC DPH received a web-based foodborne illness report (FBIR) stating that all eight people who ate a lunch buffet at a bridge club where they attend daily bridge classes and/or tournaments became ill with diarrhea, vomiting, nausea, stomach cramps, fever, and headache. The initial exposure was believed to have occurred on May 22nd; the food was prepared by club staff. ACDC initiated an epidemiological investigation to determine the extent of the outbreak, risk factors for the disease, and steps needed to prevent further infections.

METHODS

ACDC requested line lists of club attendees and staff then developed two separate questionnaires. Questionnaires were administered to attendees and staff who were present during the classes and/or tournaments from May 21-26, 2012. Attendees were interviewed by telephone. Some club staff members were interviewed by telephone while others self-administered the questionnaire.

F&M contacted the complainant to obtain additional information on food and drinks eaten at the bridge club. F&M conducted a facility inspection of the bridge club in question on Tuesday, May 29, 2012. On June 5, 2012, a second visit was made by both F&M and ACDC staff to ensure compliance with recommendations.

An outbreak-associated case was defined as a person eating or drinking anything at the bridge club during the week of May 22 - 26, 2012 and were: 1) a laboratory confirmed case of *Shigella sonnei*, 2) had diarrhea (three or more loose stools in a 24 hour period) with fever, or 3) had diarrhea with at least two of the following symptoms: bloody diarrhea, fever, abdominal cramps, body aches, fatigue, dizziness, nausea, headache, and chills. An outbreak-associated control was defined as a person eating or drinking anything during the same time period who did not become ill.

Stool samples were collected by ACDC and LAC DPH Community Health Services (CHS) from employees and members with clinical symptoms for testing in the LAC DPH Public Health Laboratory (PHL).

ACDC calculated frequency and distribution of symptoms among cases. An analysis of foods eaten by cases and controls was also performed. All analyses were conducted using SAS 9.2 statistical analysis software.

RESULTS

Setting

The bridge club in question convenes in a facility that has three rooms and separate bathrooms for men and women. The room that functioned as the “kitchen” contained a sink and a refrigerator. The space is only for bridge club members, except for the occasional chess club meeting on Sundays. Food is not

supplied for the chess club. The club employs a total of 15 staff (2 co-owners, 11 teachers, 2 food handlers). There are about 100 to 130 bridge club members who attend either bridge classes and/or open play that were held Monday through Saturday (May 22-26, 2012). Members play bridge in two separate rooms. The larger of the two rooms is for more seasoned players and can accommodate up to 100 members per day. Daily classes are offered in the smaller of the two rooms and accommodate up to 30 members.

A small luncheon buffet is included as part of the club fees and is provided daily to attendees and as well as employees. The food is prepared in the "kitchen" at the facility. The daily menu for the week in question included egg salad, tuna salad, cut fresh vegetables (celery, cucumbers, carrots, and tomatoes), bagels, sliced bread, coffee, and hot tea. No cold beverages were served.

ACDC Investigation

ACDC attempted to contact all staff present during the week in question for interviews (n=13); two teachers who were not present were not interviewed. Of the 13, only one employee (teacher) did not return calls from ACDC for interview. The teachers that ACDC interviewed are part-time bridge instructors who teach at least one or two sessions a week. Of the two food handlers interviewed, one is employed full time and the other works on Fridays only. The two co-owners interviewed are present at the facility a majority of the time. Employees reported no illness prior to, or during the classes and/or tournaments. All staff were interviewed by EHS and initially denied any recent GI illness. Neither of the two food handlers present during the week in question reported illness. One of the co-owners reported symptoms after a second interview was conducted by a CHS public health nurse. CHS collected stool specimens on a total of nine staff members for testing by PHL.

ACDC called all club members in attendance May 21-26, 2013. Two line lists were obtained: one by F&M (members participating in events taking place in the larger room) and one by ACDC (participants of the small room events). The list obtained by ACDC required a personal trip to the bridge club as they were initially unwilling to provide the information. According to the lists, 108 members were in attendance; ACDC was able to interview 103 of them (95%).

Cases

There were a total of 43 cases (one case was reported after the investigation was completed and therefore not included in the analysis). Of these 43 cases, 14 had positive *Shigella* lab cultures. Four of the confirmed cases were reported to ACDC by a healthcare provider and found to be associated with the bridge club by CHS. The remainder of the cases (10 confirmed and 29 presumptive cases) were identified through the interviews.

Slightly more than half the cases were female (55%) and had an average age of 75.3 years (range 54-98 years) (Table 1). Symptoms reported by cases included diarrhea (95%), abdominal cramps (71%), and fever (57%) (Table 2). The average duration of illness was 5.9 days (range 1-14 days). The average incubation period from the lunch (Tuesday, May 22, 12 pm) was 49.6 hours (range 9-101 hours). Illness onsets occurred from Thursday, May 24, 2012 to Saturday, May 26, 2012 (Figure 1).

Table 1. Case Demographics (N=42)

	n	Percent
Gender		
Male	19	45%
Female	23	55%
Age Group		
1-4	0	0%
5-19	0	0%
20-49	0	0%
50-59	1	2%

60-69	8	19%
70-79	19	45%
80-89	11	26%
90-99	3	7%
Mean Age	**Median Age**	**Range**
75.3 years	75 years	54-98 years

Table 2. Reported Symptoms (N=42)

Symptom	n	Percent
Diarrhea	40	95%
Bloody Diarrhea	4	10%
Abdominal cramps	30	71%
Fatigue	29	69%
Nausea	26	62%
Chills	24	57%
Fever	24	57%
Fever > 102˚F	5	12%
Body Aches	18	43%
Dizziness	17	40%
Headache	16	38%
Vomiting	14	33%
Tingling	0	0%
Rash	0	0%
Medical Care	23	55%
Duration (days)*		
Mean = 5.9	Median = 6	Range (1-14)
Incubation (hrs)**		
Mean = 49.6	Median = 48	Range (9-101)

* Based on 35 cases

** Based on 36 cases



*Onset dates and/or times for seven cases were not provided; three cases only provided onset date, four cases did not provide either onset date or onset time.

Food Analysis

All food served at the event was prepared by a bridge club employee. The results of the cohort analysis of food items eaten at the bridge club are shown in Table 3. Consuming any cut vegetables (tomatoes, celery, carrots, and cucumbers) was associated with illness (relative risk [RR] = 3.07, confidence interval [CI]: 1.53 to 3.60), with a food specific attack rate of 67%. All cases ate at least one of these vegetable items. These cut vegetables were also individually associated with illness. Vegetables that were not cut, such as pickles and olives, were not associated with illness. Consuming the egg salad at this event was also associated with illness (RR=1.94, CI: 1.15 to 3.21) with a food specific attack rate of 66%, as was the tuna salad (RR = 1.65, CI: 1.01 to 2.28) with a food specific attack rate of 57%.

Table 3. Food-Specific Attack Rate

	Ate/drank				Did not eat /drink						
	Ill	Not Ill	Total	Attack Rate (%)	Ill	Not Ill	Total	Attack Rate (%)	Difference in rates	Relative Risk	95% Confidence
Food Item	(a)	(b)	(a+b)	(a/a+b x 100)	(c)	(d)	(c+d)	(c/c+d x 100)	(a/a+b)-(c/c+d)	(a/a+b)/(c/c+d)	Interval
Bagels	9	4	13	69%	33	48	81	41%	28	1.70	0.9298 -11.5196
Cream Cheese	1	4	5	20%	41	48	89	46%	-26	0.43	0.4178 - 1.0878
Potato Chips	10	7	17	59%	32	45	77	42%	17	1.42	0.7800 - 2.5824
Crackers	15	16	31	48%	27	36	63	43%	6	1.13	0.7404 - 1.6556
Cookies	12	7	19	63%	30	45	75	40%	23	1.58	0.6876 - 2.1669
Peanut Butter	13	8	21	62%	29	44	73	40%	22	1.56	0.8893 - 2.8150
Jelly	2	1	3	67%	40	51	91	44%	23	1.52	0.3359 - 8.4165
Onion Dip	1	5	6	17%	41	47	88	47%	-30	0.36	0.4264 - 0.9634
Salsa	1	1	2	50%	41	51	92	45%	5	1.12	0.2740 - 4.4868
Egg Salad	21	11	32	66%	21	41	62	34%	32	1.94	1.1543 - 3.2052
Tuna Salad	24	18	42	57%	18	34	52	35%	23	1.65	1.0213 - 2.2790
Bread	7	2	9	78%	35	50	85	41%	37	1.89	0.7698 - 9.1027
Canned Fruit	8	7	15	53%	34	45	79	43%	10	1.24	0.6876 - 2.1669
Cut Vegetables (Tomato, Celery, Cucumber, Carrots)	32	16	48	67%	10	36	46	22%	45	3.07	1.5302 - 3.6023
Tomatoes	18	9	27	67%	24	43	67	36%	31	1.86	1.0969 - 3.3796
Celery	14	9	23	61%	28	43	71	39%	21	1.54	0.8991 - 2.6644
Cucumber	18	9	27	67%	24	43	67	36%	31	1.86	1.0969 - 3.3796
Carrots	19	12	31	61%	23	40	63	37%	25	1.68	1.0140 - 2.6531
Pickles	9	7	16	56%	33	45	78	42%	14	1.33	0.7330 - 2.3722
Olives	8	5	13	62%	34	47	81	42%	20	1.47	0.7402 - 3.0751
Milk	1	0	1	100%	41	52	93	44%	56	2.27	-
Water	12	9	21	57%	30	43	73	41%	16	1.39	0.8092 - 2.3344
Iced Tea	5	8	13	38%	37		44	84%	-46	0.46	0.5496 - 1.4176
Coffee	10	12	22	45%	32	40	72	44%	1	1.02	0.6600 - 1.5717

Bridge Club Inspection

On Tuesday, May 29, F&M conducted an inspection of the bridge club and kitchen facility. This facility had no public health permit for preparing food and the health inspector ordered that all food preparation cease. All non-packaged food that was available to patrons at the time of inspection was discarded. The health inspector identified numerous health code violations, finding several food items held at unsafe temperatures (i.e., egg salad, tuna salad, tomatoes, onion dip, and cream cheese). The health inspector recommended that any food served to attendees be limited to pre-packaged food items. Also identified were building and safety violations pertaining to an employee (food handler) living and sleeping in

quarters within the facility without partitioning. An administrative office hearing was held on May 31, 2012, to discuss health code violations, legal consequences, and results of findings. A second joint visit was made on June 5, 2012, by F&M and ACDC staff to ensure compliance with all recommendations for food storage and preparation. During this second inspection the preparation of coffee and tea by club staff was observed and stopped. The co-owners were instructed to serve only pre-packaged items and to purchase pre-brewed coffee.

Laboratory Results

Among the 43 cases, 14 were culture-confirmed as *Shigella sonnei*. Four of eight employees tested were positive for *S. sonnei* (one co-owner, two teachers, and one food handler). Ten isolates underwent pulsed-field gel electrophoresis (PFGE), all yielding an indistinguishable pattern. CDC's PulseNet national surveillance network identified two additional isolates indistinguishable from the outbreak PFGE pattern. One was from a 23-year-old man in Pennsylvania who had visited Los Angeles in April. The other isolate was from a 53-year-old man in Hawaii who visited Los Angeles during April and May. Both men were hospitalized with diarrhea. Neither case was epidemiologically linked to the bridge club or to each other.

Four isolates submitted to CDC's National Antimicrobial Resistance Monitoring System (NARMS) displayed resistance to streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. Unlike most *Shigella* isolates tested by NARMS, these isolates also showed elevated azithromycin minimum inhibitory concentrations (MIC) of >16 μg/mL[1] and harbored a plasmid-encoded macrolide resistance gene, *mphA*.[2]

DISCUSSION

A common source outbreak of *Shigella sonnei* occurred among persons eating, playing bridge, and utilizing the bathroom facilities at the bridge club over a period of one week (May 22-26, 2012). Laboratory testing of bridge club members and staff confirmed the etiology of this outbreak as *Shigella* and symptoms and duration of reported cases are consistent with shigellosis.[3] The median incubation time of 48 hours is consistent with a common source exposure occurring at the bridge club on May 22. The incubation period for shigellosis in humans is usually between 24 and 72 hours.[3]

ACDC's investigation identified a food handler at the bridge club who tested positive for *Shigella sonnei* with the outbreak PFGE pattern. This food handler was involved in the preparation of the egg salad and cut vegetables which were food items statistically significantly associated with illness in the cohort food analysis. These food items require considerable hand manipulation and are food items that were the apparent source of this outbreak.

Shigella has a human reservoir and can be found in the stool of infected individuals. Transmission occurs from ingestion of the bacteria, either by direct person-to-person contact or via food or drink contamination. Food may become contaminated by an infected food handler when there is a lack of good hygiene, such as practicing proper hand washing technique or having long, dirty fingernails.[4]

Although sporadic cases of shigellosis caused by *Shigella* strains with increased azithromycin MICs have been reported in the US, this is the first such outbreak documented in the US and might indicate increasing circulation of such strains.[1] Illnesses in this outbreak tended to be severe; however, the affected population was much older than the general US population. Clinical management of such illnesses in children is likely to be complex; although azithromycin currently is recommended for treatment of infections caused by multidrug-resistant *Shigella,* options for alternative treatment for children with such infections primarily include parenteral antimicrobial medications.[5,6]

Guidelines for azithromycin susceptibility testing and criteria for interpretation of MICs for *Shigella* species have not been published. Clinicians are urged to report azithromycin treatment failure among shigellosis patients to public health authorities and to retain *Shigella* isolates from such cases for further analysis.

PREVENTION

F&M and CHS distributed information about the control of shigellosis to the co-owner of the bridge club establishment along with specific recommendations, including frequent and vigorous hand-washing, and the exclusion of infected persons from handling food and being on the premises until they were demonstrated to be free of *Shigella* by LAC DPH. During the investigation, members and staff of the bridge club were interviewed via telephone and were educated regarding the practice of good hand washing technique. A Public Health Investigator was involved in the removal of the employee in a sensitive occupation (food handler) who was confirmed with *Shigella sonnei*. CHS provided educational material about the control of *Shigella* to this employee and initiated the clearance process.

LIMITATIONS

The possibility of recall bias of persons interviewed limited the usefulness of the results. There was also a lack of cooperation from some club staff regarding the submission of stool collection to identify additional cases.

CONCLUSIONS

An outbreak of *Shigella sonnei* occurred among members and staff of a bridge club in May 2012. The symptoms and duration reported by cases were consistent with *Shigella* infection and the PHL confirmed this etiology. The outbreak was likely due to an employee who reported asymptomatic *Shigella* infection and worked as a food handler at the bridge club. This employee most likely contaminated multiple food items, including the egg salad and vegetables. There were no other reports of illness from persons attending this facility and it appeared that public health control efforts limited the outbreak to a one week period.

REFERENCES

1. Howie RL, Folster JP, Bowen A, Barzilay EJ, Whichard JM. Reduced azithromycin susceptibility in *Shigella sonnei*, United States. *Microb Drug Resist.* Dec 2010;16(4):245-248.

2. Karlsson MS, Bowen A, Reporter R, et al. Outbreak of infections caused by *Shigella sonnei* with reduced susceptibility to azithromycin in the United States. *Antimicrob Agents Chemother.* Mar 2013;57(3):1559-1560.

3. Heymann DL, American Public Health Association. *Control of communicable diseases manual*. 19th ed. Washington, DC: American Public Health Association; 2008.

4. Centers for Disease Control and Prevention. Shigellosis. 2013; http://www.cdc.gov/nczved/divisions/dfbmd/diseases/shigellosis/.

5. American Academy of Pediatrics. *Shigella*. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. *Red Book: 2012 Report of the Committee on Infectious Diseases*. 29th ed2012:645-647.

6. World Health Organization. *Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1*. Geneva: World Health Organization; 2005. Available at http://www.who.int/cholera/publications/shigellosis/en/

Staphylococcus epidermidis Outbreak Associated With a Cardio-Thoracic Surgeon With Dermatitis on The Hands

Lorraine Sisneros, RN, PHN, MSN/MPH; L'Tanya English, RN, MPH; and Dawn Terashita, MD, MPH

BACKGROUND

Hospital associated infections have been documented in the literature as being associated with increased morbidity and mortality. Patients hospitalized in the intensive care unit (ICU) and those undergoing cardiac surgery are among those at greatest risk of such infections[1], this is especially true in prosthetic valve replacement surgeries where infections occur postoperatively in 5% to 34% of cases. *Staphylococcus (S) epidermidis*, a common skin colonizer, is a predominant organism isolated in post cardiac valve related surgeries.[2]

On October 1, 2012, the infectious disease (ID) physician and infection preventionist (IP) from Hospital A notified the Los Angeles County (LAC) Department of Public Health (DPH), Acute Communicable Disease Control Program (ACDC) of five cases of *S. epidermidis* infections post-cardiac valve surgery; four with endocarditis and one pacemaker lead infection. All cases had aortic valve replacement surgery between January and May 2012. Three cases were identified in June 2012, and two cases were identified in September 2012. All cases were discharged home after surgery and required readmission. Four of the five patients required a second surgery as a result of the endocarditis. All cases had the same cardio-thoracic (CT) surgeons, Surgeon A, who was training at the facility during the outbreak period and had contact dermatitis on the hands and Surgeon B who was primary surgeon for each case. Surgeon A performed approximately 100 valve replacement surgeries from September 2011 through June 2012. On completion of the training in June 2012, Surgeon A started a job at another hospital in LAC (Hospital B).
This report describes an outbreak investigation of *S. epidermidis* infections among patients who underwent cardiac valve replacement surgery at Hospital A, measures taken to enhance patient safety, and collaborations between DPH and Hospitals A and B.

METHODS

Case Definition
A case was defined as a patient who was *S. epidermidis* culture positive between February 1, 2012 and August 31, 2012 post cardiac surgery.

Case Characterization

ACDC staff conducted a comprehensive review of case medical records, including surgical and microbiological records.

Surgeon Evaluations

The primary surgeon (Surgeon B) and surgeon in training (Surgeon A) for each case were interviewed by the facility. Cultures were obtained by the facility of Surgeon A's axilla, nares, and hands. Cultures of the hands and nares of Surgeon B were also obtained by the facility.

Microbiological Analysis

We reviewed culture reports and sensitivity patterns for the five patient cases and Surgeon A.

Molecular strain testing by polymerase chain reaction (PCR) was performed by the facility on four available S. *epidermidis* positive blood isolates, surgeon A's isolate, and one S. *epidermidis* positive control (background) isolate. One case had a S. *epidermidis* positive aortic root culture. This isolate had been discarded and was not available for genetic testing.

Background Surveillance

On June 15, 2012, the facility initiated a retrospective review of all surgical site infection (SSI) surveillance in valve surgeries from September 2011 to June 2012. On September 23, 2012 upon identification of two additional cases, this review was then expanded to include any SSI post coronary artery bypass graft with both chest and donor site incisions (CBGB) and all other cardiac surgeries from January 2011 to July 2012.

Control Measures
The facility implemented control measures upon identification of the outbreak.

Hospital B

On October 3, 2012, ACDC contacted Hospital B to discuss the concerns/issues surrounding Surgeon A.

RESULTS

Case Definition
Five patients met the case definition.

Case Characterization

All cases were male between the ages of 55 to 88 years, with a mean age of 69 years. All cases had multiple complex medical problems with significant comorbidities, including diabetes, hypertension, renal insufficiency and chronic obstructive pulmonary disease. Four cases had a second surgery subsequent to their *S. epidermidis* infection.

Surgeon Evaluations
Surgeon A reported having a rash to his hands since November 2011 that was being treated with topical ointments. Surgeon A was S. *epidermidis* culture positive from the axilla, nares and hands. Surgeon A also reported a change in the type of gloves used in surgery since January 2012 and noted a change in gloving procedure during surgery, switching from double-gloves use to single-glove use. Surgeon B reported no skin impairments. Surgeon B's cultures were negative for *S. epidermidis*.

Microbiological Analysis

All cases were S. *epidermidis* culture positive. Sensitivity patterns of two cases matched those of Surgeon A. Sensitivity patterns differed among the rest of the cases. All four patient cases and Surgeon A isolates were indistinguishable by polymerase chain reaction (PCR), indicating a common source.

Background Surveillance

Upon look-back from January 2011, 62 patients were identified as having Surgeon A as one of their surgeons. No additional cases were identified.

Control Measures

Hospital A performed a review of operating room protocols as it relates to infection control, reinforced staff hand hygiene principles, and revised the facility's policy/guidelines for glove use during implant surgery. Double gloving protocol was reinstated in late April 2012. Antibiotic prophylaxis was changed from cefazolin to vancomycin as this strain was resistant to cefazolin.

Surgeon A was advised not to perform any additional operations until hands were healed completely. Infection control operating room policies were reviewed. In October 2012, notification of the 62 identified exposed patients was initiated by CT surgeons. A call center staffed by registered nurse practitioners was established to handle follow-up calls. The facility also conducted cardiology assessments of all exposed

cases for signs and symptoms of endocarditis, echocardiogram for baseline assessments of all exposed, and follow-up surveillance for 12 months post-surgery. Hospital A contacted Hospital B, where Surgeon A was now employed, and notified the hospital epidemiologist of the outbreak.

Hospital B

Upon evaluation of Surgeon A's hands, Hospital B determined it was safe for Surgeon A to perform surgical procedures with the following restrictions: 1) report any recurrence of dermatitis immediately and cease surgical procedures, 2) double-glove for all procedures, and 3) change to new double-gloves during specified periods of the surgical procedures. Additionally, Hospital B will conduct enhanced surveillance of all surgeries performed by Surgeon A for one year.

DISCUSSION

This report describes an investigation of a cluster of *S. epidermidis* infections post cardiac valve replacement surgery. S. *epidermidis* is a gram positive bacterium that is a common skin commensal; primarily colonized from the axillae, head, and nares. Bacterial contamination of the surgical site by skin flora occurs in a high proportion of open heart surgeries. S. *epidermidis* is the predominant organism isolated in post cardiac valve related surgeries and has a high probability of device contamination.[3,4] Other sources of coagulase negative Staphylococcus (CNS) surgical site infections have been attributed to the hands of healthcare workers.

The epidemiologic data supports the hypothesis that transmission likely occurred during surgery with Surgeon A as the source. Prior to their infection, all five cases had exposure during surgery to Surgeon A while he had infection on his hands. Additionally, there was the change in protocol, from double gloving to single gloving. Genetic testing done on Surgeon A's isolate substantiated this hypothesis; all four patient isolates genetically matched Surgeon A's isolate and the sensitivity patterns of two patient cases identically matching the sensitivity patterns of Surgeon A. Hospital A suggested contamination may have occurred due to nicks and tears of the surgical gloves that may have occurred due to the types of suturing and knots that are used in cardiac surgery. Hospital A conducted their own informal glove study and found nicks and tears in surgical gloves. The literature suggests that perforated gloves may play a role in contamination of the surgical site. Microscopic tears in gloves occur in 6%-20% of operative procedures; however, this greatly increases in cardiac surgery due to irregularity of the sternal edges and the frequency in which wire sutures are used. [5,6] One study measured the rate of glove breakage immediately after open heart surgery and found that holes were identified in 39% of gloves post-operatively. The rate was increased when gloves that were changed during the surgical procedure were tested, increasing the glove breakage rate to 48%.[6]

Dermatitis among healthcare workers is well documented in the literature. However, there are very few reports that directly link outbreaks of *S. epidermidis* to individual carriers. One report described a cluster of four positive cases of CNS post cardiac surgery, where the surgeon was found to be the source of contamination, presumably contaminating the surgical site via accidental puncture of gloves.[7] Another report indicated the surgical resident in a cluster of patients who developed CNS SSIs post cardiac surgery, during which the surgical resident had dermatitis to his hands and was a carrier of the epidemic strain that caused the majority of infections during the outbreak.[4]

In summary, ACDC investigated an outbreak of *S. epidermidis* infections post cardiac valve replacement surgery at a local hospital. After control measures were implemented, no further cases were identified at either hospital A or B.

REFERENCES

1. Michalopoulos, A., Geroulanos, S., Rosmarakis, E., Falagas M. Frequency, characteristics, and predictors of microbiologically documented nosocomial infections after cardiac surgery. European Journal of Cardio-thoracic Surgery 2006;456-460.

2. Lomas, J.M., Martinez-MarcosF.J., Ivanova, R., Galvez, J., Reguera, J.M., Noureddine, M., De la Torre, J., De Alarcon, A. Healthcare-associated infective endocarditis: an undesireable effect of healthcare universalization. Clinical Microbiological and Infectious Diseases 2010;16:1683-1690.
3. Otto, M. Staphylococcus *epidermidis*–the "accidental" pathogen. Nature Reviews Microbiology 2009;7(8):555-567.
4. Lark, R.L., VanderHyde, K., Deeb, M., Dietrich, S., Massey, J.P., Chenoweth, C. An outbreak of coagulase-negative staphylococcal surgical-site infections following aortic valve replacement. Infection Control and Hospital Epidemiology 2001;22(10):618-623.
5. Boyce, J.M., Potter-Bynoe, G., Opal, Steven M., Dziobek, L., Medeiros, A.A. A common-source outbreak of *Staphylococcus epidermidis* infections among patients undergoing cardiac surgery. The Journal of Infectious Diseases 1990;161:493-499.
6. Eklund, A.M., Ojajarvi, J., Laitinen, K., Valtonen, M., Werkkala, K.A. Glove punctures and postoperative skin flora of hands in cardiac surgery. The Annals of Thoracic Surgery 2002; 74:149-153.

   Van Den Broek, PJ., Lampe, A.S., Berbee, G.A.M., Thompson, J., Mouton, R.P. Epidemic of prosthetic valve endocarditis caused by *Staphylococcus epidermidis*. British Medical Journal 1985;291:949-950.

POSSIBLE ASPERGILLOSIS OUTBREAK IN A BONE MARROW TRANSPLANT UNIT: HIGHLIGHTING THE DIFFICULTY OF INTERPRETING NON-CULTURE LABORATORY TECHNIQUES

L'Tanya English, RN, MPH; Patricia Marquez, MPH; and Dawn Terashita, MD, MPH

BACKGROUND

Invasive aspergillosis (IA) causes significant morbidity and mortality in post-bone marrow transplant (BMT) and other immunocompromised people. According to Weber and Peppercorn, et al., "Invasive *Aspergillus* infections have been reported in 2-26% of hematopoietic stem cell transplant (HSCT) recipients and in 1-15% of solid organ transplant recipients…mortality rate has ranged from 74-92%."[1]
A non-invasive assay to detect circulating galactomannan (GM) in serum or bronchoalveolar lavage (BAL) fluid became available in the United States in May 2003. GM is a cell wall polysaccharide released by *Aspergillus* species (spp.) during fungal growth in tissue. Circulating GM may be detected at a median of five to eight days before clinical manifestation of aspergillosis.[2, 3]

In September 2012, Hospital A notified Los Angeles County (LAC) Department of Public Health (DPH) Acute Communicable Disease Control Program (ACDC) of nine patients with blood specimens positive for GM *Aspergillus* antigen. All patients were hospitalized in the bone marrow transplant (BMT) unit, had a BMT during their current or a recent admission, and were GM positive between September 3, 2012 and September 11, 2012.

Prior to this cluster, three patients were GM positive in June 2012 (two blood specimens, one BAL). The hospital infection preventionist initiated enhanced surveillance and GM testing on all patients in the unit increased by 160%, going from an average of 19 GM tests per month from January 2010–May 2012 to an average of 48 GM tests per month from June–September 2012. On September 3, 2012, six patients, including one patient who was GM BAL positive in June 2012, converted from a negative GM value to markedly high positive GM values. Four additional newly positive patients were identified between September 7, 2012 and September 11, 2012, resulting in a total of 10 newly positive patients (83% GM positive) in September 2012.

This report describes the investigation of a GM antigen positive cluster among patients on a BMT unit, the process used to identify *Aspergillus* infection in this medically complex population and efforts made to categorize the cluster as an outbreak or pseudo-outbreak.

METHODS

A case was defined as a patient in the BMT unit who had a BMT procedure in the current or previous admission and who had a newly positive blood or BAL GM test, with or without symptoms, from June 1, 2012 to September 30, 2012. Criteria developed by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group[4] were used to categorize and define invasive fungal disease (IFD) in immunocompromised patients with cancer and hematopoietic stem cell transplant patients. A comprehensive review of case clinical, laboratory, pharmacy, nutrition and related data was conducted. Case medical history questionnaires prepared by a BMT clinician were also reviewed.

An analysis of all patients who were tested for GM hospital-wide from August 15, 2012 - September 11, 2012 was conducted to identify medications or other administered items that might cross-react with the Bio-Rad Platelia™ *Aspergillus* Ag EIA test (Platelia). Case BMT schedules were reviewed for conditioning agents (chemotherapy medications and/or radiation treatments) that are used to eliminate the patient's existing bone marrow to prepare for transplantation that may cross-react with the GM test and may interfere with test.

Hospital A conducted routine water sampling in BMT patient rooms for random surveillance. The sampling schedule varied and two rooms were sampled every few weeks on a rotating basis. Tap water was collected from March through August 2012 and the samples were tested for fungus. Public health staff collected 25 water and swab samples from three case rooms. The samples were cultured by the LAC public health laboratory for fungus only. Details of construction were reviewed.

Multiple control measures were implemented and included an environmental investigation and enhanced environmental cleaning. Initial environmental sampling was conducted in June, July and August 2012 by outside environmental consultants. Air and surface samples from the BMT unit work areas, nurses' stations and the air handling system were tested. In October 2012, comprehensive air and surface sampling of all BMT patient rooms, staff work areas, public areas (e.g., family lounge, restrooms) and other targeted locations throughout the facility was conducted to obtain baseline air quality data. The investigation included multiple site investigations and phone consultations to discuss the status and provide interim management recommendations. ACDC consulted with the manufacturer of the Platelia *Aspergillus* Antigen kit, Bio-Rad, regarding any changes in the kit or similar complaints.

RESULTS

Twelve patients met the case definition. There were eight males. All cases were immunocompromised with an underlying hematological and/or genetic disorder (e.g., leukemia, severe combined immunodeficiency). Ten cases had a BMT procedure during their current admission and two cases had a BMT procedure during their previous hospitalization. Case age ranged from 6 months to 17 years, with a mean age of 7 years. There were no obvious commonalities among the cases. The number of days from admission to first positive GM test ranged from 3 to 164 days, with a mean of 58 days.

Ten cases were GM positive ≥7 days after admission and considered healthcare-associated possible aspergillosis infections (HAI). Two cases were not considered HAI; one case was symptomatic on admission with a history of chronic cough for seven months and was GM BAL positive seven days after admission. This case subsequently had three negative GM values prior to becoming GM seropositive in September. The second case had a BMT in March 2012, was discharged and re-admitted in September 2012 for a second procedure and was GM positive three days after admission.

Five cases (42%) experienced respiratory symptoms during their hospitalization. Six cases (50%) had radiographic changes consistent with fungal infection. Four cases (33%) had neither clinical symptoms nor radiographic changes and were considered by the BMT clinician to have *Aspergillus* infection that was treated early.

ACDC used criteria developed by the EORTC/MSG to categorize and define invasive fungal disease (IFD) in immunocompromised patients with cancer and hematopoietic stem cell transplant patients. The categories are "proven", "probable" and "possible" IFD, and each category has specific requirements. Proven requires tissue culture and identification. Probable IFD requires a host factor, clinical features and mycological evidence. Possible IFD requires host factors with clinical evidence consistent with IFD but for which there was no mycological support. Based on these classifications, ACDC designated four cases as probable aspergillosis and eight cases as possible aspergillosis. There were no proven aspergillosis cases.

The facility used the Bio-Rad Platelia™ *Aspergillus* Ag EIA test kit (Platelia) to test all case specimens for GM. The assay is a non-invasive test for early detection of aspergillosis before clinical signs and symptoms begin and used in conjunction with other diagnostic techniques, such as computed tomography (CT) scan.

All cases were *Aspergillus* antigen GM blood and/or BAL positive at least once during their hospitalization, and ten cases were GM blood positive multiple times throughout the surveillance period, from June 1 through November 30, 2012 (Figure 1).

Figure 1. Galactomannan Case Results, June-November 2012



Weekly GM testing was conducted on most BMT patients beginning in July or August 2012. During a two week period in September 2012, case GM levels ranged from 0.63 to 8.15. Six cases had three consecutive high GM positive levels; among all the cases identified after September 3, 2012 there was an average of seven positive GM tests per case (range 1-14). Blood specimens collected on September 5, 2012, for the six patients who were GM high positive on September 3rd were sent to an outside laboratory for confirmation. The outside laboratory used the same GM test as the hospital laboratory, and all were confirmed. Nine cases had a fluctuating high/low pattern, as tested by the Hospital A laboratory, after their highest GM value which is not uncommon.

During the outbreak period, 47 patients, including the BMT patients, were tested using the GM assay hospital-wide, of which 13 were GM positive. GM positive patients were more likely to be BMT cases (10 of 15 patients, 67%) than GM negative patients (6 of 32 patients, 9%). In addition, the positive GM test values of the non-BMT patients were not as high as the BMT unit positive patients, with the highest value at 3.18, compared to a high value of 8.15 among the BMT patients. Case antifungal prophylactic medication dosages were increased to treatment doses and a second or third antifungal was ordered for many cases upon identification of the positive GM assay. Review of medications showed that all BMT unit patients during this review period were on either prophylactic or treatment doses of mold-active antifungals and at least one antimicrobial, compared to only seven (22%) of the non-BMT unit GM positive patients. None of the conditioning agents were found to cross-react. The Platelia test kit was current, and there were no changes in hospital laboratory procedure that may have indicated these were false positive tests.

Major construction was ongoing at Hospital A for several years prior to the cluster. Construction on a new building was completed in 2010 and patients, including those on the BMT unit, were moved into the new structure in July 2011. Construction of a pedestrian bridge crossing to the other side of the street near the main hospital entrance, visible from the windows of the west side of the BMT unit, began in January 2011 and was ongoing at the time of the outbreak. Patients, staff and visitors passed by the construction area to access the main entrance. Shoe covers were mandatory for anyone entering the unit. Environmental cleaning was enhanced in all patient rooms and the cleaning frequency of the BMT common areas increased from once a day to three times a day during the outbreak period.

Initial environmental sampling on the BMT unit was conducted in June, July and August 2012 and showed a few fungal colonies, e.g., *Cladosporium cladosporioides*, *Phyllosticta maydis* and *Penicillium oxalicum*. No *Aspergillus* was found. Comprehensive air and surface sampling was conducted over six

consecutive days to obtain baseline air quality data. *Aspergillus* species were recovered in ten BMT rooms, mostly in small amounts; *A. fumigatus* was recovered on a surface sample on the window blinds of one room. A variety of other common environmental fungal organisms were found in the rooms, such as penicillium species, *Paecilomyces lilacinus* and *Cladosporium* species.

Random sampling of tap water in BMT patient rooms was conducted from March through August 2012. None of the samples were positive for *Aspergillus*. DPH EH staff collected 24 water and swab samples. All were negative for fungal growth with the exception of a showerhead swab which was positive for *Paecilomyces lilacinus*.

Six cases expired, five cases while hospitalized and one case after discharge home. The death certificate and/or death summary or final progress note was reviewed. Invasive aspergillosis (IA) was listed among the causes of death on the death certificates for two cases. IA infection was documented on the final progress report for one case. IA was also listed as contributing to the cause of death for a third case. Two of the six cases who expired were among the cases with the highest GM levels. An autopsy was not performed on any of the cases due to parental declination secondary to religious or personal reasons.

DISCUSSION

This was a complex investigation that involved a GM antigen positive cluster with all cases testing positive by blood or BAL assay and none confirmed by specimen culture or histology. There were two distinct GM positive clusters, the first cluster occurred in June 2012 and the second cluster occurred in September 2012. *Aspergillus* species are fungi commonly found in the environment. Certain species, especially *A. fumigatus* and *A. flavus,* frequently cause disease in immunocompromised individuals. In the acute care hospital setting, aspergillosis clusters are frequently discovered after construction, demolition or renovation activities. Transmission is not person-to-person but by direct inhalation of spores or direct contact with wound or skin. According to Pfeiffer and Fine, et al., "IA occurs in 8%-15% of patients undergoing allogeneic stem cell transplantation…despite advances, IA is associated with considerable morbidity and mortality, ranging from 30% to 70% in transplant recipients." [5]

Aspergillus infection in immunocompromised patients is difficult to identify due to subtle symptom changes in patients. Review of the literature shows that the definition of *Aspergillus* infection has been inconsistent among clinicians and researchers alike and is dependent on many factors, such as the patient's clinical condition and x-ray changes. As stated by DePauw, et al., "These revised definitions…are intended to advance clinical and epidemiological research and, as such, may serve as a useful model for defining other infections in high-risk patients. The definitions are not meant to be used to guide clinical practice."[4]

The Platelia assay is a non-invasive test used for the early detection of aspergillosis before clinical signs and symptoms begin. Early detection is significant in this patient population, as invasive procedures such as tissue culture or biopsy are not tolerated well due to their immunocompromised status. A GM test result of <0.5 is interpreted as negative and a GM test result of >0.5 is interpreted as positive. Test specificity varies depending on multiple factors, including patient population, antibiotic treatment and food products consumed. A negative test does not rule out an aspergillosis diagnosis, and, conversely, a positive result may not indicate aspergillosis infection.[6] The literature notes that many common food items (cereals, cow's milk, pepper, peanut butter, popcorn), antibiotics (piperacillin/tazobactam, ampicillin-sulbactam and amoxicillin-clavulanic acid) and fungal organisms (*Penicillium* species, *Paecilomyces lilacinus* [*P. lilacinus*]) may cross-react with GM, creating a false-positive result. [3, 7, 8]

ACDC analyzed available case GM levels from June through November 2012. Weekly, or more frequent, GM testing began in July and August for all BMT patients. On September 3, 2012, GM levels spiked for six cases then decreased sharply within a few days. After September 3, 2012 case GM levels fluctuated. All cases were placed on antifungal prophylaxis upon admission per protocol; after the positive GM result all cases were started on aspergillosis treatment with the addition of a second or third antifungal and/or initiation of a treatment dose, which may be an indication of partially-treated disease as they were continuously on prophylaxis or therapeutic doses of antifungals.[7]

Air sampling conducted on the unit in October 2012 was to provide a baseline sample. Testing did not reveal an obvious mold reservoir and there was no obvious evidence of environmental contamination. *Penicillium* species and *P. lilacinus* were found in small amounts, and both cross-react with the Platelia test. *Aspergillus* species such as *A. fumigatus, A. brasiliensis* and *A. flavus* were found in ten BMT rooms in small amounts. These organisms do not typically cause illness in immunocompetent people but may be the cause of significant morbidity and/or mortality in immunocompromised persons. As noted by Vonberg and Gastmeier "...any *Aspergillus* species in air samples from special care areas should raise concern of invasive infection…even concentrations of airborne *Aspergillus* spores below 1 CFU/m^3 have been shown to be sufficient to cause outbreaks in immunocompromised patients."[9]

Several Hospital A physicians believed that this cluster was a pseudo-outbreak based on a number of factors, including 1) six GM tests were positive on the same day, 2) there was a rapid decline of GM positive to GM negative in the blood levels, 3) many of the blood levels were very high and the patient's clinical condition did not match the GM level and 4) there was no evidence of an environmental source based on routine and enhanced environmental testing. These concerns are valid and the possibility of a pseudo-outbreak cannot be excluded, since there was no culture or biopsy from a sterile site to confirm the diagnosis.

Conversely, there were significant reasons to suggest that an outbreak occurred. Specimens from the six cases who were GM positive on September 3, 2012, were sent to an outside laboratory and confirmed positive. Additionally, five cases had respiratory symptoms, six cases had x-ray changes and four cases had documentation of *Aspergillus* infection in the medical record. IA was listed among the causes of death on the death certificate for two cases and as a contributing factor for another case. Lastly, four cases were considered to possibly have had an *Aspergillus* infection that was treated early by the BMT physicians.

Non-culture based diagnostic methods for mycotic infections have evolved to include PCR and GM antigen detection in patient serology.[10] The lack of confirmatory identification of the suspected disease-causing organism places the burden of diagnosis on documentation of corresponding symptomatology in tested patients. In this investigation the highly positive GM tests did not decisively diagnose aspergillosis due to the difficulty determining if case symptoms were due to fungal infection or a by-product of their underlying illnesses.

We were unable to conclusively determine that this was a true aspergillosis outbreak. Review of the literature shows that pseudo-outbreaks of aspergillosis have been reported, frequently due to specimen contamination; however, the Platelia test kit was within the expiration date and there were no changes in the laboratory test procedure or problems reported. After comprehensive analysis of all the evidence, the most likely hypothesis is that the cases in this GM cluster were exposed to a source in the environment that caused the cluster of positive GM tests, and the probable source was *Aspergillus.* No additional GM clusters were identified after September 2012.

REFERENCES

1. Weber, D, Peppercorn, A and Miller, M, et. al., Preventing Healthcare-Associated Aspergillus Infections: Review of Recent CDC/HICPAC Recommendations*, Medical Mycology* 2009, 47 (Supplement 1) S199-S209.

2. Sulahian, A, Boutboul F, Ribaud P, et al. Value of Antigen Detection Using an Enzyme Immunoassay in the Diagnosis and Prediction of Invasive Aspergillosis in Two Adult and Pediatric Hematology Units during a 4-Year Prospective Study. Cancer 2001;91: 311-318.

3. Pasqualotto, A and Denning, D,, Diagnosis of Invasive Fungal Infections – Current Limitations of Classical and New Diagnostic Methods, Business Briefing: European Oncology Review, 2005.

4. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 June 15; 46(12): 1813–1821. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671227/, accessed May 29, 2013.

5. Pfeiffer, C, Fine, J and Safdar, N Diagnosis of Invasive Aspergillosis Using a Galactomannan Assay: A Meta-Analysis, Clinical Infectious Diseases, 2006;42:1417-27.

6. Bio-Rad Laboratories Platelia™ Aspergillus Ag, 96 Tests- 62794, IVD, package insert , code: 881051;03/2011.

7. Steinbach, A, McLaughlin, L, et al. Prospective Aspergillus Galactomannan Antigen Testing in Pediatric Hematopoietic Stem Cell Transplant Recipients. Pediatr Infect Dis J. 2007;26:558-564.

8. Morrissey, C, Chen, S, Sorrell, T., et al. Galactomannan and PCR Versus Culture and Histology for directing Use of Antifungal Treatment for Invasive Aspergillosis in High-Risk Haematology Patients? A Randomised Controlled Trial. Lancet Infect Dis 2013; 13: 519-28.

9. Vonberg, R-P and Gastmeier, P, Nosocomial Aspergillosis in Outbreak Settings, Journal of Hospital Infection, 2006 63, 246-254. Available online at www.sciencedirect.com.
10. Reiss, E, Obayashi T, et al. Non-culture based diagnostic tests for mycotic infections. Med Mycol, 2000;38:147-59.

KNOWLEDGE OF PUBLIC HEALTH CONTACTS FOR EMERGENT OR URGENT COMMUNICABLE DISEASE SITUATIONS IN LOCAL EMERGENCY DEPARTMENTS

Laura Coelho; Sharon Sakamoto, RN, MSN/MPH; Alison Itano, MPH;
Y. Silvia Shin, RN, PHN, MSN/MPH; and Dawn Terashita, MD, MPH

BACKGROUND

Timely disease reporting to local Public Health Departments is essential to prevent and control outbreaks and ensure rapid responses to public health emergencies and urgent communicable disease situations. The emergency department (ED) is often the first health care contact for a patient exposed to an emerging pathogen or agent of bioterrorism. In fact, a survey of 11 hospital EDs in the District of Columbia suggested that "reporting is most complete if it is controlled by emergency department administration and integrated into the department's routine quality assurance activities."[1]

Recently, physicians on call from the Los Angeles County (LAC) Department of Public Health's (DPH) Acute Communicable Disease Control Program (ACDC) noticed a considerable number of misdirected calls received from local EDs, particularly after normal business hours. For example, EDs called the Centers for Disease Control and Prevention (CDC) or the California Department of Public Health (CDPH) to report or request consultation on infectious disease situations, instead of LAC DPH. This concerned ACDC because these calls had to be directed back to LAC DPH and potentially delayed the response to public health emergencies or urgent communicable disease situations.

To increase EDs' awareness of local public health contacts, ACDC's Hospital Outreach Unit (HOU) created and distributed the *Frequently Called Directory for Communicable Diseases,* a single-page document listing important local public health references and telephone numbers. Between August and November 2012, all hospital infection preventionists (IPs) were sent the document through email and in-person communications with instructions to provide it to ED staff. The HOU worked with ACDC's Planning and Evaluation Unit (PEU) to develop a method to evaluate whether local EDs know to call LAC DPH in public health emergencies or urgent communicable disease situations after the distribution of the *Frequently Called Directory for Communicable Diseases*. In November 2012, the Units implemented a test call strategy for the evaluation and then conducted follow-up interviews with selected EDs between February and May 2013.

METHODS

To assess whether local EDs know to call LAC DPH in public health emergencies or urgent communicable disease situations, the HOU and PEU conducted test calls to all 72 EDs in LAC during the month of November 2012. The EDs in the cities of Long Beach and Pasadena were excluded as they function within their own independent local Public Health Departments. The test call strategy was to interview two different ED staff members by telephone, ideally a member of the ED's clerical staff and a member of the ED's clinical staff. Each ED staff member interviewed was asked the following questions in a standardized telephone survey:

- What is your role in the Emergency Department?
- If a patient with a public health emergency or urgent situation presents to your Emergency Department during or after normal business hours, for example with suspect botulism or meningococcal infection, do you know who to call outside your hospital/externally to report the disease or to seek consultation?
    - If yes, who would you call? Please provide name and telephone number of person and organization.

At the end of each call, the final interviewee was offered an additional copy of the *Frequently Called Directory for Communicable Diseases*. Both ED staff members interviewed were reminded to contact LAC DPH for disease reporting and consultation, particularly for public health emergencies or urgent communicable disease situations, both during and after normal business hours. Length of interviews ranged from two to three minutes.

After analyzing results from the test calls, the HOU and PEU developed a follow-up questionnaire and conducted fifteen minute interviews with ED management at ten EDs in LAC to learn more about ED staff knowledge of LAC DPH, internal processes for reporting, and methods for information distribution among ED staff. EDs where interviews were conducted were chosen based on test call results and availability of ED management.

RESULTS

ED Test Calls

Response Rate

The test call response rate was 100% with all 72 EDs in LAC participating with at least one member of the ED staff. Response rates are summarized in Table 1. The response rate was 85% with a total of 61 responses from the first ED staff member interviewed, designated as "Interviewee 1" in the tables, and 97% with a total of 70 responses from the second ED staff member interviewed, designated as "Interviewee 2" in the tables.

Table 1: Hospital ED Response Rates (N=72)*

	Interviewee 1		Interviewee 2		Interviewee 1 or 2	
	n	%	n	%	n	%
Responded	61	85%	70	97%	72	100%
Unavailable	9	13%	2	3%		
Refused	2	3%				

Respondent Characteristics

Respondent roles are summarized in Graph 1 and Graph 2. Interviewee 1 respondents were categorized as clerk/secretary (70%), nurse (13%), supervisor/manager/director (6%), ER technician (5%), ER assistant (2%), ER registration (2%), and ER coordinator (2%). Interviewee 2 respondents were categorized as charge nurse (77%), nurse (14%), supervisor/manager/director (7%), and Patient Care Coordinator (PCC) (2%).





*Percentages in tables and graphs may add up to greater than 100% due to rounding.

Table 2: Characteristics of hospitals where ED staff were interviewed (N=72)			
Characteristics	**Mean**	**Median**	**Range**
Bed Capacity	293	262	12-958
Average Daily Census	179	150	10-775
Number of beds in ED	22	19	2-63
Number of hospital IPs	2	2	1-10
Teaching (Count)	16		

Descriptive characteristics about the hospitals obtained by the HOU from hospital IPs are summarized in Table 2. Interviewed hospitals had a median bed capacity of 262 (mean: 179; range: 10-775), median average daily census of 150 (mean: 179; range: 10-775), median number of beds in the ED of 19 (mean: 22; range 2-63), and between one to ten IPs (mean: 2; median: 2). Sixteen hospitals were teaching institutions.

Findings

Among the 131 ED staff members interviewed, 57% (n=75) responded "yes" to knowing who to call to report a disease or to seek consultation (Table 3). Parsing out by interviewee groups, 48% of interviewee 1 respondents and 66% of interviewee 2 respondents indicated knowing who to call.

Table 3: ED staff responses to question: ***Do you know who to call outside your hospital/externally to report the disease or to seek consultation?***						
Response	**All Respondents (N=131)**		**Interviewee 1 (N=61)**		**Interviewee 2 (N=70)**	
	n	**%**	**n**	**%**	**n**	**%**
Yes	75	57%	29	48%	46	66%
No	56	43%	32	52%	24	34%

Among the 75 ED staff members who indicated they knew who to call to report a disease or seek consultation (Table 3), 43% (n=32) specifically indicated the local Public Health Department (Table 4). Looking by interviewee groups, 38% of interviewee 1 respondents and 46% of interviewee 2 respondents specifically indicated the local Public Health Department. Thirty-six percent (n=26) of all EDs had at least one interviewee indicate the local Public Health Department. Three interviewee 1 respondents and three interviewee 2 respondents, together representing five different EDs, provided specific, accurate LAC DPH telephone numbers as well.

Table 4: Responses of who to call in public health emergencies or urgent situations*				
	Interviewee 1 (N=29)		**Interviewee 2 (N=46)**	
Responses	**n**	**%**	**n**	**%**
Local Public Health Department[±]	11	38%	21	46%
Hospital infectious disease doctor, IP, or unit	8	28%	7	15%
Reference hospital binder, list, poster or form	5	17%	6	13%
Consultation with another member of the ED staff	3	10%	2	4%
Centers for Disease Control & Prevention (CDC)	2	7%	3	7%
Other[×]			3	7%
Unable to specify			4	9%

[±]Local Public Health Department includes the following responses: LAC DPH, DPH, Department of Health Services (DHS), Department of Health, Local Public Health, Public Health, and County

[×]Other includes Medical Alert Center (MAC), Department of Mental Health (DMH), and Poison Control

[*]Percentages may add up to greater than 100% due to rounding

In Table 4, other responses of who to call in the case of a public health emergency or urgent situation included the hospital's infectious disease doctor, preventionist, or unit (Interviewee 1: 28%; Interviewee 2:

15%); reference to an internal binder, list, poster, or form (Interviewee 1: 17%; Interviewee 2: 13%); and consultation with another member of the ED staff (Interviewee 1: 10%; Interviewee 2: 4%). Seven percent of respondents from each interviewee group specified contacting the CDC and 7% of interviewee 2 respondents specified other external organizations, such as the Medical Alert Center (MAC), Department of Mental Health (DMH), and Poison Control. Another 9% of interviewee 2 respondents were unable to specify a person or organization to call in the case of a public health emergency or urgent situation after indicating "yes" to know who to call.

Eighty-eight percent (n=63) of all EDs requested an additional copy of the *Frequently Called Directory for Communicable Diseases* at the end of the interview.

There are no considerable differences in descriptive characteristics between hospitals with EDs where at least one interviewee indicated to call the local Public Health Department and hospitals with EDs that did not (Table 5).

Table 5: Characteristics of hospitals by EDs who knew to call the local Public Health Department in the case of a public health emergency or urgent situation

	Indicated local Public Health Department (N=26)			**NOT indicate local Public Health Department (N=46)**		
	Mean	**Median**	**Range**	**Mean**	**Median**	**Range**
Bed Capacity	269	234	12-603	307	264	76-958
Average Daily Census	160	148	10-472	189	160	25-775
Number of beds in ED	23	21	2-57	21	18	3-63
Number of hospital IPs	2	2	1-4	2	2	1-10
Teaching (%)	5 (19%)			11 (24%)		

ED Interviews

Respondent Characteristics

Ten EDs were asked to participate in follow-up interviews; however, only nine EDs agreed based on availability of hospital personnel. ACDC interviewed ED management at seven (78%) participating EDs. Management roles included ED Directors, ED Assistant Directors, ED Managers, and ED Nurse Managers. One interview was conducted with an ED Charge Nurse and one was conducted with the hospital IP alone. In seven (78%) of the nine interviews, the hospital IP was present.

Of participating EDs, five (56%) had at least one respondent indicate the local Public Health Department as who to call to report a disease or seek consultation during the test calls; three (33%) had respondents who indicated not knowing who to call outside the hospital/externally to report a disease or seek consultation; and one (11%) had at least one respondent indicate the hospital's infectious disease doctor, preventionist, or unit as who to call to report a disease or seek consultation during the test calls.

Findings

Among the nine interviewees, six (67%) indicated that ED staff contact LAC DPH, primarily to report diseases and seek consultation. Respondents specified reporting and seeking consultation for influenza, meningitis, tuberculosis, sexually transmitted diseases, smallpox, measles, and suspected outbreaks.
Five (56%) interviewees were familiar with ACDC and three of the five indicated they knew their HOU Liaison Public Health Nurse (LPHN) prior to their interview. All interviewees noted that ED staff and the hospital IP knew one another. Contact between ED staff and the hospital IP ranged from multiple times per day to an "as needed" basis. Four (44%) interviewees indicated contact between the ED and hospital

IP occurring once to multiple times per day, three (33%) indicated once to multiple times per month, one (11%) indicated multiple times per week, and one (11%) indicated as needed.

All nine EDs had a policy and/or procedure for reporting urgent communicable diseases after normal business hours. Six (67%) EDs kept written policies and/or procedures and three (33%) kept unwritten policies and/or procedures. All nine EDs' policies and/or procedures required contacting the hospital IP first, who may then advise ED staff to call LAC DPH. When asked who would be contacted if the hospital IP is unavailable, five (56%) interviewees indicated LAC DPH, one (11%) indicated CDC, and three (33%) provided no answer, stating that the hospital IP is always available. Among those who indicated contacting LAC DPH or CDC should the hospital IP be unavailable, interviewees specified that such contact would be initiated by a physician, charge nurse, or any registered or licensed vocational nurse.

When asked about methods for information dissemination, interviewees were presented with six methods and an "Other" option and asked to identify which methods were commonly used to reach all ED staff on all shifts. Two methods that multiple respondents indicated when choosing the other option were distributing or posting memos and shift huddles. Shift huddles occur at the beginning of each ED shift and involve all ED staff coming together to share announcements. Once methods were identified, interviewees were asked to rank each selected method on a scale from 1 to 5, with 1 being not effective and 5 being extremely effective. Results are summarized in Table 6.

Table 6: Methods and rankings for information dissemination to all ED staff on all shifts

Method	**Number of EDs**	**Average Ranking**
In-person in-service	8	4.5
Regular staff meetings	7	3.5
Email	7	3.6
Brochures	6	3.7
Training-of-Trainer Session(s)	5	3.8
Online video or webinar	3	3.7
Originated from Other Option		
Shift huddles	4	4.3
Distributing or posting memos	2	4.5

In-person in-service was the method of information dissemination most commonly used at participating EDs and also received the highest average ranking for effectiveness.

At the end of each interview, interviewees were asked to share how ACDC could help clarify the distinctions between CDC, CDPH, and LAC DPH for hospitals and EDs. Three interviewees suggested that a chart, defining each organization and their roles, which could be emailed or posted in EDs may be helpful; however, two interviewees said that additional information may be overwhelming. Instead, the latter two interviewees emphasized that establishing and fostering personal relationships with hospital IPs will be more helpful to clarify the distinctions between CDC, CDPH, and LAC DPH.

LIMITATIONS

While the test calls provide a snapshot of EDs' knowledge to call LAC DPH in the case of public health emergencies or urgent communicable disease situations, there are important limitations to note. ACDC spoke to a limited number of ED staff members from each hospital; therefore, the responses are not generalizable to all ED staff members or shifts within a single hospital or, more broadly, to EDs throughout LAC. Furthermore, due to the chaotic and demanding nature of EDs, test calls had to be very brief, which prohibited ACDC from asking meaningful follow-up questions when ED staff members specified contacting the hospital's infectious disease doctor, IP, or unit; referenced a hospital binder, list, poster, or form; or said that they would consult with another member of the ED staff. In each of these

scenarios, ACDC was unable to determine if these processes would eventually result in timely contact to LAC DPH. As such, ED staff stating an alternative process to calling the local Public Health Department does not clearly indicate whether or not EDs know to call LAC DPH in the case of a public health emergency or urgent communicable disease situation. Considering the HOU's close relationships with hospital IPs and previous outreach to EDs, it is likely the case that if given sufficient time during the test call, ED staff would know to call LAC DPH. Additionally, given that all test calls were conducted during normal business hours to accommodate ACDC staff work schedules, ED staff responses may have been influenced by the fact that during normal business hours internal personnel, such as hospital IPs, are more readily available. It may be the case that ED staff working after normal business hours knows to call LAC DPH more readily, as fewer internal personnel are available to consult. However, it may also be true that ED staff working after normal business hours would be less likely to know to LAC DPH possibly due to less experience with LAC DPH.

Similarly, an important limitation of the follow-up interviews is that only nine EDs were included. Therefore, responses, though informative, are not representative of all EDs throughout LAC.

DISCUSSION

Only a small percentage of respondents specified an inaccurate external Public Health agency, such as the CDC, to call in the case of a public health emergency or urgent communicable disease situation during the test calls. Although ACDC physicians on call observed a number of misdirected calls from local EDs, the information obtained from the test calls indicates that the likelihood for misdirected calls is low, but can be improved.

Considerable percentages of respondents from both interviewee groups from the test calls indicated an alternative process to contacting LAC DPH when asked to specify who to call external to their hospital to report a disease or seek consultation. These alternative processes included contacting the hospital's infectious disease doctor, IP, or unit; referencing a hospital binder, list, poster, or form; and consulting with another member of the ED staff. As noted in the Limitations Section, this does not necessarily mean that LAC DPH would not eventually be contacted, nor does it clearly indicate a lack of knowledge to call LAC DPH. In fact, the follow-up interviews suggest that alternative processes would likely result in contact to LAC DPH if needed. For example, contacting the hospital IP first, who then may advise ED staff to contact LAC DPH, was standard policy and/or procedure for urgent communicable disease situations at all EDs who received a follow-up interview.

The vast majority of interviewee 1 respondents were ED clerks and secretaries and the vast majority of interviewee 2 respondents were ED charge nurses in the test calls. A higher percentage of interviewee 2 respondents specified to call the local Public Health Department than interviewee 1 respondents and a higher percentage of interviewee 1 respondents specified an alternative process to contacting LAC DPH than interviewee 2 respondents. As such, it appears that charge nurses tend to know to call the local Public Health Department in the case of a public health emergency or urgent communicable disease situation more so than clerical staff. As made evident in the follow-up interviews, it may be the case that it is the responsibility of ED charge nurses to report diseases or seek consultation with Public Health, which could explain the differences between interviewee 1 and interviewee 2 specifications of who to call. Respondents to the follow-up interviews indicated that should LAC DPH be contacted, such contact would be initiated by a physician, charge nurse, or any registered or licensed vocational nurse, not clerical staff.

A high percentage of EDs requested an additional copy of the *Frequently Called Directory for Communicable Diseases* during the test calls. Potential explanations for this request may include: (1) The ED did not receive the directory from the hospital IP; (2) The ED received the directory, but the staff member interviewed was not aware of it; (3) The ED received it and the staff member asked was aware, but wanted an additional copy for the ED or themself. Based on the chaotic and demanding nature of EDs, it is likely the case that the first two explanations are applicable for many EDs. As such, it is imperative that ACDC identify appropriate and effective channels to disseminate information to hospitals to continue to outreach to ED staff. From the follow-up interviews it appears that establishing and

fostering personal relationships with hospital IPs and communicating with ED staff in-person can facilitate effective outreach and communication going forward.

CONCLUSION

The test calls and follow-up interviews garnered important information for internal program improvement at ACDC despite limitations. While ACDC found that a low percentage of EDs who indicated LAC DPH as the external Public Health organization to call in the case of a public health emergency or urgent communicable disease situation during the test calls, an even lower percentage of EDs indicated an inaccurate external Public Health organization. This demonstrates room for improvement in ED knowledge of LAC DPH, but at the same time reveals that the problem of misdirected calls by local EDs to LAC DPH is likely small. ACDC also learned that a deeper understanding of internal hospital contacts and processes for reporting diseases and seeking consultation as well as the appropriate channels of information dissemination are needed to prevent misdirected calls by local EDs in the future. The follow-up interviews helped ACDC to learn more about EDs' internal reporting processes and methods for information dissemination. Moving forward, ACDC will continue to build close personal relationships with hospital IPs through HOU LPHNs to facilitate effective outreach and communication to EDs.

REFERENCES

1. Kirsch, T and Shesser, R. A Survey of Emergency Department Communicable Disease Reporting Practices. *The Journal of Emergency Medicine*, Vol. 9, pp. 211-214, 1991.

MONITORING THE IMPACT OF HEAT WAVES WITH EMERGENCY SERVICE UTILIZATION DATA IN LOS ANGELES COUNTY, JANUARY 1, 2010 TO OCTOBER 15, 2012

Emily Kajita, MS, MPH, Patricia Araki, MPH, Monica Luarca, MPH, Bessie Hwang, MD, MPH

OBJECTIVE

To assess current indicators for situational awareness during heat waves derived from electronic emergency department (ED) and 911 emergency dispatch call (EDC) center data.

INTRODUCTION

Los Angeles County's (LAC) early event detection system captures over 60% of total emergency department (ED) visits, as well as 800 to 1,000 emergency dispatch center (EDC) calls from Los Angeles City Fire (LACF) daily. Both ED visits and EDC calls are classified into syndrome categories, and then analyzed for aberrations in count and spatial distribution. We describe how syndromic surveillance serves as an important near real-time, population-based instrument for measuring the impact of heat waves on emergency service utilization (ESU) in LAC.

METHODS

Daily electronic ED registration data, EDC calls, and maximum daily temperatures from Palmdale, California were queried from January 1, 2010 to October 15, 2012. A custom "heat exposure" category was created by searching ED chief complaints and diagnoses for key terms such as "heat stroke," "hyperthermia," "overheat," "heat rash" and relevant International Classification of Diseases (ICD) 9 diagnosis codes. Similarly, EDC calls were classified as related to heat exposure.

Pearson correlation tests were used to determine correlation between total ED visits, heat-related ED visits, heat-related EDC calls, and averaged maximum temperatures per Centers for Disease Control and Prevention (CDC) week. Counts were mapped for weeks in 2012 with the highest heat-related ESU. Daily counts were used for calculating rates and rate ratios per temperature range and age group.

RESULTS

From January 1, 2010 through October 15, 2012 counts have exceeded cumulative to October 15th for the past two years in the number of heat-related ED visits, heat-related EDC calls, and hot days (Table 1). There were 937 heat-related ED visits and 509 heat-related EDC calls during the study period; 78.3% and 82.6% (respectively) occurred on days that were ≥80ºF (N=478).

Table 1. Number of heat-related ED visits, EDC calls, and days exceeding temperatures to October 15th and to the year's end.

	2010 to 10/15 (year end total)	2011 to 10/15 (year end total)	2012 to 10/15	Study period total
Heat-related ED visits	294(323)	266(297)	317	937
Heat-related 911 calls	158(169)	116(128)	212	509
Days 90˚-99˚F	79(80)	76(77)	92	249
Days >=100˚F	29(29)	23(23)	35	87

Heat-related ESU increases seasonally with increased temperatures (Figure 1). Weekly heat-related ED visits and EDC calls were moderately correlated with weekly averaged maximum daily temperatures (r=0.60 p<0.0001 and r=0.57 p<0.0001, respectively), and more strongly correlated with each other (r=0.83 p<0.0001). Total ED visits did not increase during summer months and were therefore not found

to be correlated to temperature ((*p*=0.73), heat-related ED visits or EDC calls (*p*=0.18 and *p*=0.17, respectively).



Figure 1. Weekly heat-related ED visits and heat-related EDC calls (left axis); and 7-day averaged maximum daily temperatures in Palmdale, California (right axis). Heat-related ED visits are stratified by age group.

Maps depict weekly counts of heat-related ED visits and EDC calls leading to and during the peak weeks of heat-related ESU activity and temperature in 2012 (Figure 2). Note that while coverage of ED visits is widespread, EDC calls are only captured for the LA City region, which does not include cities such as Santa Monica, Pasadena and Long Beach.



Figure 2: From left to right, heat-related ESU during CDC weeks 31 (7/29-8/4), 32 (8/5-8/11) and 33 (8/12-8/18) in 2012. The greatest single day numbers of heat-related ED visits and EDC calls in 2012 occurred on 8/8-8/10; highest temperatures occurred on 8/11-8/13. Shaded areas represent number of heat-related ED visits per resident zip code. Size of circles represent number of heat-related EDC calls by resident zip code.



Figure 3: Total counts and daily rates of heat-related EDC calls and ED visits from 1/1/2010-10/15/2012 by age group and by temperature ranges 80ºF-89ºF (N=142), 90ºF-99ºF (N=249), and ≥100ºF (N=87). Divisions within age groups mark 5 year intervals

There were 3.6 times as many heat-related ED visits per day on days ≥100ºF compared to 80ºF-89ºF; days 90ºF-99ºF had rates 1.56 times greater (Figure 3). There were 5.6 times as many heat-related EDC calls per day on days ≥100ºF compared to 80ºF-89ºF; days 90ºF-99ºF had rates 1.74 times greater (Figure 3). Mean age of heat-related ED visitors increased with hotter temperature ranges, with values of 36.5, 37.2, and 39.8 years for 80ºF-89ºF, 90ºF-99ºF, and ≥100ºF days, respectively. Mean age of heat-related EDC calls did not increase with hotter temperatures, with values of 41.3, 38.2, and 41.1 years, respectively.



Figure 4: Count and percentage of heat-related ED visits by age group in five year intervals.

Analyzed in five year intervals, 0-4 year olds (10.4%), 20-24 year olds (9.6%) and 15-19 year olds (8.8%) experienced the most heat-related ED visits (Figure 4). As a percentage of total ED visits however, 10-14 year olds (22.2%), 15-19 year olds (21%) and 65-69 year olds (20.1%) formed the majority.

CONCLUSIONS

The average number of heat-related ED visits is very small compared to total ED visits; therefore total ED visits do not increase with hotter temperatures, have little to no correlation with heat-related ED visits and EDC calls, and thus may not serve as a good indicator of heat-related ESU in LAC. Filtering chief complaints to obtain heat-specific ED visits, however, enables patterns of increase to emerge which correlate with higher temperatures and heat-related emergency dispatch calls. About 36% of the week to week variation in heat-related ED visits, and 32% of the week to week variation in heat-related EDC calls can be explained by week to week variations in averaged maximum daily temperatures. These correlations may be exaggerated since temperatures from Palmdale, one of the hottest regions of Los Angeles County, were used; correlations will be calculated more precisely in future studies using temperature data from specific zip codes.

Heat-related ED visits are most common among 10 to 19 year olds, possibly because of more time spent outdoors. That heat-related visits were otherwise similarly distributed in age as all ED visitors suggests that heat does not disproportionately affect young children and the elderly any more than the rest of the acute health conditions that bring visitors to the ED.

The syndromic surveillance system provides an underestimate of heat-related healthcare seeking behavior since it does not capture information on visits to private providers, urgent care and other facilities. In addition,some syndrome misclassification of heat-related ED visits is inevitable due to having symptoms common to other illnesses. For instance, while even moderate heat may trigger cardiac arrest or syncope, adverse events such as these can also be prompted by other factors such as stress, extra physical exertion, or secondary illnesses. Accepting some misclassification, however, syndromic surveillance databases are useful for providing baselines and quantifiable, age-based measures of the effects of environmental exposure on ESU otherwise difficult to measure in near real-time.

REFERENCES

The Weather Channel Companies. *Weather underground.* Accessed August 27, 2012. http://www.wunderground.com.

EVALUATING THE LOS ANGELES COUNTY PUBLIC HEALTH URGENT DISEASE REPORTING SYSTEM: PAST AND PRESENT

Alison Itano, MS; Laura Coelho; and Michael Tormey, MPH

To improve Local Public Health Agencies' (LPHAs) ability to detect and respond to bioterrorism events and natural disease outbreaks, the Centers for Disease Control and Prevention (CDC) issued guidance that clarified LPHA responsibilities for receiving and responding to urgent disease case reports and outbreaks [1]. This guidance included four primary recommendations: 1) a single, well-publicized telephone number to receive urgent case reports; 2) a phone triage system to process urgent case reports; 3) capacity to receive urgent case reports 24 hours a day, 7 days a week and 4) a trained public health (PH) professional to respond within 30 minutes of receiving the report. To evaluate the LPHA disease reporting system, the RAND Corporation developed a set of methods [2]. In 2006 [3], 2010 [4], and 2011 [5], the Los Angeles County (LAC) Department of Public Health (DPH) Acute Communicable Disease Control Program (ACDC) evaluated LAC's Disease Reporting System . During the last months of 2012, another test of the system was performed. This report reviews the most recent test results and summarizes all evaluations since 2006.

BACKGROUND

Los Angeles County maintains a disease reporting system capable of receiving reports 24 hours a day, 7 days a week via an 888 toll-free disease reporting hotline. This hotline is publicized on LAC DPH's website and in numerous publications and health education materials. In addition to the hotline, urgent disease reports can also be called in directly to ACDC.

Calls received through the hotline during normal business hours—Monday-Friday, 8am-5pm—go directly to the LAC DPH Morbidity Unit (Figure 1). If a caller is requesting information or assistance related to infectious disease, the call is transferred to ACDC. Other non-ACDC diseases such as tuberculosis, sexually transmitted diseases, and HIV are triaged to their respective programs. ACDC calls are triaged by ACDC clerical staff based on whether the caller is a healthcare provider and the exact nature of the call.



All hotline calls received after-hours—Monday-Friday, 5pm-8am, weekends, and holidays—are forwarded directly to the County Operator [CO] (serves as the answering service for *all* county departments) (Figure 1). Healthcare providers with questions related to infectious disease are transferred to the Public Health physician on call, referred to as the Administrator On Duty (AOD).

METHODS

The RAND technical manual provides a template for evaluating the competency of disease reporting systems. The manual was used to test how quickly a connection can be made between a caller and the action officer[1] (AO). The call process consisted of three phases: 1) initiating a call, 2) reaching an AO and

[1] For purposes of this test, an Action Officer (AO) is defined as a Public Health professional responsible for responding to public health emergencies at the time of the test call.

3) debriefing. A call was initiated when a test caller phoned the disease reporting system, used a lead-in (a short message designed to move the call to an AO) and asked to speak to an AO. The caller would either be transferred directly to the AO (a warm transfer) or be asked to leave a message for the AO (callback). Once the caller reached an AO and confirmed that the person was responsible for handling urgent disease case reports, the AO was "debriefed"—informed that the call was only a test and that no further action was required.

Selected ACDC staff persons with jobs unrelated to the immediate receipt and processing of urgent disease situations were used to perform test calls. For callers without previous experience with the project, a brief training session was given. Test callers received a script to follow for each call initiation that had them pose as a healthcare worker trying to get information regarding a potential case or cluster of infectious disease. During the call, each caller would complete a worksheet to keep track of specific call details such as the exact time the call was initiated, how long the caller was on hold, if the caller reached an AO, whether they had a warm transfer or a call back and how long the entire call took from start to finish. The test of the urgent disease reporting system was not announced to physician staff and the exact schedule of test calls was kept secret. Dates and times of test calls were varied throughout the month.

Information collected during the test calls was used to measure several outcomes—if contact with an AO was made within 30 minutes of call initiation (where contact was treated as a yes/no variable); the time from call initiation to contact with an AO; and the number of calls with warm transfers as opposed to callbacks.

RESULTS

2012 Test Calls

In November and December 2012, a total of ten test calls were made to the disease reporting system. Contact with an AO was made within 30 minutes for all ten calls (Table 1). Response times for successful calls ranged from 3 to 15 minutes with a mean of 7.6 minutes from initiating the phone call to reaching an AO. Eight calls were warm transfers and two were callbacks.

Table 1. Successful Call Line List

Call #	Type of Call	Time of Call	Out-come	Time on hold			Total Time to reach AO
				County Operator	Morbidity Unit	ACDC/IP	
1	After Hrs	Evening	WT	90 sec	----	----	4 min
2	After Hrs	Morning	CB	4 min	----	----	13 min
3	After Hrs	Morning	CB	----	----	----	7 min
4	Business Hrs	Morning	WT	----	10 sec	75 sec	9 min
5	After Hrs	Evening	WT	12 min	----	----	15 min
6	Business Hrs	Afternoon	WT	----	30 sec	1 min	3 min
7	Business Hrs	Afternoon	WT	----	10 sec	30 sec	3 min
8	Business Hrs	Morning	WT	----	1 min	2 min	10 min
9	Business Hrs	Afternoon	WT	----	45 sec	----	8 min
10	Business Hrs	Afternoon	WT	----	15 sec	10 sec	4 min

WT=Warm Transfer
CB=Call Back

Review of All Test Calls from 2006-2012:

ACDC has evaluated LAC's Public Health Disease Reporting System five times since 2006. There have been a total of 48 test calls administered with nine or ten per evaluation. Table 2 summarizes these calls.

Eighty-one percent (39) of the calls successfully reached an AO within 30 minutes and nine calls were unsuccessful due to response times of 30 minutes or greater (4) or no response (5). The overall mean time for successful calls was 7.7 minutes with a range of 3 to 29 minutes, which was similar to the 2012 mean time but with a lower upper range of 15 minutes. Ninety-seven percent of the warm transfers had a successful outcome whereas 73% of call backs were successful. A higher proportion of the successful calls occurred after-hours (89%) rather than during business hours (76%). Also, evening was the most successful time to call (100%) followed by the afternoon (85%) and morning (66%). Type of call and time of call were not statistically associated with a successful call (p-value ≤ 0.05). In Graph 1, there were one to three unsuccessful test calls per evaluation in past years but 2012 was the first evaluation where all the calls were successful.

Table 2. A Retrospective Review of LAC's Disease Reporting System Evaluations, 2006-2012

Characteristic	Successful (percent)	Unsuccessful (percent)	Total number
All test calls	39(81)	9(19)	48
Mean time to reach AO (minutes)	7.7 (3 -29) median = 6	65.8 (30-144)* median = 45	
Call outcome			
Warm transfer	31(97)	1**(3)	32
Call back	8(73)	3(27)	11
No response	0(0)	5(100)	5
Type of call			
After-hours	17(89)	2(11)	19
Business hours	22(76)	7(24)	29
Time of call			
Evening	10(100)	0(0)	10
Afternoon	17(85)	3(15)	20
Morning	12(67)	6(33)	18

*Only 4 calls analyzed. No response was received for other five calls.
**Warm transferred but disconnected after being put on hold.



DISCUSSION

For the 2012 evaluation, all test calls reached an AO within 15 minutes; well under the 30 minute standard recommended by the CDC. The telephone hardware systems functioned appropriately, but the need for improvements with the human element of the system were noted.

Since its inception in 2006, ACDC has demonstrated that the LAC Public Health Disease Reporting System is functioning well within the LPHA responsibilities outlined by the CDC for receiving and responding to urgent disease case reports and outbreaks. Almost all the calls were handled in a timely manner and customer service issues were identified and addressed. The most successful calls seem to occur after-hours, in the evening hours and after a warm transfer.

The County maintains a system to receive reports 24 hours a day, 7 days a week and a toll-free hotline specific for receiving urgent disease case reports. The findings of this report have been shared with ACDC administration and areas of improvement have been discussed with appropriate staff affected by this response protocol. Routine testing of the LAC's Disease Reporting System should be maintained so new issues may be identified and dealt with immediately.

REFERENCES

1. U.S. Centers for Disease Control and Prevention. Improving Surveillance Infrastructure for Terrorism Detection: The Eight-Cities Project Resource Materials. April 7, 2004. Available at: http://www.cdc.gov/epo/dphsi/8city.htm
2. Dausey DJ, Lurie N, Diamond A. Public Health Response to Urgent Case Reports. Health Affairs 2005; W5: 412—419.
3. Zelenay A. Responding to Urgent Case Reports: Testing the Los Angeles County Disease Reporting System. Acute Communicable Disease Control Special Studies Report 2006.
4. Zelenay A. Evaluating the Los Angeles County Public Health Urgent Disease Reporting System. Acute Communicable Disease Control Special Studies Report 2010.
5. Zelenay A. Evaluating the Los Angeles County Public Health Urgent Disease Reporting System. Acute Communicable Disease Control Special Studies Report 2011.

PARTNERING WITH EARLY CHILDHOOD EDUCATION PROVIDERS TO PREVENT INFECTIOUS DISEASE: A REVIEW OF A *FOTONOVELA* INTERVENTION

Laura Coelho; Elaine Waldman; and Y. Silvia Shin RN, PHN, MSN/MPH

BACKGROUND

The Los Angeles County (LAC) Department of Public Health (DPH) Acute Communicable Disease Control Program (ACDC) is committed to engaging in collaborative projects with diverse stakeholders to build community capacity for infectious disease prevention. This report briefly reviews ACDC's work with LAC early childhood education (ECE) providers on the topic of reptile-associated salmonellosis (RAS).

Reptile-associated Salmonellosis (RAS)

Over 1,200 cases of *Salmonella* are reported to ACDC each year in LAC.[1] Although largely considered a foodborne illness, an average of 9% of locally reported *Salmonella* cases is associated with reptile exposure, primarily turtle exposure.[1] This is higher than the national average; reptile exposure accounts for 6% of total reported *Salmonella* cases nationally.[2] According to ACDC surveillance data, low-income Spanish-speaking Latino families with young children living in apartments in LAC Service Planning Areas (SPAs) 2 and 4 who have had exposure to baby turtles as pets are disproportionately affected by RAS, accounting for the majority of RAS cases in LAC.[1, 2, 3]

Federal law, established in 1975, prohibits the sale or distribution of turtles with shells less than four inches in length and the Centers for Disease Control and Prevention (CDC) recommends that children under age five have no contact with reptiles or amphibians.[2, 4] Despite regulations and recommendations, small turtles are often sold illegally at swap meets and open air markets in LAC and have been popular pets in child care programs and preschool classrooms (i.e., ECE provider sites) throughout LAC.[2]

Building Relationships with ECE Providers

In order to target ECE providers to partner in a RAS initiative, a RAS Working Group was formed in 2007. The RAS Working Group began connecting with ECE providers by participating in monthly Los Angeles County-wide Child Care Planning Committee (CCPC) meetings with public health updates during the public comment period on a range of infectious disease prevention topics. The CCPC monthly meetings are attended by diverse ECE stakeholders, such as family-based and center-based providers, parents, advocates, and representatives of community-based organizations. Attending these meetings helped the RAS Working Group understand the important role that ECE providers play in linking families to needed health and social services.

In 2009, RAS Working Group members conducted field visits with seven ECE providers to exchange information, share LAC DPH resources and health education materials, and understand the context within which ECE providers serve local children, families, and communities.[2] The field visits strengthened the RAS Working Group's relationships with ECE providers, demonstrated that the issue of RAS was relevant at both center-based and family-based programs, and reinforced the important role that ECE providers play in reaching local children, families, and communities with relevant health messages. Recognizing the significance of partnering with local ECE providers, the RAS Working Group began planning strategies for reaching vulnerable children and parents in a standardized way about the issue of RAS through center-based and family-based programs.

RAS Fotonovela and Readers' Theater Activity

In late 2009, ACDC staff suggested that a *fotonovela* may be an effective approach to engage Spanish-speaking communities in LAC based on research showing that comics, stories, and pictures can effectively reach Spanish-speaking individuals with health messages.[5] A team of graduate public health students from a local university, in collaboration with the RAS Working Group, drafted, field tested, and

produced a 12-page glossy, bilingual *fotonovela* booklet telling a story about RAS with photographs and text based on real experiences from ECE providers and parents.[3]

ACDC developed an interactive readers' theater activity and plan to disseminate the *fotonovelas*. The readers' theater approach involved acting out the story in front of a group of peers. Three tools were developed to standardize the readers' theater process for presenting and discussing the *fotonovela*. The tools included a 1) readers' theater leaders' guide with a checklist of steps for facilitating the activity, 2) group evaluation form asking participants about their knowledge and practices related to RAS before and after the session, and 3) fax coversheet to send to ACDC after each readers' theater session summarizing the challenges, successes, and next steps.[3]

After developing the tools, the RAS Working Group began conducting hour-long training-of-trainer (TOT) sessions with nine ECE partners from 2009 to 2011.[3] ACDC staff facilitated TOT sessions with the ECE providers, who then presented the *fotonovela* and readers' theater activity to parents of enrolled children at regular parent meetings. Two large ECE partners who serve thousands of low-income Spanish-speaking families with children ages 0-5 regularly provided feedback to ACDC.[3] Results from one sample of 2010 group evaluation forms are presented in Table 1.

Table 1: Responses of *Fotonovela* and Readers' Theater Activity Participants from single ECE program to Group Evaluation Forms, 2010[4]

Group Evaluation Form Item	ECE Providers (n=78)	Parents (n=211)
Have seen baby turtles for sale	90%	84%
Before this meeting, knew that turtles could make you sick	67%	25%
Will not buy pet turtle if asked by child	97%	96%
Think this fotonovela is a good way to learn about the problem of *Salmonella*	99%	99%
Will share lessons learned with others	100%	99%

METHODS

In August 2012, ACDC staff developed a 16-question discussion guide for facilitating in-depth phone interviews with ECE providers to obtain their feedback on the *fotonovela* and readers' theater activity. Questions asked about their use of the *fotonovela*, how parents and staff were reached with the *fotonovela* and readers' theater activity, challenges and successes with implementing the readers' theater activity, progress with their next steps post learning about RAS, ideas for improving the activity, satisfaction with LAC DPH, recent changes to their organization, and interest in future trainings. The 16-question discussion guide included both quantitative and qualitative elements. While developing the 16-question discussion guide, ACDC staff reconnected with the nine ECE providers who initially implemented the *fotonovela* and readers' theater activity through email and phone communications to schedule interviews. Phone interviews were conducted from September through November 2012.

RESULTS

To date, there have been 5,590 *fotonovelas* disseminated, 143 ECE providers trained by ACDC, 4,721 families of children ages 0-5 reached, and considerable numbers of programs, providers, and parents committed to reducing the risk of RAS in their communities through 1) policy change, prohibiting reptiles from classrooms; 2) encouraging parents read the *fotonovela* to their child; 3) adding the *fotonovela* to classroom libraries; and 4) spreading RAS prevention messages by sharing the *fotonovela* with neighbors, friends, and relatives.[6]

Response Rate

Seven (78%) of the nine ECE provider sites who initially implemented the *fotonovela* and readers' theater activity were interviewed in 2012. Eight interviews within the seven sites were conducted because two

separate interviews with distinct contacts at a single ECE provider with multiple sites were needed due to the size of the organization.

Use of Fotonovela

While ACDC conducted TOT sessions with all nine ECE partners in 2009, not all providers were able to facilitate the readers' theater activity at their sites. When asked to indicate all the ways that the *fotonovela* was used, all eight interviewees used the *fotonovela* in one or more ways—six (75%) of the interviewees indicated that they facilitated the readers' theater activity, all eight (100%) distributed the *fotonovela* to parents, three (38%) gave copies of the *fotonovela* to community partners, five (63%) added the *fotonovela* to a classroom library, and one (13%) brought copies of the *fotonovela* on home visits to parents. The six interviewees who indicated that they facilitated the readers' theater activity as part of their use of the *fotonovela* facilitated the readers' theater activity primarily at parent meetings and staff trainings.

Challenges and Successes with Facilitating Reader's Theater Activity

When asked about their experience facilitating the readers' theater activity, all six of the interviewees that indicated that they used the *fotonovela* in this way reported that their experience was excellent. The six interviewees were presented with a series of statements inquiring about specific aspects of implementing the readers' theater activity and were asked to select one of the following answers in response to each statement: strongly disagree, disagree, neutral, agree, strongly agree, unsure, or not applicable. The number of ECE providers that selected strongly disagree, disagree, neutral, agree, strongly agree, unsure, or not applicable for each of the statements is presented in Table 2.

Table 2: Number of ECE providers per response option to each statement, 2012

Statement	Number of ECE providers per response option						
	Strongly Disagree	**Disagree**	**Neutral**	**Agree**	**Strongly Agree**	**Unsure**	**N/A**
It was easy to obtain permission to facilitate the RAS *Fotonovela* and readers' theater at my organization					6		
It was easy to gather participants to conduct the RAS *Fotonovela* and readers' theater activity				2	4		
It was easy to use the RAS *Fotonovela* and readers' theater activity as a health education tool					6		
The topic of RAS was relevant to participants (i.e., many had seen baby turtles for sale)				2	4		
Attendants participated in the RAS *Fotonovela* and readers' theater activity				2	4		
Participants felt that the RAS *Fotonovela* and readers' theater activity was a good way to learn about the problem of RAS				1	5		
Participants were committed to not purchasing pet turtles after participating in the RAS *Fotonovela* and readers' theater activity				2	4		
Participants were willing to share what they learned with others				1	5		

Interviewees were also given opportunities to provide qualitative feedback about their challenges and successes. When asked about reactions from parents after learning about the issue of RAS, multiple

interviewees noted that parents were surprised to learn about the dangers associated with owning baby turtles. Overall, parents were very receptive to the message and committed to not purchasing baby turtles, which was a success noted by multiple interviewees. Challenges included the competing priorities that parents face in attending parent meetings, since they struggle to balance family, work, school, and other commitments; conducting the readers' theater activity in both English and Spanish simultaneously if the audience required it; and not permitting classroom pets when children were used to having baby turtles or other reptiles at the site(s).

Progress and Next Steps

Four (50%) of the eight interviewees indicated that they had reptiles at their ECE site(s) prior to trainings from LAC DPH; however, the interviewees who had reptiles at their sites found more suitable homes for the reptiles and did not have them in the classroom at the time of the phone interview in 2012. All six interviewees who indicated that they facilitated the readers' theater activity also implemented changes to their organization in response to their knowledge about RAS. Four (67%) out of the six interviewees said that they changed policy, not allowing reptiles or other pets in the classroom; three (50%) gave parents homework of reading the *fotonovela* to their child; five (83%) added the *fotonovela* to classroom libraries; and one (17%) sent an organization-wide memo to their director and staff to inform them about RAS. Respondent next steps are summarized in Figure 1.

Figure 1:
Respondent reported next steps post learning about RAS



*Respondent who indicated other, specified sending an organization-wide memo about RAS

Ideas for Improvement

Interviewees proposed a number of suggestions when presented with the open ended question, "What could we do to improve the *Fotonovela* and readers' theater activity?" Suggestions included translating the *fotonovela* into additional languages, making the *fotonovela* easier to copy, from color to black and white for mass distribution, and more clearly labeling the dialogue bubbles as well as reducing the amount of text in the *fotonovela* to ease reading and acting it out.

Satisfaction with LAC DPH

Interviewees were asked to rank their satisfaction with LAC DPH's previous trainings, visits to their programs, and promotion materials on a scale from 1 to 5, with 5 being extremely satisfied. When asked for their overall satisfaction with LAC DPH's previous trainings and visits, seven interviewees provided answers with an average score of 4.93 (median: 5, range: 4.5 to 5). When asked how satisfied they were with the materials received from LAC DPH (i.e., *fotonovelas*, readers' theater activity handouts, educational materials on RAS and other health topics), eight interviewees provided answers with an average score of 4.81 (median: 5, range: 4.5 to 5).

Changes to ECE Provider Sites

Many ECE providers interviewed noted multiple changes to their organizations since 2009. Changes included staff turnover, budget cuts, and reductions in enrollment, making it difficult to continue implementing the readers' theater activity. In fact, one interviewee said that while the organization can continue to distribute the *fotonovela*, it may be difficult for their ECE providers to keep conducting the readers' theater activity due to scarce resources, limited time with parents, and reduced staffing.

Future Trainings and Topics of Interest

Two (25%) interviewees said that they would like additional training about the *fotonovela* and readers' theater activity, five (63%) were not interested in additional training, and one (13%) interviewee was not able to respond to the question as the interviewee no longer worked at the partner ECE organization. All of those able to respond to the question indicated that they were interested in participating in future disease prevention and health promotion activities on other topics, including food safety (6), hand washing (6), public health resources (5), emergency preparedness (7), influenza (6), and bats and rabies (2), among others.

DISCUSSION

The work of the RAS Working Group and ACDC staff from 2008 through 2012 demonstrates the relevance of RAS to local ECE providers and the parents and children they serve. The field visits in 2009, feedback from an ECE partner in 2010, and recent phone interviews in 2012 all indicate that the *fotonovela* and readers' theater activity are useful tools for local communities served by ACDC's ECE partner organizations to learn about the issue of RAS and motivate change in community norms around purchasing baby turtles as pets. The data from 2009 through 2012 show willingness by ECE providers and the parents that they serve to share what they learn about RAS with others, reaffirming ECE providers as important community partners in Public Health.

Since 2009, the RAS Working Group and ACDC have seen considerable success working with ECE providers to inform local communities about RAS with the *fotonovela* and readers' theater activity, reaching nearly 5000 families of children ages 0-5. However, limited staff resources, funds, and time are increasingly inhibiting ECE providers' abilities to focus on health education activities. Although deeply committed to promoting infectious disease prevention in their communities, ACDC's ECE partners may not be able to implement the readers' theater activity as rigorously as in previous years. Despite this shift, all partners are enthusiastic about continuing to distribute copies of the *fotonovela* to parents, making *fotonovelas* available in classroom libraries, and enforcing policies to not permit reptiles at their site(s). With this in mind, ACDC recently distributed remaining copies of the *fotonovela* to ECE providers in attendance at CCPC's first meeting of 2013 and the Los Angeles County Office of Education Head Start programs. As ECE partners interviewed in 2012 expressed satisfaction with LAC DPH health promotion materials and interest in receiving resources on multiple other infectious disease topics in the future, ACDC anticipates continued partnership with ECE providers throughout LAC to reach vulnerable communities with needed health resources.

CONCLUSION

ECE providers continue to be important partners in reaching often vulnerable and underserved, local communities with relevant health promotions materials and public health messages. ACDC's partnership with ECE providers on the *fotonovela* and readers' theater activity not only proved successful in informing parents and children about the issue of RAS locally, but also in generating lessons learned for future collaborations with the ECE provider community.

REFERENCES

1. Acute Communicable Disease Control's Surveillance Data

2. Waldman E and Chow L. Building Relationships with Early Childhood Education Providers to Prevent Infectious Disease. *Acute Communicable Disease Control 2009 Special Studies Report.*

3. Waldman E. Engaging Early Childhood Educators and Parents with a *Fotonovela* Intervention to Prevent Infectious Disease. *Acute Communicable Disease Control 2010 Special Studies Report.*

4. National Association of State Public Health Veterinarians, Inc. (NASPHV) Compendium of Measures to Prevent Disease Associated with Animals in Public Settings. CDC, Morbidity and Mortality Weekly Report (MMWR). July 6, 2007, 56 (RR05); 18-19.

5. Green MJ, Myers KR. Graphic medicine: use of comics in medical education and patient care. *British Medical Journal*, March 3, 2010.

6. Waldman E, Bagby R and Coelho L. The *Fotonovela* Readers' Theater: Engaging Early Childhood Education Providers and Parents in Infectious Disease Prevention. *2011 Health Education Practice Conference.*

SYNDROMIC SURVEILLANCE DETECTION OF TRADITIONALLY REPORTED TYPHOID FEVER CASES IN LOS ANGELES COUNTY

Monica Luarca, MPH; Emily Kajita, MS, MPH; Leticia Martinez, RN, PHN, MPH; and
Bessie Hwang, MD, MPH

BACKGROUND

Typhoid fever, or enteric fever, is a life-threatening disease caused by *Salmonella typhi*, a gram negative enteric bacillus. Transmission may occur person-to-person or by ingestion of food or water contaminated by the urine or feces of acute cases or carriers. The characteristic symptom of typhoid fever is a sustained fever of 103° to 104°F. Other symptoms may include stomach pain, headache, or loss of appetite[1]. Typhoid fever is a laboratory-reportable disease in Los Angeles County (LAC); all confirmed isolates must be forwarded to the LAC Department of Public Health Laboratory within one working day for confirmation and surveillance activities.

The Syndromic Surveillance (SS) system at LAC uses emergency department (ED) patient registration data, among other data sources, to help provide early detection of disease outbreaks and assist in monitoring of the population's health. The SS system places chief complaints (CC), the primary symptom that a patient states as the reason for seeking medical care, and diagnoses into categories, or syndromes, and monitors for any aberrations from established baselines and thresholds.

Between May 2011 and May 2012 a total of 16 confirmed cases of typhoid fever were reported to the LAC Department of Public Health (DPH) Acute Communicable Disease Control Program (ACDC) (average cases per year =16)[2]. ACDC queried its SS database to assess the ability of the SS system to correctly classify the cases' CCs, to locate reported cases of typhoid fever in LAC, and to detect potentially missed cases. All cases were also mapped to better gage the disease's distribution within our county.

The purpose of this report is to determine the distribution of reported typhoid fever cases in LAC, their presence within the SS data, and what CCs cases were presenting with to EDs in LAC.

METHODS

We acquired all confirmed case files between May 1, 2011 and May 31, 2012 from ACDC staff responsible for typhoid fever surveillance. A total of 16 case files were reviewed. Zip codes were obtained for each case from their respective case file and were mapped using ArcMap 10.

We attempted to locate confirmed cases among ED visitors within the SS database using two methods; first, by searching for specific CCs and diagnoses. Key words for this query included "typhoid fever", "salmonella", the International Classification of Diseases (ICD)-9 code for typhoid fever, and multiple variations in the spelling of these words to capture errors in data entry.

Secondly, we queried the SS database for matches based on known demographic information. Once a case was found, we noted the CCs cases were presenting to the ED with and whether they were classified into one of four syndrome categories: neurological, gastrointestinal, rash, and respiratory.

RESULTS

A total of 16 typhoid fever cases were identified in LAC between May 1, 2011 and May 31, 2012. Most cases resided in Service Planning Area (SPA) 2 (n=4, 25%) and SPA 5 (n=4, 25%) followed by SPA 7 (n=3, 19%) (Figure 1).



Overall we were able to locate 13 of the 16 cases (81.3%) reported to LAC in the SS database. Three of the 13 located cases reported to an ED more than once before a confirmed diagnosis was given. The first query, which searched CCs and diagnoses, resulted in only one match (6%) that explicitly stated the diagnosis as “acute typhoid fever”. The demographic information based query resulted in 12 more matches; reported CCs from this query included “cough”, “diarrhea, abd pain, vomiting”, and “fever for 5 days/headache/weak” (Table 1).

Of the 13 cases found in the SS database, ten were classified into one of four syndrome categories during at least one ED visit (six respiratory, three gastrointestinal, and one neurological). Two of the

remaining three cases were not classified into a syndrome category because the CCs did not contain any patient symptoms and were thus classified as "other" (Table 1); the last case had a CC of "chest pain" which does not fit into either of the four syndrome classification and was also classified as "other". Seven of the 13 cases reported "fever" in their CC (the most notable symptom of typhoid fever). A typographical error in entering the CC for case #3 as "fewer" resulted in incorrectly classifying his first ED visit as other rather than respiratory.

Table 1. Emergency Department Chief Complaints Recorded from Confirmed Typhoid Fever Cases in LAC, May 2011-May 2012

Case	Number of ED Visits	Chief Complaint	Syndrome Category
1	2	ABNORMAL LAB RESULTS FEVER	Other Respiratory
2	1	DIARRHEA, ABD PAIN, VOMITING	Gastrointestinal
3	2	FEWER FEVER X 1 WEEK	Other Respiratory
4	3	FEVER, VOMITING, ABDOMINAL CRAMPS FEVER, VOMITING, WEAKNESS POSS FEVER	Gastrointestinal Gastrointestinal Respiratory
5	1	COUGH	Respiratory
6	1	FEVER FOR 5 DAYS, HEADACHE, WEAK	Neurological
7	1	VOMITING, DIARRHEA, FEVER	Gastrointestinal
8	1	QUICK REG	Other
9	1	ABNORMAL LAB RESULTS	Other
10	1	SYNCOPE AND COLLAPSE, FEVER	Respiratory
11	1	CHEST PAIN	Other
12	1	FEVER OF UNKNOWN ORIGIN	Respiratory
13	1	FEVER X 1 MONTH	Respiratory

A total of three confirmed cases were not located within our SS database (18.7%). One case was not found because he did not visit an ED and instead visited an urgent care center. A second case was not found within the SS system because he reported to one of the hospital EDs not currently participating in the SS system. One case's chart states that he was admitted through one of the hospitals monitored by the SS system; however, it is possible that his visit was registered for inpatient care. We were not able to locate any additional cases aside from the 16 reported cases.

DISCUSSION

The 16 confirmed typhoid fever cases reported to LAC between May 2011 and May 2012 showed distribution patterns consistent with previous years[2], with the majority of cases residing in SPA 2 in 2007, 2008, and 2009.

Traditionally typhoid fever is thought to be a systemic or gastrointestinal illness, even though the characteristic symptom of typhoid fever is sustained fever. Of the 13 confirmed cases found within the SS database, eight (62%) included "fever" in their CC during at least one of their ED visits, however, the syndromic classification algorithm currently assigns the term "fever" when appearing alone to the respiratory category. As a result, of the ten cases that were classified into one of the four syndrome categories, three were classified as gastrointestinal while six fell into the respiratory syndrome category. This finding will help guide our future efforts to detect a community-wide increase in ED visits due to typhoid fever; we will be more successful in querying for "fever" visits rather than querying for visits classified under gastrointestinal and/or respiratory syndromes.

In general, using demographic information to search retrospectively for confirmed typhoid cases within SS databases is much more effective than searching for key words within the CC and diagnosis fields. As in the case with "fever" misspelled as "fewer", misspellings and typographical errors within CC and diagnosis fields limit our ability to correctly identify all disease events. Another limitation in querying the SS databases is that the ED data is de-identified; thus, we cannot be sure that the cases we match are in fact the same person. While we are fairly certain that cases matched on date of birth, zip code, visit date, and hospital are legitimate, missing variables in the ED registration data hinder our ability to easily perform case finding.

Despite these limitations, SS databases can be used to locate a high percentage of confirmed cases as long as symptoms are severe enough to warrant visits to the ED. Typhoid fever appears to be particularly suited for SS queries, as a striking 15 of 16 (94%) confirmed cases reported to an ED. Although CCs for typhoid fever are not specific and can fall into multiple syndrome categories, expanded queries for other illnesses can detect potential outbreaks or diseases not found in automated syndrome categories[3]. This near real-time surveillance can be useful during large scale outbreaks to capture disease events or clusters that have not yet been identified. Future studies evaluating the SS system's capacity to detect reportable disease clusters will be beneficial.

REFERENCES

1. Centers for Disease Control and Prevention. *Typhoid fever.* (2010, OCT 05). Retrieved from http://www.cdc.gov/nczved/divisions/dfbmd/diseases/typhoid_fever/technical.html
2. Los Angeles County Department of Public Health, Acute Communicable Disease Control Program. (2010). *Annual Morbidity Report.*
3. O'Connell EK, Zhang G, Leguen F, Llau A, Rico E. Innovative uses for syndromic surveillance. *Emerg Infect Dis* [serial on the Internet]. 2010 April [cited 2012 November 5]. http://wwwnc.cdc.gov/eid/article/16/4/09-0688.htm.